Issuu on Google+

out14t

03-07-07

12:27

™ÂÏ›‰·3

Δƒπª∏¡π∞π√ ¶∂ƒπ√¢π∫√ §π¶π¢πø¡

¶·ıÔÊ˘ÛÈÔÏÔÁ›·

Δ∂ÀÃ√™ 14 ñ π√À¡π√™ 2007

2

4 10 16

¶·Ú¿ÁÔÓÙ˜ ∫ÈÓ‰‡ÓÔ˘ ∫ÏÈÓÈΤ˜ ªÂϤÙ˜

£ÂÚ·›· - º¿Ú̷η

¶ÚÔÙÂÈÓfiÌÂÓË μÈ‚ÏÈÔÁÚ·Ê›·

31


out14t

03-07-07

12:28

™ÂÏ›‰·4

IA

™YNTAKTIKH E¶ITPO¶H ¢È¢ı˘ÓÙ‹˜ ™‡ÓÙ·Í˘ XÂÈÌÒÓ·˜ HÏ›·˜ K·Ú‰ÈÔÏfiÁÔ˜ YÔÙ¤Ú·Ú¯Ô˜ Â.·.

M¤ÏË Õı˘ÚÔ˜ B·Û›ÏÂÈÔ˜ AÓ·ÏËÚˆÙ‹˜ ¢È¢ı˘ÓÙ‹˜ E™Y K·Ú‰ÈÔÏÔÁÈÎfi TÌ‹Ì· B’ ¶ÚÔ·È‰Â˘ÙÈ΋˜ KÏÈÓÈ΋˜ A¶£ IÔÎÚ¿ÙÂÈÔ NÔÛÔÎÔÌÂ›Ô £ÂÛÛ·ÏÔӛ΢ ∫·Ú·ÁÈ¿ÓÓ˘ ∞ÛÙ¤ÚÈÔ˜ ∞Ó·ÏËÚˆÙ‹˜ ∫·ıËÁËÙ‹˜

¶A£√ºÀ™π√§√°π∞ ¶·ıÔÏÔÁÈΤ˜ ∫·Ù·ÛÙ¿ÛÂȘ Ô˘ ™˘Óԉ‡ÔÓÙ·È ·fi ÷ÌËÏ‹ ÃÔÏËÛÙÂÚfiÏË ÃÚ‹ÛÙÔ˜ ∞ÓÙÒÓÔÁÏÔ˘, ∂›ÎÔ˘ÚÔ˜ ∫·ıËÁËÙ‹˜ ¶·ıÔÏÔÁ›·˜ ΔÌ‹Ì·ÙÔ˜ π·ÙÚÈ΋˜ ™¯ÔÏ‹˜ ¢ËÌÔÎÚÈÙ›Ԣ ¶·ÓÂÈÛÙËÌ›Ô˘ £Ú¿Î˘

2

¶∞ƒ∞°√¡Δ∂™ ∫π¡¢À¡√À ΔÔ ∞ÏÎÔfiÏ ˆ˜ ¶·Ú¿ÁÔÓÙ·˜ ∫ÈÓ‰‡ÓÔ˘ ÁÈ· ÙËÓ ∂ÌÊ¿ÓÈÛË ∫·Ú‰È·ÁÁÂÈ·ÎÒÓ ™˘Ì‚·Ì¿ÙˆÓ ∂. ¡¿ÎÔ˘, ∂ÈÛÙËÌÔÓÈÎfi˜ ™˘ÓÂÚÁ¿Ù˘ ÙÔ˘ ∂Í. π·ÙÚ›Ԣ ¢È·Ù·Ú·¯ÒÓ ÙÔ˘ ªÂÙ·‚ÔÏÈÛÌÔ‡ ÙˆÓ §Èȉ›ˆÓ ª. ∂ÏÈÛ¿Ê, ∫·ıËÁËÙ‹˜ ¶·ıÔÏÔÁ›·˜ π·ÙÚÈ΋˜ ™¯ÔÏ‹˜ ¶·ÓÂÈÛÙËÌ›Ô˘ πˆ·ÓÓ›ÓˆÓ ΔÔ̤·˜ ¶·ıÔÏÔÁ›·˜ π·ÙÚÈ΋˜ ™¯ÔÏ‹˜ ¶·ÓÂÈÛÙËÌ›Ô˘ πˆ·ÓÓ›ÓˆÓ

4

¶ÚfiÏË„Ë ÙÔ˘ ™·Î¯·ÚÒ‰Ë ¢È·‚‹ÙË Δ‡Ô˘ 2 ¡›ÎÔ˜ ¢È·ÎÔ˘Ì¿ÎÔ˜, ∫·Ú‰ÈÔÏfiÁÔ˜. ¢È·ÁÓˆÛÙÈÎfi ∫·Ú‰ÈÔÏÔÁÈÎfi ∫¤ÓÙÚÔ ¶ÂÈÚ·È¿, ™˘ÓÂÚÁ¿Ù˘ ¡ÔÛÔÎÔÌ›Ԣ Metropolitan

8

¶·ıÔÏÔÁ›·˜ π·ÙÚÈ΋˜ ™¯ÔÏ‹˜

∫§π¡π∫∂™ ª∂§∂Δ∂™

∞ÚÈÛÙÔÙÂÏ›Ԣ ¶·ÓÂÈÛÙËÌ›Ô˘

ΔÔ ∂ÈÎÔÛÈÂÓÙ·ÓÔ˚Îfi √͇ ªÂÈÒÓÂÈ Ù· ªÂ›˙ÔÓ· ∫·Ú‰È·ÁÁÂȷο ∂ÂÈÛfi‰È· Û ÀÂÚ¯ÔÏËÛÙÂÚÔÏ·ÈÌÈÎÔ‡˜ ∞ÛıÂÓ›˜. ªÂϤÙË JELIS (Japan EPA lipid intervention study): Δ˘¯·ÈÔÔÈË̤ÓË, ·ÓÔȯً˜ ¯ÔÚ‹ÁËÛ˘ Î·È Ù˘ÊÏ‹˜ ·Ó¿Ï˘Û˘ ÙÂÏÈÎÒÓ ÛËÌ›ˆÓ ÌÂϤÙË. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators

10

¶ÏÂÈfiÙÚÔ˜ ¢Ú¿ÛÂȘ Ù˘ ∞ÙÔÚ‚·ÛÙ·Ù›Ó˘ ∏Ï›·˜ ÃÂÈÌÒÓ·˜, ∫·Ú‰ÈÔÏfiÁÔ˜

11

£ÂÛÛ·ÏÔӛ΢, πÔÎÚ¿ÙÂÈÔ ¡ÔÛÔÎÔÌÂ›Ô £ÂÛÛ·ÏÔӛ΢. EÏÈÛ¿Ê Mˆ˘Û‹˜ K·ıËÁËÙ‹˜ ¶·ıÔÏÔÁ›·˜ I·ÙÚÈ΋˜ ™¯ÔÏ‹˜ ¶·ÓÂÈÛÙËÌ›Ô˘ Iˆ·ÓÓ›ÓˆÓ ¶ÂÚÈÊÂÚÂÈ·Îfi ¶·ÓÂÈÛÙËÌÈ·Îfi NÔÛÔÎÔÌÂ›Ô Iˆ·ÓÓ›ÓˆÓ KÔÏÔ‚Ô‡ °ÂÓÔ‚¤Ê· K·Ú‰ÈÔÏfiÁÔ˜ YԉȢı‡ÓÙÚÈ· A’ K·Ú‰ÈÔÏÔÁÈ΋˜ KÏÈÓÈ΋˜ Î·È Y‡ı˘ÓÔ˜ §Èȉ·ÈÌÈÎÔ‡ I·ÙÚ›Ԣ øÓ·Û›Ԣ K·Ú‰ÈÔ¯ÂÈÚÔ˘ÚÁÈÎÔ‡ K¤ÓÙÚÔ˘ °Ô˘‰¤‚ÂÓÔ˜ πˆ¿ÓÓ˘, ∫·ıËÁËÙ‹˜ ∫·Ú‰ÈÔÏÔÁ›·˜ π·ÙÚÈ΋˜ ™¯ÔÏ‹˜ ¶·ÓÂÈÛÙËÌ›Ô˘ πˆ·ÓÓ›ÓˆÓ, ¶ÂÚÈÊÂÚÂÈ·Îfi ¶·ÓÂÈÛÙËÌÈ·Îfi ¡ÔÛÔÎÔÌÂ›Ô πˆ·ÓÓ›ÓˆÓ. ¶›ÙÛ·‚Ô˜ XÚ‹ÛÙÔ˜ AÓ·ÏËÚˆÙ‹˜ K·ıËÁËÙ‹˜ K·Ú‰ÈÔÏÔÁ›·˜, I·ÙÚÈ΋˜ ™¯ÔÏ‹˜ ¶·ÓÂÈÛÙËÌ›Ô˘ AıËÓÒÓ IÔÎÚ¿ÙÂÈÔ NÔÛÔÎÔÌÂ›Ô AıËÓÒÓ

£EPA¶EIA — ºAPMAKA ∂ÂÌ‚·ÙÈ΋ E·Ó·ÈÌ¿ÙˆÛË ‹ º·Ú̷΢ÙÈ΋ ∞ÁˆÁ‹ ÛÙËÓ ∞Û˘Ìو̷ÙÈ΋ ™Ù·ıÂÚ‹ ™ÙÂÊ·ÓÈ·›· ¡fiÛÔ; μ. ’∞ı˘ÚÔ˜, ∞. ∫·Î·Ê‹Î·, ∂. ¶·ÁÎÔ˘Ú¤ÏÈ·˜, Ã. ∫Ô˘Ì·Ú¿˜, ∞. ™Î·¤Ú‰·˜, ∞. ∫·Ú·ÁÈ¿ÓÓ˘. μ’ ¶ÚÔ·È‰Â˘ÙÈ΋ ¶·ıÔÏÔÁÈ΋ ∫ÏÈÓÈ΋, ∞¶£, πÔÎÚ¿ÙÂÈÔ £ÂÛÛ·ÏÔӛ΢

16

∏ ∫ÏÈÓÈ΋ ™ËÌ·Û›· Ù˘ ÃÔÚ‹ÁËÛ˘ ™Ù·ÙÈÓÒÓ ¶ÚÈÓ ·fi ∂ÂÌ‚·ÙÈ΋ ∂·Ó·ÈÌ¿ÙˆÛË ÙÔ˘ ª˘Ôηډ›Ô˘. μ. ’∞ı˘ÚÔ˜, ∞. ∫·Î·Ê‹Î·, ∂. ¶·ÓÎÔ˘Ú¤ÏÈ·˜, ™. ™·‚‚·ÙÈ·Ófi˜, ∞. ¶ÈÚ·ÛÔÔ‡ÏÔ˘, Ã. ∫Ô˘Ì·Ú¿˜, ∞. ™Î·¤Ú‰·˜, ∫. Δ˙ÈfiÌ·ÏÔ˜, ∞. ∫·Ú·ÁÈ¿ÓÓ˘. μ ¶ÚÔ. ¶·ıÔÏÔÁÈ΋ ∫ÏÈÓÈ΋ ∞¶£, πÔÎÚ¿ÙÂÈÔ ¡ÔÛÔÎÔÌ›Ô, £ÂÛÛ·ÏÔÓ›ÎË.

18

∂ÈÛÓÂfiÌÂÓË πÓÛÔ˘Ï›ÓË: Δ· ¢Â‰Ô̤ӷ Î·È ÔÈ ¶ÚÔ‚ÏËÌ·ÙÈÛÌÔ› ¢Ú. ∞Ó‰Ú¤·˜ ªÂÏȉÒÓ˘ À‡ı˘ÓÔ˜ ¢È·‚ËÙÔÏÔÁÈÎÔ‡ ∫¤ÓÙÚÔ˘, °.¡. ¶ÂÈÚ·È¿

21

√È ‚-∞ÔÎÏÂÈÛÙ¤˜ ÛÙËÓ ∫ÏÈÓÈ΋ ¶Ú¿ÍË ª. ºÏˆÚÂÓÙ›Ó, ∂ÈÛÙËÌÔÓÈÎfi˜ ™˘ÓÂÚÁ¿Ù˘ ÙÔ˘ π·ÙÚ›Ԣ §Èȉ›ˆÓ ª. ∂ÏÈÛ¿Ê, ∫·ıËÁËÙ‹˜ ¶·ıÔÏÔÁ›·˜ π·ÙÚÈ΋˜ ™¯ÔÏ‹˜ ¶·ÓÂÈÛÙËÌ›Ô˘ πˆ·ÓÓ›ÓˆÓ ΔÔ̤·˜ ¶·ıÔÏÔÁ›·˜ π·ÙÚÈ΋˜ ™¯ÔÏ‹˜ ¶·ÓÂÈÛÙËÌ›Ô˘ πˆ·ÓÓ›ÓˆÓ

25

¶POTEINOMENH BIB§IO°PAºIA

31


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·1

› ÂȘ, ÌÔÚ Û ‹ ı ·  ›˜ · ÁÁÂÓÂ Ù·È ÛÂ Û˘ ‹ Û‡Ó‰ÚÔÌ Ó Ô Ô Û ›Ï  fi Ó Ê Ô ‹ Î fi Ú› Ó· Ë·ÙÈ ·›Ì· ÌÔ ·Ù‡ÂÈ · Ï¿ÛÌ·Ù·, Ù Ô  Û Ù Ô Ô Û Â Ú Ó  Ó , È fi ›ˆ Ù Ì ‰ ˘ ÂȉÈÛ ÂÙ·È fi È̤˜ ÏÈÈ Ô˘ ÌÂÙÚ›Ô ˘ÂÚı˘ÚÂÔ Ù ·ÙÔ˜ Ê·›Ó Ì Ó ‡ ˆ ˘ ÷ÌËϤ˜ Ù Â Ó Ô Ó ¿  ›Ó Ô · Ë Ó Ì È ÛË Î·È ÚÈψÛË Ô Ó· ˘ÔÛË ›Ó·È Ë  Úȷ΋ ›Â · ηٷӿ Â Ë È Ù Ú fï˜ Î·È ‹ Ú Ù Î ¤ È · Ì Ù Ó  ∏ Ë · · ‚Ï Ù˘ ¿ÓÂÈ Ù fiÊËÛ˘. . π‰È·›ÙÂÚ Ë˜ ‰È·‚‹ ·ÏÏ¿ ·˘Í · ‰ È Ò · ‰ ‰˘Û·ÔÚÚ Ù Ú fi · · Û È Ì ¯  ‹ Î  Û · ÂÈ· ˜. √ Û ·ÏÈο  Âȷο ÓÔ ÙËÓ ·ÒÏ Ó‡̷ÙÔ Î¿ ÂÁÎÂÊ Â Ô · Ì Î·Ú‰È·ÁÁ È Ó È Â Ó Ô Á Ò Á Ó Ó ·  ˆ ÛÔÙ‹Ù ‚·ˆÓ ·Ûı Í¿ÓÂÈ Ù· Á¿ÏˆÓ Ô ·¯‡Û·ÚÎ · Î·È ÙË Â Ù ¯Ú‹ÛË ·˘ Ì fi Ë Ù Ù Ë Û fi Û Ó Ô ¯ Û ˆ ˘ Ï Ô ÙË Û ÙËÓ Á¿ÏÔ  ηٷӿ Ë ÌÂÈÒÓÂÈ ›Ù·È ÚÈÓ ›Ó ı› Û Ì  ٠ÛÙ·Ûȷ΋ Ê Á · Ë Ë Ù Ï Ú Û Ô Ô · Ú ¯ ‚  Ó ·ÙÔÚ ÂÓ‹ , fiÙ· ·ÙfiÓ Ó· Ôηډ›Ô˘ È Ù· ‰˘ÛÌ ¿ÛÎËÛË. ∏ ˘ · Ì Â›Ó·È ‰˘Ó Î ‹ Î ˘ ˜ È Ô Ù Ò Ù ı · Ì · ˜ Î ˆ Ù¿Á¯Ë ¿ÁÌ·ÙÔ ·È ÙË Û Ì Ôͤ· Û ÎÔ‡ ÂÌÊÚ ıÂÚ‹ ÛÙËı È ‚¿ÚÔ˘˜ Î · Ù ›˜ Ù Â · Û Ó ‚ Â Ì Â ı Â Ì Û  Â È Û · ÛÂȘ ˘ ÂÚÈ ÛıÂÓ›˜ ΋ Á›ÓÂÙ·  ÂÁ¯ÂÈÚ‹ È Û ÂÙ·È Û · Ú‡ÙËÙ· ÙÔ Ù Û ˜ ›Ó · ‹ Á Ï Á  ˘ ˘ Ô Ú Ô È  · ·ÁÁ ̷ÚÌ ¤Ú˜ ÛÙÈ΋ ÎÔÏÈ΋˜ ÙÔÓ 7 ËÌ · fiÙ·Ó Ë Û Ù ·ÁÁÂÈÔÏ· È · · È ¯ Ì ‰ ¿ ¿ Ï fi ‚ ˘ Û È Ì Ô Â ˘ Ù  È Ù·  ‹ ‰ÂÓ Ú¯›˙ÂÈ Âȷο Û ÛË Ù˘ · ˘ ÌÂÈÒÓ ÈÔÏ·ÛÙÈΠηډȷÁÁ Ë Û Â › Á Á  ‹ Á ∂ Ú · Ô . ¯ Ë · Ì ÓfiÛÔ Â ˆ˜ Ù·Ó Ë ‡Ó‰ÚÔ ›ˆÛË Ô‡Ù ÂÊ·ÓÈ·›· η̄˘ fi ‚ Ê·ÓÈ·›· Û Ù È ¿ Û  Ú Â · ‹  Ú Ó Â Ë ˜ ı Ù · ÚÔ˜ Ì ÛÙ ‡ ÈÔ Ê·ÓÈ·›· Ô‡Ù ˆ˜ ·ÛıÂÓ›˜ Â›Ó·È ÔÏ ·ÔÚÙÔÛÙ ˜  ‹ · ™ Á Ù Â ˆ . ı Á Ë › · Û Ù Ó · ÙÈ΋˜ ·È Û Â¤Ì‚ ¯Ë). ∞ Ê·Ú̷΢ Ô‚¿ÏÏÔÓÙ ÚÈÓ ÙËÓ Ó ÛÙËı¿Á  Ë ˜ ˘ Ù ‹ Ù ˘ fi Û Ô  ˆ  · Û › Ù˘ ¿ÛÂˆÓ ÛıÂÓ›˜ Ô‡ÊÈÛË ÏÂÔÓÂÎÙ ÌÂÓÒÓ Â΂ Èο Û · ‹˜ (·Ó·Î Ù Û ˆ ˘ Ë ˙ ‰ Ú È · Â Ó Ù ¯ ˆ Ë Á Ù Ù Â ÚÔ ÔÈfi  ÙËÓ Â›ˆÛË ÛÙ·Ù›Ó˘ ÛÌ·ÙÈ΋ Ì ÚÔ˜ ÙËÓ ˘Á¯¿ÓÂÈ Ì Â Ë Ù Ï È Û Â  Ë Ù Â Á Ô ‹  ˜ Ú · Ë Ô „ ›ÛÔ˘ . ∏ ¯ Ú¿Î·Ì ·ÎÙÈ΋ Ë Â›Ó·È ÂÍ ‰··ÓËÚ‹ ÛÂÈ ÂÓ·ÏÏ ÓÈ·›·˜ · ¤ ›Ó · Ï Ï Ê Â ˘ Â Ù Ô Ù Ô Û Û Ó  È Ô · Ù ·ÔÚ › Ó·  ¯ÚfiÂfiÌÂÓË Î·È ÌÔÚ ÂÁ¯Â›ÚËÛË . ∏ ÂÈÛÓ ÛıÂÓ›˜ Ì Ó ¿ · Ò Î Ó È Â Â Ù Û ı Ë È Û Ú È · ·  ٠ÂÙÂÁ¯ Ó Û˘ÛÙ‹Ó √È ‚-·Ô ·ÙËÁÔڛ˜  Π. ¢ ¿ ˜ È .  ·Ì¤Ûˆ˜ Ì ‰ Ë Ú È Ù Â · ‹ Ù  ‚ fi Û Ë ‰È· ·È Û ÙȘ ÂÚÈÛ Û·Î¯·ÚÒ‰ ÓÈÛÙ¤˜ Î Ë Ù˘ ·Ó · Û ˘ Î È Ô  Ù Â Ò ÂÓ¤ÛÈÌË Û Û Ù Ë Â , Û È Ì · È  ¿ÛıÌ Ó ·ÓÙ ·ÓÙÈÌÂÙÒ ıÂÈ· ‹ Ì ‹ ηډȷÏÔÁ‹˜ ÛÙË ¿ È ˜   Ô Ô Â Ó Û Ï‡ÛË ÛÙËÓ ˜ Ô fi Ë Ì Ó Ù ˘ Â Ò ›· Ó ·ÓÈ· ·Î· Ú Ú·ÎÙÈ΋  Ú¯ÂÈ ÛÙÂÊ È ÔÈ ÓÂfiÙ ¤ÔÓ Ê¿ÚÌ ¿ Ï ·   Î ˘ Ó ÓÈ· ·ÔÊ È Ó ˘ · Ò Û Ù Ù Ó Ó Û ‡ È ÔÎÏ Ùfi˜ ¿ ·È ‰ÂÓ ıˆÚÔ ÙˆÓ ‚-· ÔÏfiÏ˘ Î Ù·Û˘, ÂÎ ‡ Ó Ú Í Â ¤ Ù ·  ÎÏÂÈÛÙ¤˜ Ù · ˘ Â Ì ˜ ˜ Ë ‹ ˜ Ù Î Ì·Ù· È·ÊÔÚ¤ ·ÚÙËÚÈ· ¿Ú¯Ô˘Ó ‰ ÌÂÈÔÓÂÎÙ‹  ˘ · ›ÏÂÎÙ˘ Ù ˜ ˆ Ó › ˘ · Ô ‚ Ê·Ó›˙ ÚÎÂÈ·. μÂ Ù·È Ó· ÂÌ Â ›Ó ΋ ·ÓÂ¿ · Ê Ó Â ·˘ÙÔ‡˜ ‰ ÈÌÒÓ·˜ ÚÔÈ ·fi  à ˜ . ˜ · Ë › Ï Ï fi ∏ Ï ÚÔ Ù˘ ÌÂÙÔ Ù·Í˘

Ù·Í˘ T˘ ™‡Ó

˜ ™‡Ó ¢È¢ı˘ÓÙ‹


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·2

π√À¡π√™ 2007

¶·ıÔÏÔÁÈΤ˜ ∫·Ù·ÛÙ¿ÛÂȘ Ô˘ ™˘Óԉ‡ÔÓÙ·È ·fi ÷ÌËÏ‹ ÃÔÏËÛÙÂÚfiÏË ÃÚ‹ÛÙÔ˜ ∞ÓÙÒÓÔÁÏÔ˘ ∂›ÎÔ˘ÚÔ˜ ∫·ıËÁËÙ‹˜ ¶·ıÔÏÔÁ›·˜ π·ÙÚÈ΋˜ ™¯ÔÏ‹˜ ¢ËÌÔÎÚÈÙ›Ԣ ¶·ÓÂÈÛÙËÌ›Ô˘ £Ú¿Î˘

∞. ™˘ÁÁÂÓ›˜ ·ı‹ÛÂȘ ∏ ·‚ËÙÔÏÈÔÚˆÙÂïÓ·ÈÌ›· Â›Ó·È Û¿ÓÈ· ÓfiÛÔ˜, ÎÏËÚÔÓÔÌÔ‡ÌÂÓË Ì ÙÔÓ ˘ÔÏÂÈfiÌÂÓÔ ·˘ÙÔۈ̷ÙÈÎfi ¯·Ú·ÎÙ‹Ú·. X·Ú·ÎÙËÚ›˙ÂÙ·È ·fi ȉȷ›ÙÂÚ· ¯·ÌËÏ¿ Â›‰· ¯ÔÏËÛÙÂÚfiÏ˘ Î·È ÙÚÈÁÏ˘ÎÂÚȉ›ˆÓ ÛÙÔ Ï¿ÛÌ·. OÊ›ÏÂÙ·È ÛÙËÓ ¤ÏÏÂÈ„Ë ÂÓ˙‡ÌÔ˘ Ô˘ Â›Ó·È ˘‡ı˘ÓÔ ÁÈ· ÙËÓ ÂÓ‰Ô΢ÙÙ¿ÚÈÔ ÌÂÙ·ÊÔÚ¿ ÙˆÓ ÏÈȉ›ˆÓ ÛÙÔ ¤ÓÙÂÚÔ Î·È ÙÔ ‹·Ú Ì ·ÔÙ¤ÏÂÛÌ· ÙÔÓ ÌË Û¯ËÌ·ÙÈÛÌfi ÙˆÓ ¯˘ÏÔÌÈÎÚÒÓ Î·È ÙˆÓ Ôχ ¯·ÌËÏ‹˜ ˘ÎÓfiÙËÙ·˜ ÏÈÔÚˆÙÂïÓÒÓ (VLDL). Δ· ·ÚÈ· Û˘ÌÙÒÌ·Ù· Ù˘ ÓfiÛÔ˘ ÚÔ¤Ú¯ÔÓÙ·È ·fi ÙÔ ÎÂÓÙÚÈÎfi Ó¢ÚÈÎfi Û‡ÛÙËÌ·, ÂÌÊ·Ó›˙ÔÓÙ·È ÛÙË ‰Â‡ÙÂÚË ‰ÂηÂÙ›· Ù˘ ˙ˆ‹˜ Î·È ÔÊ›ÏÔÓÙ·È Î˘Ú›ˆ˜ ÛÙËÓ ·‰˘Ó·Ì›· ·ÔÚÚfiÊËÛ˘ Î·È ÌÂÙ·ÊÔÚ¿˜ ÙˆÓ ÏÈÔ‰È·Ï˘ÙÒÓ ‚ÈÙ·ÌÈÓÒÓ Î·È È‰È·›ÙÂÚ· Ù˘ ‚ÈÙ·Ì›Ó˘ ∂ ÛÙÔ˘˜ ÈÛÙÔ‡˜. √È ÂÙÂÚfi˙˘ÁÔÈ ‰ÂÓ ÂÌÊ·Ó›˙Ô˘Ó ¯·ÌËϤ˜ Û˘ÁÎÂÓÙÚÒÛÂȘ ÏÈȉ›ˆÓ ÛÙÔ ·›Ì· Ô‡ÙÂ Û˘ÌÙÒÌ·Ù·. ∏ ÔÈÎÔÁÂÓ‹˜ ˘Ô‚ËÙ·ÏÈÔÚˆÙÂïÓ·ÈÌ›· ÔÊ›ÏÂÙ·È Û ¤Ó· ·ÚÈıÌfi ÌÂÙ·ÏÏ¿ÍÂˆÓ Ô˘ ·Ú·ÙËÚÔ‡ÓÙ·È ÛÙÔ ÁÔÓ›‰ÈÔ Ù˘ ·ÔÚˆÙ½Ó˘ μ (ApoB) Î·È ÔÈ Ôԛ˜ ¤¯Ô˘Ó Û·Ó ·ÔÙ¤ÏÂÛÌ· ÙËÓ ·Ú·ÁˆÁ‹ ÌÔÚ›Ô˘ ApoB100 ÌÈÎÚfiÙÂÚÔ˘ Ì‹ÎÔ˘˜ ·fi ÙÔ Ê˘ÛÈÔÏÔÁÈÎfi. ΔÔ Ï‹ÚÔ˘˜ Ì‹ÎÔ˘˜ ApoB-100 ÌfiÚÈÔ Â›Ó·È ··Ú·›ÙËÙÔ ÁÈ· ÙËÓ Û‡ÓıÂÛË Î·È ·¤ÎÎÚÈÛË ·fi ÙÔ ‹·Ú Ù˘ VLDL. ∂ÈϤÔÓ Ë ÌÈÎÚfiÙÂÚÔ˘ Ì‹ÎÔ˘˜ ApoB ÂÌÊ·Ó›˙ÂÈ Ù·¯‡ÙÂÚË Î¿ı·ÚÛË. 2,3 ŒÙÛÈ ÔÈ ·ÛıÂÓ›˜ ·˘ÙÔ› ¤¯Ô˘Ó ¯·ÌËÏ¿ Â›‰· ÛÙÔ Ï¿ÛÌ· Ù˘ ÔÏÈ΋˜ (Tc) Î·È Ù˘ ¯ÔÏËÛÙÂÚfiÏ˘ ÙˆÓ ¯·ÌËÏ‹˜ ˘ÎÓfiÙËÙ·˜ ÏÈÔÚˆÙÂïÓÒÓ (LDL), Ù˘ ApoB Î·È Û˘Ó‹ıˆ˜ Î·È ÙˆÓ ÙÚÈÁÏ˘ÎÂÚȉ›ˆÓ (TG). ∏ ÓfiÛÔ˜ ÌÂÙ·‰›‰ÂÙ·È Ì ÙÔÓ ·˘ÙÔۈ̷ÙÈÎfi ÂÈÎÚ·ÙÔ‡ÓÙ· ¯·-

2

Ú·ÎÙ‹Ú· Ì ·ÔÙ¤ÏÂÛÌ· ÔÈ ÂÙÂÚÔ˙˘ÁÒÙ˜ Ó· ¤¯Ô˘Ó Û˘ÁÎÂÓÙÚÒÛÂȘ ÛÙÔ Ï¿ÛÌ· ÔÏÈ΋˜ Î·È LDL ¯ÔÏËÛÙÂÚfiÏ˘ ÛÙÔ 1/3 ¤ˆ˜ 1/4 ÙÔ˘ Ê˘ÛÈÔÏÔÁÈÎÔ‡ (¶›Ó·Î·˜ 1) 4. Δ· ·ÓÙ›ÛÙÔȯ· Â›‰· Ù˘ ApoB Â›Ó·È 25-50%. √È ÔÌÔ˙˘ÁÒÙ˜ ÂÌÊ·Ó›˙Ô˘Ó Ú·ÎÙÈο ·‚ËÙ·ÏÈÔÚˆÙÂïÓ·ÈÌ›· (ApoB<5%). ™Â ÔÚÈṲ̂ÓÔ˘˜ Ù‡Ô˘˜ ÔÈÎÔÁÂÓÔ‡˜ ˘Ô‚ËÙ·ÏÈÔÚˆÙÂïÓ·ÈÌ›·˜ fï˜, ‰ÂÓ ·Ú·ÙËÚÂ›Ù·È Ë ·Ú·ÁˆÁ‹ ‚Ú·¯Â›·˜ ApoB Î·È Ë ·ÈÙ›· Ù˘ ÓfiÛÔ˘ Û ·˘Ù¤˜ ÙȘ ÂÚÈÙÒÛÂȘ ·Ú·Ì¤ÓÂÈ ·‰È¢ÎÚ›ÓÈÛÙË. ∏ ÓfiÛÔ˜ ÛÙËÓ ÂÙÂÚfi˙˘ÁË ÌÔÚÊ‹ Â›Ó·È Û¯ÂÙÈο Û¿ÓÈ· ·Ó Î·È ·Ó¢ڛÛÎÔÓÙ·È ÂÚÈÛÙ·ÙÈο ÛÙÔÓ ¤ÏÂÁ¯Ô ÚÔ˘Ù›Ó·˜ Ô˘ Á›ÓÂÙ·È ÛÙÔÓ ÁÂÓÈÎfi ÏËı˘ÛÌfi. Δ· ¿ÙÔÌ· ·˘Ù¿ Â›Ó·È Û˘Ó‹ıˆ˜ ·Û˘Ìو̷ÙÈο Î·È ¤¯Ô˘Ó ¯·ÌËÏfiÙÂÚÔ Î›Ó‰˘ÓÔ ÂÌÊ¿ÓÈÛ˘ ÛÙÂÊ·ÓÈ·›·˜ ÓfiÛÔ˘ ·fi ÙÔÓ ÁÂÓÈÎfi ÏËı˘ÛÌfi 6. √ÚÈṲ̂Ó˜ ÊÔÚ¤˜ ·ÚÔ˘ÛÈ¿˙Ô˘Ó ·Û˘Ìو̷ÙÈ΋ ·‡ÍËÛË ÙˆÓ ÙÚ·ÓÛ·ÌÈÓ·ÛÒÓ Î·È Û·Ó›ˆ˜ Â˘Ú‹Ì·Ù· ÏÈÒ‰Ô˘˜ ‰È‹ıËÛ˘ ÙÔ˘ ‹·ÙÔ˜ 7. ∏ ÂÏ¿ÙÙˆÛË Ù˘ ·¤ÎÎÚÈÛ˘ ÙˆÓ ÙÚÈÁÏ˘ÎÂÚȉ›ˆÓ ·fi ÙÔ ‹·Ú, ÏfiÁˆ ÌÂȈ̤Ó˘ ·Ú·ÁˆÁ‹˜ VLDL, ¤¯ÂÈ ˆ˜ ·ÔÙ¤ÏÂÛÌ· ÙËÓ ÂÓ·fiıÂÛË ÙÔ˘˜ ÛÙ· Ë·ÙÔ·ÙÙ·Ú· Î·È ÙËÓ ·Ó¿Ù˘ÍË ÏÈÒ‰Ô˘˜ ‰È‹ıËÛ˘ 2. ΔÔ ÙÂÏÈÎfi ·ÔÙ¤ÏÂÛÌ· Â›Ó·È Û˘Ó¿ÚÙËÛË Î·È ÙÔ˘

Ú˘ıÌÔ‡ Û‡ÓıÂÛ˘ ÙˆÓ ÙÚÈÁÏ˘ÎÂÚȉ›ˆÓ. ∏ ·fiÊ·ÛË ‰ÈÂÓ¤ÚÁÂÈ·˜ ‚ÈÔ„›·˜ ‹·ÙÔ˜ ÁÈ· ÙËÓ ÙÂÎÌËÚ›ˆÛË Ù˘ ‰È¿ÁÓˆÛ˘ ÌÔÚ› Ó· ÛÙËÚȯı› ÛÙÔÓ ��ÏÈÓÈÎfi Î·È ÂÚÁ·ÛÙËÚÈ·Îfi ¤ÏÂÁ¯Ô ÁÈ· ÈÔÁÂÓ‹, ·ÓÔÛÔÏÔÁÈ΋ Î·È ÙÔÍÈ΋ ‚Ï¿‚Ë ÙÔ˘ ‹·ÙÔ˜, ÛÙÔ ¯·Ú·ÎÙËÚÈÛÙÈÎfi ÏÈȉ·ÈÌÈÎfi ÚÔÊ›Ï Ù˘ ˘Ô‚ËÙ·ÏÈÔÚˆÙÂïÓ·ÈÌ›·˜, ÛÙËÓ ·Ó‡ÚÂÛË ·ÚÔÌÔ›Ô˘ ÏÈȉ·ÈÌÈÎÔ‡ ÚÔÊ›Ï Û ¤Ó· Û˘ÁÁÂÓ‹ ÚÒÙÔ˘ ‚·ıÌÔ‡ Î·È ‚¤‚·È· ÌÔÚ› Ó· ÂÍ·ÙÔÌÈ΢ı› 8.9. √È ÔÌfi˙˘Á˜ ÌÔÚʤ˜ Â›Ó·È Û¿ÓȘ Î·È ÌÔÚÔ‡Ó Ó· ·ÚÔ˘ÛÈ¿ÛÔ˘Ó Û˘ÌÙÒÌ·Ù· ·Ó¿ÏÔÁ· Ù˘ ·‚ËÙ·ÏÈÔÚˆÙÂïÓ·ÈÌ›·˜. ∏ ‰È¿ÎÚÈÛË ·fi ÙËÓ ‰Â‡ÙÂÚË ÌÔÚ› Ó· Á›ÓÂÈ Ì ‚¿ÛË ÙÔ ÏÈȉ·ÈÌÈÎfi ÚÔÊ›Ï (LDLc Î·È apoB) ÙˆÓ ÁÔÓ¤ˆÓ. ™ÙËÓ ÔÌfi˙˘ÁË ˘Ô‚ËÙ·ÏÈÔÚˆÙÂ˚Ó·ÈÌ›· ·ÌÊfiÙÂÚÔÈ ·ÚÔ˘ÛÈ¿˙Ô˘Ó ÙÈ̤˜ ¯·ÌËÏfiÙÂÚ˜ ÙÔ˘ ‹ÌÈÛ˘ ÙˆÓ Ê˘ÛÈÔÏÔÁÈÎÒÓ.

μ. ∂›ÎÙËÙ˜ ηٷÛÙ¿ÛÂȘ (‰Â˘ÙÂÚÔ·ı›˜) ¶ÔÏϤ˜ ·ı‹ÛÂȘ Ô˘ Û˘Ó‰˘¿˙ÔÓÙ·È Ì η΋ ıÚ¤„Ë Î·È ÂÈ‚·Ú˘Ì¤ÓË ÁÂÓÈ΋ ηٿÛÙ·ÛË ·ÔÙÂÏÔ‡Ó ·ÈÙ›· ¯·ÌËÏ‹˜ ¯ÔÏËÛÙÂÚfiÏ˘ fiˆ˜ Ù· ÓÂÔÏ¿ÛÌ·Ù·, ÔÈ ‚·ÚȤ˜ ÏÔÈÌÒÍÂȘ, Ë ‚·ÚÈ¿ Ë·ÙÈ΋ ÓfiÛÔ˜ Î·È Ù· Û‡Ó‰ÚÔÌ· ‰˘Û·ÔÚÚfiÊËÛ˘. ™Ù· ÙÂÏÂ˘Ù·›· Û ‹Ș ·‰È¿ÁÓˆ-

¶›Ó·Î·˜ 1: §Èȉ·ÈÌÈΤ˜ ·Ú¿ÌÂÙÚÔÈ Û ·ÛıÂÓ›˜ Ì ÔÈÎÔÁÂÓ‹ ÂÙÂÚfi˙˘ÁÔ ˘Ô‚ËÙ·ÏÈÔÚˆÙÂïÓ·ÈÌ›· Û ۇÁÎÚÈÛË Ì ÙËÓ ÔÌ¿‰· ÂϤÁ¯Ô˘ ¶·Ú¿ÌÂÙÚÔ˜ Tc (mg%) LDL-c (mg%) HDL-c (mg%) TG (mg%) ApoB (mg%)

∞ÛıÂÓ›˜ (n=7) 88 ± 12 28 ± 12 56 ± 12 28 ± 16,3 23,3 ± 6,5

√Ì¿‰· ÂϤÁ¯Ô˘ (n=7) 184 ± 28 120 ± 24 52 ± 16 90 ± 31 96,3 ± 16,6

P <0,001 <0,001 NS <0,001 <0,001

√È ÙÈ̤˜ ÂÎÊÚ¿˙ÔÓÙ·È ˆ˜ Ë Ì¤ÛË ÙÈÌ‹ ± ÛÙ·ıÂÚ‹ ·fiÎÏÈÛË. Tc: ÔÏÈ΋ ¯ÔÏËÛÙÂÚfiÏË, LDL-c: LDL ¯ÔÏËÛÙÂÚfiÏË, HDL-c: HDL ¯ÔÏËÛÙÂÚfiÏË, TG: ΔÚÈÁÏ˘ÎÂÚ›‰È·, ApoB: ·ÔÚˆÙ½ÓË μ, NS: ÌË ÛËÌ·ÓÙÈ΋ ‰È·ÊÔÚ¿


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·3

¶∞£√ºÀ™π√§√°π∞ ÂÓ˙‡ÌÔ˘ Ô˘ Â›Ó·È ˘‡ı˘ÓÔ ÁÈ· ÙË ÌÂÙ·ÊÔÚ¿ ÂÛÙ¤ÚˆÓ ¯ÔÏËÛÙÂÚfiÏ˘ ·fi Ù˘ ˘„ËÏ‹˜ ˘ÎÓfiÙËÙ·˜ ÏÈÔÚˆÙ½Ó˜ (HDL) ÛÙȘ VLDL. ΔÔ Â‡ÚÔ˜ ÙˆÓ ÌÂÙ·‚ÔÏÒÓ Ù˘ LDL ¯ÔÏËÛÙÂÚfiÏ˘ ÔÈΛÏÂÈ ·Ó Î·È ‰ÂÓ Â›Ó·È ÙfiÛÔ ÛËÌ·ÓÙÈÎfi fiÛÔ ÛÙÔÓ ˘Ôı˘ÚÂÔÂȉÈÛÌfi (¶›Ó·Î·˜ 2) 12.

ÛÙ˜ ÌÔÚʤ˜ ÔÊÂÈÏfiÌÂÓ˜ Û ÎÔÈÏÈÔοÎË ˘¿Ú¯ÂÈ ¯·ÌËÏ‹ ÔÏÈ΋ ¯ÔÏËÛÙÂÚfiÏË Î·È ¯·ÌËÏ‹ HDLc ÔÈ Ôԛ˜ Û˘Û¯ÂÙ›˙ÔÓÙ·È Ì ¯·ÌËÏ¿ Â›‰· ÏÂ˘ÎˆÌ·Ù›Ó˘ Î·È ˘fi¯ÚˆÌË ·Ó·ÈÌ›· 10. ∏ ÛËÌ·ÓÙÈÎfiÙÂÚË fï˜ ·ÈÙ›· Â›ÎÙËÙ˘ ˘Ô‚ËÙ·ÏÈÔÚˆÙÂïÓ·ÈÌ›·˜ Â›Ó·È Ô ˘ÂÚı˘ÚÂÔÂȉÈÛÌfi˜. ∏ ·Ú·ÙËÚÔ‡ÌÂÓË ÂÏ¿ÙÙˆÛË Ù˘ ÔÏÈ΋˜ Î·È LDL ¯ÔÏËÛÙÂÚfiÏ˘ ÔÊ›ÏÂÙ·È ÛÙÔÓ ·˘ÍË̤ÓÔ Î·Ù·‚ÔÏÈÛÌfi ÙˆÓ LDL ̤ۈ Ù˘ ÂÓÂÚÁÔÔ›ËÛ˘ ÙˆÓ LDL ˘Ô‰Ô¯¤ˆÓ ÛÙÔ ‹·Ú ·fi ÙËÓ ı˘ÚÔÍ›ÓË. ∏ HDL ¯ÔÏËÛÙÂÚfiÏË ·Ú·Ì¤ÓÂÈ ·ÌÂÙ¿‚ÏËÙË ‹ ÂÏ·ÙÙÒÓÂÙ·È ÏfiÁˆ Ù˘ Â›‰Ú·Û˘ Ù˘

ı˘ÚÔ͛Ӣ ÛÙË ‰Ú·ÛÙËÚÈfiÙËÙ· Ù˘ ÚˆÙ½Ó˘ ÌÂÙ·ÊÔÚ¿˜ ÂÛÙ¤ÚˆÓ ¯ÔÏËÛÙÂÚfiÏ˘ (CETP), ÙÔ˘

™Â οı ¿ÙÔÌÔ Ì ¯·ÌËÏ¿ ÏÈ›‰È· ÛÙÔ ·›Ì· Î·È Û¯ÂÙÈο ηϋ ÁÂÓÈ΋ ηٿÛÙ·ÛË Â›Ó·È Èı·Ó‹ Ë ‰È¿ÁÓˆÛË Ù˘ ÔÈÎÔÁÂÓÔ‡˜ ˘Ô‚ËÙ·ÏÈÔÚˆÙÂïÓ·ÈÌ›·˜, ÂÊfiÛÔÓ ·ÔÎÏÂÈÛı› Ô ˘ÂÚı˘ÚÂÔÂȉÈÛÌfi˜ Î·È ‹È· Û‡Ó‰ÚÔÌ· ‰˘Û·ÔÚÚfiÊËÛ˘, ÂÓÒ ÌÈ· ·ÓÂÍ‹ÁËÙË ·‡ÍËÛË ÙˆÓ ÙÚ·ÓÛ·ÌÈÓ·ÛÒÓ Ì ˘ÂÚ˯ÔÁÚ·ÊÈο Â˘Ú‹Ì·Ù· ÏÈÒ‰Ô˘˜ ‰È‹ıËÛ˘ ÙÔ˘ ‹·ÙÔ˜ ÌÔÚ› Â›Û˘ Ó· ˘ÔÎÚ‡ÙÂÈ ÙË ÓfiÛÔ.

¶›Ó·Î·˜ 2: ªÂÙ·‚ÔϤ˜ ÛÙȘ ÏÈȉ·ÈÌÈΤ˜ ·Ú·Ì¤ÙÚÔ˘˜ ˘ÂÚı˘ÚÂÔÂȉÈÎÒÓ ·ÛıÂÓÒÓ (n=47) Ì ÙËÓ ·ÔηٿÛÙ·ÛË Ù˘ ı˘ÚÂÔÂȉÈ΋˜ ÏÂÈÙÔ˘ÚÁ›·˜ ¶·Ú¿ÌÂÙÚÔÈ TSH (mU/l) Tc (mg%) LDL-c (mg%) HDL-c (mg%) TG (mg%) ApoB (mg%)

∞ÛıÂÓ›˜ ÚÔ ıÂÚ·›·˜ <0,01 179,6 ± 43 107 ± 116 50 ± 13,2 100,9 ± 37,2 82 ± 27

∞ÛıÂÓ›˜ ÌÂÙ¿ ıÂÚ·›· 1,0 232,4 ± 48,4 148 ± 44 59,2 ± 16,8 120 ± 55,4 113 ± 30

P <0,005 <0,005 <0,005 <0,005 <0,05 <0,005

√È ÙÈ̤˜ ÂÎÊÚ¿˙ÔÓÙ·È ˆ˜ Ë Ì¤ÛË ÙÈÌ‹ ± ÛÙ·ıÂÚ‹ ·fiÎÏÈÛË. Tc: ÔÏÈ΋ ¯ÔÏËÛÙÂÚfiÏË, LDL-c: LDL ¯ÔÏËÛÙÂÚfiÏË, HDL-c: HDL ¯ÔÏËÛÙÂÚfiÏË, TG: ΔÚÈÁÏ˘ÎÂÚ›‰È·, ApoB: ·ÔÚˆÙ½ÓË μ, TSH: £˘ÚÂÔÂȉÔÙÚfiÔ˜ ÔÚÌfiÓË

μÈ‚ÏÈÔÁÚ·Ê›· 1.

Rader DJ, Brewer HB Jr: Abetalipoproteinemia: new insights in into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA 1993; 270: 865

2.

Schonfeld G et al.: Familial hypobetalipoproteinemia: genetics and metabolism. Cell. Mol. Life Sci. 2005 ; 62 :1372

3.

4.

Rader DJ: Primary hypolipidemias. In: David Humes, ed Kelley’s Textbook of Internal Medicine, forth ed. Philadelphia; Lippincott Williams & Wilkins, 2000; 90-92 Nizar E, Bruce W, Patterson B, Schonfeld G: Decreased production rates of VLDL Triglycerides and ApoB-100 in subjects heterozygous for Familial Hypobetalipoproteinemia. Arterioscler. Thromb. Vasc. Biol., 1999; 19: 2714

5.

Marsh JB, Welty FK, Lichtenestein AH et al: Apolipoprotein B metabolism in human: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 2002;162: 227

6.

Young SG: Recent progress in understanding apolipoprotein B. Circulation 1990; 82: 1574

7.

Ahmed A, Keeffe EB : Asymptomatic elevation of aminotransferase levels and fatty liver secondary to heterozygous hypobetalipoproteinemia. Am J Gastroenterol 1998; 93: 2598

8.

Bayard M et al: Nonalcoholic fatty liver disease. Am Fam Physician 2006; 11: 1961

9.

Castellano G, Garcia C, Gomez-Coronado D et al: Diffuse fatty liver in familial heterozygous hypobetalipoproteinemia. J Clin Gastroenterology 1997 ; 92 : 379

10. Ciacci C et al; Low plasma cholesterol: a correlate of nondiagnosed celiac disease in adults with hypochromic anemia. Am J Gastroenterol. 1999; 94: 1888 11. Duntas LH.: Thyroid disease and lipids. Thyroid 2002; 12: 287 12. Diekman M, Angelescu N, Endert E et al: Changes in plasma LDL and HDL cholesterol in hypo and hyperthyroid patients are related to changes in free thyroxine, not to polymorphisms in LDL receptor or CETP genes. J Clin Endocrinol Metab. 2000; 85: 1857

3


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·4

π√À¡π√™ 2007

ΔÔ ∞ÏÎÔfiÏ ˆ˜ ¶·Ú¿ÁÔÓÙ·˜ ∫ÈÓ‰‡ÓÔ˘ ÁÈ· ÙËÓ ∂ÌÊ¿ÓÈÛË ∫·Ú‰È·ÁÁÂÈ·ÎÒÓ ™˘Ì‚·Ì¿ÙˆÓ ∂. ¡¿ÎÔ˘, ∂ÈÛÙËÌÔÓÈÎfi˜ ™˘ÓÂÚÁ¿Ù˘ ÙÔ˘ ∂Í. π·ÙÚ›Ԣ ¢È·Ù·Ú·¯ÒÓ ÙÔ˘ ªÂÙ·‚ÔÏÈÛÌÔ‡ ÙˆÓ §Èȉ›ˆÓ

ª. ∂ÏÈÛ¿Ê, ∫·ıËÁËÙ‹˜ ¶·ıÔÏÔÁ›·˜ π·ÙÚÈ΋˜ ™¯ÔÏ‹˜ ¶·ÓÂÈÛÙËÌ›Ô˘ πˆ·ÓÓ›ÓˆÓ ΔÔ̤·˜ ¶·ıÔÏÔÁ›·˜ π·ÙÚÈ΋˜ ™¯ÔÏ‹˜ ¶·ÓÂÈÛÙËÌ›Ô˘ πˆ·ÓÓ›ÓˆÓ ™‡Ìʈӷ Ì ÚfiÛÊ·Ù· ‚È‚ÏÈÔÁÚ·ÊÈο ‰Â‰Ô̤ӷ Ë Î·Ù·Ó¿ÏˆÛË ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Û ÌÈÎÚ¤˜ ÔÛfiÙËÙ˜ Û˘Û¯ÂÙ›˙ÂÙ·È Ì ÌÂȈ̤ÓË Â›ÙˆÛË Î·Ú‰È·ÁÁÂȷ΋˜ ÓfiÛÔ˘ (1,2) Î·È ‰Ú· ÚÔÛٷ٢ÙÈο ÛÙȘ ÓÔËÙÈΤ˜ ÏÂÈÙÔ˘ÚÁ›Â˜ ÙÔ˘ ÂÁÎÂÊ¿ÏÔ˘(3). øÛÙfiÛÔ, ÙÔ ·ÏÎÔfiÏ ·˘Í¿ÓÂÈ ÙËÓ ·ÚÙËÚȷ΋ ›ÂÛË Î·È ÂÈϤÔÓ ‰˘ÛÎÔχÂÈ ÙËÓ ·ÒÏÂÈ· ‚¿ÚÔ˘˜ Û ˘¤Ú‚·Ú· Î·È ·¯‡Û·Úη ¿ÙÔÌ·. ∫·È Â›Ó·È ÁÓˆÛÙfi fiÙÈ Ë ˘¤ÚÙ·ÛË Â›Ó·È ·ÓÂÍ¿ÚÙËÙÔ˜ ·Ú¿ÁÔÓÙ·˜ ÎÈÓ‰‡ÓÔ˘ ÁÈ· ÙËÓ ÂÌÊ¿ÓÈÛË Î·Ú‰È·ÁÁÂÈ·ÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ (ÛÙÂÊ·ÓÈ·›·˜ ÓfiÛÔ˘ Î·È ·ÁÁÂÈ·ÎÒÓ ÂÁÎÂÊ·ÏÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ). ΔÔ ·ÏÎÔfiÏ ˆ˜ ·Ú¿ÁÔÓÙ·˜ ÎÈÓ‰‡ÓÔ˘. H ηٷӿψÛË ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Û˘Û¯ÂÙ›˙ÂÙ·È Ì ̷ÎÚÔ¯ÚfiÓȘ ÂÈÙÒÛÂȘ ÛÙÔÓ ·ÓıÚÒÈÓÔ ÔÚÁ·ÓÈÛÌfi ‰È· ̤Ûo˘ ÙÚÈÒÓ Ì˯·ÓÈÛÌÒÓ: Ù˘ ÙÔ͛ΈÛ˘, Ù˘ ÂÍ¿ÚÙËÛ˘ Î·È Ù˘ ¿ÌÂÛ˘ ‚ÈÔÏÔÁÈ΋˜ ‰Ú¿Û˘ (4). ∂ȉÈÎfiÙÂÚ·, ÛÙÔÓ ¶›Ó·Î· 1 Ê·›ÓÔÓÙ·È ÔÈ ÂȉڿÛÂȘ Ù˘ ηٷӿψÛ˘ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ(5), ÂÎÙfi˜ ·fi ÙËÓ Â›‰Ú·Û‹ ÙÔ˘˜ ÛÙÔ Î·Ú‰È·ÁÁÂÈ·Îfi Û‡ÛÙËÌ·. °È· ÙȘ ÂÚÈÛÛfiÙÂÚ˜ ·fi ·˘Ù¤˜ ÙȘ ηٷÛÙ¿ÛÂȘ ˘¿Ú¯ÂÈ ÌÈ· ‰ÔÛÔÂÍ·ÚÙÒÌÂÓË Û˘Û¯¤ÙÈ-

ÛË, ·ÊÔ‡ Ô Î›Ó‰˘ÓÔ˜ ·˘Í¿ÓÂÙ·È Ì ÙËÓ ·‡ÍËÛË Ù˘ ÚfiÛÏ˄˘ ·ÏÎÔfiÏ. AÏÎÔfiÏ Î·È ·ÚÙËÚȷ΋ ›ÂÛË. ™‡Ìʈӷ Ì ̛· ÌÂÙ·Ó¿Ï˘ÛË (6), ˘¿Ú¯ÂÈ ‰ÔÛÔÂÍ·ÚÙÒÌÂÓË Û˘Û¯¤ÙÈÛË ·Ó¿ÌÂÛ· ÛÙËÓ ÂÏ¿ÙÙˆÛË Ù˘ ηٷӿψÛ˘ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Î·È ÙËÓ ·Ú·ÙËÚÔ‡ÌÂÓË Ì›ˆÛË Ù˘ Û˘ÛÙÔÏÈ΋˜ ·ÚÙËÚȷ΋˜ ›ÂÛ˘ (™∞¶) Î·È Ù˘ ‰È·ÛÙÔÏÈ΋˜ ·ÚÙËÚȷ΋˜ ›ÂÛ˘ (¢∞¶). ªÂ›ˆÛË Ù˘ ηٷӿψÛ˘ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Î·Ù¿ 76% ·ÓÙÈÛÙÔȯ› Û Ì›ˆÛË Ù˘ ™∞¶ ηٿ 3,3 mmHg Î·È Ì›ˆÛË Ù˘ ¢∞¶ ηٿ 2,0 mmHg. Δ· ·ÓÙ›ÛÙÔȯ· ·ÔÙÂϤÛÌ·Ù· Û ·ÛıÂÓ›˜ Ì ˘¤ÚÙ·ÛË Â›Ó·È Ì›ˆÛË Ù˘ ™∞¶ ηٿ 3,9 mmHg Î·È Ù˘ ¢∞¶ ηٿ 2,4 mmHg, ÂÓÒ ÛÙÔ˘˜ ·ÛıÂÓ›˜ Ô˘ ·›ÚÓÔ˘Ó ·ÓÙÈ˘ÂÚÙ·ÛÈ΋ ·ÁˆÁ‹ Ì›ˆÛË Ù˘ ™∞¶ ηٿ 4,0 mmHg Î·È Ì›ˆÛË Ù˘ ¢∞¶ ηٿ 3,1 mmHg. ∏ Ì›ˆÛË ·˘Ù‹ Â›Ó·È È‰È·›ÙÂÚ· ÛËÌ·ÓÙÈ΋ ·Ó Ï¿‚ÂÈ Î·Ó›˜ ˘fi„Ë fiÙÈ Û‡Ìʈӷ Ì ÚfiÛÊ·Ù˜ ÌÂϤÙ˜ Ì›· ÂÏ¿ÙÙˆÛË Ù˘ ¢∞¶ ηٿ 2 mmHg ¤¯ÂÈ ˆ˜ ·ÔÙ¤ÏÂÛÌ· Ì›ˆÛË Ù˘ Â›ÙˆÛ˘ Ù˘ ˘¤ÚÙ·Û˘ ηٿ 17%, Ì›ˆÛË ÙÔ˘ ÎÈÓ‰‡ÓÔ˘ ÁÈ· ÛÙÂÊ·ÓÈ·›· ÓfiÛÔ (™¡) ηٿ 6% Î·È Ì›ˆÛË ÙÔ˘ ÎÈÓ‰‡ÓÔ˘ ÁÈ· ·Á-

¶π¡∞∫∞™ 1. √È ÂȉڿÛÂȘ Ù˘ ηٷӿψÛ˘ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ÛÙÔÓ ·ÓıÚÒÈÓÔ ÔÚÁ·ÓÈÛÌfi, ÂÎÙfi˜ ·fi ÙËÓ Â›‰Ú·Û‹ ÙÔ˘˜ ÛÙÔ Î·Ú‰È·ÁÁÂÈ·Îfi Û‡ÛÙËÌ·. ™¯ÂÙÈÎfi˜ ΛӉ˘ÓÔ˜ ∫›ÚÚˆÛË ÙÔ˘ ‹·ÙÔ˜ ΔÚ·˘Ì·ÙÈÛÌÔ› ¶·ÁÎÚ·ٛÙȉ· ∫·ÚΛÓÔ˜ Ù˘ ÛÙÔÌ·ÙÈ΋˜ ÎÔÈÏfiÙËÙ·˜ ∫·ÚΛÓÔ˜ ÙÔ˘ ÔÈÛÔÊ¿ÁÔ˘ ∫·ÚΛÓÔ˜ ÙÔ˘ ·¯¤Ô˜ ÂÓÙ¤ÚÔ˘ ∫·ÚΛÓÔ˜ ÙÔ˘ Ï¿Ú˘ÁÁ· ∫·ÚΛÓÔ˜ ÙÔ˘ Ì·ÛÙÔ‡ ∫·ÚΛÓÔ˜ ÙÔ˘ ÔÚıÔ‡

4

2 ÔÙ¿/Ë̤ڷ 1,6-3,0 1,1-1,4 1,3 1,9-2,3 1,5-1,6 1,0-1,4 1,2-1,6 1,2-1,4 1,1-2,3

8 ÔÙ¿/Ë̤ڷ 4,4-59,3 1,3-4,0 3,2 6,4-12,5 4,5-6,0 1,1-3,6 2,1-7,1 2,2-3,4 1,5-25,7

ÁÂȷο ÂÁÎÂÊ·ÏÈο (∞∂∂) ηٿ 15% (7).

ÂÂÈÛfi‰È·

¶·ÚfiÌÔÈ· ‹Ù·Ó Ù· ·ÔÙÂϤÛÌ·Ù· Ù˘ ÌÂϤÙ˘ INTERSALT (8, 9), ÛÙËÓ ÔÔ›· ¿Ó‰Ú˜ Ô˘ ¤ÈÓ·Ó 300-400 ml ·ÏÎÔfiÏ/‚‰ÔÌ¿‰· ›¯·Ó ηٿ ̤ÛÔ fiÚÔ ˘„ËÏfiÙÂÚË ™∞¶/¢∞¶ ηٿ 2,7/1,6 mmHg Û ۇÁÎÚÈÛË Ì ·˘ÙÔ‡˜ Ô˘ ‰ÂÓ ¤ÈÓ·Ó ·ÏÎÔÔÏÔ‡¯· ÔÙ¿, ÂÓÒ ¿Ó‰Ú˜ Ô˘ ¤ÈÓ·Ó ¿Óˆ ·fi 500 ml ·ÏÎÔfiÏ/ ‚‰ÔÌ¿‰· ›¯·Ó ·ÓÙ›ÛÙÔȯ· ·ÚÙËÚȷΤ˜ ȤÛÂȘ ηٿ 4,6/ 3,0mmHg ˘„ËÏfiÙÂÚ˜ ·fi ÙÔ ÁÂÓÈÎfi ÏËı˘ÛÌfi. ™ÙËÓ ›‰È· ÌÂϤÙË Ë Î·Ù·Ó¿ÏˆÛË ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Û Ôχ ÌÂÁ¿Ï˜ ÔÛfiÙËÙ˜ (>500 ml ·ÏÎÔfiÏ ÁÈ· ÙÔ˘˜ ¿Ó‰Ú˜ Î·È >300 ml ÁÈ· ÙȘ Á˘Ó·›Î˜) Û˘Û¯ÂÙ›ÛıËΠ̠ٷ Â›‰· Ù˘ ·ÚÙËÚȷ΋˜ ›ÂÛ˘ Î·È ÛÙ· ‰‡Ô ʇϷ. ™‡Ìʈӷ Ì ̛· ÌÂÙ··Ó¿Ï˘ÛË 61 ÚÔÔÙÈÎÒÓ ÌÂÏÂÙÒÓ(10), Ì›ˆÛË Ù˘ ™∞¶ ηٿ 4 mmHg Î·È Ù˘ ¢∞¶ ηٿ 2 mmHg ¤¯ÂÈ ˆ˜ ·ÔÙ¤ÏÂÛÌ· Ì›ˆÛË Ù˘ ıÓËÙfiÙËÙ·˜ ·fi ∞∂∂ ηٿ 18% Î·È Ì›ˆÛË Ù˘ ıÓËÙfiÙËÙ·˜ ·fi ÛÙÂÊ·ÓÈ·›· ÓfiÛÔ Î·Ù¿ 12%. øÛÙfiÛÔ, Û ÔÏϤ˜ ÌÂϤÙ˜ ·Ú·ÙËÚ‹ıËΠ·‡ÍËÛË Ù˘ ıÓËÙfiÙËÙ·˜ ·fi ™¡ Û ¿ÙÔÌ· Ô˘ ‰ÂÓ ¤ÈÓ·Ó ·ÏÎÔÔÏÔ‡¯· ÔÙ¿. ∂ÈϤÔÓ, Û ÔÚÈṲ̂Ó˜ ÂȉËÌÈÔÏÔÁÈΤ˜ ÌÂϤÙ˜ ·Ú·ÙËÚ‹ıËΠ̛· Û˘Û¯¤ÙÈÛË, Û¯‹Ì·ÙÔ˜ J, ·Ó¿ÌÂÛ· ÛÙËÓ Î·Ù·Ó¿ÏˆÛË ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Î·È Ù· Â›‰· Ù˘ ·ÚÙËÚȷ΋˜ ›ÂÛ˘(11, 12, 13). ™˘Û¯¤ÙÈÛË Ù˘ ηٷӿψÛ˘ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Ì ÙË ıÓËÙfiÙËÙ·. ¶ÔÏϤ˜ ÌÂϤÙ˜ ¤‰ÂÈÍ·Ó ÙË Û˘Û¯¤ÙÈÛË Ù˘ ηٷӿψÛ˘ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Ì ÙË ıÓËÙfiÙËÙ·. ™ÙÔÓ ¶›Ó·Î· 2 ÛËÌÂÈÒÓÔÓÙ·È ÔÚÈṲ̂Ó˜ ·fi ·˘Ù¤˜ ÙȘ ÌÂϤÙ˜, ηıÒ˜ Î·È Ë ÚÔÛÏ·Ì‚·ÓfiÌÂÓË ÔÛfiÙËÙ· ÙˆÓ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Ô˘ Û˘Û¯ÂÙ›˙Â-


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·5

¶APA°ONTE™ KIN¢YNOY Ù·È Ì ÙËÓ ÂÏ¿¯ÈÛÙË ıÓËÙfiÙËÙ· ·fi ™¡, ∞∂∂, ηıÒ˜ Î·È Ì ÙËÓ ÂÏ¿¯ÈÛÙË ÔÏÈ΋ ıÓËÙfiÙËÙ·. Y¿Ú¯ÂÈ Ì›· Û˘Û¯¤ÙÈÛË Û¯‹Ì·ÙÔ˜ J ‹ U ·Ó¿ÌÂÛ· ÛÙËÓ ÔÛfiÙËÙ· ÙˆÓ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Ô˘ ηٷӷÏÒÓÂÙ·È Î·È ÙË ıÓËÙfiÙËÙ· ·fi ÛÙÂÊ·ÓÈ·›· ÓfiÛÔ, Ì ÙÔ Î·ÙÒÙÂÚÔ fiÚÈÔ Ù˘ ÁÚ·ÊÈ΋˜ ·Ú¿ÛÙ·Û˘ Ó· ·Ú·ÙËÚÂ›Ù·È ÛÙ· ‰‡Ô ÔÙ¿ ÙËÓ Ë̤ڷ ÁÈ· ÙÔ˘˜ ¿Ó‰Ú˜ (20-24 g ÔÈÓÔÓ‡̷ÙÔ˜) Î·È ÛÙÔ ¤Ó· ÔÙ��� ÙËÓ Ë̤ڷ ÁÈ· ÙȘ Á˘Ó·›Î˜ (10-12 g ÔÈÓÔÓ‡̷ÙÔ˜)(5). ™Â Ì›· ÌÂϤÙË Ô˘ ¤ÁÈÓ Û ¿Ó‰Ú˜, ¿ÁÁÏÔ˘˜ ÁÈ·ÙÚÔ‡˜ (ÌÂϤÙË Male-British doctors) ÂÎÙÈÌ‹ıËÎÂ Ë ıÓËÙfiÙËÙ· ·fi ™¡(14). ™‡Ìʈӷ Ì ٷ ‰Â‰Ô̤ӷ Ù˘ ÌÂϤÙ˘ ÛÙ· ¿ÙÔÌ· Ô˘ ¤ÈÓ·Ó 8-28 ·ÏÎÔÔÏÔ‡¯· ÔÙ¿/‚‰ÔÌ¿‰· (‰ËÏ·‰‹ ÂÚ›Ô˘ 96-336 ml ·ÏÎÔfiÏ/‚‰ÔÌ¿‰·) Ë ıÓËÙfiÙËÙ· ‹Ù·Ó 7,1-8,5/1000 ¿ÙÔÌ·-¤ÙË, ÂÓÒ ÛÙ· ¿ÙÔÌ· Ô˘ ‰ÂÓ Î·Ù·Ó¿ÏˆÓ·Ó ·ÏÎÔÔÏÔ‡¯· ÔÙ¿ ‹Ù·Ó 10/1000 ¿ÙÔÌ·-¤ÙË. ™ÙÔ˘˜ ‰‡Ô ·Ú·¿Óˆ ÏËı˘ÛÌÔ‡˜, Ë ÔÏÈ΋ ıÓËÙfiÙËÙ· ‹Ù·Ó 24-27/1000 ¿ÙÔÌ·-¤ÙË Î·È 34/1000 ¿ÙÔÌ·-¤ÙË ·ÓÙ›ÛÙÔȯ·. ∏ ıÓËÙfiÙËÙ· ·fi ∞∂∂ ‹Ù·Ó 6/1000 ¿ÙÔÌ·-¤ÙË ÛÙ· Ù· ¿ÙÔÌ· Ô˘ ¤ÈÓ·Ó >43 ÔÙ¿/‚‰ÔÌ¿‰· (>516 ml ·ÏÎÔfiÏ /‚‰ÔÌ¿‰·), 2,6-3,3/1000 ¿ÙÔÌ·¤ÙË ÛÙ· ¿ÙÔÌ· Ô˘ ¤ÈÓ·Ó 1-42 ·ÏÎÔÔÏÔ‡¯· ÔÙ¿/‚‰ÔÌ¿‰·, ÂÓÒ ÛÙ· ¿ÙÔÌ· Ô˘ ‰ÂÓ Î·Ù·Ó¿ÏˆÓ·Ó Î·ıfiÏÔ˘ ·ÏÎÔÔÏÔ‡¯· ÔÙ¿ Ë ıÓËÙfiÙËÙ· ‹Ù·Ó 3,6/1000 ¿ÙÔÌ·-¤ÙË. AÓÙ›ıÂÙ· Û ̛· ÌÂϤÙË ÛÙË ‰˘ÙÈ΋ ™ÎˆÙ›·, (ÌÂϤÙË Men-Western Scotland) ‰ÂÓ ‰È·ÈÛÙÒıËΠ‰È·ÊÔÚ¿ ÛÙËÓ ÔÏÈ΋ ıÓËÙfiÙËÙ· ·Ó¿ÌÂÛ· ÛÙ· ¿ÙÔÌ· Ô˘ ¤ÈÓ·Ó 1-14 ÔÙ¿/‚‰ÔÌ·‰· Î·È ÛÙÔ

ÁÂÓÈÎfi ÏËı˘ÛÌfi. ∂ÈϤÔÓ Û ·˘Ù‹ ÙË ÌÂϤÙË, Ë Î·Ù·Ó¿ÏˆÛË ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ‰ÂÓ ÚÔÛٷهÂÈ ·fi ÙË ÛÙÂÊ·ÓÈ·›· ÓfiÛÔ Î·È ÔÈ ¿Ó‰Ú˜ Ô˘ Î·Ù·Ó¿ÏˆÓ·Ó 35 ‹ ÂÚÈÛÛfiÙÂÚ· ·ÏÎÔÔÏÔ‡¯· ÔÙ¿ ÙËÓ Â‚‰ÔÌ¿‰· ›¯·Ó ‰ÈÏ¿ÛÈÔ Î›Ó‰˘ÓÔ ÁÈ· ∞∂∂(15). ¶·ÚfiÌÔÈ· ·ÔÙÂϤÛÌ·Ù· ‚Ú¤ıËÎ·Ó Î·È Û ̛· ÌÂϤÙË Ô˘ ¤ÁÈÓ ÛÙË ƒˆÛ›·,(16), ηıÒ˜ Î·È Û ¿ÏϘ ÌÂϤÙ˜ ÂÚÈÛÙ·Ûȷ΋˜ ηٷӿψÛ˘ ˘ÂÚ‚ÔÏÈο ÌÂÁ¿ÏˆÓ ÔÛÔÙ‹ÙˆÓ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ (binge drinking). ™‡Ìʈӷ Ì ÚfiÛÊ·Ù· ‚È‚ÏÈÔÁÚ·ÊÈο ‰Â‰Ô̤ӷ, ·˘Ùfi˜ Ô ÙÚfiÔ˜ ηٷӿψÛ˘ ·ÏÎÔÔÏÔ‡¯ˆÓ (binge drinking) ÔÙÒÓ ¤¯ÂÈ ˆ˜ ·ÔÙ¤ÏÂÛÌ· ·‡ÍËÛË Ù˘ ·ÚÙËÚȷ΋˜ ›ÂÛ˘, ÙÔ˘ ηډȷÎÔ‡ Ú˘ıÌÔ‡ Î·È Ù˘ ËÎÙÈÎfiÙËÙ·˜ ÙÔ˘ ·›Ì·ÙÔ˜(17). ™Â ·ÓÙ›ıÂÛË Ì ٷ ·Ú·¿Óˆ ‚È‚ÏÈÔÁÚ·ÊÈο ‰Â‰Ô̤ӷ, Ì›· ÌÂϤÙË Û πÙ·ÏÔ‡˜ ·ÁÚfiÙ˜ (ÌÂϤÙË ªen-rural Italy) ¤‰ÂÈÍ fiÙÈ Ë Î·Ù·Ó¿ÏˆÛË ·fi 20 ¤ˆ˜ 54 ·ÏÎÔÔÏÔ‡¯· ÔÙ¿/‚‰ÔÌ¿‰· Û˘Û¯ÂÙ›ÛıËΠ̠ηχÙÂÚ· ÔÛÔÛÙ¿ ÂÈ‚›ˆÛ˘ Î·È Ì ÙË ÌÈÎÚfiÙÂÚË ıÓËÙfiÙËÙ· ·fi ηډȷÁÁÂȷο Û˘Ì‚¿Ì·Ù· (7/1000-10/1000 ¿ÙÔÌ· ÙÔ ¯ÚfiÓÔ) Û ۇÁÎÚÈÛË Ì ÙÔ ÁÂÓÈÎfi ÏËı˘ÛÌfi(18, 19). ∏ ÌÂϤÙË ·˘Ù‹ ¤‰ÂÈÍ ̛· Û˘Û¯¤ÙÈÛË Û¯‹Ì·ÙÔ˜ J ·Ó¿ÌÂÛ· ÛÙËÓ Î·Ù·Ó¿ÏˆÛË ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Î·È ÙË ıÓËÙfiÙËÙ· ·fi ηډȷÁÁÂȷο Û˘Ì‚¿Ì·Ù·, ηıÒ˜ Î·È ÙËÓ ÔÏÈ΋ ıÓËÙfiÙËÙ·. ™ÙËÓ ÚÔÛ¿ıÂÈ· Ó· ·ÍÈÔÏÔÁ‹ÛÔ˘Ì ٷ ·ÔÙÂϤÛÌ·Ù· ÙˆÓ ‰È·ÊfiÚˆÓ ÌÂÏÂÙÒÓ Î·È Ó· ÂÍËÁ‹ÛÔ˘Ì ÙȘ ‰È·ÊÔÚÂÙÈΤ˜ ÂȉڿÛÂȘ Ù˘ ηٷӿψÛ˘ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Û ‰È·ÊÔÚÂÙÈΤ˜ ¯ÒÚ˜ Ú¤ÂÈ Ó· Ï¿‚Ô˘ÌÂ

˘fi„Ë Ù· ÂÍ‹˜: ∞) ¶·Ú¿ÁÔÓÙ˜, fiˆ˜ Ô ÙÚfiÔ˜ Î·È ÔÈ Û˘Ó‹ıÂȘ ηٷӿψÛ˘ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ (‰ËÏ·‰‹ Â¿Ó Â›Ó·È Û˘¯Ó‹ ‹ ÂÚÈÛÙ·Ûȷ΋, Â¿Ó Û˘Óԉ‡ÂÙ·È ·fi Á‡̷ٷ ‹ Â›Ó·È ·ÓÂÍ¿ÚÙËÙË ·fi ÙÔ Ê·ÁËÙfi) ı· ÌÔÚÔ‡Û·Ó Ó· ‰È·ÊÔÚÔÔÈ‹ÛÔ˘Ó ÙȘ ÂȉڿÛÂȘ ÙÔ˘ ·ÏÎÔfiÏ ÛÙË ıÓËÙfiÙËÙ·. ™‡Ìʈӷ Ì ̛· ÌÂÙ·-·Ó¿Ï˘ÛË(20), Ë Î·Ù·Ó¿ÏˆÛË ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ·ÓÂÍ¿ÚÙËÙ· ·fi ÙÔ Ê·ÁËÙfi Û˘Û¯ÂÙ›˙ÂÙ·È Ì ·˘ÍË̤ÓÔ Î·Ú‰È·ÁÁÂÈ·Îfi ΛӉ˘ÓÔ, οÙÈ Ô˘ ‰ÂÓ ÂȂ‚·ÈÒÓÂÙ·È ·fi ¿ÏϘ ÌÂϤÙ˜(21). μ) ÿÛˆ˜ οÔÈÔ ÚfiÏÔ Ó· ‰È·‰Ú·Ì·Ù›˙ÂÈ Î·È ÙÔ Â›‰Ô˜ ÙÔ˘ ·ÏÎÔÔÏÔ‡¯Ô˘ ÔÙÔ‡. ΔÔ ÎÚ·Û› ¤¯ÂÈ ÔÏ˘Ê·ÈÓfiϘ Î·È Â›Ó·È ÂȂ‚·ÈˆÌ¤ÓË Ë Â˘ÂÚÁÂÙÈ΋ ÙÔ˘ Â›‰Ú·ÛË. ΔÈ Á›ÓÂÙ·È fï˜ Ì ٷ ¿ÏÏ· ÔÙ¿, fiˆ˜ Â›Ó·È Ë Ì‡Ú·; ™‡Ìʈӷ Ì ̛· ÌÂÙ··Ó¿Ï˘ÛË(22), ÌÈÎÚ¤˜ ÔÛfiÙËÙ˜ (1-4 ÔÙ¿/Ë̤ڷ) Ì‡Ú·˜, ÎÚ·ÛÈÔ‡ Î·È ¿ÏÏˆÓ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Â›Ó·È ÂÍ›ÛÔ˘ ˆÊ¤ÏÈ̘ ÁÈ· ÙÔ Î·Ú‰È·ÁÁÂÈ·Îfi Û‡ÛÙËÌ·. °) Δ¤ÏÔ˜ ÛÙËÓ ÂÎÙ›ÌËÛË ÙÔ˘ ηډȷÁÁÂÈ·ÎÔ‡ ÎÈÓ‰‡ÓÔ˘ Ú¤ÂÈ ¿ÓÙÔÙ ӷ Ï·Ì‚¿ÓÔ˘Ì ˘fi„Ë Î·È ÙÔ˘˜ ÎÏ·ÛÈÎÔ‡˜ ·Ú¿ÁÔÓÙ˜ ÎÈÓ‰‡ÓÔ˘ ÁÈ· ÙËÓ ÂÌÊ¿ÓÈÛË Î·Ú‰È·ÁÁÂÈ·ÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ. ™˘ÓÔ„›˙ÔÓÙ·˜, ÛÙËÓ ÏÂÈÔ„ËÊ›· ÙˆÓ ÌÂÏÂÙÒÓ Ë Î·Ù·Ó¿ÏˆÛË 1-30 ÌÔÓ¿‰ˆÓ ·ÏÎÔfiÏ/ ‚‰ÔÌ¿‰· Û˘Û¯ÂÙ›˙ÂÙ·È Ì ٷ ηχÙÂÚ· ÔÛÔÛÙ¿ ÂÈ‚›ˆÛ˘, ·ÓÂÍ¿ÚÙËÙ· ·fi ÙÔ Â›‰Ô˜ ÙÔ˘ ·ÏÎÔÔÏÔ‡¯Ô˘ ÔÙÔ‡. ™ÙÂÊ·ÓÈ·›· ÓfiÛÔ˜ Î·È ·ÏÎÔfiÏ. ™‡Ìʈӷ Ì ̛· ÌÂÙ·-·Ó¿Ï˘ÛË (4) Ë Û˘Û¯¤ÙÈÛË ·Ó¿ÌÂÛ· ÛÙËÓ

¶π¡∞∫∞™ 2: ∏ Û˘Û¯¤ÙÈÛË Ù˘ ηٷӿψÛ˘ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ (ÔÙ¿/‚‰ÔÌ¿‰·) Ì ÙËÓ ÂÏ¿¯ÈÛÙË ıÓËÙfiÙËÙ·.

ª∂§∂Δ∂™ Male-British doctors(14) Men-Western Scotland(15) Men-rural Italy(18,19) ª∂Δ∞-∞¡∞§À™∂π™ Cleophas(21) Rehm et.al.(4) Reynoldw et al.(24)

™Δ∂º∞¡π∞π∞ ¡√™√™ ¶ÔÙ¿/‚‰ÔÌ¿‰· 8-28 0-14

∞∂∂ ¶ÔÙ¿/‚‰ÔÌ¿‰· 1-42 0-14

√§π∫∏ £¡∏Δ√Δ∏Δ∞ ¶ÔÙ¿/‚‰ÔÌ¿‰· 8-21 0-14

23-54 ¶ÔÙ¿/‚‰ÔÌ¿‰· 8-28 1-23(Á˘Ó·›Î˜) 1-35(¿Ó‰Ú˜) -

23-54 ¶ÔÙ¿/‚‰ÔÌ¿‰· 1-23(Á˘Ó·›Î˜) 0 (¿Ó‰Ú˜) 1-14(ÈÛ¯·ÈÌÈο,1-14 ·ÈÌÔÚÚ·ÁÈο)

23-54 ¶ÔÙ¿/‚‰ÔÌ¿‰· 8-28 -

5


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·6

π√À¡π√™ 2007

ÚfiÛÏË„Ë ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Î·È ÙË ÛÙÂÊ·ÓÈ·›· ÓfiÛÔ Â›Ó·È ÂÚ›ÏÔÎË. H Û˘¯Ó‹ ηٷӿψÛË ÌÈÎÚ‹˜ ¤ˆ˜ ̤ÙÚÈ·˜ ÔÛfiÙËÙ·˜ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ¤¯ÂÈ Û˘Û¯ÂÙÈÛı› Ì ¢ÂÚÁÂÙÈΤ˜ ÂȉڿÛÂȘ ÛÙÔ Î·Ú‰È·ÁÁÂÈ·Îfi Û‡ÛÙËÌ·, ÂÓÒ Ë ÂÚÈÛÙ·Ûȷ΋ ηٷӿψÛË Ôχ ÌÂÁ¿ÏˆÓ ÔÛÔÙ‹ÙˆÓ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ, ·ÎfiÌË Î·È ·Ó Û˘Ó‰˘¿˙ÂÙ·È Ì ̛· ηٿ ̤ÛÔ fiÚÔ ÌÈÎÚ‹ ¤ˆ˜ ̤ÙÚÈ· ηٷӿψÛË Û ٷÎÙÈ΋ ‚¿ÛË, ¤¯ÂÈ Û˘Û¯ÂÙÈÛı› Ì ·˘ÍË̤ÓÔ Î·Ú‰È·ÁÁÂÈ·Îfi ΛӉ˘ÓÔ. ™˘ÁÎÂÎÚÈ̤ӷ, Û‡Ìʈӷ Ì ̛· ÌÂÙ·-·Ó¿Ï˘ÛË(22), Ë Î·Ù·Ó¿ÏˆÛË 1 - 4 ÔÙÒÓ/Ë̤ڷ(12 - 48 ml ·ÏÎÔfiÏ) ÌÔÚ› Ó· ÌÂÈÒÛÂÈ ÙË ıÓËÙfiÙËÙ· ·fi ¤ÌÊÚ·ÁÌ· ÙÔ˘ Ì˘Ôηډ›Ô˘ ηٿ 20 - 30%. ™‡Ìʈӷ Ì ̛· ¿ÏÏË ÌÂÙ· - ·Ó¿Ï˘ÛË(4), Ë Î·Ù·Ó¿ÏˆÛË ÏÈÁfiÙÂÚÔ ·fi 3,5 ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ/ Ë̤ڷ ÁÈ· ÙȘ Á˘Ó·›Î˜ Î·È ÏÈÁfiÙÂÚÔ ·fi 5 ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ÁÈ· ÙÔ˘˜ ¿Ó‰Ú˜ ÌÔÚ› Ó· ÌÂÈÒÛÂÈ ÙËÓ Â›ÙˆÛË Ù˘ ÛÙÂÊ·ÓÈ·›·˜ ÓfiÛÔ˘ ηٿ 20%. ™Â Ì›· ÚfiÛÊ·ÙË ÌÂϤÙË(21), ‰È·ÈÛÙÒıËΠfiÙÈ Ë Û˘¯Ó‹ ηٷӿψÛË 1 - 4 ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ/ Ë̤ڷ Û˘Û¯ÂÙ›ÛıËΠ̠ÌÂȈ̤ÓË Â›ÙˆÛË ÂÌÊÚ¿ÁÌ·ÙÔ˜ ÙÔ˘ Ì˘Ôηډ›Ô˘ Î·È fiÙÈ Ë Î·Ù¿ ¤Ó· ÔÙfi ·‡ÍËÛË Ù˘ ηٷӿψÛ˘ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Û˘Û¯ÂÙ›˙ÔÓÙ·Ó Ì ۯÂÙÈÎfi ΛӉ˘ÓÔ ÁÈ· ¤ÌÊÚ·ÁÌ· ÙÔ˘ Ì˘Ôηډ›Ô˘ 0,78. ∂›Û˘, Ì›· ¿ÏÏË ÌÂÙ·-·Ó¿Ï˘ÛË(23) ¤‰ÂÈÍ fiÙÈ Ô Û¯ÂÙÈÎfi˜ ΛӉ˘ÓÔ˜ ÁÈ· ·ÁÁÂȷο ÓÔÛ‹Ì·Ù· Â›Ó·È 0,68 ÁÈ· Ù· ¿ÙÔÌ· Ô˘ ηٷӷÏÒÓÔ˘Ó ÌÈÎÚ¤˜ ÔÛfiÙËÙ˜ ÎÚ·ÛÈÔ‡ Î·È 0,78 ÁÈ· ·˘ÙÔ‡˜ Ô˘ ηٷӷÏÒÓÔ˘Ó ÌÈÎÚ¤˜ ÔÛfiÙËÙ˜ Ì‡Ú·˜. √È ·ıÔÊ˘ÛÈÔÏÔÁÈÎÔ› Ì˯·ÓÈÛÌÔ› Ô˘ ÂÍËÁÔ‡Ó ·˘ÙfiÓ ÙÔÓ ÚÔÛٷ٢ÙÈÎfi ÚfiÏÔ ÙˆÓ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Â›Ó·È ÔÈ ÂÍ‹˜: ∞) ∏ ÚfiÛÏË„Ë ÌÈÎÚ‹˜ ÔÛfiÙËÙ·˜ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ÚÔηÏ› ‚ÂÏÙ›ˆÛË ÙÔ˘ ÏÈȉ·ÈÌÈÎÔ‡ ÚÔÊ›Ï, ΢ڛˆ˜ ·‡ÍËÛË Ù˘ ∏DL ¯ÔÏËÛÙÂÚfiÏ˘. Œ¯ÂÈ ÂÎÙÈÌËı› Ì¿ÏÈÛÙ· fiÙÈ ÙÔ 4050% Ù˘ ÚÔÛٷ٢ÙÈ΋˜ ‰Ú¿Û˘ ÙÔ˘ ·ÏÎÔfiÏ ·Ô‰›‰ÂÙ·È Û ·˘Ùfi ÙÔ Ì˯·ÓÈÛÌfi. μ) ∏ Û˘¯Ó‹ ηٷӿψÛË ÌÈÎÚ‹˜ ¤ˆ˜ ̤ÙÚÈ·˜ ÔÛfiÙËÙ·˜ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ÂËÚ¿˙ÂÈ ÙÔ Ì˯·ÓÈÛÌfi ‹Í˘ ‰È· ̤ÛÔ˘ Ù˘ ‰Ú¿Û˘ Ù˘ ·ÏÎÔfiÏ˘ ÛÙË Û˘Û-

6

ÛÒÚ¢ÛË ÙˆÓ ·ÈÌÔÂÙ·Ï›ˆÓ Î·È ÛÙËÓ ÈÓˆ‰fiÏ˘ÛË. ∏ ÚÔÛٷ٢ÙÈ΋ ÁÈ· ÙÔ Î·Ú‰È·ÁÁÂÈ·Îfi Û‡ÛÙËÌ· ‰Ú¿ÛË Ô˘ ¤¯ÂÈ Ë Î·Ù·Ó¿ÏˆÛË ÌÈÎÚ‹˜ ‹ ̤ÙÚÈ·˜ ÔÛfiÙËÙ·˜ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ¤¯ÂÈ ·Ô‰Âȯı› ÛÙËÓ ÏÂÈÔ„ËÊ›· ÙˆÓ ÏËı˘ÛÌÒÓ Ù˘ ¢˘ÙÈ΋˜ ∂˘ÚÒ˘ Û˘ÌÂÚÈÏ·Ì‚·ÓÔÌ¤ÓˆÓ Î·È ÂÎÂ›ÓˆÓ ÙˆÓ ·ÙfiÌˆÓ Ô˘ ¤¯Ô˘Ó ۷ί·ÚÒ‰Ë ‰È·‚‹ÙË Î·È Î·Ú‰È·ÁÁÂȷ΋ ÓfiÛÔ (ÛÙÂÊ·ÓÈ·›· ÓfiÛÔ, ∞∂∂). ∞ÓÙ›ıÂÙ·, Ë ÂÚÈÛÙ·Ûȷ΋ ηٷӿψÛË ˘ÂÚ‚ÔÏÈο ÌÂÁ¿ÏˆÓ ÔÛÔÙ‹ÙˆÓ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Û˘Û¯ÂÙ›˙ÂÙ·È Ì ·˘ÍË̤ÓÔ Î·Ú‰È·ÁÁÂÈ·Îfi ΛӉ˘ÓÔ ‰È· ̤ÛÔ˘ Ù˘ ·‡ÍËÛ˘ Ù˘ ËÎÙÈÎfiÙËÙ·˜ ÙÔ˘ ·›Ì·ÙÔ˜(24). ∞ÏÎÔfiÏ Î·È ·ÁÁÂȷο ÂÁÎÂÊ·ÏÈο ÂÂÈÛfi‰È·. ™‡Ìʈӷ Ì ̛· ÌÂϤÙË(25), Ë ÂÏ¿¯ÈÛÙË ıÓËÙfiÙËÙ· ·fi ∞∂∂ Û˘Û¯ÂÙ›ÛıËΠ̠ÙËÓ Î·Ù·Ó¿ÏˆÛË 1 - 14 ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ/‚‰ÔÌ¿‰·. °ÂÓÈο Ê·›ÓÂÙ·È fiÙÈ ˘¿Ú¯ÂÈ Ì›· ÁÚ·ÌÌÈ΋ Û˘Û¯¤ÙÈÛË ·Ó¿ÌÂÛ· ÛÙËÓ Î·Ù·Ó¿ÏˆÛË ·ÏÎÔfiÏ Î·È ÙËÓ Â›ÙˆÛË ÙˆÓ ·ÈÌÔÚÚ·ÁÈÎÒÓ ∞∂∂, ΢ڛˆ˜ Ù˘ ˘·Ú·¯ÓÔÂȉԇ˜ ·ÈÌÔÚÚ·Á›·˜. ¶Ú¤ÂÈ Î·È Â‰Ò Ó· Ï¿‚Ô˘Ì ˘fi„Ë fiÙÈ Ô ÙÚfiÔ˜ ÚfiÛÏ˄˘ ·ÏÎÔfiÏ (ÂÚÈÛÙ·Ûȷ΋ ‹ Û˘¯Ó‹ ηٷӿψÛË ÌÈÎÚÒÓ ÔÛÔÙ‹ÙˆÓ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ‹ binge drinking) ‰È·‰Ú·Ì·Ù›˙ÂÈ ÛËÌ·ÓÙÈÎfi ÚfiÏÔ ˆ˜ ·Ú¿ÁÔÓÙ·˜ ÎÈÓ‰‡ÓÔ˘ ÁÈ· fiÏÔ˘˜ ÙÔ˘˜ Ù‡Ô˘˜ ÙˆÓ ∞∂∂, ΢ڛˆ˜ ÛÙ· Ó·ڿ ¿ÙÔÌ·. ªÂϤÙ˜ Ô˘ ¤ÁÈÓ·Ó ÁÈ· ÙË Û˘Û¯¤ÙÈÛË Ù˘ ηٷӿψÛ˘ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Ì ٷ ∞∂∂ ¤‰ÂÈÍ·Ó ·ÓÙÈÎÚÔ˘fiÌÂÓ· ·ÔÙÂϤÛÌ·Ù·, Èı·Ó¿ ÁÈ·Ù› Ë Û˘Û¯¤ÙÈÛË ·˘Ù‹ Â›Ó·È ‰È·ÊÔÚÂÙÈ΋ ÁÈ· Ù· ·ÈÌÔÚÚ·ÁÈο ∞∂∂ Î·È ÁÈ· Ù· ÈÛ¯·ÈÌÈο ∞∂∂. ™˘ÁÎÂÎÚÈ̤ӷ, οÔȘ ÌÂϤÙ˜ ¤‰ÂÈÍ·Ó fiÙÈ Ô Î›Ó‰˘ÓÔ˜ ÁÈ· ·ÈÌÔÚÚ·ÁÈο ∞∂∂ ·˘Í¿ÓÂÙ·È Ì ÙËÓ Î·Ù·Ó¿ÏˆÛË ÙˆÓ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ(26). ∞ÓÙ›ıÂÙ· οÔȘ ¿ÏϘ ÌÂϤÙ˜ ¤‰ÂÈÍ·Ó ÌÂȈ̤ÓÔ Î›Ó‰˘ÓÔ ÁÈ· ÈÛ¯·ÈÌÈο ∞∂∂ Û ÂÚÈÙÒÛÂȘ Û˘¯Ó‹˜ ηٷӿψÛ˘ ÌÈÎÚÒÓ ÔÛÔÙ‹ÙˆÓ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Î·È ·˘ÍË̤ÓÔ Î›Ó‰˘ÓÔ ‹ η̛· Â›‰Ú·ÛË(26, 27) Û ÂÚÈÙÒÛÂȘ ÂÚÈÛÙ·Ûȷ΋˜ ηٷӿψÛ˘ Ôχ ÌÂÁ¿ÏˆÓ ÔÛÔÙ‹ÙˆÓ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ. √È

ÂȉڿÛÂȘ ÙÔ˘ ·ÏÎÔfiÏ ÛÙËÓ ·ÚÙËÚȷ΋ ›ÂÛË Î·È ÛÙÔ Ì˯·ÓÈÛÌfi ‹Í˘ ı· ÌÔÚÔ‡Û·Ó Ó· ÂÍËÁ‹ÛÔ˘Ó ÙÔÓ ·˘ÍË̤ÓÔ Î›Ó‰˘ÓÔ ·ÈÌÔÚÚ·ÁÈÎÒÓ ∞∂∂ Û ¿ÙÔÌ· Ô˘ ηٷӷÏÒÓÔ˘Ó ÌÂÁ¿Ï˜ ÔÛfiÙËÙ˜ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ. ™˘ÓÔÙÈο Ê·›ÓÂÙ·È fiÙÈ Ì›· Ôχ ÌÈÎÚ‹ ÔÛfiÙËÙ· ·ÏÎÔfiÏ (1 - 2 ÔÙ¿/Ë̤ڷ) Èı·Ó¿ Û˘Ì‚¿ÏÏÂÈ ÛÙËÓ ÚÔÛÙ·Û›· ·fi Ù· ∞∂∂. ª›· ÌÂϤÙË ÛÙË ™Ô˘Ë‰›·(28) ¤‰ÂÈÍ fiÙÈ Ì¤¯ÚÈ ÙËÓ ËÏÈΛ· ÙˆÓ 59 ÂÙÒÓ ÔÈ ı¿Ó·ÙÔÈ Ô˘ ÚÔÎÏ‹ıËÎ·Ó ·fi ÙËÓ Î·Ù·Ó¿ÏˆÛË ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ‹Ù·Ó ÂÚÈÛÛfiÙÂÚÔÈ ·fi ·˘ÙÔ‡˜ Ô˘ ·ÔÙÚ¿ËηÓ, ÂÓÒ Û ¿ÙÔÌ· ËÏÈΛ·˜ >70 ÂÙÒÓ ÙÔ ·ÏÎÔfiÏ ÚÔÏ·Ì‚¿ÓÂÈ ÙÔ 5% ÙˆÓ ı·Ó¿ÙˆÓ ÛÙÔ˘˜ ¿Ó‰Ú˜ Î·È ÙÔ 4.4% ÙˆÓ ı·Ó¿ÙˆÓ ÛÙȘ Á˘Ó·›Î˜. ∞˘Ùfi ÙÔ ÂÍ·ÚÙÒÌÂÓÔ ·fi ÙËÓ ËÏÈΛ· fiÊÂÏÔ˜ ¤¯ÂÈ ˘ÔÛÙËÚȯı› Î·È ·fi ¿ÏÏÔ˘˜ ÌÂÏÂÙËÙ¤˜(29) Ô˘ ¤‰ÂÈÍ·Ó fiÙÈ Ë ÚÔÛٷ٢ÙÈ΋ ‰Ú¿ÛË Ù˘ ÌÈÎÚ‹˜ ¤ˆ˜ ̤ÙÚÈ·˜ ÔÛfiÙËÙ·˜ ·ÏÎÔfiÏ ÛÙË ıÓËÙfiÙËÙ· ˘ÂÚ‚·›ÓÂÈ ÙÔ˘˜ ÎÈÓ‰‡ÓÔ˘˜ ÁÈ· ÙÔ˘˜ ¿Ó‰Ú˜ ÛÙËÓ ËÏÈΛ· ÙˆÓ 40 ÂÙÒÓ Î·È ÁÈ· ÙȘ Á˘Ó·›Î˜ ÛÙËÓ ËÏÈΛ· ÙˆÓ 50 ÂÙÒÓ. √ ˘ÂÚÙ·ÛÈÎfi˜ ·ÛıÂÓ‹˜. ™ÙËÓ ÚÔÛ¿ıÂÈ· ÂÎÙ›ÌËÛ˘ Ù˘ ÈÛÔÚÚÔ›·˜ ΤډԘ/ΛӉ˘ÓÔ˜ ·fi ÙËÓ Î·Ù·Ó¿ÏˆÛË ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Û ¤Ó· ˘ÂÚÙ·ÛÈÎfi ·ÛıÂÓ‹ Ú¤ÂÈ Ó· Ï¿‚Ô˘Ì ˘fi„Ë ÙÔ Û˘Ó‰˘·ÛÌfi ÙˆÓ ÂȉڿÛÂˆÓ Ù˘ ·ÚÙËÚȷ΋˜ ˘¤ÚÙ·Û˘ Î·È Ù˘ ÚÔÛÏ·Ì‚·ÓfiÌÂÓ˘ ÔÛfiÙËÙ·˜ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ÛÙÔ Î·Ú‰È·ÁÁÂÈ·Îfi Û‡ÛÙËÌ·. ª›· ÌÂϤÙË Ô˘ ¤ÁÈÓ Û 14.125 ¿Ó‰Ú˜ Ì ÈÛÙÔÚÈÎfi ˘¤ÚÙ·Û˘ ¤‰ÂÈÍ fiÙÈ Ë Î·Ù·Ó¿ÏˆÛË ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ÌÂÈÒÓÂÈ ÙËÓ Â›ÙˆÛË ÙˆÓ Î·Ú‰È·ÁÁÂÈ·ÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ Î·È Ù˘ ÔÏÈ΋˜ ıÓËÙfiÙËÙ·˜ Û ۇÁÎÚÈÛË Ì ÙÔ ÁÂÓÈÎfi ÏËı˘ÛÌfi(30). πÛ¯‡ÂÈ Î¿ÙÈ Ù¤ÙÔÈÔ ÛÙÔÓ ˘ÂÚÙ·ÛÈÎfi ·ÛıÂÓ‹ Ô˘ ηٷӷÏÒÓÂÈ ˘ÂÚ‚ÔÏÈο ÌÂÁ¿Ï˜ ÔÛfiÙËÙ˜ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ; ™‡Ìʈӷ Ì ÚfiÛÊ·Ù· ‚È‚ÏÈÔÁÚ·ÊÈο ‰Â‰Ô̤ӷ Û ¤Ó· ˘ÂÚÙ·ÛÈÎfi ·ÛıÂÓ‹ Ô˘ ηٷӷÏÒÓÂÈ >64 ·ÏÎÔÔÏÔ‡¯· ÔÙ¿/‚‰ÔÌ¿‰·, Ì›· Ì›ˆÛË Ù˘ ÚÔÛÏ·Ì‚·ÓfiÌÂÓ˘ ÔÛfiÙËÙ·˜ ηٿ 25% ÌÂÈÒÓÂÈ ÙËÓ Â›ÙˆÛË Ù˘ ÛÙÂÊ·ÓÈ·›·˜ ÓfiÛÔ˘. ∂ȉÈÎfiÙÂÚ·, ÙÔ ÌÂÁ·Ï‡ÙÂÚÔ fiÊÂÏÔ˜ fiÛÔÓ ·ÊÔÚ¿


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·7

¶APA°ONTE™ KIN¢YNOY ÙËÓ Â›ÙˆÛË Ù˘ ÛÙÂÊ·ÓÈ·›·˜ ÓfiÛÔ˘ ·Ú·ÙËÚÂ›Ù·È fiÙ·Ó Ë Î·Ù·Ó¿ÏˆÛË ÙˆÓ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ÂÏ·ÙÙˆı› ÛÙ· 1 - 16 ÔÙ¿/‚‰ÔÌ¿‰·. ∂›Û˘, Ô ˘ÂÚÙ·ÛÈÎfi˜ ·ÛıÂÓ‹˜ Ô˘ ›ÓÂÈ 17 - 64 ÔÙ¿/‚‰ÔÌ¿‰· ı· ˆÊÂÏËı› (fiÛÔÓ ·ÊÔÚ¿ ÙËÓ Â›ÙˆÛË ÙˆÓ Î·Ú‰È·ÁÁÂÈ·ÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ) ·fi ÙËÓ ÂÏ¿ÙÙˆÛË ÛÙËÓ Î·Ù·Ó¿ÏˆÛË ÙˆÓ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ÛÙ· 1-16 ÔÙ¿/‚‰ÔÌ¿‰·. ™ÙȘ ‰‡Ô ·Ú·¿Óˆ ÔÌ¿‰Â˜ ·ÛıÂÓÒÓ (·˘ÙÔ› Ô˘ ηٷӷÏÒÓÔ˘Ó >64 ·ÏÎÔÔÏÔ‡¯· ÔÙ¿/‚‰ÔÌ¿‰· Î·È ·˘ÙÔ› Ô˘ ηٷӷÏÒÓÔ˘Ó 17 - 64 ·ÏÎÔÔÏÔ‡¯· ÔÙ¿/ ‚‰ÔÌ¿‰·), Ô Û¯ÂÙÈÎfi˜ ΛӉ˘ÓÔ˜ ÁÈ· ÛÙÂÊ·ÓÈ·›· ÓfiÛÔ ÂÏ·ÙÙÒÓÂÙ·È ·fi 1 Î·È 0,8 ·ÓÙ›ÛÙÔȯ· ÛÙÔ 0,7. ∞˘Ùfi ÙÔ fiÊÂÏÔ˜ ‰ÂÓ ·Ú·ÙËÚ‹ıË-

ΠÛÙÔ˘˜ ˘ÂÚÙ·ÛÈÎÔ‡˜ ·ÛıÂÓ›˜ Ô˘ ·ÔÙ˘Á¯¿ÓÔ˘Ó Ó· ÂÏ·ÙÙÒÛÔ˘Ó ÙËÓ Â‚‰ÔÌ·‰È·›· ÚfiÛÏË„Ë ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ. ™ÙÔ˘˜ ˘ÂÚÙ·ÛÈÎÔ‡˜ ·ÛıÂÓ›˜ Ô˘ ηٷӷÏÒÓÔ˘Ó ÌfiÓÔ 1 - 4 ·ÏÎÔÔÏÔ‡¯· ÔÙ¿/ ‚‰ÔÌ¿‰· Î·È ‰È·ÎfiÙÔ˘Ó ÙËÓ ÚfiÛÏË„Ë Ë ·ÚÙËÚȷ΋ ÙÔ˘˜ ›ÂÛË ‰ÂÓ ÂÏ·ÙÙÒÓÂÙ·È Ô˘ÛÈ·ÛÙÈο Î·È ·˘Í¿ÓÂÙ·È Ô Û¯ÂÙÈÎfi˜ ΛӉ˘ÓÔ˜ ÁÈ· ηډȷÁÁÂȷο Û˘Ì‚¿Ì·Ù· ·fi ÙÔ 0,8 ÛÙÔ 1. ™˘ÓÔ„›˙ÔÓÙ·˜, Û‡Ìʈӷ Ì ٷ ÚfiÛÊ·Ù· ‚È‚ÏÈÔÁÚ·ÊÈο ‰Â‰Ô̤ӷ, ÙÔ ·ÏÎÔfiÏ Û¯ÂÙ›˙ÂÙ·È Ì ÂÚÈÛÛfiÙÂÚ˜ ·fi 60 ÓÔÛËÚ¤˜ ηٷÛÙ¿ÛÂȘ. º·›ÓÂÙ·È fiÙÈ Ë Û˘Û¯¤ÙÈÛË Ù˘ ηٷӿψÛ˘ ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ Ì ٷ ηډȷÁÁÂȷο Û˘Ì‚¿Ì·Ù· Î·È ÙË ıÓËÙfiÙËÙ· Â›Ó·È Ô-

χÏÔÎË Î·È ÔÏ˘‰È¿ÛÙ·ÙË. ™Â ˘ÂÚÙ·ÛÈÎÔ‡˜ ·ÛıÂÓ›˜ ÙˆÓ ¢˘ÙÈÎÒÓ ∂˘Úˆ·˚ÎÒÓ ¯ˆÚÒÓ ËÏÈΛ·˜ >60 ÂÙÒÓ Ô˘ ηٷӷÏÒÓÔ˘Ó >16 ·ÏÎÔÔÏÔ‡¯· ÔÙ¿/‚‰ÔÌ¿‰· Ë ÂÏ¿ÙÙˆÛË Î·È fi¯È Ë ‰È·ÎÔ‹ Ù˘ ÚfiÛÏ˄˘ Û˘Û¯ÂÙ›˙ÂÙ·È Ì ÌÂȈ̤ÓË Â›ÙˆÛË Î·Ú‰È·ÁÁÂÈ·ÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ. ªÂϤÙ˜ ÛÙÔ ÁÂÓÈÎfi ÏËı˘ÛÌfi ‰Â›¯ÓÔ˘Ó fiÙÈ Û ¿ÙÔÌ· ËÏÈΛ·˜ >60 ÂÙÒÓ ÙÔ fiÊÂÏÔ˜ ·fi ÙËÓ Î·Ù·Ó¿ÏˆÛË ·ÏÎÔÔÏÔ‡¯ˆÓ ÔÙÒÓ ˘ÂÚ‚·›ÓÂÈ ÙÔ˘˜ ÎÈÓ‰‡ÓÔ˘˜. Δ¤ÏÔ˜, Ï·Ì‚¿ÓÔÓÙ·˜ ˘fi„Ë ÙÔ˘˜ ·Ú¿ÁÔÓÙ˜ ÎÈÓ‰‡ÓÔ˘ ÁÈ· ηډȷÁÁÂȷο Û˘Ì‚¿Ì·Ù·, Ú¤ÂÈ Ó· ÂÍ·ÙÔÌÈ·ÔÓÙ·È ÔÈ Ô‰ËÁ›Â˜ Ô˘ ‰›ÓÔÓÙ·È Û οı ·ÛıÂÓ‹ ̤۷ ÛÙ· Ï·›ÛÈ· Ù˘ ÚˆÙÔÁÂÓÔ‡˜ ÚfiÏ˄˘ Ù˘ ηډȷÁÁÂȷ΋˜ ÓfiÛÔ˘.

μÈ‚ÏÈÔÁÚ·Ê›· 1.

Marmot M, Brunner E. Alcohol and cardiovascular disease: The status of the U shaped curve. BMJ 1991;303:565-568

data for one million adults in 61 prospective studies. Lancet 2002;360: 1903 -1913.

2.

Jamrozik K, Broadhurst RJ, Anderson CS, Stewart-Wynne EG. The role of lifestyle factors in the etiology of stroke: a populatiÔn-based case-control study in Peth, Western Australia. Stroke 1994; 25:51-59

11. He J,Bazzano LA. Effects of lifestyle modification on treatment and prevention of hypertension. Curr Opin Nephrol Hypertens 2000;9:267-271

3.

4.

5.

6.

Britton A, Singh-Manoux A ,Marmot M. Alcohol consumption and cognitive function in the Whitehall II study. Am J Epidemiol 2004;160:240-247 Rehm J, Room R, Monteiro M, Gmel G, Sempos CT. The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease :an overview. Addiction 2003;98: 1209 -1228. Corrao G, Bagnardi V, Zambon A, Ari-co S. Exploring the dose-response relationship between alcohol consumption and the risk of several alcohol-related conditions: a meta-analysis. Addiction 1999;94:1551-1573 Ãin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effeects of alcohol reduction on blood pressure. Hypertension 2001;38:1112

7.

Cook NR, Cohen J, Hebert PR, Taylor JO, Henneckens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995;155:701-709

8.

Marmot MG, Elliot P, Shipley MJ, Dyer A, Ueshima H, Beevers DG, et al. Alcohol and blood pressure: the INTRESALT study. BMJ 1994;308:1263-1267.

9.

Stampler J, Rose G, Stampler R, Elliott P, Dyer A, Marmot M. INTERSALT study findings. Public health and medical care implications. Hypertension 1989;14: 570-577.

10. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality :a meya-analysis of individual

12. Keil U, Liese A, Filipiak B, Swales JD, Grobbee DE. Alcohol, blood pressure and hypertension. Novartis Found Symp 1998;216:125-144 13. Beilin LJ, Puddey IB. Alcohol, hypertension and cardiovascular disease-implications for management Clin Exp Hypertens. 1993;15:1157-1170 14. Doll R, Peto R, Hall E, Wheatley K, Gray R. Mortality in relation to consumption of alcohol: 13 years` observation on male British doctors . BMJ 1994;309:911-918 15. Hart CL, Smith GD, Hole DJ, Hawthorne VM. Alcohol consumption and mortality from all causes, coronary heart disease and stroke: results from prospective cohort study of Scottish men with 21 years of follow up. BMJ 1999;318:17251729.

21. Mukamai KJ, Conigrave KM, Mittleman MA, Camargo CA, Stamfer MJ, Willet WC, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart di-sease in men. N Engl J Med 2003; 348:109-118. 22. Cleophas TJ. Wine, beer and spirits and the risk of myocardial infarction :a systematic review. Biomed Phasmacother 1999;53:417-423. 23. Di Castelnuovo A, Rotondo S, Iacoviello L,Donati MD, de Gaetano G. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 2002;105:2836-2844 24. McKee M, Britton A. The positive relationship between alcohol and heart disease in Eastern Europe: potential physiological mechanisms. J R Soc Med 1998; 91:402-407. 25. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J.Alcohol consumption and risk of stroke. JAMA 2003; 289: 579-588.

16. Room R, Babor T, Rehm J. Alcohol and public health. Lancet 2005;365:519-530.

26. Palomaki H. Kaste M. Regular light to moderate intake of alcohol and the risk of ischemic stroke. Is there a beneficial effect? Stroke 1993;24:1828-32.

17. Chenet L, Britton A, Kalediene R, Petrausiene J. Daily variations in deaths in Lithuania: the possible contribution of binge drinking. Int J Epidemiol 2001;30: 743-748

27. Iso H, Kitamura A, Shimamoto T, Sankai T, Naito Y, Sato S, et al. Alcohol intake and the risk of cardiovascular disease in middle aged Japanese men. Stroke 1995; 26:767-773.

18. Farchi G, Fidanza F, Mariotti A. Alcohol and mortality in the Italian rural cohorts of the Seven Cpuntries Study. Int J Epidemiol 1992;21:74-82.

28. Griffith MJ. A new year toast…to the cardioprotective effects of alcohol. Br Heart J 1995;73:8-9

19. Farchi G, Fidanza F, Giampaoli S, Marlotti S, Menotti A. Alcohol and survival in the Italian rural cohorts of the Seven Countries Study. Int J Epidemiol 2000:29:667-671. 20. Trevisan MT, Schisterman E, Mennoti, MA, Farchi G, Conti S. Drinking pattern and mortality. The Italian Risk Factor and life Expectancy Pooling Project. Ann Epidemiol 2001;11:312-319.

29. Jackson R, Beaglehole R. Alcohol consumption guidelines: relative safety vs absolute risks and benefits. Lancet 1995; 346:716. 30. Malinski MK, Sesso HD, Lopez-Jimenez F, Buring JE, Gaziano JM. Alcohol consumption and cardiovascular disease mortality in hypertensive men. Arch Int Med 2004;164:623-628.

7


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·8

π√À¡π√™ 2007

¶ÚfiÏË„Ë ÙÔ˘ ™·Î¯·ÚÒ‰Ë ¢È·‚‹ÙË Δ‡Ô˘ 2 ¡›ÎÔ˜ ¢È·ÎÔ˘Ì¿ÎÔ˜, ∫·Ú‰ÈÔÏfiÁÔ˜. ¢È·ÁÓˆÛÙÈÎfi ∫·Ú‰ÈÔÏÔÁÈÎfi ∫¤ÓÙÚÔ ¶ÂÈÚ·È¿, ™˘ÓÂÚÁ¿Ù˘ ¡ÔÛÔÎÔÌ›Ԣ Metropolitan ¶ÚfiÛÊ·Ù· (Ù‡¯Ô˜ π·ÓÔ˘·Ú›Ô˘ ÙÔ˘ 2007) ‰ËÌÔÛȇıËÎ·Ó ÔÈ ∫·Ù¢ı˘ÓÙ‹ÚȘ √‰ËÁ›Â˜ ÁÈ· ÙÔ ¢È·‚‹ÙË, ÙÔ ¶Úԉȷ‚‹ÙË Î·È ÙȘ ∫·Ú‰È·ÁÁÂȷΤ˜ ·ı‹ÛÂȘ, Ù˘ ∂˘Úˆ·˚΋˜ ∫·Ú‰ÈÔÏÔÁÈ΋˜ ∂Ù·ÈÚ›·˜ (ESC) Î·È Ù˘ ∂˘Úˆ·˚΋˜ ∂Ù·ÈÚ›·˜ ÁÈ· ÙË ªÂϤÙË ÙÔ˘ ¢È·‚‹ÙË (EASD). ªÂٷ͇ ¿ÏψÓ, ˘¿Ú¯ÂÈ Ì›· Û‡ÓÙÔÌË ·Ó·ÛÎfiËÛË ÙˆÓ ‰Â‰ÔÌ¤ÓˆÓ ÁÈ· ÙË ÚfiÏË„Ë ÙÔ˘ ™·Î¯·ÚÒ‰Ë ¢È·‚‹ÙË Ù‡Ô˘ 2 (™¢ 2), Ô˘ ·ÚÔ˘ÛÈ¿˙ÂÈ ÂӉȷʤÚÔÓ, ·ÊÔ‡ ·ÔÙÂÏ› Ì›· Ï‹ÚË ÂÚ›ÏË„Ë ÙˆÓ ÛÙÔȯ›ˆÓ ·fi ÙȘ ̤¯ÚÈ Û‹ÌÂÚ· ÌÂϤÙ˜. √ ‰È·‚‹Ù˘ Î·È ÔÈ Î·Ú‰È·ÁÁÂȷΤ˜ ·ı‹ÛÂȘ ÂÌÊ·Ó›˙ÔÓÙ·È Û˘¯Ó¿ Û·Ó ÔÈ ‰‡Ô fi„ÂȘ ÙÔ˘ ›‰ÈÔ˘ ÓÔÌ›ÛÌ·ÙÔ˜. √ ‰È·‚‹Ù˘ ¤¯ÂÈ ıˆÚËı› ÈÛÔ‰‡Ó·ÌÔ Ù˘ ÛÙÂÊ·ÓÈ·›·˜ ÓfiÛÔ˘ (™¡) ηÈ, ·ÓÙ›ÛÙÚÔÊ·, ÔÏÏÔ› ·ÛıÂÓ›˜ Ì ÂÁηÙÂÛÙË̤ÓË ™¡ ¿Û¯Ô˘Ó ·fi ‰È·‚‹ÙË, ‹ ·fi ÚÔ-‰È·‚ËÙÈΤ˜ ηٷÛÙ¿ÛÂȘ, ÂÓÒ Ë Û˘¯ÓfiÙÂÚË ·ÈÙ›· ı·Ó¿ÙÔ˘ ÛÙÔ˘˜ ∂˘Úˆ·›Ô˘˜ ‰È·‚ËÙÈÎÔ‡˜ ÂÓËÏ›ÎÔ˘˜ Â›Ó·È Ë ™¡. ∞ÚÎÂÙ¤˜ ÌÂϤÙ˜ ¤¯Ô˘Ó ‰Â›ÍÂÈ fiÙÈ ÔÈ ·ÛıÂÓ›˜ ·˘ÙÔ› ‰È·ÙÚ¤¯Ô˘Ó 2Ï¿ÛÈÔ ˆ˜ 3Ï¿ÛÈÔ Î›Ó‰˘ÓÔ, Û ۯ¤ÛË Ì ٷ ¿ÙÔÌ· ¯ˆÚ›˜ ‰È·‚‹ÙË1. ¶ÚÈÓ ·fi ÙËÓ ÂÌÊ¿ÓÈÛË ÙÔ˘ ™¢ 2 ·Ú·ÙËÚÔ‡ÓÙ·È Û˘¯Ó¿ ÌÂÙ·‚ÔϤ˜ ‰È·ÊfiÚˆÓ ÌÂÙ·‚ÔÏÈÎÒÓ ·Ú·Ì¤ÙÚˆÓ, fiˆ˜ ‰˘Û·ÓÂÍ›· ÛÙË ÁÏ˘Îfi˙Ë (IGT-Impaired Glucose Tolerance), ‰˘ÛÏÈȉ·ÈÌ›· Î·È ·ÓÙ›ÛÙ·ÛË ÛÙËÓ ÈÓÛÔ˘Ï›ÓË (π∞)2. ∞Ó Î·È ‰ÂÓ Î·Ù·Ï‹ÁÔ˘Ó Û ‰È·‚‹ÙË fiÏÔÈ ÔÈ ·ÛıÂÓ›˜ Ì ·ÚfiÌÔȘ ÌÂÙ·‚ÔÏÈΤ˜ ‰È·Ù·Ú·¯¤˜, Ô Î›Ó‰˘ÓÔ˜ ÂÌÊ¿ÓÈÛ˘ Ù˘ ÓfiÛÔ˘ Û ·˘ÙÔ‡˜ Â›Ó·È ÛËÌ·ÓÙÈο ·˘ÍË̤ÓÔ˜. ¶ÚÔÛÂÎÙÈο ۯ‰ȷṲ̂Ó˜ ÎÏÈÓÈΤ˜ ÌÂϤÙ˜ ¤‰ÂÈÍ·Ó fiÙÈ ÔÈ ÛÙÚ·ÙËÁÈΤ˜ ·ÔÙÂÏÂÛÌ·ÙÈ΋˜ ·Ú¤Ì‚·Û˘ ÛÙÔ ÙÚfiÔ ˙ˆ‹˜ Â›Ó·È Û ı¤ÛË Ó· ·ÚÂÌÔ‰›ÛÔ˘Ó, ‹ ÙÔ˘Ï¿¯ÈÛÙÔÓ, Ó· ÂÈ‚Ú·‰‡ÓÔ˘Ó ÙËÓ ÂÌÊ¿ÓÈÛË ™¢ 2 ÛÙ· ˘„ËÏÔ‡ ÎÈÓ‰‡ÓÔ˘ ¿ÙÔÌ·. ™ÙË ™Ô˘Ë‰È΋ ÌÂϤÙË ÙÔ˘ Malmö, Ë ·˘ÍË̤ÓË Ê˘ÛÈ΋ ¿ÛÎËÛË Î·È

8

Ë ·ÒÏÂÈ· ‚¿ÚÔ˘˜ ·ÚÂÌfi‰ÈÛ·Ó ‹ ÂÈ‚Ú¿‰˘Ó·Ó ÙËÓ ÂÌÊ¿ÓÈÛË ÙÔ˘ ‰È·‚‹ÙË Û ¿ÙÔÌ· Ì IGT. ™ÙËÓ ÔÌ¿‰· ·Ú¤Ì‚·Û˘ 63% ÏÈÁfiÙÂÚ· ¿ÙÔÌ· ÂÌÊ¿ÓÈÛ·Ó ™¢ 2 Û˘ÁÎÚÈÙÈο Ì ÙËÓ ÔÌ¿‰·, Û ·Ú·ÎÔÏÔ‡ıËÛË 5 ÂÙÒÓ3. ™Â Ì›· ∫ÈÓÂ˙È΋ ÌÂϤÙË ·fi ÙÔ Da Qing, 577 ¿ÙÔÌ· Ì IGT Ù˘¯·ÈÔÔÈ‹ıËÎ·Ó Û ̛· ·fi ÙȘ 4 ·ÎfiÏÔ˘ı˜ ÔÌ¿‰Â˜: ÌfiÓÔ ¿ÛÎËÛË, ÌfiÓÔ ‰›·ÈÙ·, ‰›·ÈÙ· Î·È ¿ÛÎËÛË, η̛· ·Ú¤Ì‚·ÛË (ÔÌ¿‰· ÂϤÁ¯Ô˘)4. ∏ Û˘ÓÔÏÈ΋ Û˘¯ÓfiÙËÙ· ÙÔ˘ ™¢ 2, ÛÙË ‰È¿ÚÎÂÈ· ·Ú·ÎÔÏÔ‡ıËÛ˘ 6 ÂÙÒÓ, ‹Ù·Ó ÛËÌ·ÓÙÈο ÌÈÎÚfiÙÂÚË ÛÙȘ ÙÚÂȘ ÔÌ¿‰Â˜ ·Ú¤Ì‚·Û˘ (46%), Û ۯ¤ÛË Ì ÙËÓ ÔÌ¿‰· ÂϤÁ¯Ô˘ ™ÙË Finnish Diabetes Prevention Study (FDPS), Ì›ˆÛË ÙÔ˘ ۈ̷ÙÈÎÔ‡ ‚¿ÚÔ˘˜ ≥5%, Ô˘ ÂÈÙ‡¯ıËΠ̠¤Ó· ÚfiÁÚ·ÌÌ· ÂÓÙ·ÙÈ΋˜ ‰›·ÈÙ·˜ Î·È ¿ÛÎËÛ˘, Û˘Óԉ¢fiÙ·Ó ·fi Ì›ˆÛË Î·Ù¿ 58% ÙÔ˘ ÎÈÓ‰‡ÓÔ˘ ÂÌÊ¿ÓÈÛ˘ ™¢ 2, Û ˘¤Ú‚·ÚÔ˘˜ ¿Ó‰Ú˜ Î·È Á˘Ó·›Î˜ Ì IGT5. √ ‚·ıÌfi˜ Ì›ˆÛ˘ ÙÔ˘ ÎÈÓ‰‡ÓÔ˘ ÂͤÏÈ͢ Û ™¢ 2 Û¯ÂÙÈ˙fiÙ·Ó ¿ÌÂÛ· Ì ÙËÓ ¤ÓÙ·ÛË ÙˆÓ ÌÂÙ·‚ÔÏÒÓ ÙÔ˘ ÙÚfiÔ˘ ˙ˆ‹˜. ΔÔ Diabetes Prevention Programme (DPP), ÛÙȘ ∏¶∞, Ô˘ Û‡ÁÎÚÈÓ ÙËÓ ÂÓÂÚÁfi ÌÂÙ·‚ÔÏ‹ ÙÔ˘ ÙÚfiÔ˘ ˙ˆ‹˜, ‹ ÙË ÌÂÙÊÔÚÌ›ÓË, Ì ÙË ÎÏ·ÛÈ΋ ·ÚÔ¯‹ Û˘Ì‚Ô˘ÏÒÓ ÁÈ· ÙÔÓ ÙÚfiÔ ˙ˆ‹˜ ÛÂ Û˘Ó‰˘·ÛÌfi Ì ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ, ‰È·›ÛÙˆÛ fiÙÈ Ë ÂÓÂÚÁfi˜ ÌÂÙ·‚ÔÏ‹ ÙÔ˘ ÙÚfiÔ˘ ˙ˆ‹˜ Ì›ˆÛ ÙË Û˘¯ÓfiÙËÙ· ÂÌÊ¿ÓÈÛ˘ ™¢ 2 ηٿ 58%, Û ¤Ó· ÏËı˘-

ÛÌfi ˘¤Ú‚·ÚˆÓ ∞ÌÂÚÈηÓÒÓ ÌÂÛËÏ›ÎˆÓ Ì IGT6. O ÛÙfi¯Ô˜ ÙÔ˘ ÚÔÁÚ¿ÌÌ·ÙÔ˜ ‹Ù·Ó Ó· ÂÈÙ¢¯ı› Ì›ˆÛË ÙÔ˘ ۈ̷ÙÈÎÔ‡ ‚¿ÚÔ˘˜ ≥7% Î·È Ê˘ÛÈ΋ ‰Ú·ÛÙËÚÈfiÙËÙ· ̤Û˘ ¤ÓÙ·Û˘ ÁÈ· 150 ÙÔ˘Ï¿¯ÈÛÙÔÓ ÏÂÙ¿ ÙËÓ Â‚‰ÔÌ¿‰·. ∏ Û˘ÓÔÏÈ΋ Â›ÙˆÛË ÙÔ˘ ‰È·‚‹ÙË ‹Ù·Ó 4.8, 7.8 Î·È 11.0 ÂÚÈÙÒÛÂȘ ·Ó¿ 100 ·ÓıÚˆÔ/¤ÙË, ÛÙȘ ÔÌ¿‰Â˜ Ù˘ ÂÓÂÚÁÔ‡ ÌÂÙ·‚ÔÏ‹˜ ÙÔ˘ ÙÚfiÔ˘ ˙ˆ‹˜, Ù˘ ÌÂÙÊÔÚÌ›Ó˘ Î·È ÙÔ˘ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘, ·ÓÙ›ÛÙÔȯ·. ∞˘Ù‹ Ë Ì›ˆÛË Ù˘ Û˘¯ÓfiÙËÙ·˜ ÂÌÊ¿ÓÈÛ˘ ™¢ 2 ·ÓÙÈÛÙÔȯ› Û ÚfiÏË„Ë 1 ÂÚ›ÙˆÛ˘ Ó¤Ô˘ ‰È·‚‹ÙË ÁÈ· οı 7 ıÂÚ·¢fiÌÂÓ· ¿ÙÔÌ· Ì IGT Â› 3 ¯ÚfiÓÈ·, ÛÙËÓ ÔÌ¿‰· ·Ú¤Ì‚·Û˘ ÛÙÔ ÙÚfiÔ ˙ˆ‹˜, Û ۇÁÎÚÈÛË Ì 14 ¿ÙÔÌ· ÛÙËÓ ÔÌ¿‰· Ù˘ ÌÂÙÊÔÚÌ›Ó˘. Œ¯ÔÓÙ·˜ ˘fi„Ë ·˘Ù¿ Ù· ÂÓÙ˘ˆÛȷο ·ÔÙÂϤÛÌ·Ù·, Ë ∞merican Diabetes Association (ADA) Î·È ÙÔ National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) Û˘ÓÈÛÙÔ‡Ó ¤ÏÂÁ¯Ô ÁÈ· ÂӉ¯fiÌÂÓÔ ˘„ËÏfi Â›Â‰Ô ÁÏ˘Îfi˙˘ ÛÙÔ ·›Ì·, Û ¿ÙÔÌ· >45 ÂÙÒÓ Ì μªπ ≥25 Kg/m2. ™Ù· ¿ÙÔÌ· Ì ÛÙÔȯ›· ÚÔ-‰È·‚ËÙÈ΋˜ ηٿÛÙ·Û˘ ı· Ú¤ÂÈ Ó· ·Ú¤¯ÂÙ·È Î·Ù¿ÏÏËÏË Û˘Ì‚Ô˘Ï¢ÙÈ΋ ‚Ô‹ıÂÈ· ÁÈ· ÙËÓ ·ÒÏÂÈ· ‚¿ÚÔ˘˜, ‰È·Ì¤ÛÔ˘ ÚÔÁÚ·ÌÌ¿ÙˆÓ ‰È·ÈÙËÙÈ΋˜ ÙÚÔÔÔ›ËÛ˘ Î·È ¿ÛÎËÛ˘7. √ ·ÚÈıÌfi˜ ÙˆÓ ·ÛıÂÓÒÓ Ô˘ ¯ÚÂÈ¿˙ÂÙ·È Ó· ıÂÚ·¢ıÔ‡Ó (¡¡Δ) ÁÈ· Ó· ÚÔÏËÊı› Ì›· ÂÚ›ÙˆÛË ™¢ 2, Ì ·Ú¤Ì‚·ÛË ÛÙÔ ÙÚfiÔ ˙ˆ‹˜, Û ¿ÙÔÌ· Ì IGT, Â›Ó·È ÂÍ·ÈÚÂÙÈο ¯·ÌËÏfi˜ (¶›Ó·Î·˜ 1).

¶π¡∞∫∞™ 1 ªÂϤÙË

ª¤ÁÂıÔ˜ √Ì¿‰·˜

ª¤ÛÔ˜ μªπ

¢È¿ÚÎÂÈ· (¤ÙË)

Malmö FDPS DPP DaQing

217 523 2161 500

26.6 31.0 34.0 25.8

5 3 3 6

RRR (%)

ARR (%)

NNT

63 58 58 46

18 12 15 27

28 22 21 25

RRR= Ì›ˆÛË ÙÔ˘ Û¯ÂÙÈÎÔ‡ ÎÈÓ‰‡ÓÔ˘, ∞RR=Ì›ˆÛË ÙÔ˘ ·fiÏ˘ÙÔ˘ ÎÈÓ‰‡ÓÔ˘/100 ·ÓıÚˆÔ-¤ÙË, ¡¡Δ = ·ÚÈıÌfi˜ ·ÙfiÌˆÓ Ô˘ Ú¤ÂÈ Ó· ıÂÚ·¢ıÔ‡Ó ÁÈ· Ó· ÚÔÏËÊı› Ì›· ÂÚ›ÙˆÛË ‰È·‚‹ÙÔ˘ Û ‰È¿ÛÙËÌ· 12 ÌËÓÒÓ.


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·9

¶APA°ONTE™ KIN¢YNOY ™ÙË ÌÂϤÙË Indian Diabetes Prevention Programme (IDPP), Ô˘ ·Ó·ÎÔÈÓÒıËΠÚfiÛÊ·Ù· 8, ÔÈ ÌÂÙ·‚ÔϤ˜ ÙÔ˘ ÙÚfiÔ˘ ˙ˆ‹˜ Î·È Ë ÌÂÙÊÔÚÌ›ÓË ·ÚÔ˘Û›·Û·Ó ·ÚfiÌÔÈ· ÌÂٷ͇ ÙÔ˘˜ ‰˘Ó·ÙfiÙËÙ· Ì›ˆÛ˘ Ù˘ Û˘¯ÓfiÙËÙ·˜ ÂÌÊ¿ÓÈÛ˘ ‰È·‚‹ÙË, Û ¿ÙÔÌ· Ì IGT, ·ÏÏ¿ Ô Û˘Ó‰˘·ÛÌfi˜ ÙˆÓ ‰‡Ô ıÂÚ·¢ÙÈÎÒÓ ÙÚfiˆÓ ‰ÂÓ ‚ÂÏÙ›ˆÛ ÙËÓ ¤Î‚·ÛË. ∏ ÌÂϤÙË Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM), ÂÚ‡ÓËÛ ·Ó ·˘Ù¿ Ë Ú·ÌÈÚ›ÏË ‹ Ë ÚÔÛÈÁÏ˘Ù·˙fiÓË ÌÔÚÔ‡Ó Ó· ÌÂÈÒÛÔ˘Ó ÙËÓ ¤Ó·ÚÍË ÙÔ˘ ‰È·‚‹ÙË, Û ¿ÙÔÌ· Ì IGT, ·ıÔÏÔÁÈ΋ ÁÏ˘Îfi˙Ë ÓËÛÙ›·˜ (IFG), ‹ Î·È Ù· ‰‡Ô. ΔÔ Î‡ÚÈÔ ÙÂÏÈÎfi ÛËÌÂ›Ô Ù˘ ÌÂϤÙ˘ ‹Ù·Ó Ë ÂÌÊ¿ÓÈÛË ™¢ 2 ‹ ı¿Ó·ÙÔ˜ ÔÔÈ·Û‰‹ÔÙ ·ÈÙÈÔÏÔÁ›·˜. ªÂÙ¿ ·fi ·Ú·ÎÔÏÔ‡ıËÛË 3 ÂÙÒÓ, Ë ÂÌÊ¿ÓÈÛË ÙÔ˘ ·ÚÈÔ˘ ηٷÏËÎÙÈÎÔ‡ ÛËÌ›Ԣ ‰ÂÓ ‰È¤ÊÂÚ ÛËÌ·ÓÙÈο ÌÂٷ͇ Ú·ÌÈÚ›Ï˘ Î·È ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ (18.1% ¤Ó·ÓÙÈ 19.5%, HR 0.91), ‰ËÏ., Ì›ˆÛË ÙÔ˘ Û¯ÂÙÈÎÔ‡ ÎÈÓ‰‡ÓÔ˘ ηٿ 9% 9. ∏ ÚÔÛÈÁÏÈÙ·˙fiÓË Ì›ˆÛ ÛËÌ·ÓÙÈο ÙÔ Î‡ÚÈÔ ÙÂÏÈÎfi ÛËÌ›Ô, ¤Ó·ÓÙÈ ÙÔ˘ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ (11.6% ¤Ó·ÓÙÈ 26%, HR 0.40 ), ‰ËÏ. Ì›ˆÛË ÙÔ˘ Û¯ÂÙÈÎÔ‡ ÎÈÓ‰‡ÓÔ˘ ηٿ 60% 10. √ Û˘ÓÔÏÈÎfi˜ ·ÚÈıÌfi˜ ÙˆÓ Î·Ú‰È·ÁÁÂÈ·ÎÒÓ ÂÂÈÛÔ‰›ˆÓ ‰ÂÓ ‰È¤ÊÂÚ ÛËÌ·ÓÙÈο ÌÂٷ͇ ÙˆÓ ÔÌ¿‰ˆÓ Ù˘ ÚÔÛÈÁÏÈÙ·˙fiÓ˘ Î·È ÙÔ˘ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘, ·ÏÏ¿ ÛÙËÓ ÔÌ¿‰· Ù˘ ÚÔÛÈÁÏÈÙ·˙fi-

Ó˘ ·Ú·ÙËÚ‹ıËÎ·Ó ÛËÌ·ÓÙÈ΋ ·‡ÍËÛË ÙÔ˘ ۈ̷ÙÈÎÔ‡ ‚¿ÚÔ˘˜ (p<0.0001) Î·È ÂÚÈÛÛfiÙÂÚ˜ ÂÚÈÙÒÛÂȘ ηډȷ΋˜ ·ÓÂ¿ÚÎÂÈ·˜ (0.5% ¤Ó·ÓÙÈ 0.1%, p<0.01). ¶Ú¤ÂÈ, fï˜, Ó· ÛËÌÂȈı› fiÙÈ Ë ÌÂϤÙË DREAM ‰ÂÓ Û¯Â‰È¿ÛıËÎÂ, Ô‡Ù ›¯Â ÙËÓ ··Ú·›ÙËÙË ÈÛ¯‡ Ó· ÂÎÙÈÌ‹ÛÂÈ, ÙË Î·Ú‰È·ÁÁÂȷ΋ ¤Î‚·ÛË. ŒÙÛÈ, Ë ÚÔÛÈÁÏÈÙ·˙fiÓË ‰ÂÓ ÌÔÚ›, ˆ˜ fiÙÔ˘ ˘¿ÚÍÔ˘Ó Î·È ¿ÏÏ· ÛÙÔȯ›·, Ó· ıˆÚËı› ηٿÏÏËÏË ıÂÚ·›· ÁÈ· ÙË Ì›ˆÛË Ù˘ ηډȷÁÁÂȷ΋˜ ÓfiÛÔ˘ (∫∞¡) Û ¿ÙÔÌ· Ì ‰È·Ù·Ú·¯¤˜ Ù˘ ÔÌÔÈfiÛÙ·Û˘ Ù˘ ÁÏ˘Îfi˙˘ (IGH). Δ· ÚfiÛÊ·Ù· ÛÙÔȯ›· ·fi ÙË Study TO Prevent Non-InsulinDependent Diabetes Mellitus (STOP-NIDDM), ¤‰ÂÈÍ·Ó ÁÈ· ÚÒÙË ÊÔÚ¿, ÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈΤ˜ ÌÂÈÒÛÂȘ ÙˆÓ Î·Ú‰È·ÁÁÂÈ·ÎÒÓ ÂÂÈÛÔ‰›ˆÓ Û ¿ÙÔÌ·

Ì IGT, ¤Ó·ÓÙÈ ÙˆÓ Ì·ÚÙ‡ÚˆÓ, ‰È·Ì¤ÛÔ˘ Ù˘ Ì›ˆÛ˘ ÙˆÓ ÌÂÙ·ÁÂ˘Ì·ÙÈÎÒÓ ÂÈ¤‰ˆÓ Ù˘ ÁÏ˘Îfi˙˘ Ì ·Î·Ú‚fi˙Ë 11 ∂ÈÚfiÛıÂÙ·, ÛÙÔȯ›· ·fi ÙË NHANES III, ¤‰ÂÈÍ·Ó fiÙÈ Ô ¤ÏÂÁ¯Ô˜ Ù˘ ¯ÔÏËÛÙÂÚfiÏ˘ ÙˆÓ ¯·ÌËÏ‹˜ ˘ÎÓfiÙËÙ·˜ ÏÈÔÚˆÙÂ˚ÓÒÓ (LDL-C), Ù˘ ¯ÔÏËÛÙÂÚfiÏ˘ ÙˆÓ ˘„ËÏ‹˜ ˘ÎÓfiÙËÙ·˜ ÏÈÔÚˆÙÂ˚ÓÒÓ (HDL-C), Î·È Ù˘ ·ÚÙËÚȷ΋˜ ›ÂÛ˘ ÛÂ Ê˘ÛÈÔÏÔÁÈο Â›‰·, Û ·ÛıÂÓ›˜ Ì ª™ (¯ˆÚ›˜ ‰È·‚‹ÙË, ‹ ™¡), Ô‰ËÁÔ‡Ó Û Ì›ˆÛË ÙˆÓ ÛÙÂÊ·ÓÈ·›ˆÓ ÂÂÈÛÔ‰›ˆÓ ηٿ 51% ÛÙÔ˘˜ ¿Ó‰Ú˜ Î·È Î·Ù¿ 43% ÛÙȘ Á˘Ó·›Î˜, ÂÓÒ Ô ¤ÏÂÁ¯Ô˜ ·˘ÙÒÓ ÙˆÓ ·Ú·ÁfiÓÙˆÓ ÎÈÓ‰‡ÓÔ˘ ÛÙ· ¿ÚÈÛÙ· Â›‰· Ô‰ËÁ› Û ÚfiÏË„Ë ÙÔ˘ 81% Î·È 82% ÙˆÓ ÂÂÈÛÔ‰›ˆÓ, ·ÓÙ›ÛÙÔȯ· 12

μÈ‚ÏÈÔÁÚ·Ê›· 1.

Laakso M. Hyperglycaemia and cardiovascular disease in type 2 diabetes. Dia-betes 1999; 48: 937-942.

2.

Knowler WC, et al . Preventing noninsulin-dependent diabetes. Diabetes 1995; 44:483-488.

3.

4.

5.

and physical activity. Diabetes Care 2003; 26: 3230-3236. 6.

Eriksson KF, et al . Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6year Malmö feasibility study. Diabetologia 1991;-34: 891-898.

Knowler WC, et al. Reduction in the incidence of type 2 diabetes with life style intervention or metformin. N Engl J Med 2002; 346: 393-403.

7.

American Diabetes Association. The prevention or delay of type 2 diabetes. Diabetes Care 2002;

Pan X et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose Tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.

8.

Lindstrom J et al. The Finnish Diabetes Prevention Study (DPS): life style intervention and 3-year results on diet

25: 742-749.

9.

Ramanchandran A, et al. Indian Diabetes Prevention Programme (IDPP). Diabetologia 2006; 49:289-297. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.

10. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006; 68: 1096-1105. 11. Chiasson JL, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STPNIDDM trial. JAMA 2003; 290: 486494. 12. Wong ND, et al. Preventing coronary eve-nts by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003; 91: 1421-1426.

9


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·10

π√À¡π√™ 2007

ΔÔ ∂ÈÎÔÛÈÂÓÙ·ÓÔ˚Îfi √͇ ªÂÈÒÓÂÈ Ù· ªÂ›˙ÔÓ· ∫·Ú‰È·ÁÁÂȷο ∂ÂÈÛfi‰È· Û ÀÂÚ¯ÔÏËÛÙÂÚÔÏ·ÈÌÈÎÔ‡˜ ∞ÛıÂÓ›˜. ªÂϤÙË JELIS (Japan EPA lipid intervention study): Δ˘¯·ÈÔÔÈË̤ÓË, ·ÓÔȯً˜ ¯ÔÚ‹ÁËÛ˘ Î·È Ù˘ÊÏ‹˜ ·Ó¿Ï˘Û˘ ÙÂÏÈÎÒÓ ÛËÌ›ˆÓ ÌÂϤÙË. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators Lancet 2007 Mar 31;369(9567):1090-8 ¶·Ï·ÈfiÙÂÚ˜ ÂȉËÌÈÔÏÔÁÈΤ˜ ÌÂϤÙ˜ ¤¯Ô˘Ó ‰Â›ÍÂÈ fiÙÈ ÏËı˘ÛÌÔ›, fiˆ˜ ÔÈ ∂ÛÎÈÌÒÔÈ ÙÔ˘ μ. ∫·Ó·‰¿ Î·È Ù˘ ∞Ï¿Ûη˜ Î·È ÔÈ °È·ˆÓ¤˙ÔÈ Ô˘ ηٷӷÏÒÓÔ˘Ó ·ÚÎÂÙ‹ ÔÛfiÙËÙ· ÏÈ·ÚÒÓ „·ÚÈÒÓ ¤¯Ô˘Ó ÌÂȈ̤ÓÔ Î›Ó‰˘ÓÔ Î·Ú‰È·ÁÁÂÈ·ÎÒÓ ÓÔÛËÌ¿ÙˆÓ. ∂›Û˘ ÎÏÈÓÈΤ˜ ÌÂϤÙ˜ Û ·ÛıÂÓ›˜ ÌÂÙ¿ ¤ÌÊÚ·ÁÌ· ÙÔ˘ Ì˘Ôηډ›Ô˘ ¤‰ÂÈÍ·Ó Â›Û˘ fiÊÂÏÔ˜ ™ÙË ÌÂϤÙË DART Û˘ÛÙ‹ıËΠÚfiÛÏË„Ë Ì ÙËÓ ÙÚÔÊ‹ „·ÚÈÒÓ 2 ÊÔÚ¤˜ ÙËÓ Â‚‰ÔÌ¿‰· ‹ ‰fiıËÎ·Ó Î¿„Ô˘Ï˜ ȯı˘ÂÏ·›Ô˘. ™Ù· 2 ¯ÚfiÓÈ· ·Ú·ÙËÚ‹ıËΠ̛ˆÛË ÙˆÓ ı·Ó¿ÙˆÓ ·fi fiÏ· Ù· ·›ÙÈ· ηٿ 29%. ™ÙË ÌÂϤÙË GISSI-P ‰fiıËÎ·Ó 850 mg ηı·ÚÒÓ ˆ-3 ÏÈ·ÚÒÓ ÔͤˆÓ ·fi ȯı˘¤Ï·È· Û ÌÂÙÂÌÊÚ·ÁÌ·ÙÈÎÔ‡˜ ·ÛıÂÓ›˜. ¶·Ú·ÙËÚ‹ıËΠ̛ˆÛË ÙˆÓ ı·Ó¿ÙˆÓ ·fi οı ·ÈÙ›· ηٿ 20%, ÙˆÓ Î·Ú‰È·ÁÁÂÈ·ÎÒÓ ı·Ó¿ÙˆÓ ηٿ 30% Î·È ÙˆÓ ·ÈÊÓȉ›ˆÓ ı·Ó¿ÙˆÓ ηٿ 45%. ¢ÂÓ ·Ú·ÙËÚ‹ıËΠfï˜ Ì›ˆÛË ÙˆÓ ÌË ı·Ó·ÙËÊfiÚˆÓ ÂÌÊÚ·ÁÌ¿ÙˆÓ Ô‡Ù Û ·˘Ù‹ ÙË ÌÂϤÙË Ô‡Ù ÛÙËÓ DART. ∏ ÌÂϤÙË JELIS, Ë ÔÔ›· ‰ÈÂÍ‹¯ıË ÛÙÔ Kobe University Graduate School of Medicine ÛÙÔ Kobe Ù˘ π·ˆÓ›·˜, ÛÎÔfi ›¯Â Ó· ÌÂÏÂÙ‹ÛÂÈ ·Ó Ë Û˘ÌÏËڈ̷ÙÈ΋ ¯ÔÚ‹ÁËÛË ÂÈÎÔÛÈÂÓÙ·ÓÔ˚ÎÔ‡ ÔͤԘ (∂ƒ∞) Û ¤Ó·Ó ÏËı˘ÛÌfi Ô˘ οÓÂÈ ·ÚÎÂÙ‹ ηٷӿψÛË „·ÚÈÒÓ ¤¯ÂÈ Î¿ÙÈ ÂÚÈÛÛfiÙÂÚÔ Ó· ÚÔÛʤÚÂÈ ÛÙËÓ ÚfiÏË„Ë ÙˆÓ Î·Ú‰È·ÁÁÂÈ·ÎÒÓ ÓÔÛËÌ¿ÙˆÓ. ¶ÂÚȤϷ‚ 19.466 ·ÛıÂÓ›˜ (5.859 ¿Ó‰Ú˜ ËÏÈΛ·˜ 40-59 ÂÙÒÓ Î·È 12.786 Á˘Ó·›Î˜ ÌÂÙÂÌËÓÔ·˘Ûȷ΋˜ ËÏÈΛ·˜ ̤-

10

¯ÚÈ 75 ÂÙÒÓ) Ì ˘ÂÚ¯ÔÏËÛÙÂÚÔÏ·ÈÌ›· (ÔÏÈ΋ ¯ÔÏËÛÙÂÚfiÏË > 250 mg% Î·È LDL-¯ÔÏËÛÙÂÚfiÏË > 175 mg%). ΔÔ 90% ÙˆÓ ·ÛıÂÓÒÓ ¤Ï·‚ ÌÈÎÚ‹ ‰fiÛË ÛÙ·Ù›Ó˘ (Ú·‚·ÛÙ·Ù›ÓË 10 mg/ËÌÂÚËÛ›ˆ˜ ‹ ÛÈÌ‚·ÛÙ·Ù›ÓË 5 mg/ËÌÂÚ.) √È ÌÈÛÔ› ·ÛıÂÓ›˜ (9.326) ¤Ï·‚·Ó ο„Ô˘Ï˜ ˘„ËÏ‹˜ ηı·ÚfiÙËÙ·˜ ∂ƒ∞ Û ‰fiÛË 600 mg ÙÚÂȘ ÊÔÚ¤˜ ÙËÓ Ë̤ڷ (ËÌÂÚ‹ÛÈ· ‰fiÛË 1.800 mg). ¶ÚˆÙ‡ÔÓ ÙÂÏÈÎfi Û˘Ì‚¿Ó ÔÚ›ÛÙËΠÔÔÈÔ‰‹ÔÙ Ì›˙ÔÓ ÛÙÂÊ·ÓÈ·›Ô ÂÂÈÛfi‰ÈÔ, ÂÚÈÏ·Ì‚·ÓÔÌ¤ÓˆÓ ÙˆÓ ·ÈÊÓȉ›ˆÓ ηډȷÎÒÓ ı·Ó¿ÙˆÓ, ı·Ó·ÙËÊfiÚˆÓ Î·È ÌË ı·Ó·ÙËÊfiÚˆÓ ÂÌÊÚ·ÁÌ¿ÙˆÓ, Ù˘ ·ÛÙ·ıÔ‡˜ ÛÙËı¿Á¯Ë˜ Î·È ÙˆÓ ÂÂÌ‚¿ÛÂˆÓ ‰È·‰ÂÚÌÈ΋˜ ·ÁÁÂÈÔÏ·ÛÙÈ΋˜ ‹ ·ÔÚÙÔÛÙÂÊ·ÓÈ·›·˜ ·Ú¿Î·Ì„˘. ∏ ·Ú·ÎÔÏÔ‡ıËÛË ÙˆÓ ·ÛıÂÓÒÓ ÎÚ¿ÙËÛ ηٿ ̤ÛÔ fiÚÔ 4,6 ¯ÚfiÓÈ·. ΔÔ ÚˆÙ‡ˆÓ ÙÂÏÈÎfi Û˘Ì‚¿Ó ·Ú·ÙËÚ‹ıËΠ۠2,8% ÙˆÓ ·ÛıÂÓÒÓ Ù˘ ÔÌ¿‰·˜ Ô˘ ¤Ï·‚ ∂ƒ∞ Î·È ÛÙÔ 3,5% Ù˘ ÔÌ¿‰·˜ ÂϤÁ¯Ô˘, Ì›ˆÛË Ì ÙËÓ ·ÁˆÁ‹ ÙÔ˘ Û¯ÂÙÈÎÔ‡ ÎÈÓ‰‡ÓÔ˘ ηٿ 19% (p=0,011). ™ÙËÓ ÔÌ¿‰· ÙˆÓ ·ÙfiÌˆÓ Ô˘ ‰ÂÓ Â›¯·Ó ¤Î‰ËÏË ÛÙÂÊ·ÓÈ·›· ÓfiÛÔ ÚÈÓ ÙËÓ ¤Ó·ÚÍË Ù˘ ·ÁˆÁ‹˜ (ÚˆÙÔÁÂÓ‹˜ ÚfiÏË„Ë) Ë Ì›ˆÛË ÙÔ˘ Û¯ÂÙÈÎÔ‡ ÎÈÓ‰‡ÓÔ˘ ‹Ù·Ó 18% (1,4% ÛÙËÓ ÔÌ¿‰· ıÂÚ·›·˜ ¤Ó·ÓÙÈ 1,7% ÛÙËÓ ÔÌ¿‰· ÂϤÁ¯Ô˘) ·ÏÏ¿ ÙÔ ·ÔÙ¤ÏÂÛÌ· ‰ÂÓ ‹Ù·Ó ÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈÎfi (p=0,132). ∞ÓÙ›ıÂÙ·, ÛÙËÓ ÔÌ¿‰· Ù˘ ‰Â˘ÙÂÚÔÁÂÓÔ‡˜ ÚfiÏ˄˘ ÙÔ ·ÔÙ¤ÏÂÛÌ· ‹Ù·Ó ÛËÌ·ÓÙÈÎfi (8,7% ¤Ó·ÓÙÈ 10,7%, Ì›ˆÛË ÎÈÓ‰‡ÓÔ˘ ηٿ 19%). ∏ Ì›ˆÛË ·Ú·ÙËÚ‹ıËÎÂ

΢ڛˆ˜ ÛÙ· ÂÚÈÛÙ·ÙÈο ·ÛÙ·ıÔ‡˜ ÛÙËı¿Á¯Ë˜ Î·È ÌË ı·Ó·ÙËÊfiÚˆÓ ÛÙÂÊ·ÓÈ·›ˆÓ ÂÂÈÛÔ‰›ˆÓ, ÂÓÒ Ù· ÂÚÈÛÙ·ÙÈο ·ÈÊÓȉ›Ô˘ ı·Ó¿ÙÔ˘ ‹ ı·Ó·ÙËÊfiÚˆÓ ÂÌÊÚ·ÁÌ¿ÙˆÓ ‰ÂÓ ÌÂÈÒıËηÓ. ∞˘Ùfi Â›Ó·È Û ·ÓÙ›ıÂÛË Ì ÙË ÌÂϤÙË GISSI-P Î·È ÙË ÌÂϤÙË DART, ÛÙȘ Ôԛ˜ ·Ú·ÙËÚ‹ıËΠ̛ˆÛË ÙˆÓ ı·Ó·ÙËÊfiÚˆÓ ÂÂÈÛÔ‰›ˆÓ ·ÏÏ¿ fi¯È ÙˆÓ ÌË ı·Ó·ÙËÊfiÚˆÓ. ∞˘Ùfi ÂÓ‰¤¯ÂÙ·È Ó· ÔÊ›ÏÂÙ·È ÛÙÔ ÁÂÁÔÓfi˜ fiÙÈ Ô °È·ˆÓ¤˙ÈÎÔ˜ ÏËı˘ÛÌfi˜ ÚÔÛÏ·Ì‚¿ÓÂÈ Ì ÙËÓ ÙÚÔÊ‹ ÙÔ˘ ÌÂÁ¿ÏË ÔÛfiÙËÙ· ˆ-3 ÏÈ·ÚÒÓ ÔͤˆÓ Î·È Û˘ÓÂÒ˜ ·ÔÏ·Ì‚¿ÓÂÈ ‹‰Ë ÙËÓ ·ÓÙÈ·ÚÚ˘ıÌÈ΋ ÚÔÛÙ·Û›· Ô˘ ÚÔÛʤÚÂÈ Ë ¯·ÌËÏ‹ ‰fiÛË ÙˆÓ ˆ-3 ÏÈ·ÚÒÓ ÛÙÔ˘˜ ·ÛıÂÓ›˜ Ì ÈÛÙÔÚÈÎfi ·Ï·ÈÔ‡ ÂÌÊÚ¿ÁÌ·ÙÔ˜ ÙÔ˘ Ì˘Ôηډ›Ô˘. ™Â ÌÂÁ·Ï‡ÙÂÚ˜ ‰fiÛÂȘ ÂÌÊ·Ó›˙ÂÙ·È ÙÔ ÚÔÛٷ٢ÙÈÎfi ·ÔÙ¤ÏÂÛÌ· ÁÈ· Ù· ÌË ı·Ó·ÙËÊfiÚ· ÂÂÈÛfi‰È·, ¯¿ÚȘ ÛÙËÓ ·ÓÙÈ˘ÂÚÙ·ÛÈ΋ ‹ ·ÓÙÈÊÏÂÁÌÔÓÒ‰Ë ‰Ú¿ÛË ÙˆÓ ˆ-3 ÏÈ·ÚÒÓ ÔͤˆÓ. ΔÔ Â˘ÓÔ˚Îfi ·ÔÙ¤ÏÂÛÌ· ÛÙË ÌÂϤÙË JELIS, ηٿ ÙÔ˘˜ ÂÚ¢ÓËÙ¤˜ ‰ÂÓ ÔÊ›ÏÂÙ·È Û ˘Ô¯ÔÏËÛÙÂÚÔÏ·ÈÌÈ΋ ‰Ú¿ÛË ÙˆÓ ˆ-3 ÏÈ·ÚÒÓ ÔͤˆÓ, ‰Â‰Ô̤ÓÔ˘ fiÙÈ Ë ÔÏÈ΋ Î·È Ë LDL-¯ÔÏËÛÙÂÚfiÏË ÌÂÈÒıËÎ·Ó Î·Ù¿ 19% Î·È 25% ·ÓÙ›ÛÙÔȯ· Î·È ÛÙȘ ‰‡Ô ÔÌ¿‰Â˜ ÂÓÒ Ù· ÙÚÈÁÏ˘ÎÂÚ›‰È· ÌÂÈÒıËÎ·Ó Î·Ù¿ 9% ÛÙËÓ ÔÌ¿‰· Ô˘ ¤Ï·‚ ∂ƒ∞ Î·È 4% ÛÙËÓ ÔÌ¿‰· Ô˘ ‹Ú·Ó ÌfiÓÔ ¯·ÌËÏ‹ ‰fiÛË ÛÙ·Ù›Ó˘ (p<0,0001). Δ· ˆ-3 ÏÈ·Ú¿ Ôͤ· ¤¯Ô˘Ó ¤Ó· ¢ڇ Ê¿ÛÌ· ‚ÈÔÏÔÁÈÎÒÓ ‰Ú¿ÛˆÓ, ÌÂٷ͇ ÙˆÓ ÔÔ›ˆÓ ·ÓÙÈıÚÔÌ‚ˆÙÈ΋, ·ÓÙÈÊÏÂÁÌÔÓÒ‰Ë, ·ÓÙÈ-


ATHIROSK 14

03-07-07

12:06

™ÂÏ���‰·11

K§INIKE™ ME§ETE™ ·ÚÚ˘ıÌÈ΋ Î·È ·ÓÙÈ·ıËÚÔÁfiÓÔ, ¤Ú·Ó Ù˘ ÙÚÔÔÔÈËÙÈ΋˜ ÙˆÓ ÏÈȉ›ˆÓ ‰Ú¿Ûˆ˜ ÙˆÓ. ™Â ¿ÚıÚÔ Ù˘ ™‡ÓÙ·Í˘ (editorial) Ô˘ ‰ËÌÔÛȇÂÙ·È ÛÙÔ ›‰ÈÔ Ù‡¯Ô˜ ÙÔ˘ Lancet ÙÔÓ›˙ÂÙ·È fiÙÈ, ÌÔÏÔÓfiÙÈ Ë ÌÂϤÙË ‰ÂÓ

Â›Ó·È ‰ÈÏ¿-Ù˘ÊÏ‹ Î·È Ù· ÙÂÏÈο Û˘Ì‚¿ÓÙ· Ô˘ ·Ú·ÙËÚ‹ıËÎ·Ó Â›Ó·È fi¯È ÛÎÏËÚ¿, Ù· Û˘ÌÂÚ¿ÛÌ·Ù· Ù˘ ‰ÂÓ Ú¤ÂÈ Ó· ·ÁÓÔËıÔ‡Ó. ™Â ÌÈ· ÂÔ¯‹ Ô˘ Ë Ìfi‰· ÂÓÙÔ›˙ÂÙ·È ÛÙ· ·ÎÚÈ‚¿ Ê¿Ú̷η, ÙȘ ·ÈÌ·ÙËÚ¤˜ ÂÂÌ‚¿ÛÂȘ Î·È ÛÙȘ ÂÍÂÏÈÁ̤Ó˜ Û˘-

Û΢¤˜, ̤ÙÚȘ ‰È·ÈÙËÙÈΤ˜ ·ÏÏ·Á¤˜, ÔÈ Ôԛ˜ Â›Ó·È ·Î›Ó‰˘Ó˜, ¯·ÌËÏÔ‡ ÎfiÛÙÔ˘˜ Î·È Â˘Ú¤ˆ˜ ÂÊ·ÚÌfiÛÈ̘, ‰˘Ó·ÙfiÓ Ó· ·Ô‚Ô‡Ó È‰È·›ÙÂÚ· ˆÊ¤ÏÈ̘. ∂È̤ÏÂÈ·: ∏Ï›·˜ ÃÂÈÌÒÓ·˜

¶ÏÂÈfiÙÚÔ˜ ¢Ú¿ÛÂȘ Ù˘ ∞ÙÔÚ‚·ÛÙ·Ù›Ó˘ ∏Ï›·˜ ÃÂÈÌÒÓ·˜, ∫·Ú‰ÈÔÏfiÁÔ˜

1. Atorvastatin for Reduction of MYocardial Damage during Angioplasty (ARMYDA) trial(12). ¢ÈÏ¿-Ù˘ÊÏ‹, ÌÂ Ù˘¯·›· ηٷÓÔÌ‹ ÙˆÓ ·ÛıÂÓÒÓ, ÂÏÂÁ¯fiÌÂÓË Ì ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ, ÚÔÔÙÈ΋ ÎÏÈÓÈ΋ ÌÂϤÙË. ¶ÂÚȤϷ‚ 153 ·ÛıÂÓ›˜ Ì ¯ÚÔÓ›· ÛÙ·ıÂÚ‹ ÛÙËı¿Á¯Ë, ÁÈ· ÙÔ˘˜ ÔÔ›Ô˘˜ ˘‹Ú¯Â ¤Ó‰ÂÈÍË ·ÁÁÂÈÔÏ·ÛÙÈ΋˜ Î·È ÔÈ ÔÔ›ÔÈ ‰ÂÓ Ï¿Ì‚·Ó·Ó ÛÙ·Ù›ÓË Ì¤¯ÚÈ ÙËÓ ¤ÓÙ·ÍË ÙÔ˘˜ ÛÙË ÌÂϤÙË. √È ·ÛıÂÓ›˜ ηٷÓÂÌ‹ıËÎ·Ó Ù˘¯·›· Û ‰‡Ô ÔÌ¿‰Â˜, ·ÓÂÍ¿ÚÙËÙ· ·fi Ù· Â›‰· ÏÈȉ›ˆÓ ÙÔ˘˜ Î·È Ë Ì›· ÔÌ¿‰· (76 ·ÛıÂÓ›˜) ¤Ï·‚ ·ÙÔÚ‚·ÛÙ·Ù›ÓË

Û˘ Î·È Â› ¤Ó· Ì‹Ó·. ΔÔ ÚˆÙ‡ÔÓ ÙÂÏÈÎfi ÛËÌÂ›Ô ·Ú·ÙËÚ‹ıËΠ۠ÔÛÔÛÙfi 5% ÙˆÓ ·ÛıÂÓÒÓ Ù˘ ÔÌ¿‰·˜ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ Î·È Û 18% ÛÙËÓ ÔÌ¿‰· ÙÔ˘ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ (ƒ=0,025). ∞‡ÍËÛË Ù˘ CK-MB ¿Óˆ ·fi ÙÔ Ê˘ÛÈÔÏÔÁÈÎfi ·Ú·ÙËÚ‹ıËΠÛÙÔ 12% Ù˘ ÔÌ¿‰·˜ Ô˘ ¤Ï·‚ ·ÙÔÚ‚·ÛÙ·Ù›ÓË Î·È ÛÙÔ 35% ÛÙËÓ ÔÌ¿‰· ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ (ƒ=0,001). ∂›Û˘ ·Ú·ÙËÚ‹ıËΠÛËÌ·ÓÙÈ΋ ‰È·ÊÔÚ¿ ÛÙËÓ ·‡ÍËÛË Î·È ÙˆÓ ¿ÏÏˆÓ ÂÓ˙‡ÌˆÓ: ÙÚÔÔÓ›Ó˘-π 20% ¤Ó·ÓÙÈ 48% (ƒ=0,0004) Î·È Ì˘ÔÛÊ·ÈÚ›Ó˘ 22% ¤Ó·ÓÙÈ 51% (ƒ=0,0005). ∏ ηٷÓÔÌ‹ Ù˘ CK-MB Î·È Ù˘ ÙÚÔÔÓ›Ó˘-π ηٿ Â›‰· ÌÂÙ¿ ÙËÓ Â¤Ì‚·ÛË Ê·›ÓÂÙ·È ÛÙËÓ ∂ÈÎfiÓ· 1. √ ̤ÛÔ˜ fiÚÔ˜ ÙˆÓ Ì¤ÁÈÛÙˆÓ ·˘Í‹ÛÂˆÓ ÙˆÓ ÙÈÌÒÓ ÂÓ˙‡ÌˆÓ ÌÂÙ¿ ÙËÓ Â¤Ì‚·ÛË Ê·›ÓÂÙ·È ÛÙËÓ ∂ÈÎfiÓ· 2. ∫·Ù¿ ÙÔÓ ¤Ó· Ì‹Ó· ·Ú·ÎÔÏÔ‡ıËÛ˘ ‰ÂÓ ·Ú·ÙËÚ‹ıËÎ·Ó ¿ÏÏ· Ì›˙ÔÓ· ηډȷÁÁÂȷο ÂÂÈÛfi‰È· ¤Ú·Ó ÙÔ˘ ÂÌÊÚ¿ÁÌ·ÙÔ˜ ÙÔ˘ Ì˘Ôηډ›Ô˘. ¶ÔÏ˘·Ú·ÁÔÓÙÈ΋ ·Ó¿Ï˘ÛË ¤‰ÂÈÍ fiÙÈ Ë Ì›ˆÛË ÙÔ˘ ÂÚÈÂÂÌ‚·ÙÈÎÔ‡ ÂÌÊÚ¿ÁÌ·ÙÔ˜ ÙÔ˘ Ì˘ÔηÚ-

40

50 P=0.001

40

30

ΔÚÔÔÓ›ÓË-π (%)

¶ÚfiÛÊ·Ù· ‰ËÌÔÛȇıËΠÌÈ· ÛÂÈÚ¿ ÎÏÈÓÈÎÒÓ ÌÂÏÂÙÒÓ Ô˘ ·ÊÔÚÔ‡Ó ÛÙËÓ ·ÙÔÚ‚·ÛÙ·Ù›ÓË Î·È ‰È¢ڇÓÔ˘Ó ÙÔ Ê¿ÛÌ· ÙˆÓ ÏÂÈfiÙÚÔˆÓ ‰Ú¿ÛÂˆÓ Ù˘ ÛÙ·Ù›Ó˘ ·˘Ù‹˜ Ì ÎÏÈÓÈÎfi ÂӉȷʤÚÔÓ

Û ‰fiÛË 40 mg ËÌÂÚËÛ›ˆ˜ Î·È Ë ¿ÏÏË (77 ·ÛıÂÓ›˜) ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ. ª›· ‚‰ÔÌ¿‰· ÌÂÙ¿ ÙËÓ ¤Ó·ÚÍË Ù˘ Ê·Ú̷΢ÙÈ΋˜ ·ÁˆÁ‹˜ ‰ÈÂÓÂÚÁ‹ıËΠ۠fiÏÔ˘˜ ·ÁÁÂÈÔÏ·ÛÙÈ΋, Û‡Ìʈӷ Ì ÙÔ Î·ıÈÂڈ̤ÓÔ ÚˆÙfiÎÔÏÏÔ Î¿ı ΤÓÙÚÔ˘. ªÂÙ¿ ÙËÓ ·ÁÁÂÈÔÏ·ÛÙÈ΋ fiÏÔÈ ÔÈ ·ÛıÂÓ›˜ Î·È ÙˆÓ ‰‡Ô ÔÌ¿‰ˆÓ ¤Ï·‚·Ó 40 mg ·ÙÔÚ‚·ÛÙ·Ù›Ó˘. ∏ ‰È¿ÚÎÂÈ· Ù˘ ÌÂϤÙ˘ ‹Ù·Ó ¤Ó·˜ Ì‹Ó·˜. ¶ÚˆÙ‡ÔÓ ÙÂÏÈÎfi ÛËÌÂ›Ô ‹Ù·Ó Ë ·‡ÍËÛË, ·Ì¤Ûˆ˜ ÌÂÙ¿ ÙËÓ Â¤Ì‚·ÛË, Ù˘ CK-MB ¿Óˆ ·fi ÙÔ ‰ÈÏ¿ÛÈÔ Ù˘ ·Ú¯È΋˜ ÙÈÌ‹˜, ‰ËψÙÈ΋˜ ÂÌÊÚ¿ÁÌ·ÙÔ˜ ÙÔ˘ Ì˘Ôηډ›Ô˘. ¢Â˘ÙÂÚ‡ÔÓÙ· ÙÂÏÈο ÛËÌ›· ‹Ù·Ó (·) ÔÔÈ·‰‹ÔÙ ·‡ÍËÛË, ÌÂÙ¿ ÙËÓ Â¤Ì‚·ÛË, ÙˆÓ Ì˘ÔηډȷÎÒÓ ÂÓ˙‡ÌˆÓ (CK-MB, ÙÚÔÔÓ›Ó˘-π, Ì˘ÔÛÊ·ÈÚ›Ó˘) ¿Óˆ ·fi Ù· Ê˘ÛÈÔÏÔÁÈο fiÚÈ· (‚) Ô Ì¤ÛÔ˜ fiÚÔ˜ ÙˆÓ Ì¤ÁÈÛÙˆÓ ·˘Í‹ÛÂˆÓ ÙˆÓ ·ÓˆÙ¤Úˆ ÂÓ˙‡ÌˆÓ ÌÂÙ¿ ÙËÓ Â¤Ì‚·ÛË Î·È (Á) Ë ÂÌÊ¿ÓÈÛË fiÏˆÓ ÙˆÓ ÌÂÈ˙fiÓˆÓ ‰˘ÛÌÂÓÒÓ Î·Ú‰È·ÎÒÓ Û˘Ì‚¿ÓÙˆÓ (ı¿Ó·ÙÔ˜, ¤ÌÊÚ·ÁÌ· ÙÔ˘ Ì˘Ôηډ›Ô˘ ‹ ·Ó¿ÁÎË Â·Ó·ÁÁ›ˆÛ˘) ·fi ÙË ÛÙÈÁÌ‹ Ù˘ Â¤Ì‚·-

CK-MB (%)

¶ÏÂÈfiÙÚÔ˜ ‰Ú¿ÛÂȘ (pleiotropic effects) ÙˆÓ ÛÙ·ÙÈÓÒÓ ¤¯Ô˘Ó ÔÓÔÌ·Ûı› Ù· ·ÔÙÂϤÛÌ·Ù· Ù˘ ¯ÔÚ‹ÁËÛ˘ ÙˆÓ Ê·ÚÌ¿ÎˆÓ ·˘ÙÒÓ Ô˘ ‰ÂÓ ÔÊ›ÏÔÓÙ·È ¿ÌÂÛ· ÛÙËÓ ˘ÔÏÈȉ·ÈÌÈ΋ ÙÔ˘˜ ‰Ú¿ÛË Î·È ¤¯Ô˘Ó ‰È·ÈÛÙˆı› ›Ù ÎÏÈÓÈο ÛÙȘ ÌÂÁ¿Ï˜ Ù˘¯·ÈÔÔÈË̤Ó˜ ÎÏÈÓÈΤ˜ ÌÂϤÙ˜, ›Ù ÂÈÚ·Ì·ÙÈο ÛÙÔ ÂÚÁ·ÛÙ‹ÚÈÔ, in vitro ‹ in vivo. ∞ÔÙÂÏÔ‡Ó ¤Ó· ¢ڇ Ê¿ÛÌ· ÂΉËÏÒÛÂˆÓ Î·È Û ·˘Ù¤˜ ÂÚÈÏ·Ì‚¿ÓÂÙ·È Ë ·ÓÙÈÔÍÂȉˆÙÈ΋ ‰Ú¿ÛË(1, 2, 3), Ë ‚ÂÏÙ›ˆÛË Ù˘ ÏÂÈÙÔ˘ÚÁ›·˜ ÙÔ˘ ÂÓ‰ÔıËÏ›Ô˘(4, 5), Ë ·ÓÙÈÊÏÂÁÌÔÓ҉˘(6, 7) Î·È Ë ·ÓÙÈıÚÔÌ‚ˆÙÈ΋(8) ‰Ú¿ÛË, Ë ‰Ú¿ÛË ÛÙ· Ï›· Ì˘˚ο(9) Î·È ÛÙ· Ì˘Ôηډȷο ·ÙÙ·Ú·(10), Ë ·ÁÁÂÈԉȷÛÙ·ÏÙÈ΋ ‰Ú¿ÛË ÛÙ· ÌÈÎÚ¿ ·ÁÁ›·(11) ÎÏ. ¶ÔÏϤ˜ ·fi ÙȘ ·Ú·¿Óˆ ‰Ú¿ÛÂȘ Â›Ó·È ÎÔÈÓ¤˜ ÁÈ· fiϘ; ÙȘ ÛÙ·Ù›Ó˜, ÔÚÈṲ̂Ó˜ fï˜ ·ÔÙÂÏÔ‡Ó ¯·Ú·ÎÙËÚÈÛÙÈÎfi ÌÈ·˜ ‹ ÌÂÚÈÎÒÓ ÌfiÓÔ ÛÙ·ÙÈÓÒÓ.

P=0.006

20 10

0

30 20 10 0

∂ÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ

∞ÙÔÚ‚·ÛÙ·Ù›ÓË

1 ÊÔÚ¿

2-5 ÊÔÚ¤˜

∂ÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ

∞ÙÔÚ‚·ÛÙ·Ù›ÓË

> 5 ÊÔÚ¤˜ ∞ÓÒÙÂÚÔ Ê˘ÛÈÔÏÔÁÈÎfi fiÚÈÔ

∂ÈÎfiÓ· 1. ¶ÔÛÔÛÙfi ·‡ÍËÛ˘ Ù˘ CK-MB Î·È Ù˘ ÙÚÔÔÓ›Ó˘-π ÌÂÙ¿ ÙËÓ Â¤Ì‚·ÛË Î·Ù¿ >1, 2-5 Î·È >5 ÊÔÚ¤˜ ¿Óˆ ·fi ÙÔ Ê˘ÛÈÔÏÔÁÈÎfi fiÚÈÔ ÛÙËÓ Î¿ı ÔÌ¿‰·.

11


03-07-07

12:06

™ÂÏ›‰·12

π√À¡π√™ 2007

10

0,8

6 4

2 0

100 ª¤ÁÈÛÙË ÙÈÌ‹ myoglobin ng/mL

P=0.007 8

ª¤ÁÈÛÙË ÙÈÌ‹ Troponin-I ng/mL

ª¤ÁÈÛÙË ÙÈÌ‹ CK-MB ng/mL

ATHIROSK 14

P=0.0008 0,6

0,4

0,2

0

∂ÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ

P=0.0002

80 60 40 20

0

∞ÙÔÚ‚·ÛÙ·Ù›ÓË

∂ÈÎfiÓ· 2. ª¤ÛÔ˜ fiÚÔ˜ ̤ÁÈÛÙˆÓ ·˘Í‹ÛÂˆÓ ÙˆÓ ÙÈÌÒÓ ÙˆÓ ÂÓ˙‡ÌˆÓ ÌÂÙ¿ ÙËÓ ·ÁÁÂÈÔÏ·ÛÙÈ΋ ÛÙȘ ‰‡Ô ÔÌ¿‰Â˜ ÙˆÓ ·ÛıÂÓÒÓ.

‰›Ô˘ ‰ÂÓ ÔÊ›ÏÂÙ·È Û ¿ÏÏÔ˘˜ ·Ú¿ÁÔÓÙ˜ ÏËÓ Ù˘ ¯ÔÚ‹ÁËÛ˘ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ Î·È fiÙÈ Ë ¯Ú‹ÛË ‚-·Ó·ÛÙÔϤˆÓ, ·Ó·ÛÙÔϤˆÓ ÙˆÓ ˘Ô‰Ô¯¤ˆÓ ππb/IIIa ÁÏ˘ÎÔÚˆÙ½Ó˘ ‹ ∞ª∂∞ ‰ÂÓ Ì›ˆÛ ÙÔÓ Î›Ó‰˘ÓÔ. ∂›Ó·È ÁÓˆÛÙfi fiÙÈ Ë ·‡ÍËÛË Ù˘ CK-MB ÌÂÙ¿ ÙËÓ ·ÁÁÂÈÔÏ·ÛÙÈ΋ ·˘Í¿ÓÂÈ ÙÔÓ Î›Ó‰˘ÓÔ Î·Ú‰È·ÎÔ‡ ı·Ó¿ÙÔ˘. ªÈ· ÌÂÙ·-·Ó¿Ï˘ÛË Ô˘ ÂÚȤϷ‚ 23.230 ·ÛıÂÓ›˜ ¤‰ÂÈÍ fiÙÈ ·‡ÍËÛË Ù˘ CK-MB ηٿ 1 - 3 ÊÔÚ¤˜ ¿Óˆ ÙÔ˘ Ê˘ÛÈÔÏÔÁÈÎÔ‡ ÔÚ›Ô˘ ·˘Í¿ÓÂÈ ÙÔÓ Î›Ó‰˘ÓÔ ı·Ó¿ÙÔ˘ Û ¤Ó· ¯ÚfiÓÔ Î·Ù¿ 1,7%, ·‡ÍËÛË Î·Ù¿ 3 - 5 ÊÔÚ¤˜ ·˘Í¿ÓÂÈ ÙÔÓ Î›Ó‰˘ÓÔ Î·Ù¿ 2,8% Î·È ·‡ÍËÛË Î·Ù¿ > 5 ÊÔÚ¤˜ ·˘Í¿ÓÂÈ ÙÔÓ Î›Ó‰˘ÓÔ Î·Ù¿ 7,4%(13). 2. Atorvastatin for Reduction of MYocardial Damage during Angioplasty - Acute Coronary Syndromes (ARMYDA-ACS) trial(14). ™ÎÔfi˜ Ù˘ ÌÂϤÙ˘ ·˘Ù‹˜ ‹Ù·Ó Ó· ÂÚ¢ӋÛÂÈ ÙË ‰Ú¿ÛË Ù˘ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ Û ·ÛıÂÓ›˜ Ì Ô͇ ÛÙÂÊ·ÓÈ·›Ô Û‡Ó‰ÚÔÌÔ Ô˘ ˘Ô‚¿ÏÏÔÓÙ·È Û ·ÁÁÂÈÔÏ·ÛÙÈ΋, ·Ó ‰Ôı› Ï›Á˜ ÒÚ˜ ÚÈÓ ÙËÓ Â¤Ì‚·ÛË. ¶ÚfiÎÂÈÙ·È ÁÈ· ÌÈ· ÔÏ˘ÎÂÓÙÚÈ΋ (ÙÚ›· ΤÓÙÚ· ÛÙËÓ πÙ·Ï›·), Ù˘¯·ÈÔÔÈË̤ÓË, ‰ÈÏ¿ Ù˘ÊÏ‹, ÚÔÔÙÈ΋, ÂÏÂÁ¯fiÌÂÓË Ì ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ ÌÂϤÙË. 191 ·ÛıÂÓ›˜ Ì Ô͇ ÛÙÂÊ·ÓÈ·›Ô Û‡Ó‰ÚÔÌÔ ¯ˆÚ›˜ ·Ó¿Û·ÛË ÙÔ˘ ST (non-ST elevation ACS) Ô˘ ‰ÂÓ ÂÏ¿Ì‚·Ó·Ó ÛÙ·Ù›ÓË Ì¤¯ÚÈ ÙËÓ ¤Ó·ÚÍË Ù˘ ÌÂϤÙ˘ Î·È ‰ÂÓ Â›¯·Ó ¤Ó‰ÂÈÍË Â›ÁÔ˘Û·˜ ·ÁÁÂÈÔÏ·ÛÙÈ΋˜ ηٷÓÂÌ‹ıËÎ·Ó Ù˘¯·›· Ó· Ï¿‚Ô˘Ó ·ÙÔÚ‚·ÛÙ·Ù›ÓË

12

80 mg 12 ÒÚ˜ ÚÈÓ ÙËÓ ·ÁÁÂÈÔÁÚ·Ê›· Î·È ·ÏÏ¿ 40 mg ÂÚ›Ô˘ 2 ÒÚ˜ ÚÈÓ ÙËÓ Â¤Ì‚·ÛË ‹ ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ ÙȘ ›‰È˜ ÒÚ˜. ªÂÙ¿ ÙËÓ Ù˘¯·ÈÔÔ›ËÛË ·ÔÎÏ›ÛıËÎ·Ó 10 ·ÛıÂÓ›˜ ·fi οı ÔÌ¿‰·, ÁÈ·Ù› Ë ÛÙÂÊ·ÓÈÔÁÚ·Ê›· ¤‰ÂÈÍ fiÙÈ ‰ÂÓ ‹Ù·Ó ηٿÏÏËÏÔÈ ÁÈ· ·ÁÁÂÈÔÏ·ÛÙÈ΋. ŒÙÛÈ ÂÚÈÂÏ‹ÊıËÎ·Ó 86 ·ÛıÂÓ›˜ ÛÙËÓ ÔÌ¿‰· Ù˘ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ Î·È 85 ·ÛıÂÓ›˜ ÛÙËÓ ÔÌ¿‰· placebo. ªÂÙ¿ ÙËÓ Â¤Ì‚·ÛË fiÏÔÈ ÔÈ ·ÛıÂÓ›˜ ¤Ï·‚·Ó 40 mg ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ ËÌÂÚËÛ›ˆ˜, ·ÓÂÍ¿ÚÙËÙ· ·fi ÙËÓ ÔÌ¿‰· ÛÙËÓ ÔÔ›· Ù˘¯·ÈÔÔÈ‹ıËηÓ. ¶ÚˆÙ‡ÔÓ ÙÂÏÈÎfi ÛËÌÂ›Ô ÔÚ›ÛıËΠÙÔ Û‡ÓÔÏÔ ÙˆÓ ÌÂÈ˙fiÓˆÓ ‰˘ÛÌÂÓÒÓ Î·Ú‰È·ÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ (ı¿Ó·ÙÔ˜, ¤ÌÊÚ·ÁÌ· ÙÔ˘ Ì˘Ôηډ›Ô˘ Î·È ·Ó¿ÁÎË Â·Ó·ÁÁ›ˆÛ˘ ÛÙÔ ›‰ÈÔ ·ÁÁ›Ô) ̤۷ ÛÙÔÓ ÚÒÙÔ Ì‹Ó· ·fi ÙËÓ ·ÁÁÂÈÔÏ·ÛÙÈ΋. ¢È·ÁÓˆÛÙÈÎfi ÎÚÈÙ‹ÚÈÔ ÔͤԘ ÂÌÊÚ¿ÁÌ·ÙÔ˜ ηıÔÚ›ÛıËÎÂ Ë ·‡ÍËÛË Ù˘ CK-MB ‰‡Ô ÊÔÚ¤˜ ¿Óˆ ÙÔ˘ Ê˘ÛÈÔÏÔÁÈÎÔ‡ ÔÚ›Ô˘ ÛÙÔ˘˜ ·ÛıÂÓ›˜ Ô˘ Ë ÙÈÌ‹ ÙÔ˘ ÂÓ˙‡ÌÔ˘ ‹Ù·Ó ÂÓÙfi˜ ÙˆÓ Ê˘ÛÈÔÏÔÁÈÎÒÓ ÔÚ›ˆÓ ÚÈÓ ÙËÓ ·ÁÁÂÈÔÏ·ÛÙÈ΋ ‹ Ô ‰ÈÏ·ÛÈ·ÛÌfi˜ Ù˘ ·Ó ‹Ù·Ó ·˘ÍË̤ÓË ‹‰Ë ÚÈÓ ÙËÓ ·ÁÁÂÈÔÏ·ÛÙÈ΋. ∂·Ó·ÁÁ›ˆÛË ÛÙÔ ›‰ÈÔ ·ÁÁÂ›Ô ÂÚÈÂÏ¿Ì‚·Ó ÙËÓ ·ÔÚÙÔÛÙÂÊ·ÓÈ·›· ·Ú¿Î·Ì„Ë ‹ ÙËÓ ·ÁÁÂÈÔÏ·ÛÙÈ΋ ÛÙÔ ›‰ÈÔ ÛËÌÂ›Ô ÙÔ˘ ·ÁÁ›Ԣ. ∏ ·ÁÁÂÈÔÏ·ÛÙÈ΋ ‹Ù·Ó ÂÈÙ˘¯‹˜ Û fiÏÔ˘˜ ÙÔ˘˜ ·ÛıÂÓ›˜. ¢Â˘ÙÂÚ‡ÔÓÙ· ÙÂÏÈο ÛËÌ›· ‹Ù·Ó (·) οı ·‡ÍËÛË ÙˆÓ ‰ÂÈÎÙÒÓ Ì˘Ôηډȷ΋˜ ‚Ï¿‚˘ (CK-MB, ÙÚÔÔÓ›ÓË-π,

Ì˘ÔÛÊ·ÈÚ›ÓË) ÌÂÙ¿ ÙËÓ Â¤Ì‚·ÛË Î·È (‚) ÌÂÙ·‚ÔϤ˜ Ù˘ ÙÈÌ‹˜ Ù˘ CRP ÌÂÙ¿ ÙËÓ ·ÁÁÂÈÔÏ·ÛÙÈ΋. ªÂ›˙ÔÓ· ‰˘ÛÌÂÓ‹ ηډȷο Û˘Ì‚¿Ì·Ù· ·Ú·ÙËÚ‹ıËÎ·Ó Û 5% ÙˆÓ ·ÛıÂÓÒÓ Ù˘ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ Î·È Û 17% ÙˆÓ ·ÛıÂÓÒÓ ÙÔ˘ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ (ƒ=0,01) Î·È ·ÊÔÚÔ‡Û·Ó Î˘Ú›ˆ˜ ¤ÌÊÚ·ÁÌ· ÙÔ˘ Ì˘Ôηډ›Ô˘. ¢ÂÓ Û˘Ó¤‚Ë Î·Ó¤Ó·˜ ı¿Ó·ÙÔ˜ ÛÙȘ 30 Ë̤Ú˜. √È Î·Ì‡Ï˜ ÂÈ‚›ˆÛ˘ ÙˆÓ ‰‡Ô ÔÌ¿‰ˆÓ (Kaplan-Meier) Ê·›ÓÔÓÙ·È ÛÙËÓ ∂ÈÎfiÓ· 3. ΔÔ ÔÛÔÛÙfi ÙˆÓ ·ÛıÂÓÒÓ, ÛÙÔ˘˜ ÔÔ›Ô˘˜ ·˘Í‹ıËÎ·Ó Ù· Ì˘Ôηډȷο ¤Ó˙˘Ì· ÌÂÙ¿ ÙËÓ Â¤Ì‚·ÛË ‹Ù·Ó ÛËÌ·ÓÙÈο ÌÈÎÚfiÙÂÚÔ ÛÙËÓ ÔÌ¿‰· Ù˘ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ Û˘ÁÎÚÈÙÈο Ì ÙËÓ ÔÌ¿‰· ÙÔ˘ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ (CK-MB 7% ¤Ó·ÓÙÈ 27%, ƒ=0,001 Î·È ÙÚÔÔÓ›ÓË-π 41% ¤Ó·ÓÙÈ 58%, ƒ=0,039) Δ· Â›‰· Ù˘ CRP ÛÙÔÓ ÔÚfi ·˘Í‹ıËÎ·Ó Î·È ÛÙȘ ‰‡Ô ÔÌ¿‰Â˜ ÌÂÙ¿ ÙËÓ ·ÁÁÂÈÔÏ·ÛÙÈ΋, Ë ·‡ÍËÛË fï˜ ‹Ù·Ó ÛËÌ·ÓÙÈο ÌÂÁ·Ï‡ÙÂÚË ÛÙËÓ ÔÌ¿‰· ÙÔ˘ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ (63±114% ÛÙËÓ ÔÌ¿‰· Ô˘ ¤Ï·‚ ·ÙÔÚ‚·ÛÙ·Ù›ÓË Î·È 147±274% ÛÙËÓ ÔÌ¿‰· Ô˘ ‰ÂÓ ¤Ï·‚Â). ∏ ÔÏ˘·Ú·ÁÔÓÙÈ΋ ·Ó¿Ï˘ÛË ¤‰ÂÈÍ fiÙÈ Ë ¯ÔÚ‹ÁËÛË ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ ÚÈÓ ÙËÓ Â¤Ì‚·ÛË Ì›ˆÛ ÙÔÓ Î›Ó‰˘ÓÔ Û˘Ì‚·Ì¿ÙˆÓ ÛÙȘ 30 Ë̤Ú˜ (odds ratio 0,12, fiÚÈ· ·ÍÈÔÈÛÙ›·˜ 95% ·fi 0,05 ̤¯ÚÈ 0,50, ƒ=0,004). ∞ÛıÂÓ›˜ Ô˘ ¯ÚÂÈ¿ÛıËÎ·Ó ·Ó·ÛÙÔÏ›˜ Ù˘ ÁÏ˘ÎÔÚˆÙ½Ó˘ IIb/IIIa ‹ ›¯·Ó ÎÏ¿ÛÌ· Â͈ı‹Ûˆ˜ ≤ 40% ÂÌÊ¿ÓÈÛ·Ó ÌÂÁ·Ï‡ÙÂÚÔ Î›Ó‰˘ÓÔ. £ÂÚ·›· Ì ∞ª∂∞


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·13

∫§π¡π∫∂™ ª∂§∂Δ∂™

EÈ‚›ˆÛË ¯ˆÚ›˜ Ì›˙ÔÓ· Û˘Ì‚¿Ì·Ù· (%)

∞ÙÔÚ‚·ÛÙ·Ù›ÓË

∂ÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ

100 80

60 P=0.01

40 20

0 1

2

3

7

14

21

30

∏̤Ú˜ ÌÂÙ¿ ÙËÓ ·ÁÁÂÈÔÏ·ÛÙÈ΋ ∂ÈÎfiÓ· 3. ∫·Ì‡Ï˜ ÂÈ‚›ˆÛ˘ ¯ˆÚ›˜ Ì›˙ÔÓ· ηډȷο Û˘Ì‚¿Ì·Ù·, ÌÂÙ¿ ÙËÓ Ù˘¯·ÈÔÔ›ËÛË.

‹ ‚-·Ó·ÛÙÔÏ›˜ ηٿ ÙÔ ¯ÚfiÓÔ Ù˘ ·ÁÁÂÈÔÏ·ÛÙÈ΋˜ ‰ÂÓ Ì›ˆÛ ÙÔÓ Î›Ó‰˘ÓÔ.

∂È‚›ˆÛË ¯ˆÚ›˜ ÎÔÏÈ΋ Ì·ÚÌ·Ú˘Á‹ (%).

3. Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery - (ARMYDA-3) Study (15). H ÌÂϤÙË ·˘Ù‹ ÂͤٷÛ ÙË ‰˘Ó·ÙfiÙËÙ· Ù˘ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘, fiÙ·Ó ¯ÔÚËÁÂ›Ù·È ÚÔÂÁ¯ÂÈÚËÙÈο Û ηډÈÔ¯ÂÈÚÔ˘ÚÁÈΤ˜ ÂÂÌ‚¿ÛÂȘ ·ÓÔÈÎÙ‹˜ ηډȿ˜, Ó· ÚÔÏ·Ì‚¿ÓÂÈ ÙË ÌÂÙÂÁ¯ÂÈÚËÙÈ΋ ÎÔÏÈ΋ Ì·ÚÌ·Ú˘Á‹, Ë ÔÔ›· ˆ˜ ÁÓˆÛÙfiÓ Â›Ó·È Û˘¯Ó‹ Û ·˘Ù¤˜ ÙȘ ÂÚÈÙÒÛÂȘ Î·È Ô‰ËÁ› Û ·Ú¿Ù·ÛË Ù˘ ÓÔÛËÏ›·˜, ·‡ÍËÛË ÙÔ˘ ÎfiÛÙÔ˘˜ Î·È ÙˆÓ ÂÈÏÔÎÒÓ. ∂Ӊ›ÍÂȘ fiÙÈ ÔÈ ÛÙ·Ù›Ó˜ ÂÓ‰¤¯ÂÙ·È Ó· ÚÔÏ·Ì‚¿ÓÔ˘Ó ÙËÓ ÌÂÙÂÁ¯ÂÈÚËÙÈ΋ ÎÔÏÈ΋ Ì·ÚÌ·Ú˘Á‹ ˘‹Ú¯·Ó ·fi ÌÂϤÙ˜

·Ú·Ù‹ÚËÛ˘. ∞ÛıÂÓ›˜ Ô˘ ‹Û·Ó ˘fi ·ÁˆÁ‹ Ì ÛÙ·Ù›Ó˜ ÚÈÓ ÙËÓ ÂÁ¯Â›ÚËÛË ÂÌÊ¿ÓÈ˙·Ó ÏÈÁfiÙÂÚÔ Û˘¯Ó¿ ÂÂÈÛfi‰È· ÎÔÏÈ΋˜ Ì·ÚÌ·Ú˘Á‹˜ ÌÂÙ¿ ·ÔÚÙÔÛÙÂÊ·ÓÈ·›· ·Ú¿Î·Ì„Ë(16). ∏ ARMYDA-3 Â›Ó·È ÚÔÔÙÈ΋, Ù˘¯·ÈÔÔÈË̤ÓË, ‰ÈÏ¿-Ù˘ÊÏ‹, ÂÏÂÁ¯fiÌÂÓË Ì ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ ÌÂϤÙË, ÛÙËÓ ÔÔ›· ÂÓÙ¿¯ıËÎ·Ó 200 ·ÛıÂÓ›˜ Ô˘ ›¯·Ó ¤Ó‰ÂÈÍË Ó· ˘Ô‚ÏËıÔ‡Ó Û ÚÔÁÚ·ÌÌ·ÙÈṲ̂ÓË ÂÁ¯Â›ÚËÛË ·ÓÔÈÎÙ‹˜ ηډȿ˜ (·ÔÚÙÔÛÙÂÊ·ÓÈ·›· ·Ú¿Î·Ì„Ë ‹ ‰ÈfiÚıˆÛË ‚·Ï‚ȉÔ¿ıÂÈ·˜) Î·È ‰ÂÓ Â›¯·Ó ÈÛÙÔÚÈÎfi ÎÔÏÈ΋˜ Ì·ÚÌ·Ú˘Á‹˜ Ô‡Ù Ͽ̂·Ó·Ó ÛÙ·Ù›Ó˜ ̤¯ÚÈ ÙËÓ ¤ÓÙ·ÍË ÛÙË ÌÂϤÙË. ∫·Ù·ÓÂÌ‹ıËÎ·Ó Î·Ù¿ Ù˘¯·›Ô ÙÚfiÔ Û ‰‡Ô ÔÌ¿‰Â˜, ·ÓÂÍ¿ÚÙËÙ· ·fi Ù· Â›-

∞ÙÔÚ‚·ÛÙ·Ù›ÓË

∂ÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ

100 80 60 40 20 0

P=0.003

1

2

3

7

14

21

30

MÂÙÂÁ¯ÂÈÚËÙÈ΋ Ë̤ڷ ∂ÈÎfiÓ· 4. ∫·Ì‡Ï˜ ÂÈ‚›ˆÛ˘ ¯ˆÚ›˜ ÂÂÈÛfi‰ÈÔ ÎÔÏÈ΋˜ Ì·ÚÌ·Ú˘Á‹˜ Û οı ÔÌ¿‰·.

‰· ÏÈȉ›ˆÓ Î·È Ë Ì›· ÔÌ¿‰· (101 ¿ÙÔÌ·) ¤Ï·‚ ·ÙÔÚ‚·ÛÙ·Ù›ÓË 40 mg ÙËÓ Ë̤ڷ, ·Ú¯›˙ÔÓÙ·˜ 7 Ë̤Ú˜ ÚÈÓ ÙËÓ ÂÁ¯Â›ÚËÛË Î·È Ë ¿ÏÏË ÔÌ¿‰· (99 ¿ÙÔÌ·) ¤Ï·‚ ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ. ∏ ›‰È· ·ÁˆÁ‹ Û˘Ó¯›ÛıËΠÁÈ· fiÛÔ ‰È¿ÛÙËÌ· ÔÈ ·ÛıÂÓ›˜ ·Ú¤ÌÂÈÓ·Ó ÛÙÔ ÓÔÛÔÎÔÌ›Ô, ÂÓÒ ÌÂÙ¿ ÙËÓ ¤ÍÔ‰Ô Û˘ÓÙ·ÁÔÁÚ·Ê‹ıËΠ۠fiÏÔ˘˜ ·ÙÔÚ‚·ÛÙ·Ù›ÓË. ¶ÚˆÙ‡ÔÓ ÙÂÏÈÎfi ÛËÌÂ›Ô ‹Ù·Ó Ë ÂÌÊ¿ÓÈÛË ÛÙÔ ∏∫° ·Ú·ÎÔÏÔ‡ıËÛ˘ ÌÂÙÂÁ¯ÂÈÚËÙÈ΋˜ ÎÔÏÈ΋˜ Ì·ÚÌ·Ú˘Á‹˜ Ô˘ ‰È‹ÚÎÂÛ ÂÚÈÛÛfiÙÂÚÔ ·fi 5 ÏÂÙ¿ ‹ Ô˘ ¯ÚÂÈ¿ÛıËΠ·Ú¤Ì‚·ÛË ÏfiÁˆ ÛÙËı¿Á¯Ë˜ ‹ ·ÈÌÔ‰˘Ó·ÌÈ΋˜ ·ÛÙ¿ıÂÈ·˜. ¢Â˘ÙÂÚ‡ÔÓÙ· ÙÂÏÈο ÛËÌ›· ‹Ù·Ó Ë ‰È¿ÚÎÂÈ· Ù˘ ÌÂÙÂÁ¯ÂÈÚËÙÈ΋˜ ÓÔÛËÏ›·˜, Ù· Ì›˙ÔÓ· ηډȷÁÁÂȷο Û˘Ì‚¿ÓÙ· Û ‰È¿ÛÙËÌ· 30 ËÌÂÚÒÓ Î·È Ë ‰È·Î‡Ì·ÓÛË Ù˘ ÙÈÌ‹˜ Ù˘ CRP. ∏ ·ÙÔÚ‚·ÛÙ·Ù›ÓË Ì›ˆÛ ÛËÌ·ÓÙÈο ÙËÓ Â›ÙˆÛË Ù˘ ÎÔÏÈ΋˜ Ì·ÚÌ·Ú˘Á‹˜ (35% ¤Ó·ÓÙÈ 57%, ƒ=0.003, ∂ÈÎfiÓ· 4) Î·È Î·Ù¿ Û˘Ó¤ÂÈ· Î·È ÙË ‰È¿ÚÎÂÈ· ÓÔÛËÏ›·˜ (6,3±1,2 ¤Ó·ÓÙÈ 6,9±1,4 Ë̤Ú˜ ·ÓÙ›ÛÙÔȯ·, ƒ = 0,001). ΔÔ fiÊÂÏÔ˜ ÂÚÈÔÚ›ÛıËΠÛÙ· ÂÚÈÛÙ·ÙÈο Ô˘ ˘Ô‚Ï‹ıËÎ·Ó Û ·ÔÚÙÔÛÙÂÊ·ÓÈ·›· ·Ú¿Î·Ì„Ë Î·È ‰ÂÓ ·Ú·ÙËÚ‹ıËΠ۠ÂÁ¯ÂÈÚ‹ÛÂȘ ‚·Ï‚›‰ˆÓ. ∂›Û˘ Ë ·ÙÔÚ‚·ÛÙ·Ù›ÓË ‰ÂÓ ÚÔÛٿ٢۠ÙÔ˘˜ ·ÛıÂÓ›˜ Û ÂÚ›ÙˆÛË Ô˘ ›¯·Ó ‰È·ÙÂٷ̤ÓÔ ·ÚÈÛÙÂÚfi ÎfiÏÔ. Δ· Â›‰· Ù˘ CRP ‹Ù·Ó ¯·ÌËÏfiÙÂÚ· ÛÙÔ˘˜ ·ÛıÂÓ›˜ Ô˘ ‰ÂÓ ÂÌÊ¿ÓÈÛ·Ó ÎÔÏÈ΋ Ì·ÚÌ·Ú˘Á‹, ·ÓÂÍ¿ÚÙËÙ· ·fi ÙËÓ Ï‹„Ë ‹ ÌË ·ÙÔÚ‚·ÛÙ·Ù›Ó˘. (ƒ=0,01). ∏ ÎÔÏÈ΋ Ì·ÚÌ·Ú˘Á‹ ‹Ù·Ó ÈÔ Û˘¯Ó‹ ÛÙ· ÂÚÈÛÛfiÙÂÚÔ ËÏÈÎȈ̤ӷ ¿ÙÔÌ· (>65 ÂÙÒÓ), Û ˘ÂÚÙ·ÛÈο ¿ÙÔÌ· Î·È Û ·ıËÚÔÛÎÏ‹ÚˆÛË Ù˘ ·ÔÚÙ‹˜. ∞ÓÙ›ıÂÙ· Ë Ï‹„Ë ‚·Ó·ÛÙÔϤˆÓ Ì›ˆÛ ÙÔÓ Î›Ó‰˘ÓÔ ÎÔÏÈ΋˜ Ì·ÚÌ·Ú˘Á‹˜ ηٿ 90%. ¶ÔÏ˘·Ú·ÁÔÓÙÈ΋ ·Ó¿Ï˘ÛË ¤‰ÂÈÍ fiÙÈ Ë ·ÙÔÚ‚·ÛÙ·Ù›ÓË ÌÂÈÒÓÂÈ ÙÔÓ Î›Ó‰˘ÓÔ ÌÂÙÂÁ¯ÂÈÚËÙÈ΋˜ ÎÔÏÈ΋˜ Ì·ÚÌ·Ú˘Á‹˜ ηٿ 61% (OR 0,39, fiÚÈÔ ·ÍÈÔÈÛÙ›·˜ 95% ·fi 0,18 ̤¯ÚÈ 0,85, ƒ = 0,017), ·ÓÂÍ¿ÚÙËÙ· ·fi ËÏÈΛ·, ʇÏÔ, ‡·ÚÍË ·ÚÙËÚȷ΋˜ ›ÂÛ˘ ‹ ۷ί·ÚÒ‰Ë ‰È·‚‹ÙË. ∏ Ù·˘Ùfi¯ÚÔÓË Ï‹„Ë ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ Î·È ‚-·Ó·ÛÙÔϤˆÓ ÌÂÈÒÓÂÈ ·ÎfiÌË ÂÚÈÛÛfiÙÂÚÔ ÙÔÓ Î›Ó‰˘ÓÔ (∂ÈÎfiÓ· 5).

13


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·14

π√À¡π√™ 2007

∞Ó·ÏÔÁÈ΋ ¶Èı·ÓfiÙËÙ· ÁÈ· ªÂÙÂÁ¯ÂÈÚËÙÈ΋ ∫ÔÏÈ΋ ª·ÚÌ·Ú˘Á‹. 0

0.5

1

2

3

4

5 OR

95% CI

P

∏ÏÈΛ· > 65 ÂÙÒÓ.

2.5

∞ÚÙËÚȷ΋ ˘¤ÚÙ·ÛË.

3.9 (1.1-14)

0.039

™·Î¯·Ú҉˘ ‰È·‚‹Ù˘.

1.2 (0.50-2.7)

0.074

™˘ÌÊÔÚËÙÈ΋ ηډȷ΋ ·ÓÂ¿ÚÎÂÈ·. ∞ıËÚÔÛÎÏ‹ÚˆÛË ·ÔÚÙ‹˜.

1.6 (0.21-12.7)

¢È¿Ù·ÛË ·ÚÈÛÙÂÚÔ‡ ÎfiÏÔ˘.

1.6 (0.73-3.3)

(1.2-5.0)

2.6 (1.1-6.0)

0.19 (0.08-0.44)

£ÂÚ·›· Ì ‚-·Ó·ÛÙÔÏ›˜ πÓfiÙÚÔÔÈ ·Ú¿ÁÔÓÙ˜. ¢È·ÛˆÏ‹ÓˆÛË Î·È ÙˆÓ ‰‡Ô ÎÔ›ÏˆÓ ÊÏ‚ÒÓ. £ÂÚ·›· Ì ·ÙÔÚ‚·ÛÙ·Ù›ÓË.

0.65 0.023 0.26 0.0001

1.4 (0.59-3.2)

0.46

2.4 (0.90-6.0)

0.08

0.39 (018-0.85)

0.017

2.0 (1.2-7.0)

CRP>166 mg/L

0.02

0.01

0.10 (0.02-0.0.25) <0.0001

∞ÙÔÚ‚·ÛÙ·Ù›ÓË +‚-·Ó·ÛÙÔÏ›˜)

∂ÈÎfiÓ· 5. ∞Ó·ÏÔÁÈ΋ ¶Èı·ÓfiÙËÙ· (odds ratio) ÂÌÊ¿ÓÈÛ˘ ÌÂÙÂÁ¯ÂÈÚËÙÈ΋˜ ÎÔÏÈ΋˜ Ì·ÚÌ·Ú˘Á‹˜ Û ÔÌ¿‰Â˜ Î·È ·Ó¿ÏÔÁ· Ì ÙË ıÂÚ·¢ÙÈ΋ ·ÓÙÈÌÂÙÒÈÛË.

ªÂ Ù· ̤¯ÚÈ ÙÒÚ· ‰Â‰Ô̤ӷ ÌfiÓÔ ÔÈ ‚-·Ó·ÛÙÔÏ›˜ Î·È Ë ·ÌȈ‰·ÚfiÓË ¤¯Ô˘Ó ‰Â›ÍÂÈ fiÙÈ ÚÔÛÙ·ÙÂ‡Ô˘Ó ·fi ÙË ÌÂÙÂÁ¯ÂÈÚËÙÈ΋ ÎÔÏÈ΋ Ì·ÚÌ·Ú˘Á‹. √È ·ÓÙ·ÁˆÓÈÛÙ¤˜ ·Û‚ÂÛÙ›Ô˘, Ù· ·ÓÙÈ·ÚÚ˘ıÌÈο ηÙËÁÔÚ›·˜ π, Ë ‰·ÎÙ˘Ï›Ùȉ·, ÙÔ Ì·ÁÓ‹ÛÈÔ Î·È Ë ¤Á¯˘ÛË ‰È·Ï‡Ì·ÙÔ˜ ÁÏ˘Îfi˙˘-ÈÓÛÔ˘Ï›Ó˘-Î·Ï›Ô˘ ‰ÂÓ ‹Ù·Ó ·ÔÙÂÏÂÛÌ·ÙÈο. ™‡Ìʈӷ Ì ÙËÓ ·ÚÔ‡Û· ÌÂϤÙË Ë ÚÔıÂÚ·›· Ì ·ÙÔÚ‚·ÛÙ·Ù›ÓË Â›Ó·È ÂÍ·ÈÚÂÙÈο ·ÔÙÂÏÂÛÌ·ÙÈ΋. ÃÚÂÈ¿˙ÂÙ·È Ó· ¿ÚÔ˘Ó ıÂÚ·›· ÌfiÓÔ 4,5 ·ÛıÂÓ›˜ ÁÈ· Ó· ÚÔÏËÊı› ¤Ó· ÂÂÈÛfi‰ÈÔ ÎÔÏÈ΋˜ Ì·ÚÌ·Ú˘Á‹˜ Î·È 8 ·ÛıÂÓ›˜ ÁÈ· Ó· ÚÔÏËÊı› ·Ú¿Ù·ÛË Ù˘ ÓÔÛËÏ›·˜ ¤Ú·Ó ÙˆÓ 7 ËÌÂÚÒÓ. ¢Â‰Ô̤ÓÔ˘ fiÙÈ Ë ıÂÚ·›· Ì ·ÙÔÚ‚·ÛÙ·Ù›ÓË Â›Ó·È ·ÛÊ·Ï‹˜ Î·È ¯·ÌËÏÔ‡ ÎfiÛÙÔ˘˜, Ë ¯ÔÚ‹ÁËÛË Ù˘ ÚÔÏËÙÈο Û ÂÁ¯ÂÈÚ‹ÛÂȘ ·ÔÚÙÔÛÙÂÊ·ÓÈ·›·˜ ·Ú¿Î·Ì„˘ ÌÔÚ› Ó· ¤¯ÂÈ ÛËÌ·ÓÙÈΤ˜ ÔÈÎÔÓÔÌÈΤ˜ ÂÈÙÒÛÂȘ. √ Ì˯·ÓÈÛÌfi˜ Ì ÙÔÓ ÔÔ›Ô Ë ·ÙÔÚ‚·ÛÙ·Ù›ÓË ÌÔÚ› Ó· ÚÔÏ·Ì‚¿ÓÂÈ ÙË Ì˘Ôηډȷ΋ Ó¤ÎÚˆÛË Ô˘ Û˘¯Ó¿ Û˘Ì‚·›ÓÂÈ ÛÙËÓ ·ÁÁÂÈÔÏ·ÛÙÈ΋ (›Ù ÁÈ·

14

¯ÚfiÓÈ· ÛÙ·ıÂÚ‹ ÛÙËı¿Á¯Ë ›Ù ÁÈ· Ôͤ· ÛÙÂÊ·ÓÈ·›· Û‡Ó‰ÚÔÌ·) ηıÒ˜ Î·È ÙËÓ ÌÂÙÂÁ¯ÂÈÚËÙÈ΋ ÎÔÏÈ΋ Ì·ÚÌ·Ú˘Á‹ ‰ÂÓ Â›Ó·È Â·ÎÚÈ‚Ò˜ ÁÓˆÛÙfi˜, ‰ÂÓ ÌÔÚ› fï˜ Ó· Â›Ó·È Ë ˘ÔÏÈȉ·ÈÌÈ΋ ‰Ú¿ÛË, Ë ÔÔ›· ¯ÚÂÈ¿˙ÂÙ·È ·ÚÎÂÙfi ¯ÚfiÓÔ ÁÈ· Ó· Á›ÓÂÈ ÂÌÊ·Ó‹˜. ∏ ·ÓÙÈÊÏÂÁÌÔÓ҉˘ ‰Ú¿ÛË ÂÓ‰¤¯ÂÙ·È Ó· Â›Ó·È ¤Ó·˜ Ì˯·ÓÈÛÌfi˜ Î·È Û ·˘Ùfi Û˘ÓËÁÔÚ› ÙÔ ÁÂÁÔÓfi˜ fiÙÈ Ù· ÂÂÈÛfi‰È· ‹Ù·Ó ÈÔ Û˘¯Ó¿ ÛÙ· ¿ÙÔÌ· Ì ˘„ËϤ˜ ÙÈ̤˜ CRP Î·È fiÙÈ Ë ·ÙÔÚ‚·ÛÙ·Ù›ÓË ÌÂÈÒÓÂÈ ÙËÓ ÙÈÌ‹ Ù˘ CRP. À¿Ú¯Ô˘Ó ÂÈÚ·Ì·ÙÈΤ˜ ÂӉ›ÍÂȘ fiÙÈ ÔÈ ÛÙ·Ù›Ó˜ ÚÔÛÙ·ÙÂ‡Ô˘Ó ·fi ÙË ‚Ï¿‚Ë Â·Ó·ÁÁ›ˆÛ˘ Î·È ÂËÚ¿˙Ô˘Ó ÙË ÌÈÎÚÔ΢ÎÏÔÊÔÚ›·, ÌÂÈÒÓÔ˘Ó Ù· ÚÔÛÎÔÏÏËÙÈο ÌfiÚÈ· Î·È ‚ÂÏÙÈÒÓÔ˘Ó ÙË ÏÂÈÙÔ˘ÚÁÈÎfiÙËÙ· ÙˆÓ ·ÈÌÔÂÙ·Ï›ˆÓ. ∂›Û˘, ·ÎfiÌË Î·È ‚Ú·¯˘¯ÚfiÓÈ· ıÂÚ·›· Ì ÛÙ·Ù›Ó˜ ¤¯ÂÈ ÛËÌ·ÓÙÈο ·ÔÙÂϤÛÌ·Ù· ÛÙË ÏÂÈÙÔ˘ÚÁÈÎfiÙËÙ· ÙÔ˘ ÂÓ‰ÔıËÏ›Ô˘, ÛÙË ÊÏÂÁÌÔÓ‹, ÛÙËÓ ·ÁÁÂÈԉȷÛÙÔÏ‹ ÙˆÓ ÌÈÎÚÒÓ ·ÁÁ›ˆÓ Î·È ÛÙË ıÚfiÌ‚ˆÛË. ™ÙË ÌÂϤÙË ARMYDA-ACS Ë ·ÙÔÚ‚·ÛÙ·Ù›ÓË ÂÚÈfiÚÈÛ ÙËÓ ·‡ÍËÛË

Ù˘ CRP Ô˘ ·Ú·ÙËÚÂ›Ù·È ÂÚÈÂÂÌ‚·ÙÈο, ΢ڛˆ˜ ÛÙ· ¿ÙÔÌ· Ì ˘„ËϤ˜ ÙÈ̤˜ ÚÈÓ ÙËÓ Â¤Ì‚·ÛË. ™ÙËÓ ARMYDA-3 ÎÔÏÈ΋ Ì·ÚÌ·Ú˘Á‹ ¤·ı·Ó Ù· ¿ÙÔÌ· Ì ˘„ËÏ‹ CRP, ·ÓÂÍ¿ÚÙËÙ· ·fi ÙË ıÂÚ·›·. 4. √È ÏÂÈfiÙÚÔ˜ ‰Ú¿ÛÂȘ ‰ÂÓ ·ÎÔÏÔ˘ıÔ‡Ó ··Ú·›ÙËÙ· ÙË Ì›ˆÛË Ù˘ LDL-¯ÔÏËÛÙÂÚfiÏ˘. ™‡Ìʈӷ Ì ÌÈ· ÚfiÛÊ·ÙË ÂÚÁ·Û›·, Ô ›‰ÈÔ˜ ‚·ıÌfi˜ Ì›ˆÛ˘ Ù˘ LDL¯ÔÏËÛÙÂÚfiÏ˘ Ì ·ÙÔÚ‚·ÛÙ·Ù›ÓË Û ̤ÙÚÈ· ‰fiÛË ‹ Ì ·ÙÔÚ‚·ÛÙ·Ù›ÓË Û ÌÈÎÚ‹ ‰fiÛË Û˘Ó Â˙ÂÙÈÌ›ÌË ‰ÂÓ Â›¯Â ÙȘ ›‰È˜ ÏÂÈfiÙÚÔ˜ ‰Ú¿ÛÂȘ ÛÙ· ·ÈÌÔÂÙ¿ÏÈ· Î·È ÛÙË ÊÏÂÁÌÔÓÒ‰Ë ‰ÈÂÚÁ·Û›·(17). 56 ·ÛıÂÓ›˜ Ì ·ÁÁÂÈÔÁÚ·ÊÈο ÂȂ‚·ÈˆÌ¤ÓË ÛÙÂÊ·ÓÈ·›· ÓfiÛÔ Î·È LDL-¯ÔÏËÛÙÂÚfiÏË > 100 mg% ·Ú¿ ÙË Ï‹„Ë 10-20 mg ·ÙÔÚ‚·ÛÙ·Ù›Ó˘, ηٷÓÂÌ‹ıËÎ·Ó Ù˘¯·›· Ó· Ï¿‚Ô˘Ó Â›Ù ·ÙÔÚ‚·ÛÙ·Ù›ÓË 40 mg ÙËÓ Ë̤ڷ ›Ù Â˙ÂÙÈÌ›ÌË 10 mg Î·È ·ÙÔÚ‚·ÛÙ·Ù›ÓË 10 mg ÙËÓ Ë̤ڷ. ªÂÙ¿ 4 ‚‰ÔÌ¿‰Â˜ Ë Ì›ˆÛË Ù˘ LDL-¯ÔÏËÛÙÂÚfiÏ˘ ‹Ù·Ó ÈηÓÔÔÈËÙÈ΋ Î·È ÛÙÔÓ ›‰ÈÔ ‚·ıÌfi ÂÚ›Ô˘ Î·È Ì ٷ ‰‡Ô Û¯‹Ì·Ù· (- 40±7 mg % Ì ·ÙÔÚ‚·ÛÙ·-


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·15

∫§π¡π∫∂™ ª∂§∂Δ∂™

∏ ·ÓÙ·ÈÌÔÂÙ·Ïȷ΋ ‰Ú¿ÛË ÙˆÓ

A

B P<0.005

P<0.005

P<n.s. ƒ-ÛÂÏÂÎÙ›ÓË ¢ªFi in AU

25 ƒ-ÛÂÏÂÎÙ›ÓË ªFi in AU

Ù›ÓË Î·È -53±8,6 mg% Ì ÙË ‰ÈÏ‹ ·ÁˆÁ‹, ‰È·ÊÔÚ¿ ÌË ÛËÌ·ÓÙÈ΋ ÛÙ·ÙÈÛÙÈο) ·ÏÏ¿ ÔÈ ‰Â›ÎÙ˜ Ù˘ ·ÈÌÔÂÙ·Ïȷ΋˜ ÏÂÈÙÔ˘ÚÁ›·˜ Î·È Ù˘ ÊÏÂÁÌÔÓÒ‰Ô˘˜ ‰ÈÂÚÁ·Û›·˜ ÂÌÊ¿ÓÈ˙·Ó ÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈΤ˜ ‰È·ÊÔÚ¤˜. ∏ ƒ-ÛÂÏÂÎÙ›ÓË (‰Â›ÎÙ˘ ÂÓÂÚÁfiÙËÙ·˜ ÙˆÓ ·ÈÌÔÂÙ·Ï›ˆÓ) ÌÂÙ¿ ‰È¤ÁÂÚÛË Ì ADP ‹Ù·Ó ÛËÌ·ÓÙÈο ¯·ÌËÏfiÙÂÚË ÛÙËÓ ÔÌ¿‰· Ù˘ ÌÔÓÔıÂÚ·›·˜ Û˘ÁÎÚÈÙÈο Ì ÙËÓ ÔÌ¿‰· Ù˘ Û˘Ó‰˘·Ṳ̂Ó˘ ·ÁˆÁ‹˜ (ƒ<0,005, ∂ÈÎfiÓ· 6). ∂›Û˘ Ë Û˘ÛÛÒÚ¢ÛË ÙˆÓ ·ÈÌÔÂÙ·Ï›ˆÓ ÌÂÙ¿ ‰È¤ÁÂÚÛË Ì TRAP (Thrombin ReceptorActivating Peptide) ‹Ù·Ó ÛËÌ·ÓÙÈο ¯·ÌËÏfiÙÂÚË Ì ÙËÓ ·ÙÔÚ‚·ÛÙ·Ù›ÓË. Δ· Â›‰· ÙˆÓ ¯˘ÌÔÎÈÓÒÓ ÛÙ· Ï¿ÛÌ· (Regulated on Activation Normally T-cell Expressed and Secreted - RANTES) ÌÂÈÒıËÎ·Ó Ì ٷ 40 mg ·ÙÔÚ‚·ÛÙ·Ù›Ó˘, fi¯È fï˜ Ì ÙË ‰ÈÏ‹ ·ÁˆÁ‹. √È ¤ÎÊÚ·ÛË ÙˆÓ ¯˘ÌÔÎÈÓÒÓ, ÂÎÙfi˜ ·fi ‰Â›ÎÙ˘ ‰È¤ÁÂÚÛ˘ ÙˆÓ ·ÈÌÔÂÙ·Ï›ˆÓ, Ê·›ÓÂÙ·È fiÙÈ ‰È·‰Ú·Ì·Ù›˙ÂÈ ÚfiÏÔ ÛÙËÓ ·Ú·ÁˆÁ‹ Ù˘ MCP-1 Î·È ÛÙËÓ ·ıËڈ̷ÙÈ΋ ‰È·‰Èηۛ·.

20 15 10 5 0 ¶ÚÈÓ ÙËÓ ·ÁˆÁ‹

ªÂÙ¿ 4 ‚‰ÔÌ¿‰Â˜

MfiÓÔ ™Ù·Ù›ÓË

∂˙ÂÙÈÌ›ÌË+™Ù·Ù›ÓË

5

0

-5

-10

∂˙ÂÙÈÌ›ÌË +™Ù·Ù›ÓË MfiÓÔ ™Ù·Ù›ÓË

∂ÈÎfiÓ· 6. ¢È·ÊÔÚ¤˜ ÛÙËÓ ¤ÎÊÚ·ÛË Ù˘ ÌÂÙ¿ ‰È¤ÁÂÚÛË Ì ADP ƒ-ÛÂÏÂÎÙ›Ó˘ ÛÙ· ·ÈÌÔÂÙ¿ÏÏÈ·. (∞) ƒ-ÛÂÏÂÎÙ›ÓË ÌÂÙ¿ ‰È¤ÁÂÚÛË Ì ADP ÚÈÓ ÙËÓ ¤Ó·ÚÍË Î·È ÌÂÙ¿ 4 ‚‰ÔÌ¿‰Â˜ ıÂÚ·›·˜ Ì ·ÙÔÚ‚·ÛÙ·Ù›ÓË ÌfiÓÔ (ÎÂÓ¤˜ ÛًϘ) Î·È Ì Â˙ÂÙÈÌ›ÌË+·ÙÔÚ‚·ÛÙ·Ù›ÓË (ÁÂÌ¿Ù˜ ÛًϘ). (μ) ¢È·ÊÔÚ¤˜ ÛÙËÓ ÛÙË Ì¤ÛË ˘ÎÓfiÙËÙ· ·ÓÔÛÔÊıÔÚÈÛÌÔ‡ (¢MFI) Ù˘ ƒ-ÛÂÏÂÎÙ›Ó˘ (Â›‰· ÌÂÙ¿ 4 ‚‰ÔÌ¿‰Â˜ ˘ÔÏÈȉ·ÈÌÈ΋˜ ·ÁˆÁ‹˜ Ì›ÔÓ Â›‰· ÚÈÓ ÙËÓ ¤Ó·ÚÍË Ù˘ ·ÁˆÁ‹˜) AU= ·˘ı·›ÚÂÙ˜ ÌÔÓ¿‰Â˜.

ÛÙ·ÙÈÓÒÓ Â›Ó·È ‰ÔÛÔÂÍ·ÚÙÒÌÂÓË, ÙÔ ›‰ÈÔ Î·È Ë ·ÓÙÈÊÏÂÁÌÔÓ҉˘ ‰Ú¿ÛË. ∫·Ù¿ Û˘Ó¤ÂÈ·, fiˆ˜ ÚÔ·ÙÂÈ Î·È ·fi ÙËÓ ·ÚÔ‡Û· ÌÂϤÙË, ÔÈ ÌÈÎÚ¤˜ ‰fiÛÂȘ ÙˆÓ ÛÙ·ÙÈÓÒÓ Û˘Ó‰˘·˙fiÌÂÓ˜ Ì Â˙ÂÙÈÌ›ÌË, ·Ú¿ ÙÔ fiÙÈ ¤¯Ô˘Ó ÂÍ

›ÛÔ˘ ηÏfi ˘ÔÏÈȉ·ÈÌÈÎfi ·ÔÙ¤ÏÂÛÌ· Ì ÙȘ ÌÂÁ·Ï‡ÙÂÚ˜ ‰fiÛÂȘ ÙˆÓ ÛÙ·ÙÈÓÒÓ, ›Ûˆ˜ ‰ÂÓ ¤¯Ô˘Ó ÙÔ ›‰ÈÔ Î·Ïfi ÎÏÈÓÈÎfi ·ÔÙ¤ÏÂÛÌ·, ÂÂȉ‹ ‰ÂÓ ÂÍ·ÛÊ·Ï›˙Ô˘Ó ÛÙÔÓ ›‰ÈÔ ‚·ıÌfi ÙȘ ÏÂÈfiÙÚÔ˜ ‰Ú¿ÛÂȘ.

7.

Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/ CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 86: 64-70.

13. Ioannidis JPA, Karvouni E, Katritis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous intervention. J Am Coll Cardiol 2003;42:1412-14.

8.

Sanguigni V, Pignatelli P, Lenti L, ct al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005;111:412-9.

9.

Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH. Inhibition of proliferation of human smooth muscle cells by various HMGCoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997; 1345: 259-68.

μÈ‚ÏÈÔÁÚ·Ê›· 1.

Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of lowdensity lipoproteins by activated human rnonocyte-derived macrophages. Biochim Biophys Acta 1993;1165 :335-8.

2.

Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of low density lipoprolein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997;28:11 - 18.

3.

Fuhrman B, Koren L, Volkova N, Keidar S, Hayek T, Aviram M. Atorvastatin therapy in hypercholeslerolemic patients suppresses cellular uptake of oxidizedLDL by differentiating monocytes. Atherosclerosis 2002;164:179-85.

4.

Wassmann S, Faul A, Hennen B, Sheller B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res 2003;93:e98-103.

5.

Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering ther¬apy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.

6.

Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive proteinmediated monocyte chemoattractant protein-1 induction in endothelial cells by anti-atherosclerotic drugs. Circulation 2001;103: 2531-34.

14. Giuseppe P, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatine pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary interventions. Results of the ARMYDA-ACS randomized trial. JACC 2007;49:1272-78.

10. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocar¬dium by upregulating a pro-survival pathway. J Am Coll Cardiol 2003;41:S08-15.

15. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciasco G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery. Results of the ARMYDA-3 (Atorvastatine for Reduction of Myocardial Dysrhythmia After cardiac surgery) study. Circulation 2006;114:1455-61

11. Hinoi T, Matsuo S, Tadehara F, Tsujiyama S, Yamakido M. Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography. Am J Cardiol 2005;96:89-91.

16. Marin F, Pascual DA, Roldan V, Arribas JM, Ahumada M, Tornel PL, Oliver C, Gomez-Plana J, Lip GYH, Valdes M. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97:55-60

12. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G, ARMYDA Investigators. Randomized trial of atorvastatm for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation 2004;110:674-8.

17. Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, Schultheiss H-P, Rauch U. Treatment with Ezetimibe plus low-dose Atorvastatin compared with higher dose Atorvastatin alone. Is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007;49:1035-42.

15


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·16

π√À¡π√™ 2007

∂ÂÌ‚·ÙÈ΋ E·Ó·ÈÌ¿ÙˆÛË ‹ º·Ú̷΢ÙÈ΋ ∞ÁˆÁ‹ ÛÙËÓ ∞Û˘Ìو̷ÙÈ΋ ™Ù·ıÂÚ‹ ™ÙÂÊ·ÓÈ·›· ¡fiÛÔ; μ. ’∞ı˘ÚÔ˜, ∞. ∫·Î·Ê‹Î·, ∂. ¶·ÁÎÔ˘Ú¤ÏÈ·˜, Ã. ∫Ô˘Ì·Ú¿˜, ∞. ™Î·¤Ú‰·˜, ∞. ∫·Ú·ÁÈ¿ÓÓ˘. μ’ ¶ÚÔ·È‰Â˘ÙÈ΋ ¶·ıÔÏÔÁÈ΋ ∫ÏÈÓÈ΋, ∞¶£, πÔÎÚ¿ÙÂÈÔ £ÂÛÛ·ÏÔӛ΢ À¿Ú¯ÂÈ ÌÈ· Ì·ÎÚÔ¯ÚfiÓÈ· ‰È·ÊÔÚ¿ ·fi„ÂˆÓ fiÛÔÓ ·ÊÔÚ¿ ÛÙË ‚¤ÏÙÈÛÙË ·ÓÙÈÌÂÙÒÈÛË Ù˘ ÛÙ·ıÂÚ‹˜ ÛÙÂÊ·ÓÈ·›·˜ ÓfiÛÔ˘ (™™¡). £· Ú¤ÂÈ Ë ·ÓÙÈÌÂÙÒÈÛË Ó· Â›Ó·È ÂÂÌ‚·ÙÈ΋ Î·È Ó· Û˘ÌÏËÚÒÓÂÙ·È ·fi Ê·Ú̷΢ÙÈ΋ ·ÁˆÁ‹ ‹ Ë ‚¤ÏÙÈÛÙË Ê·Ú̷΢ÙÈ΋ ·ÁˆÁ‹ ÌfiÓË Ù˘ Â›Ó·È ·ÚÎÂÙ‹ ÙfiÛÔ ÛÙËÓ ÚfiÏË„Ë Ó¤ˆÓ ÛÎÏËÚÒÓ Î·Ú‰È·ÁÁÂÈ·ÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ (ı¿Ó·ÙÔ˜, ¤ÌÊÚ·ÁÌ· Ì˘Ôηډ›Ô˘) fiÛÔ Î·È ÛÙËÓ ·Ó·ÎÔ‡ÊÈÛË ·fi ÙË ÛÙËı¿Á¯Ë ÚÔÛ¿ıÂÈ·˜ ÁÈ· fiÛÔ˘˜ ·ÛıÂÓ›˜ ˘ÔʤÚÔ˘Ó ·fi ·˘Ù‹? ΔÔ 1997 ‰ËÌÔÛȇÙËÎÂ Ë ÌÂϤÙË Randomised Intervention Treatment of Angina (RITA-2), Ë ÔÔ›· ¤‰ÂÈÍ fiÙÈ Ë ‰È·‰ÂÚÌ·ÙÈ΋ ÛÙÂÊ·ÓÈ·›· Â¤Ì‚·ÛË (PCI) ÚÔηÏ› ·Ó·ÎÔ‡ÊÈÛË ·fi ÙË ÛÙËı¿Á¯Ë Û ·ÛıÂÓ›˜ Ì ™™¡ ·ÏÏ¿ ‰ÂÓ ÂÏ·ÙÙÒÓÂÈ Ù· ÛÎÏËÚ¿ ηډȷÁÁÂȷο Û˘Ì‚¿Ì·Ù·[1]. ªÈ· ÈÔ ÏÂÙÔÌÂÚ‹˜ ·Ó¿ÁÓˆÛË Ù˘ RITA-2 ‰Â›¯ÓÂÈ fiÙÈ ·ÚfiÏÔ fiÙÈ Ù· ÔÛÔÛÙ¿ ·ÛıÂÓÒÓ Ì ÛÙËı¿Á¯Ë ‹Ù·Ó Ôχ ¯·ÌËÏfiÙÂÚ· ÛÙËÓ ÔÌ¿‰· PCI ·' fiÙÈ ÛÙËÓ ÔÌ¿‰· Ù˘ Ê·Ú̷΢ÙÈ΋˜ ·ÁˆÁ‹˜ (15% ¤Ó·ÓÙÈ 21,4%, p=0.01), Ù· fiÚÈ· ·˘Ù¿ ÛÙ¤Ó¢·Ó Ì ÙË ¿ÚÔ‰Ô ÙÔ˘ ¯ÚfiÓÔ˘. ∞˘Ùfi ÌÔÚ› Ó· ÛËÌ·›ÓÂÈ fiÙÈ Ë ‚ÂÏÙÈÛÙÔÔ›ËÛË Ù˘ Ê·Ú̷΢ÙÈ΋˜ ·ÁˆÁ‹˜, Ô˘ ‰È·ÈÛÙÒıËΠÛÙËÓ ·Ú·ÙÂٷ̤ÓË ·Ú·ÎÔÏÔ‡ıËÛË ÙˆÓ ·ÛıÂÓÒÓ Ù˘ RITA-2 (7 ¯ÚfiÓÈ·), ı· ÌÔÚÔ‡Û ›Ûˆ˜ Ó· ¤¯ÂÈ ·ÚfiÌÔÈ· ·ÔÙÂϤÛÌ·Ù· ·fi ÙËÓ ¿Ô„Ë Ù˘ ·Ó·ÎÔ‡ÊÈÛ˘ fiÓÔ˘ Û ÙËÓ PCI [2]. ¶ÚfiÛÊ·Ù· ·Ó·ÎÔÈÓÒıËÎ·Ó Ù· ·ÔÙÂϤÛÌ·Ù· Ù˘ ÌÂϤÙ˘ Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE). [3] ∞˘Ù¿, Û˘Ó˘ÔÏÔÁÈ˙fiÌÂÓ· Ì ÚÔ¸¿Ú¯ÔÓÙ· ÛÙÔȯ›· ÁÈ· ÙË

16

ÂÂÌ‚·ÙÈ΋ Ë Ê·Ú̷΢ÙÈ΋ ıÂÚ·›· Ù˘ ™™¡, ÌÔÚÔ‡Ó Ó· ÛËÌ·ÙÔ‰ÔÙ‹ÛÔ˘Ó ÙÔ Ù¤ÏÔ˜ ÌÈ·˜ ÂÔ¯‹˜ ÁÈ· ÙËÓ ·ÓÙÈÌÂÙÒÈÛË Ù˘ ™™¡. ∏ COURAGE ¤‰ÂÈÍ fiÙÈ Ë PCI Ì ÙË ¯ÚËÛÈÌÔÔ›ËÛË stent Î·È ‚¤ÏÙÈÛÙË Ê·Ú̷΢ÙÈ΋ ·ÁˆÁ‹ ‰ÂÓ Â›Ó·È ÂÚÈÛÛfiÙÂÚÔ ·ÔÙÂÏÂÛÌ·ÙÈΤ˜ ÛÙËÓ ÚfiÏË„Ë ÌÂÏÏÔÓÙÈÎÒÓ Î·Ú‰È·ÁÁÂÈ·ÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ ·fi ÙË ‚¤ÏÙÈÛÙË Ê·Ú̷΢ÙÈ΋ ·ÁˆÁ‹ ÌfiÓË Ù˘ Û ·ÛıÂÓ›˜ Ì ™™¡. [3] √È ÂÚ¢ÓËÙ¤˜ Ù˘ ÌÂϤÙ˘ COURAGE Ù˘¯·ÈÔÔ›ËÛ·Ó 2.287 ·ÛıÂÓ›˜ (ÌÂٷ͇ 1999 Î·È 2004) ›Ù Û ıÂÚ·›· Ì PCI Û˘Ó ‚¤ÏÙÈÛÙË Ê·Ú̷΢ÙÈ΋ ·ÁˆÁ‹ ›Ù ÛÙË ‚¤ÏÙÈÛÙË Ê·Ú̷΢ÙÈ΋ ·ÁˆÁ‹ ÌfiÓÔ. ∫·Ù¿ ÙË ‰È¿ÚÎÂÈ· ·Ú·ÎÔÏÔ‡ıËÛ˘ (̤ÛÔ˜ ¯ÚfiÓÔ˜ 4,6 ¯ÚfiÓÈ·) ηÙÂÁÚ¿ÊËÛ·Ó Û˘ÓÔÏÈο 211 ı¿Ó·ÙÔÈ ‹ ÌË ı·Ó·ÙËÊfiÚ· ÂÌÊÚ¿ÁÌ·Ù· ÙÔ˘ Ì˘Ôηډ›Ô˘, ·ÚÈıÌfi˜ ·ÚfiÌÔÈÔ˜ Ì ·˘ÙfiÓ (202) Ù˘ ÔÌ¿‰·˜ Ì ‚¤ÏÙÈÛÙË Ê·Ú̷΢ÙÈ΋ ·ÁˆÁ‹ ÌfiÓÔ. [3] ŸÙ·Ó ÚÔÛÙ¤ıËÎ·Ó Ù· ·ÁÁÂȷο ÂÁÎÂÊ·ÏÈο ÂÂÈÛfi‰È· Ë ‰È·ÊÔÚ¿ ÂÍ·ÎÔÏÔ˘ıÔ‡Û ӷ ÌËÓ Â›Ó·È ÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈ΋. ∏ ÌfiÓË ÛËÌ·ÓÙÈ΋ ‰È·ÊÔÚ¿ ÌÂٷ͇ ÙˆÓ ‰‡Ô ÔÌ¿‰ˆÓ ıÂÚ·›·˜ ‹Ù·Ó Ë ÌÂȈ̤ÓË Â›ÙˆÛË Ù˘ ÛÙËı¿Á¯Ë˜ ÛÙËÓ ÔÌ¿‰· PCI ÛÙ· 1 Î·È 3 ¤ÙË. ∂ÓÙÔ‡ÙÔȘ, ÛÙ· 5 ¤ÙË ‰ÂÓ ˘‹ÚÍ η̛· ÛËÌ·ÓÙÈ΋ ‰È·ÊÔÚ¿ ÛÙÔ ÔÛÔÛÙfi ·˘ÙÒÓ Ô˘ ‹Ù·Ó ÂχıÂÚÔÈ ·fi ÛÙËı¿Á¯Ë (73% ÙˆÓ ·ÛıÂÓÒÓ Î¿ı ÔÌ¿‰·˜). ∞˘Ù¿ Ù· ·ÔÙÂϤÛÌ·Ù· ¤¯Ô˘Ó ÂÈÙÒÛÂȘ Û ¤Ó·Ó ÛËÌ·ÓÙÈÎfi ·ÚÈıÌfi ·ÛıÂÓÒÓ Ì ™™¡ Ô˘ ˘Ô‚¿ÏÏÔÓÙ·È Û PCI. ÀÔÏÔÁ›˙ÂÙ·È fiÙÈ 30% ¤ˆ˜ 40% ÙˆÓ ·ÛıÂÓÒÓ Ì ™™¡ ·ÓÙÈÌÂÙˆ›˙ÔÓÙ·È Ì PCI. ∂¿Ó Ù· ·ÔÙÂϤÛÌ·Ù· Ù˘ ÌÂϤÙ˘ COURAGE ÂÊ·ÚÌÔÛÙÔ‡Ó ÛÙËÓ ÎÏÈÓÈ΋ Ú¿ÍË, ÔÈ ÂÚÈÛÛfiÙÂÚÔÈ ·fi ·˘ÙÔ‡˜ ÙÔ˘˜ ·ÛıÂÓ›˜ ÌÔÚÔ‡Ó ÙÒÚ·

Ó· ıÂÚ·¢ıÔ‡Ó Ì ٷ Ê¿Ú̷η ÌfiÓÔ. ∞˘Ùfi ÛËÌ·›ÓÂÈ Ô˘ÛÈ·ÛÙÈ΋ ÂÍÔÈÎÔÓfiÌËÛË fiÚˆÓ ÁÈ· ÙËÓ ˘ÁÂÈÔÓÔÌÈ΋ ÂÚ›ı·Ï„Ë. [4] Δ· ÛÙÔȯ›· ¿Óˆ ÛÙÔ ˙‹ÙËÌ· ·˘Ùfi ‹Ù·Ó ‰È·ı¤ÛÈÌ· ·fi ÙÔ 1999. ∏ ÌÂϤÙË Atorvastatin Versus Revascularization Treatment (AVERT) ¤‰ÂÈÍ fiÙÈ ÛÙÔ˘˜ ¯·ÌËÏÔ‡ ÎÈÓ‰‡ÓÔ˘ ·ÛıÂÓ›˜ Ì ™™¡ Ë ÂÈıÂÙÈ΋ ˘ÔÏÈȉ·ÈÌÈ΋ Ê·Ú̷΢ÙÈ΋ ·ÁˆÁ‹ ‹Ù·Ó ÙÔ˘Ï¿¯ÈÛÙÔÓ ÙfiÛÔ ·ÔÙÂÏÂÛÌ·ÙÈ΋ fiÛÔ Ë PCI (Û˘Ó Û˘Ó‹ıË È·ÙÚÈ΋ ÊÚÔÓÙ›‰·) ÛÙË Ì›ˆÛË Ù˘ Â›ÙˆÛ˘ ÙˆÓ Î·Ú‰È·ÁÁÂÈ·ÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ. [5] ªÂÙ¿ ·fi ÙȘ ÌÂϤÙ˜ AVERT Î·È RITA-2 Ë ıÂÚ·›· Ù˘ ™™¡ ı· Ú¤ÂÈ Ó· Â›Ó·È Ôχ ÂÚÈÛÛfiÙÂÚÔ ‘ÌÂÙ·‚ÔÏÈ΋’ Î·È Ôχ ÏÈÁfiÙÂÚÔ ‘Ì˯·ÓÈ΋’. [6] ªÔÏÔÓfiÙÈ ÛÙËÓ AVERT Ë ‰È·ÊÔÚ¿ ÛÙËÓ ¤Î‚·ÛË ÌÂٷ͇ ÙˆÓ 2 ÔÌ¿‰ˆÓ ıÂÚ·›·˜ ‰ÂÓ ÔÊÂÈÏfiÙ·Ó ÚÒÙÈÛÙ· Û Â·Ó·ÛÙ¤ÓˆÛË (ÙÔ ÎÏÈÓÈο ·ÓȯÓÂ˘Ì¤ÓÔ ÔÛÔÛÙfi Â·Ó·ÛÙ¤ÓˆÛ˘ ÛÙËÓ ÔÌ¿‰· PCI ‹Ù·Ó ÌfiÓÔ 10,2%) Ë ÚÔÛ¤ÁÁÈÛË Ù˘ Ê·Ú̷΢ÙÈ΋˜ ·ÁˆÁ‹˜ ‰ÂÓ ˘ÈÔıÂÙ‹ıËΠ·fi ÙËÓ ÏÂÈÔ„ËÊ›· ÙˆÓ


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·17

£∂ƒ∞¶∂π∞ - º∞ƒª∞∫∞ ¶π¡∞∫∞™ ÃÚfiÓÔ˜

PCI ($)

º·Ú̷΢ÙÈ΋ ·ÁˆÁ‹ ($)

p

ŒÓ·ÚÍË 1 ¤ÙÔ˜ 3 ¤ÙË

7.771 10.051 19.605

1,751 4,153 6,661

<0.0001 <0.0001 <0.0001

ηډÈÔÏfiÁˆÓ ÂÂȉ‹ ˘‹ÚÍ ÂÏ›‰· ÁÈ· ·ÎfiÌ· ηχÙÂÚ· ·ÔÙÂϤÛÌ·Ù· Ì PCI fiÙ·Ó ¤ÁÈÓ·Ó ‰È·ı¤ÛÈÌ· Ù· drug eluding stents (DES) Ô˘ ˘Ôη٤ÛÙËÛ·Ó Ù· bare metal stents (BMS). ∂ÓÙÔ‡ÙÔȘ, Ë ¯Ú‹ÛË DES ÂÓ·ÓÙ›ÔÓ BMS ·ÔÙÂÏ› ·ÓÙÈΛÌÂÓÔ ¤ÓÙÔÓ˘ ‰È·Ì¿¯Ë˜, ‰Â‰Ô̤ÓÔ˘ fiÙÈ Ù· DES Û˘Ó‰¤ÔÓÙ·È ϤÔÓ Ì fi„ÈÌË ıÚfiÌ‚ˆÛË. [7] ∂ÈÛ‹¯ıË ¤ÙÛÈ ÌÈ· Ó¤· ¤ÓÓÔÈ· ÛÙËÓ ÂÂÌ‚·ÙÈ΋ ηډÈÔÏÔÁ›· ÌÈ· Û¯¤ÛË J-curve ÌÂٷ͇ Ù˘ ÚfiÛÊ·Ù˘·ÒÙÂÚ˘ ıÚfiÌ‚ˆÛ˘ Î·È ÎÏÈÓÈÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ.[8-10] ∂ÈϤÔÓ, Ù· DES Â›Ó·È ·ÎÚÈ‚fiÙÂÚ· ·fi BMS Î·È ··ÈÙÔ‡Ó Ì·ÎÚÔ¯ÚfiÓÈ· ıÂÚ·›· (›Ûˆ˜ ÌÂÚÈÎÒÓ ÂÙÒÓ) Ì ÎÏÔȉÔÁÚ¤ÏË Ô˘ Â›Û˘ ¤¯ÂÈ ˘„ËÏfi ÎfiÛÙÔ˜ ıÂÚ·›·˜.[8-10] ™Â ÌÈ· ÔÈÎÔÓÔÌÈ΋ ·Ó¿Ï˘ÛË Ù˘ COURAGE, [11] Ê¿ÓËΠfiÙÈ ÙÔ ÎfiÛÙÔ˜ ‹Ù·Ó Ôχ ¯·ÌËÏfiÙÂÚÔ ÛÙËÓ ÔÌ¿‰· Ê·Ú̷΢ÙÈ΋˜ ıÂÚ·›·˜ (¶›Ó·Î·˜).

∂ÈϤÔÓ, ÙÔ ÎfiÛÙÔ˜ ·Ó¿ ÔÈÔÙÈÎfi ¤ÙÔ˜ Ûˆ˙fiÌÂÓ˘ ˙ˆ‹˜ ‹Ù·Ó $217.000 Ì ÙËÓ PCI. [11] ∂Ô̤ӈ˜, Ë ·Ó¿Ï˘ÛË ÎfiÛÙÔ˘˜ ·ÔÙÂÏÂÛÌ·ÙÈÎfiÙËÙ·˜ ¤‰ÂÈÍ fiÙÈ ÙÔ 99% ÙˆÓ ·ÛıÂÓÒÓ Ô˘ ˘Ô‚¿ÏÏÔÓÙ·È Û PCI ÍÂÂÚÓÔ‡Ó ÙÔ fiÚÈÔ ÙˆÓ $50.000 Ô˘ ıˆÚÂ›Ù·È ·Ô‰ÂÎÙfi. [11] Œ¯Ô˘Ì ‰ËÌÔÛȇÛÂÈ ÛÙÔȯ›· ÛÙÔ ·ÚÂÏıfiÓ Ô˘ ‰Â›¯ÓÔ˘Ó fiÙÈ ÙÔ ÎfiÛÙÔ˜ ·Ó¿ ÔÈÔÙÈÎfi ¤ÙÔ˜ Ûˆ˙fiÌÂÓ˘ ˙ˆ‹˜ Û ·ÛıÂÓ›˜ Ì ™™¡ ‹Ù·Ó $8.350 Ì ‚¤ÏÙÈÛÙË Ê·Ú̷΢ÙÈ΋ ·ÁˆÁ‹. [12] √È ‰È·ÊÔÚ¤˜ Â›Ó·È ÙÂÚ¿ÛÙȘ.

Ê›· ÙˆÓ ·ÛıÂÓÒÓ Ì ·Û˘و̷ÙÈ΋ ™™¡. ∞˘Ùfi ı· ÂÍÔÈÎÔÓÔÌ‹ÛÂÈ ÛËÌ·ÓÙÈÎÔ‡˜ fiÚÔ˘˜ (·ÓıÚÒÈÓÔ˘˜ Î·È ¯ÚËÌ·ÙÈÎÔ‡˜) ÁÈ· Ó· ÂÂÓ‰˘ıÔ‡Ó ÛÙ· Ì·ÎÚÔÚfiıÂÛÌ· ÔʤÏË ·fi ÙËÓ È·ÙÚÈ΋ ÂÚ›ı·Ï„Ë Ì ʷÚ̷΢ÙÈ΋ ·ÁˆÁ‹, fiˆ˜ Ë ÂÊ·ÚÌÔÁ‹ ÙˆÓ Î·Ù¢ı˘ÓÙ‹ÚÈˆÓ Ô‰ËÁÈÒÓ ÛÙË ÎÏÈÓÈ΋ Ú¿ÍË Î·È Ë ·Ó¿Ù˘ÍË Ó¤ˆÓ ·ÔÙÂÏÂÛÌ·ÙÈÎfiÙÂÚˆÓ Ê·ÚÌ¿ÎˆÓ ÁÈ· ÙË ‰Â˘ÙÂÚÔÁÂÓ‹ ÚfiÏË„Ë Û ·ÛıÂÓ›˜ Ì ™™¡.

∂¿Ó Ô ÛÙfi¯Ô˜ Â›Ó·È Ó· ·Ó·ÎÔ˘ÊÈÛÙÔ‡Ó Ù· Û˘ÌÙÒÌ·Ù· ÛÙÔ˘˜ ·ÛıÂÓ›˜ Ì ™™¡ (Â›ÌÔÓË ÛÙËı¿Á¯Ë), ·Ú¿ Ó· ·ÔÙÚ·Ô‡Ó Ù· ÌÂÏÏÔÓÙÈο ηډȷÁÁÂȷο Û˘Ì‚¿Ì·Ù·, Ë PCI Ê·›ÓÂÙ·È Ó· ·ÔÙÂÏ› ÌÈ· ·Ô‰ÂÎÙ‹ ıÂÚ·¢ÙÈ΋ ̤ıÔ‰Ô. ¶Èı·ÓÒ˜ ‹ÚıÂ Ô Î·ÈÚfi˜ Ó· ·ÓÙÈÌÂÙˆ›ÛÔ˘Ì Ì ʷÚ̷΢ÙÈ΋ ·ÁˆÁ‹ ÙË Û˘ÓÙÚÈÙÈ΋ ÏÂÈÔ„Ë-

μÈ‚ÏÈÔÁÚ·Ê›· 1.

2.

3.

4.

No authors listed. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 1997; 350: 461-8. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG, et al. Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003; 42: 1161-70. Boden WE, O'rourke RA, Teo KK, et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl J Med. 2007 Mar 26; [Epub ahead of print] Hochman JS, Steg PG. Does preventive PCI work? N Engl J Med. 2007 Mar 26; [Epub ahead of print]

5.

6.

7.

Pitt B, Waters D, Brown WV, et al. for the Atorvastatin Versus Revascularization Treatment Investigators. N Engl J Med 1999;341:70-6 Waters D. Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the Atorvastatin Versus Revascularization (AVERT) Trial. Eur Heart J 2000; 21:1029-31 Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents. A cause for concern. Circulation 2007;115:1440-55

8. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-9 9.

sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-97 10. Mauri L, Hsieh W, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356:1020-9 11. Weintraub WS. Quality-of-life and economic outcomes analyses of the COURAGE trial. ACC Scientific Sessions, New Orle-ans, 2007. 12. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary Coronary Heart Disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2002;18:220-8

Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing

17


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·18

π√À¡π√™ 2007

∏ ∫ÏÈÓÈ΋ ™ËÌ·Û›· Ù˘ ÃÔÚ‹ÁËÛ˘ ™Ù·ÙÈÓÒÓ ¶ÚÈÓ ·fi ∂ÂÌ‚·ÙÈ΋ ∂·Ó·ÈÌ¿ÙˆÛË ÙÔ˘ ª˘Ôηډ›Ô˘. μ. ’∞ı˘ÚÔ˜, ∞. ∫·Î·Ê‹Î·, ∂. ¶·ÓÎÔ˘Ú¤ÏÈ·˜, ™. ™·‚‚·ÙÈ·Ófi˜, ∞. ¶ÈÚ·ÛÔÔ‡ÏÔ˘, Ã. ∫Ô˘Ì·Ú¿˜, ∞. ™Î·¤Ú‰·˜, ∫. Δ˙ÈfiÌ·ÏÔ˜, ∞. ∫·Ú·ÁÈ¿ÓÓ˘. μ’ ¶ÚÔ. ¶·ıÔÏÔÁÈ΋ ∫ÏÈÓÈ΋ ∞¶£, πÔÎÚ¿ÙÂÈÔ ¡ÔÛÔÎÔÌ›Ô, £ÂÛÛ·ÏÔÓ›ÎË. ΔÔ ÛÙ·Ù›Ó˜ ¯ÚËÛÈÌÔÔÈÔ‡ÓÙ·È ÂÎÙÂÓÒ˜ ÛÙË ÛÙ·ıÂÚ‹ ÛÙÂÊ·ÓÈ·›· ÓfiÛÔ (™™¡) Î·È ˘¿Ú¯ÂÈ ‹‰Ë ·˘Í·ÓfiÌÂÓË ¯Ú‹ÛË ˘„ËÏÒÓ ‰fiÛÂˆÓ ÛÙ·ÙÈÓÒÓ (΢ڛˆ˜ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘) ÛÙ· Ôͤ· ÛÙÂÊ·ÓÈ·›· Û‡Ó‰ÚÔÌ· (√™™), Ë ÔÔ›· ‚·Û›˙ÂÙ·È ÛÙ· ·ÔÙÂϤÛÌ·Ù· Ù˘ ÌÂϤÙ˘ PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection TherapyThrombolysis in Myocardial Infarction 22). [1] À¿Ú¯Ô˘Ó Â›Û˘ ÛÙÔȯ›· Ô˘ ‰Â›¯ÓÔ˘Ó fiÙÈ Ë ¯ÔÚ‹ÁËÛË ÌÈ·˜ ÛÙ·Ù›Ó˘ ÌÂÙ¿ ·fi ·ÁÁÂÈÔÏ·ÛÙÈ΋ ÛÙÂÊ·ÓÈ·›ˆÓ (PCI) [2] ‹ ÌÂÙ¿ ·fi ·ÔÚÙÔÛÙÂÊ·ÓÈ·›· ·Ú¿Î·Ì„Ë (CABG)[3] ÂÏ·ÙÙÒÓÂÈ ÛËÌ·ÓÙÈο Ù· ηډȷÁÁÂȷο Û˘Ì‚¿Ì·Ù· Î·È ÙË ıÓËÙfiÙËÙ·. ¶ÚfiÛÊ·Ù· Ù· ·ÔÙÂϤÛÌ·Ù· Ù˘ ÌÂϤÙ˘ COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation), [4] ¤‰ÂÈÍ·Ó fiÙÈ Û ·ÛıÂÓ›˜ Ì ™™¡ Ë PCI Ì·˙› Ì ‚¤ÏÙÈÛÙË Ê·Ú̷΢ÙÈ΋ ·ÁˆÁ‹ ‰ÂÓ Â›Ó·È ÂÚÈÛÛfiÙÂÚÔ ·ÔÙÂÏÂÛÌ·ÙÈ΋ ÛÙË ÚfiÏË„Ë Î·Ú‰È·ÁÁÂÈ·ÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ ·fi ÙË ‚¤ÏÙÈÛÙË Ê·Ú̷΢ÙÈ΋ ·ÁˆÁ‹ ÌfiÓË Ù˘. [4] ∂ÓÙÔ‡ÙÔȘ, ·ÎfiÌ· ÎÈ ·Ó Ù· ·ÔÙÂϤÛÌ·Ù· Ù˘

18

COURAGE ÂÊ·ÚÌÔÛÙÔ‡Ó ÂÍ ÔÏÔÎÏ‹ÚÔ˘ ÛÙËÓ ÎÏÈÓÈ΋ Ú¿ÍË, ¤Ó·˜ ÛËÌ·ÓÙÈÎfi˜ ·ÚÈıÌfi˜ ·ÛıÂÓÒÓ Ì √™™ ‹ Ì Â›ÌÔÓË ÛÙËı¿Á¯Ë ÛÙË ™™¡ ı· Ú¤ÂÈ Ó· ˘Ô‚ÏËı› Û PCI ‹ CABG. [4] À¿Ú¯Ô˘Ó οÔÈ· ÛÙÔȯ›· ÁÈ· ÙÔ fiÊÂÏÔ˜ Ù˘ ıÂÚ·›·˜ Ì ÛÙ·Ù›ÓË ÚÈÓ ·fi PCI ‹ CABG,[5,6] ·ÏÏ¿ ÚfiÛÊ·Ù· Ë ÌÂϤÙË ARMYDA ACS (Atorvastatin for Reduction of Myocardial Damage during Angioplasty in patients with Acute Coronary Syndromes) [7] ÚfiÛıÂÛ ÂÚÈÛÛfiÙÂÚ· ÛÙÔȯ›· fiÛÔÓ ·ÊÔÚ¿ ÙÔ ˙‹ÙËÌ· ·˘Ùfi.

1. £ÂÚ·›· Ì ÛÙ·Ù›ÓË ÚÈÓ ·fi CABG. ∏ Multicenter Study of Perioperative Ischemia Epidemiology II [8] ‹Ù·Ó ÌÈ· ÚÔÔÙÈ΋ ÌÂϤÙË Û 5.436 ·ÛıÂÓ›˜ Ô˘ ÂÚfiÎÂÈÙÔ Ó· ˘Ô‚ÏËıÔ‡Ó Û CABG Û 70 ΤÓÙÚ· Û 17 ¯ÒÚ˜. À¿Ú¯Ô˘Ó ÛÙÔȯ›· ÁÈ· ·ÛıÂÓ›˜ Ô˘ ÂÏ¿Ì‚·Ó·Ó (n=1.352) Î·È ÁÈ· ·˘ÙÔ‡˜ Ô˘ ‰ÂÓ ÂÏ¿Ì‚·Ó·Ó (n=1.314) ÚÔÂÁ¯ÂÈÚËÙÈ΋ ıÂÚ·›· Ì ÛÙ·Ù›ÓË. ∏ ÔÏ˘·Ú·ÁÔÓÙÈ΋ ·Ó¿Ï˘ÛË ¤‰ÂÈÍ fiÙÈ Ë ÚÔÂÁ¯ÂÈÚËÙÈ΋ ıÂÚ·›· Ì ÛÙ·Ù›ÓË Û˘Ó‰¤ıËΠ·ÓÂÍ¿ÚÙËÙ· Ì ÌÈ· ÛËÌ·ÓÙÈ΋ Ì›ˆÛË Î·Ù¿ 75% ÙÔ˘ ηډȷÁÁÂÈ·ÎÔ‡ ı·Ó¿ÙÔ˘ ÌÂÙ¿ ·fi CABG (0,3% ¤Ó·ÓÙÈ 1,4% p<0.03). ∞ÓÙ›ıÂÙ· Ë ‰È·ÎÔ‹ Ù˘ ıÂÚ·›·˜ Ì ÛÙ·Ù›ÓË ÌÂÙ¿ ·fi ÙË CABG Û˘Ó‰¤ıËΠ·ÓÂÍ¿ÚÙËÙ· Ì ÌÈ· ÛËÌ·ÓÙÈ΋ ·‡ÍËÛË ÛÙËÓ fi„ÈÌË ÔÏÈ΋ ıÓËÙfiÙËÙ· ηٿ 2,6 ÊÔÚ¤˜ Î·È ÛÙËÓ fi„ÈÌË Î·Ú‰È·Î‹ ıÓËÙfiÙËÙ· ηٿ 2,9 ÊÔÚ¤˜ (2,64% ¤Ó·ÓÙÈ 0,60% 1,91% ¤Ó·ÓÙÈ 0,45%, ·ÓÙ›ÛÙÔȯ·, p<0.01 Î·È ÁÈ· ÙȘ ‰‡Ô). ™Â ÌÈ· ·Ó·‰ÚÔÌÈ΋ ÌÂϤÙË Ë ÔÌ¿‰· ÙˆÓ ·ÛıÂÓÒÓ Ô˘ ˘Ô‚Ï‹ıËΠ۠CABG (n=1.663) ¯ˆÚ›ÛÙËΠ۠2 ÔÌ¿‰Â˜: ·ÛıÂ-

Ó›˜ Ô˘ ÂÏ¿Ì‚·Ó·Ó ÚÔÂÁ¯ÂÈÚËÙÈ΋ ıÂÚ·›· Ì ÛÙ·Ù›ÓË (n=943) Î·È ÂΛÓÔ˘˜ Ô˘ ‰ÂÓ ÂÏ¿Ì‚·Ó·Ó (n=720). [9] ∏ ÔÏ˘·Ú·ÁÔÓÙÈ΋ ·Ó¿Ï˘ÛË ¤‰ÂÈÍ fiÙÈ Ë ÚÔÂÁ¯ÂÈÚÈÙÈ΋ ıÂÚ·›· Ì ÛÙ·Ù›ÓË Û˘Ó‰¤ıËΠ·ÓÂÍ¿ÚÙËÙ· Ì ÌÈ· ÛËÌ·ÓÙÈ΋ Ì›ˆÛË Ù˘ ÔÏÈ΋˜ ıÓËÙfiÙËÙ·˜ Î·È ÙÔ˘ Û‡ÓıÂÙÔ˘ ÙÂÏÈÎÔ‡ ÛËÌ›Ԣ (ıÓËÙfiÙËÙ·˜ Û˘Ó ¤ÌÊÚ·ÁÌ· ÙÔ˘ Ì˘Ôηډ›Ô˘) ÛÙȘ 30 Ë̤Ú˜ (3,75% ¤Ó·ÓÙÈ 1,80% Î·È 7,1% ¤Ó·ÓÙÈ 4,6%, ·ÓÙ›ÛÙÔȯ·, p<0.05 Î·È ÁÈ· ÙȘ ‰‡Ô). [9] ∂›Û˘, Ë ÚÔÂÁ¯ÂÈÚËÙÈ΋ ıÂÚ·›· Ì ÛÙ·Ù›ÓË Û ·ÛıÂÓ›˜ Ô˘ ˘Ô‚Ï‹ıËÎ·Ó Û CABG Û˘Û¯ÂÙ›ÛÙËΠ̠¯·ÌËÏfi ÔÛÔÛÙfi ıÓËÙfiÙËÙ·˜ ÙÔÓ ÚÒÙÔ ¯ÚfiÓÔ ÌÂÙ¿ ÙËÓ ÂÁ¯Â›ÚËÛË ¤Ó·ÓÙÈ ÙˆÓ ÌË ıÂÚ·¢fiÌÂÓˆÓ ÚÔÂÁ¯ÂÈÚËÙÈο Ì ÛÙ·Ù›ÓË ·ÛıÂÓÒÓ [10] Δ¤ÏÔ˜, Ù· ›‰È· ·ÔÙÂϤÛÌ·Ù· ¤‰ÂÈÍ ÌÈ· ¿ÏÏË ·Ó·‰ÚÔÌÈ΋ ÌÂϤÙË Ì ·ÛıÂÓ›˜ Ô˘ ˘Ô‚¿ÏÏÔÓÙ·È Û ÚÔÂÁ¯ÂÈÚËÙÈ΋ ıÂÚ·›· Ì ÛÙ·Ù›ÓË, Ë ÔÔ›· Û˘Ó‰¤ıËΠ̠ÏÈÁfiÙÂÚ˜ ÂÚÈÂÁ¯ÂÈÚËÙÈΤ˜ ηډȷΤ˜ Î·È ÛËÌ·ÓÙÈΤ˜ ·ÁÁÂȷΤ˜ ÂÈÏÔΤ˜ (-64%, p=0.035) ÌÂÙ¿ ÙË CABG, Ì ÌÈÎÚfiÙÂÚÔ ¯ÚfiÓÔ ·Ú·ÌÔÓ‹˜ ÛÙÔ ÓÔÛÔÎÔÌÂ›Ô (p=0.003) Î·È Ì ‚ÂÏÙȈ̤ÓË Ì·ÎÚÔ¯ÚfiÓÈ· (5,5 ¤ÙË) ÂÈ‚›ˆÛË (p<0.004) Û ۇÁÎÚÈÛË Ì ÂΛÓÔ˘˜ Ô˘ ‰ÂÓ ‹Ú·Ó ÚÔÂÁ¯ÂÈÚËÙÈο ÛÙ·Ù›ÓË [11]. ∞˘Ù¿ Ù· ÛÙÔȯ›· ‰ÂÓ ·Ê‹ÓÔ˘Ó Î·Ì›· ·ÌÊÈ‚ÔÏ›· fiÙÈ ˘¿Ú¯ÂÈ Ô˘ÛÈ·ÛÙÈÎfi fiÊÂÏÔ˜ ÛÙË ¯ÔÚ‹ÁËÛË ÛÙ·Ù›Ó˘ ÚÔÂÁ¯ÂÈÚËÙÈο Û ·ÛıÂÓ›˜ Ô˘ ı· ˘Ô‚ÏËıÔ‡Ó Û CABG fiÛÔÓ ·ÊÔÚ¿ ÙË Ì›ˆÛË Ù˘ ‚Ú·¯Â›·˜, ÌÂÛÔÚfiıÂÛÌ˘ Î·È Ì·ÎÚÔÚfiıÂÛÌ˘ ηډȷÁÁÂȷ΋˜ ÓÔÛËÚfiÙËÙ·˜ Î·È ıÓËÙfiÙËÙ·˜ Î·È ÛÙËÓ Ô˘ÛÈ·ÛÙÈ΋ ÂÍÔÈÎÔÓfiÌËÛË fiÚˆÓ ÁÈ· ÙËÓ ˘ÁÂÈÔÓÔÌÈ΋ ÂÚ›ı·Ï„Ë.


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·19

£∂ƒ∞¶∂π∞ - º∞ƒª∞∫∞ 2. £ÂÚ·›· Ì ÛÙ·Ù›Ó˜ ÚÈÓ ·fi PCI. ªÈ· ÌÂÁ¿ÏË ÌÂϤÙË ÂÓfi˜ ÙÚÈÙÔ‚¿ıÌÈÔ˘ ȉڇ̷ÙÔ˜ ‰ÈÂÚ‡ÓËÛ ηٿ fiÛÔÓ Ë ˘ÂÚÏÈȉ·ÈÌ›·, Ë ¯Ú‹ÛË ÛÙ·Ù›Ó˘ Û ·ÛıÂÓ›˜ Ì ˘ÂÚÏÈȉ·ÈÌ›· ‹ Ë ÓÔÚÌÔÏÈȉ·ÈÌ›· Û˘Ó‰¤ÔÓÙ·È Ì ÙËÓ ¤Î‚·ÛË ·ÛıÂÓÒÓ Ô˘ ˘Ô‚¿ÏÏÔÓÙ·È Û PCI. [12] ∏ ÂÓ‰ÔÓÔÛÔÎÔÌÂȷΤ˜ ÂÈÏÔΤ˜ Î·È Ë Ì·ÎÚÔÚfiıÂÛÌË ¤Î‚·ÛË ÙˆÓ ·ÛıÂÓÒÓ Ì ˘ÂÚÏÈȉ·ÈÌ›· (Â›Â‰Ô ÔÏÈ΋˜ ¯ÔÏËÛÙÂÚfiÏ˘ > 240 mg/dl) ıÂÚ·¢fiÌÂÓË Ì ÛÙ·Ù›Ó˜ (n=2.052) Î·È Ì ˘ÂÚÏÈȉ·ÈÌ›· ÌË ıÂÚ·¢fiÌÂÓË Ì ÛÙ·Ù›Ó˜ (n=1.650) Û˘ÁÎÚ›ıËÎ·Ó Ì ·˘Ù¤˜ 726 ·ÛıÂÓÒÓ ÌÂ Ê˘ÛÈÔÏÔÁÈο Â›‰· ¯ÔÏËÛÙÂÚfiÏ˘. Δ· ·ÔÙÂϤÛÌ·Ù· ¤‰ÂÈÍ·Ó fiÙÈ Ë ˘ÂÚÏÈȉ·ÈÌ›· ·˘Ù‹ ηı' ·˘Ù‹ ‰ÂÓ Û˘Ó‰¤ÂÙ·È Ì ÙȘ ÂÓ‰ÔÓÔÛÔÎÔÌÂȷΤ˜ ÂÈÏÔΤ˜ ÌÂÙ¿ ·fi PCI. ΔÔ fiÊÂÏÔ˜ ÂÚÈÔÚ›ÛÙËΠÌfiÓÔ ÛÙÔ˘˜ ıÂÚ·¢fiÌÂÓÔ˘˜ Ì ÛÙ·Ù›Ó˜ ·ÛıÂÓ›˜. À‹ÚÍ ÌÈ· ÌÈÎÚfiÙÂÚË ÂÓ‰ÔÓÔÛÔÎÔÌÂȷ΋ ıÓËÙfiÙËÙ· (0% ÂÓ·ÓÙ›ÔÓ 2% ÛÙȘ ¿ÏϘ 2 ÔÌ¿‰Â˜, p<0.001), ÌÈ· ¯·ÌËÏfiÙÂÚË ·‡ÍËÛË Ù˘ CK-ªμ (14% ÂÓ·ÓÙ›ÔÓ 27% Î·È 28% ÛÙȘ ¿ÏϘ ÔÌ¿‰Â˜, p<0.001) Î·È ÏÈÁfiÙÂÚ˜ ÂÈÏÔΤ˜ Ù˘ PCI (15% ÂÓ·ÓÙ›ÔÓ 30% ÙˆÓ 2 ¿ÏÏˆÓ ÔÌ¿‰ˆÓ, p<0.001). [12] ªÂÙ¿ ‰ÈÂÚ‡ÓËÛË Ù˘ Èı·ÓfiÙËÙ·˜ Ï‹„˘ ÛÙ·Ù›Ó˘ Ô˘ ‚·Û›ÛÙËΠÛÙ· ÎÏÈÓÈο Î·È ·ÁÁÂÈÔÁÚ·ÊÈο ¯·Ú·ÎÙËÚÈÛÙÈο, ÔÈ ·ÛıÂÓ›˜ Ô˘ ¤·ÈÚÓ·Ó ÛÙ·Ù›Ó˜ ›¯·Ó ·ÎfiÌ· ÏÈÁfiÙÂÚ˜ ÂÓ‰ÔÓÔÛÔÎÔÌÂȷΤ˜ ÂÈÏÔΤ˜ Î·È ÌÂÁ·Ï‡ÙÂÚË ‰È·ÊÔÚ¿ ÛÙËÓ ÂÓ‰ÔÓÔÛÔÎÔÌÂȷ΋ ıÓËÙfiÙËÙ·. [12] Δ· ·ÔÙÂϤÛÌ·Ù· Ù˘ ÌÂϤÙ˘ ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) [5] ¤‰ÂÈÍ·Ó fiÙÈ Û ·ÛıÂÓ›˜ Ì ™™¡ Ë ¯ÔÚ‹ÁËÛË 40 mg/ËÌ. ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ ÁÈ· 7 Ë̤Ú˜ ÚÈÓ ÙË PCI ÌÂÈÒÓÂÈ ÛËÌ·ÓÙÈο ÙÔ Ì˘ÔηډȷÎfi ÙÚ·˘Ì·ÙÈÛÌfi Ô˘ ÚÔηÏÂ›Ù·È ·fi ÙË PCI. ∏ CK-ªμ, Ë ÙÚÔÔÓ›ÓË π, Î·È Ë Ì˘ÔÛÊ·ÈÚ›ÓË ÛÙȘ 8 Î·È 24 ÒÚ˜ ÌÂÙ¿ ·fi ÙËÓ PCI ‹Ù·Ó Û Ôχ ¯·ÌËÏfiÙÂÚ· Â›‰· ·fi fiÙÈ ÛÙÔ˘˜ ·ÛıÂÓ›˜ Ô˘ ‹Ú·Ó ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ. √ ΛӉ˘ÓÔ˜ ÁÈ· Ù· Û˘ÓÔÏÈο ηÚ-

‰È·ÁÁÂȷο Û˘Ì‚¿Ì·Ù· ÂÏ·ÙÙÒıËΠηٿ 81% Ì ÙËÓ ·ÙÔÚ‚·ÛÙ·Ù›ÓË, ÂÓÒ Ù· ÂÌÊÚ¿ÁÌ·Ù· ÙÔ˘ Ì˘Ôηډ›Ô˘ ‹Ù·Ó 5% ÛÙË ÔÌ¿‰· ÙˆÓ ·ÛıÂÓÒÓ Ô˘ ¤·ÈÚÓ·Ó ·ÙÔÚ‚·ÛÙ·Ù›ÓË Î·È 18% ÛÙËÓ ÔÌ¿‰· ÙÔ˘ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ (p=0.025). [5] ∏ ÌÂϤÙË ARMYDA CAMS [6] ‰ÈÂÚ‡ÓËÛÂ Â¿Ó Ë ÚÔÛÙ·Û›· Ù˘ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ ·fi ÙÔ Ì˘ÔηډȷÎfi ÙÚ·˘Ì·ÙÈÛÌfi ηٿ ÙË ‰È¿ÚÎÂÈ· Ù˘ PCI Û˘Û¯ÂÙ›˙ÂÙ·È Ì ÙË Ì›ˆÛË Ù˘ ÊÏÂÁÌÔÓÒ‰Ô˘˜ ·¿ÓÙËÛ˘ ÙÔ˘ ÂÓ‰ÔıËÏ›Ô˘. ™Â ÌÈ· ÚÔÁÚ·ÌÌ·ÙÈṲ̂ÓË ˘Ô·Ó¿Ï˘ÛË Ù˘ ÌÂϤÙ˘ ARMYDA, ÌÈ· ˘ÔÔÌ¿‰· 76 ·ÛıÂÓÒÓ ÂÍÂÙ¿ÛÙËΠÁÈ· ÙË Ì¤ÙÚËÛË ÙˆÓ ÂÈ¤‰ˆÓ ÛÙÔ Ï¿ÛÌ· ÙÔ˘ vascular cell adhesion molecule-1 (VCAM-1), ÙÔ˘ intercellular cell adhesion molecule-1 (ICAM-1), Î·È Ù˘ E-selectin. ∞fi ·˘ÙÔ‡˜ ÔÈ 38 ·ÛıÂÓ›˜ ·Ó‹Î·Ó ÛÙËÓ ÔÌ¿‰· Ù˘ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ (40 mg/ËÌ.) Î·È 38 ÛÙËÓ ÔÌ¿‰· ÙÔ˘ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘. Δ· ÌfiÚÈ· ÚÔÛÎfiÏÏËÛ˘ ·ÍÈÔÏÔÁ‹ıËÎ·Ó 7 Ë̤Ú˜ ÚÈÓ ·fi ÙËÓ Â¤Ì‚·ÛË, ·Ì¤Ûˆ˜ ÚÈÓ ·fi ÙËÓ PCI, Î·È 8 Î·È 24 ÒÚ˜ ÌÂÙ¿ ÙËÓ PCI. ¢È·ÈÛÙÒıËÎ·Ó ÛËÌ·ÓÙÈο ¯·ÌËÏfiÙÂÚ· Â›‰· ÙˆÓ Ô˘ÛÈÒÓ ·˘ÙÒÓ ÛÙËÓ ÔÌ¿‰· Ù˘ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘. ∏ PCI Ì ÙÔÔı¤ÙËÛË stent Ê·›ÓÂÙ·È fiÙÈ ÚÔηÏ› ÂÓÂÚÁÔÔ›ËÛË ÙÔ˘ Ì˯·ÓÈÛÌÔ‡ ‹Í˘ Î·È ˘ÚÔ‰ÔÙ› ÊÏÂÁÌÔÓ‹ ÙÔ˘ ·ÁÁ›Ԣ. Δ· ÔʤÏË Ù˘ ¯Ô-

Ú‹ÁËÛ˘ ÛÙ·Ù›Ó˘ ı· ÌÔÚÔ‡Û ӷ Â›Ó·È ·ÔÙ¤ÏÂÛÌ· ÙˆÓ Â˘ÓÔ˚ÎÒÓ Ù˘ ‰Ú¿ÛÂˆÓ ÛÙË ÚÔÛÎfiÏÏËÛË ÙˆÓ ·ÈÌÔÂÙ·Ï›ˆÓ, ÛÙË ıÚfiÌ‚ˆÛË, ÛÙË ÛÙ·ıÂÚfiÙËÙ· ÙˆÓ ·ıËڈ̷ÙÈÎÒÓ Ï·ÎÒÓ Î·È ÛÙË ÊÏÂÁÌÔÓ‹. Δ· ·ÓˆÙ¤Úˆ ÛÙÔȯ›· ‰Â›¯ÓÔ˘Ó fiÙÈ Ë Ì›ˆÛË Ù˘ ÂÓ‰ÔıËÏȷ΋˜ ÊÏÂÁÌÔÓÒ‰Ô˘˜ ·¿ÓÙËÛ˘ ÛÙËÓ PCI ÌÔÚ› Ó· ÂÍËÁ‹ÛÂÈ ÙËÓ ÚÔÛٷ٢ÙÈ΋ Â›‰Ú·ÛË ÙˆÓ ÛÙ·ÙÈÓÒÓ Ô˘ ¯ÔÚËÁÔ‡ÓÙ·È ÚÈÓ ÙË ‰ÈÂÓ¤ÚÁÂÈ¿ Ù˘. [6] ∞˘Ù¿ Ù· ÛÙÔȯ›· ¤‰ÂÈÍ·Ó fiÙÈ ÔÈ ÏÂÈÔÙÚÔÈΤ˜ ‰Ú¿ÛÂȘ ÙˆÓ ÛÙ·ÙÈÓÒÓ Â›Ó·È ·˘Ù¤˜ Ô˘ ÚÔηÏÔ‡Ó Ù· ¢ÂÚÁÂÙÈο ·˘Ù¿ ·ÔÙÂϤÛÌ·Ù·, fiˆ˜ ˘Ô‰ËÏÒÓÂÈ Î·È Ô Û‡ÓÙÔÌÔ˜ ¯ÚfiÓÔ˜ ̤۷ ÛÙÔÓ ÔÔ›Ô ÂΉËÏÒıËηÓ. Œ¯ÂÈ ·Ô‰Âȯı› fiÙÈ Ë ıÂÚ·›· Ì ·ÙÔÚ‚·ÛÙ·Ù›ÓË ÚÈÓ ÙËÓ PCI ÌÔÚ› Ó· ÌÂÈÒÛÂÈ ÙÔ ¤ÌÊÚ·ÁÌ· ÙÔ˘ Ì˘Ôηډ›Ô˘ Î·È ¿ÏÏ· Û˘Ì‚¿Ì·Ù· Û ·ÛıÂÓ›˜ Ì ™™¡ ηٿ ‹ ·Ì¤Ûˆ˜ ÌÂÙ¿ ÙË ‰ÈÂÓ¤ÚÁÂÈ· ÂÎÏÂÎÙÈ΋˜ PCI Î·È ÙÔÔı¤ÙËÛ˘ stent. ∂ÓÙÔ‡ÙÔȘ, ·˘Ù‹ Ë ıÂÚ·›· ‰ÂÓ Â›¯Â ‰ÈÂÚ¢ÓËı› Û ·ÛıÂÓ›˜ Ì √™™. ™ÙË ÚfiÛÊ·Ù· ‰ËÌÔÛÈÂ˘Ì¤ÓË ÌÂϤÙË ARMYDA ACS (Atorvastatin for Reduction of Myocardial Damage during Angioplasty in patients with Acute Coronary Syndromes) [7] Û˘ÓÔÏÈο 171 ·ÛıÂÓ›˜ Ì √™™ Ù˘¯·ÈÔÔÈ‹ıËÎ·Ó Û ıÂÚ·›· Ì ·ÙÔÚ‚·ÛÙ·Ù›ÓË (80 mg 12 ÒÚ˜ Î·È 40 mg 2

19


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·20

π√À¡π√™ 2007

ÒÚ˜ ÚÈÓ ·fi ÙË PCI [n=86]) ‹ Û ıÂÚ·›· Ì ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ (n=85). ™Â fiÏÔ˘˜ ÙÔ˘˜ ·ÛıÂÓ›˜ ¯ÔÚËÁ‹ıËΠÌÈ· ‰fiÛË 600 mg ÎÏÔȉÔÁÚ¤Ï˘. ΔÔ Û˘Ó‰˘·Ṳ̂ÓÔ ÙÂÏÈÎfi ÛËÌÂ›Ô (ı¿Ó·ÙÔ˜, Ì˘ÔηډȷÎfi ¤ÌÊÚ·ÁÌ·, ‹ ÌË ÚÔÁÚ·ÌÌ·ÙÈṲ̂ÓË Â·Ó·ÈÌ¿ÙˆÛË) ÂÌÊ·Ó›ÛÙËΠ۠5% ÙˆÓ ·ÛıÂÓÒÓ ÛÙÔ ÛΤÏÔ˜ Ù˘ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ Î·È Û 17% ÙˆÓ ·ÛıÂÓÒÓ ÛÙÔ ÛΤÏÔ˜ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ (p=0.01). ∞˘Ù‹ Ë ‰È·ÊÔÚ¿ ÔÊÂÈÏfiÙ·Ó Î˘Ú›ˆ˜ ÛÙË Ì›ˆÛË Ù˘ Â›ÙˆÛ˘ ÙÔ˘ ÂÌÊÚ¿ÁÌ·ÙÔ˜ Ì˘Ôηډ›Ô˘ (5% ¤Ó·ÓÙÈ 15%, p=0.04). ™˘ÓÔÏÈο, Ë ÂÏ¿ÙÙˆÛË ÙˆÓ Û˘Ì‚·Ì¿ÙˆÓ

ÛÙËÓ ÔÌ¿‰· Ù˘ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ ‹Ù·Ó 88%. ∂ÈϤÔÓ, ÌÂÙ¿ ·fi PCI, ÙÔ ÔÛÔÛÙfi ÙˆÓ ·��ıÂÓÒÓ Ì ·˘ÍË̤ÓË CK-ªμ ‹ ÙÚÔÔÓ›ÓË π ÛÙËÓ ÔÌ¿‰· Ù˘ ·ÙÔÚ‚·ÛÙ·Ù›Ó˘ ‹Ù·Ó ÛËÌ·ÓÙÈο ¯·ÌËÏfiÙÂÚÔ ·fi ·˘Ùfi Ù˘ ÔÌ¿‰·˜ ÙÔ˘ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘. [7] ΔÔ ›‰ÈÔ Û˘Ó¤‚Ë Î·È Ì ٷ Â›‰· Ù˘ CRP. [7] ∞˘Ù¿ Ù· ÛÙÔȯ›· ÌÔÚÔ‡Ó Ó· ˘ÔÛÙËÚ›ÍÔ˘Ó ÙË ¯Ú‹ÛË ˘„ËÏ‹˜ ‰fiÛ˘ ÛÙ·Ù›Ó˘ ÚÈÓ ·fi ÙËÓ PCI ÛÙÔ˘˜ ·ÛıÂÓ›˜ Ì √™™.

ÛË ÛÙ·Ù›Ó˘ ÚÈÓ ·fi CABG ‹ PCI, ÙËÓ ÔÔ›· Ô‡Ùˆ˜ ‹ ¿Ïψ˜ ı· ¿ÚÔ˘Ó ÌÂÙ¿ ÙËÓ ÂÂÌ‚·ÙÈ΋ Â·Ó·ÈÌ¿ÙˆÛË. ∞˘Ù‹ Ë Ú·ÎÙÈ΋ Â¿Ó ÁÂÓÈ΢ı› ı· ÛÒÛÂÈ ·ÓıÚÒÈÓ˜ ˙ˆ¤˜, ı· ‚ÂÏÙÈÒÛÂÈ ÙË ÔÈfiÙËÙ· ˙ˆ‹˜ ÙˆÓ ·ÛıÂÓÒÓ ÌÂÙ¿ ÙËÓ Â·Ó·ÈÌ¿ÙˆÛË Î·È ı· ÂÍÔÈÎÔÓÔÌ‹ÛÂÈ ÛËÌ·ÓÙÈÎÔ‡˜ fiÚÔ˘˜ ÁÈ· ÙËÓ ˘Á›· Ô˘ Ô‡Ùˆ˜ ‹ ¿Ïψ˜ Â›Ó·È ‰˘Û‡ÚÂÙÔÈ.

™˘ÌÂÚ·ÛÌ·ÙÈο, ·fi Ù· ·Ú·¿Óˆ ‰È·ÈÛÙÒÓÂÙ·È Ôχ ÌÂÁ¿ÏÔ fiÊÂÏÔ˜ ·fi ÙË ¯ÔÚ‹ÁË-

μÈ‚ÏÈÔÁÚ·Ê›· 1.

2.

3.

4.

5.

20

Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med 2004;350:14951504.

statin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation 2004;110:674–8. 6.

Kasai T, Miyauchi K, Kurata T, et al. Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy. Int J Cardiol 2007;114:210-217. Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of lowdensity lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 2000; 102:157-65. Boden WE, O'rourke RA, Teo KK, et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl J Med. 2007 Mar 26; [Epub ahead of print] Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G, ARMYDA Investigators. Randomized trial of atorva-

7.

8.

Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDACAMs (Atorvastatin for Reduction of Myocardial Damage During Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006;48: 1560-6. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Results of the ARMYDA-ACS Randomized Trial. J Am Coll Cardiol 2007; 49:1272-1278. Collard CD, Body SC, Shernan SK, Wang S, Mangano DT; Multicenter Study of Perioperative Ischemia (MCSPI) Research Group, Inc; Ischemia Research and Education Foundation (IREF) Investigators. Preoperative statin therapy is associated with reduced cardiac

mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2006;132:392-400. 9.

Pan W, Pintar T, Anton J, Lee VV, Vaughn WK, Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004;110 (11 Suppl 1):II45-9.

10. Dotani MI, Elnicki DM, Jain AC et al. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000;86: 1128-1130. 11. Ward RP, Leeper NJ, Kirkpatrick JN, et al. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol 2005;104: 264-268. 12. Singh M, Lennon RJ, Roger VL, et al. Relation of preprocedural statin therapy to inhospital procedural complications following percutaneous coronary interventions in patients with hyperlipidemia. Am J Cardiol 2006;98: 325-330.


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·21

£∂ƒ∞¶∂π∞ - º∞ƒª∞∫∞

∂ÈÛÓÂfiÌÂÓË πÓÛÔ˘Ï›ÓË: Δ· ¢Â‰Ô̤ӷ Î·È ÔÈ ¶ÚÔ‚ÏËÌ·ÙÈÛÌÔ› ¢Ú. ∞Ó‰Ú¤·˜ ªÂÏȉÒÓ˘ À‡ı˘ÓÔ˜ ¢È·‚ËÙÔÏÔÁÈÎÔ‡ ∫¤ÓÙÚÔ˘, °.¡. ¶ÂÈÚ·È¿ ∏ Â›Ù¢ÍË Â˘ÁÏ˘Î·ÈÌ›·˜ Û ¿ÙÔÌ· Ì ۷ί·ÚÒ‰Ë ‰È·‚‹ÙË, ·ÔÙÂÏ› ÚˆÙ·Ú¯ÈÎfi ıÂÚ·¢ÙÈÎfi ÛÙfi¯Ô, Ì ÛÎÔfi ÙËÓ Ì›ˆÛË Ù˘ Â›ÙˆÛ˘ ÙˆÓ ÌÈÎÚÔ·ÁÁÂÈ·ÎÒÓ Î·È Ì·ÎÚÔ·ÁÁÂÈ·ÎÒÓ ÂÈÏÔÎÒÓ ·ÏÏ¿ Î·È Ù˘ ÓÔÛËÚfiÙËÙ·˜ Î·È ıÓËÛÈÌfiÙËÙ·˜. ∏ ·ÓÂ·Ú΋˜ fï˜ ÁÏ˘Î·ÈÌÈ΋ Ú‡ıÌÈÛË ·ÔÙÂÏ›, ‰˘ÛÙ˘¯Ò˜, ¯·Ú·ÎÙËÚÈÛÙÈÎfi ÛÙÔÈ¯Â›Ô ÙˆÓ ÚÔÛ·ıÂÈÒÓ Ô˘ Á›ÓÔÓÙ·È ·ÁÎfiÛÌÈ·. ¢Â‰Ô̤ӷ ‰È·ÊfiÚˆÓ ÌÂÏÂÙÒÓ ‰Â›¯ÓÔ˘Ó fiÙÈ ÌfiÓÔ ÙÔ 31% ÙˆÓ ‰È·‚ËÙÈÎÒÓ ÛÙȘ ∏¶∞ Î·È ÙÔ 39% ÛÙËÓ ∂˘ÚÒË ·ÚÔ˘ÛÈ¿˙Ô˘Ó ÈηÓÔÔÈËÙÈ΋ ÁÏ˘Î·ÈÌÈ΋ Ú‡ıÌÈÛË (∏bA1C <7%). ™’ ·˘ÙfiÓ ÙÔÓ ·ÔÁÔËÙ¢ÙÈÎfi Û¯ÂÙÈο ·ÔÏÔÁÈÛÌfi ›Ûˆ˜ Û˘Ì‚¿ÏÏÂÈ Î·È ÙÔ ÁÂÁÔÓfi˜ fiÙÈ, fiˆ˜ ‰Â›¯ÓÔ˘Ó ÌÂϤÙ˜ ÛÙȘ ∏¶∞, Ë ¯Ú‹ÛË Ù˘ ÈÓÛÔ˘Ï›Ó˘ (Ô˘ Â›Ó·È ÔˆÛ‰‹ÔÙ ÙÔ Î·Ï‡ÙÂÚÔ ıÂÚ·¢ÙÈÎfi fiÏÔ Ì·˜ ÁÈ· ÙËÓ Ú‡ıÌÈÛË ÙÔ˘ ‰È·‚‹ÙË) ‰ÂÓ ¿ÏÏ·ÍÂ, ‰ÂÓ ·˘Í‹ıËΠÙËÓ ÙÂÏÂ˘Ù·›· ‰ÂηÂÙ›· (ÙÔ 27% ÙˆÓ ‰È·‚ËÙÈÎÒÓ ÙÔ 1992 ¤Î·Ó ÈÓÛÔ˘Ï›ÓË ‹ ÂÏ¿Ì‚·Ó ÈÓÛÔ˘Ï›ÓË Î·È ‰ÈÛΛ·, ÙÔ ›‰ÈÔ ÔÛÔÛÙfi ‰È·ÈÛÙÒıËÎÂ Î·È ÙÔ 2000- 2002). À¿Ú¯ÂÈ Î·ı˘ÛÙ¤ÚËÛË ‹ Î·È ·ÓÙ›ÛÙ·ÛË ·fi ÙÔ˘˜ ·ÛıÂÓ›˜ ÛÙËÓ ¤Ó·ÚÍË ÈÓÛÔ˘ÏÈÓÔıÂÚ·›·˜ ÛÙÔ˘˜ ‰È·‚ËÙÈÎÔ‡˜ Ù‡Ô˘ ππ. ∏ ÂÚ¢ÓËÙÈ΋ ÚÔÛ¿ıÂÈ· ÂÈÎÂÓÙÚÒıËΠ۠ÂÓ·ÏÏ·ÎÙÈΤ˜ ÌÔÚʤ˜ ¯ÔÚ‹ÁËÛ˘ ÈÓÛÔ˘Ï›Ó˘, ‰È· Ù˘ ÚÈÓÈ΋˜, ÛÙÔÌ·ÙÈ΋˜ Î·È Ó¢ÌÔÓÈ΋˜ Ô‰Ô‡, ÒÛÙÂ Ë ıÂÚ·¢ÙÈ΋ ·ÁˆÁ‹ Ó· Á›ÓÂÈ ϤÔÓ ·Ô‰ÂÎÙ‹ ·fi ÙÔ˘˜ ·ÛıÂÓ›˜. Δ· ‰Â‰Ô̤ӷ ÙˆÓ ÙÂÏÂ˘Ù·›ˆÓ ÂÙÒÓ ÚÔÎÚ›ÓÔ˘Ó Û·Ó È‰È·›ÙÂÚ· ˆÊ¤ÏÈÌË Î·È ·ÛÊ·Ï‹ ÙËÓ ˘fi ÚÔ¸Ôı¤ÛÂȘ ¯ÔÚ‹ÁËÛË ÈÓÛÔ˘Ï›Ó˘ ‰È· Ù˘ Ó¢ÌÔÓÈ΋˜ Ô‰Ô‡, ÙËÓ ¯ÔÚ‹ÁËÛË ‰ËÏ·‰‹ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘. ∏ ¯ÔÚ‹ÁËÛË ÈÓÛÔ˘Ï›Ó˘ ‰È· Ù˘ Ó¢ÌÔÓÈ΋˜ Ô‰Ô‡ ·ÍÈÔÔÈ› ÙÔ ÏÂÔÓ¤ÎÙËÌ· Ù˘ ÂÍ·ÈÚÂÙÈο ÌÂ-

Á¿Ï˘ ΢„ÂÏȉÈ΋˜-ÂÈıËÏȷ΋˜ ÂÈÊ¿ÓÂÈ·˜ ·ÔÚÚfiÊËÛ˘ (100m2) ÙˆÓ Ó¢ÌfiÓˆÓ, Ë ÔÔ›· Û˘Ó‰˘¿˙ÂÙ·È Ì ÏÔ‡ÛÈÔ ÙÚȯÔÂȉÈÎfi ‰›ÎÙ˘Ô ·ÈÌ¿ÙˆÛ˘. ¶ÚÔ¸fiıÂÛË ·ÔÚÚfiÊËÛ˘ οÔÈ·˜ ‰Ú·ÛÙÈ΋˜ Ô˘Û›·˜ ‰È·Ì¤ÛÔ˘ Ù˘ Ó¢ÌÔÓÈ΋˜ Ô‰Ô‡ Â›Ó·È Ó· Êı¿ÛÔ˘Ó ÛˆÌ·Ù›‰È· ·˘Ù‹˜ Ù˘ Ô˘Û›·˜ ¤ˆ˜ ÙȘ ΢„ÂÏ›‰Â˜. ∏ ÚÔ¸fiıÂÛË ·˘Ù‹ Â›Ó·È ÂÊÈÎÙ‹ ÌfiÓÔÓ fiÙ·Ó Ù· ۈ̷ٛ‰È· ¤¯Ô˘Ó ¤Ó· ȉ·ÓÈÎfi ̤ÁÂıÔ˜ Ù˘ Ù¿Í˘ ÙÔ˘ 1.5 - 5 Ìm. H ÚfiÔ‰Ô˜ Ô˘ Û˘ÓÙÂϤÛıËΠۋÌÂÚ·, ÒÛÙ ӷ Â›Ó·È ‰È·ı¤ÛÈÌË ·fi Ê·ÚÌ·ÎÔÙ¯ÓÈ΋˜ ÏÂ˘Ú¿˜ Ë ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË, ·ÊÔÚ¿ ΢ڛˆ˜ ÛÙËÓ ÂͤÏÈÍË ÙˆÓ Û˘Û΢ÒÓ ¯ÔÚ‹ÁËÛ˘ Ù˘, ÒÛÙ ӷ ‰È·ÛÊ·Ï›˙ÂÙ·È Ë Â›Ù¢ÍË ·˘ÙÔ‡ ÙÔ˘ ȉ·ÓÈÎÔ‡ ÌÂÁ¤ıÔ˘˜ ۈ̷Ùȉ›ˆÓ ÈÓÛÔ˘Ï›Ó˘. Δ· ۈ̷ٛ‰È· ·˘Ù¿ ÛÙËÓ Û˘Ó¤¯ÂÈ· ‰È¤Ú¯ÔÓÙ·È ÙËÓ Î˘„ÂÏȉÔÙÚȯÔÂȉÈ΋ ÌÂÌ‚Ú¿ÓË Î·È ·ÔÚÚÔÊÔ‡ÌÂÓ· ̤ۈ ÙÔ˘ ÏÔ‡ÛÈÔ˘ ÙÚȯÔÂȉÈÎÔ‡ ‰ÈÎÙ‡Ô˘ Êı¿ÓÔ˘Ó ÛÙËÓ Û˘ÛÙËÌ·ÙÈ΋ ΢ÎÏÔÊÔÚ›·. ΔÂÏÈο fï˜ ÌfiÓÔÓ ÙÔ 40% Ù˘ ÂÈÛÓ¢Ûı›۷˜ ÈÓÛÔ˘Ï›Ó˘ Êı¿ÓÂÈ ÛÙËÓ Û˘ÛÙËÌ·ÙÈ΋ ΢ÎÏÔÊÔÚ›·, fiÛÔ Â›Ó·È Û ÌÔÚÊ‹ ۈ̷Ùȉ›ˆÓ ‰È·Ì¤ÙÚÔ˘ 1-5 Ìm, Ù· ÔÔ›· ÂÈÙ˘Á¯¿ÓÔ˘Ó Ó· Êı¿ÛÔ˘Ó ÛÙȘ ΢„ÂÏ›‰Â˜. ™ˆÌ·Ù›‰È· ÌÂÁ·Ï‡ÙÂÚÔ˘ ÌÂÁ¤ıÔ˘˜ (5-10 Ìm.) ÂÓ·ÔÙ›ıÂÓÙ·È Î˘Ú›ˆ˜ ÛÙÔ ÙÚ·¯ÂÈÔ‚ÚÔÁ¯ÈÎfi ‰¤Ó‰ÚÔ (10% Ù˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘), ÂÓÒ ÛˆÌ·Ù›‰È· ÈÓÛÔ˘Ï›Ó˘ ·ÎfiÌ· ÌÂÁ·Ï‡ÙÂÚÔ˘ ÌÂÁ¤ıÔ˘˜ (>10 Ìm.) ÂÓ·ÔÙ›ıÂÓÙ·È ÛÙËÓ ÛÙÔÌ·ÙÈ΋ ÎÔÈÏfiÙËÙ· (20% Ù˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘). Δ¤ÏÔ˜ ˘¿Ú¯Ô˘Ó Î·È ‘·ÒÏÂȘ’ Ù˘ Ù¿Í˘ ÙÔ˘ 30% Ù˘ Û˘ÓÔÏÈ΋˜ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ ÛÙË Û˘Û΢‹ ¯ÔÚ‹ÁËÛ˘. ŒÙÛÈ Ë ÙÂÏÈ΋ ‚ÈԉȷıÂÛÈÌfiÙËÙ· Ù˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ (Ô˘ ÚÔÛÂÁÁ›˙ÂÈ ÙÔ 10- 20% Ù˘ ·ÓÙ›ÛÙÔȯ˘ ˘Ô‰fiÚÈ·˜ ¯ÔÚËÁÔ‡ÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘) ÔÈΛÏÏÂÈ, ÂÍ·ÚÙÒÌÂÓË ·fi Ù· Û˘ÛÙ‹Ì·Ù· ¯ÔÚ‹ÁËÛ˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘, Ù· ¿ÙÔÌ· Î·È ÙËÓ ÙÂ-

¯ÓÈ΋ ÂÈÛÓÔ‹˜ ÙÔ˘˜, ·ÎfiÌË Î·È ·fi ‰fiÛË Û ‰fiÛË ÛÙÔ ›‰ÈÔ ¿ÙÔÌÔ. ™˘ÛÙ‹Ì·Ù· Î·È Û˘Û΢¤˜ ¯ÔÚ‹ÁËÛ˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ ÂÚ¢ÓÒÓÙ·È Î·È ‰ÔÎÈÌ¿˙ÔÓÙ·È ·fi ‰È¿ÊÔÚ˜ Ê·Ú̷΢ÙÈΤ˜ ÂÙ·ÈÚ›˜. (‚Ï. ¶›Ó·Î· 1). ∏ ÂÈÛÓ¢ÛÙÈ΋ Û˘Û΢‹ ÙÔ˘ Exubera (¡ectar Pulmonary Inhaler) Ë ÌfiÓË ÚÔ˜ ÙÔ ·ÚfiÓ ÂÁÎÚÈı›۷ ·fi ÙÔ FDA Î·È ÙÔ˘˜ ·ÓÙ›ÛÙÔÈ¯Ô˘˜ ∂˘Úˆ·˚ÎÔ‡˜ √ÚÁ·ÓÈÛÌÔ‡˜, ÂÚȤ¯ÂÈ ÙËÓ ÛÎfiÓË ÈÓÛÔ˘Ï›Ó˘ Û ·Ϥ˜ Û˘Û΢·Û›Â˜ ÙÔ˘ ÂÓfi˜ ‹ ÙˆÓ 3 mg (ÈÛÔ‰‡Ó·Ì˜ ·fi ÏÂ˘Ú¿˜ ‰Ú¿Û˘ Ì 3 ‹ 9 ÌÔÓ¿‰Â˜ ˘Ô‰fiÚÈ·˜ Ù·¯Â›·˜ ‰Ú¿Ûˆ˜ ÈÓÛÔ˘Ï›Ó˘ ·ÓÙ›ÛÙÔȯ·). √ ı¿Ï·ÌÔ˜ Ù˘ Û˘Û΢‹˜ ‰ËÌÈÔ˘ÚÁ› ·fi ÙËÓ ÛÎfiÓË Ô˘ ‰È·Ï‡ÂÙ·È ¤Ó· ‘Ó¤ÊÔ˜ „ÂηÛÌÔ‡’ Ô˘ ÂÈÛÓ¤ÂÙ·È ·fi ÙÔ ¿ÙÔÌÔ, ÙÔ ÔÔ›Ô Ï·Ì‚¿ÓÂÈ ‰È· Ù˘ ÂÈÛÓÔ‹˜ ÙËÓ ·Ó¿ÏÔÁ· ··ÈÙÔ‡ÌÂÓË ‰fiÛË ÈÓÛÔ˘Ï›Ó˘. ∏ ηٷÛ΢‹ Î·È Ë ÏÂÈÙÔ˘ÚÁ›· Ù˘ ÂÈÛÓ¢ÛÙÈ΋˜ Û˘Û΢‹˜ Â›Ó·È Ù¤ÙÔÈ· ÒÛÙ ӷ ÂÏ·¯ÈÛÙÔÔÈ› ÙË ÌÂÙ·‚ÏËÙfiÙËÙ· ÙÔ˘ ÂÈÛÓ¢ÛÙÈÎÔ‡ ·ÔÙÂϤÛÌ·ÙÔ˜ Î·È ÙÔ Ì¤ÁÂıÔ˜ ÙˆÓ ÂÈÛÓÂfiÌÂÓˆÓ ÌÔÚ›ˆÓ. ∏ ·ÔÙÂÏÂÛÌ·ÙÈÎfiÙËÙ· Î·È Ë ·ÛÊ¿ÏÂÈ· ÙÔ˘ Exubera ¤¯ÂÈ ÌÂÏÂÙËı› Û ÂÚÈÛÛfiÙÂÚ· ·fi 3500 ¿ÙÔÌ·, Û ·ÚÎÂÙÔ‡˜ ‰Â ÂÍ ·˘ÙÒÓ ÁÈ· ÂÚÈÛÛfiÙÂÚ· ·fi 7 ¯ÚfiÓÈ·. º·ÚÌ·ÎÔÎÈÓËÙÈ΋: ∏ ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË Û˘ÁÎÚÈÓfiÌÂÓË Ì ÙËÓ ˘Ô‰fiÚÈ· ¯ÔÚ‹ÁËÛË ÎÚ˘ÛÙ·ÏÏÈ΋˜ ÈÓÛÔ˘Ï›Ó˘ ‹ ·ÎfiÌË Î·È Ì ÂÓ‰ÔÊϤ‚È· ¯ÔÚËÁÔ‡ÌÂÓË ÈÓÛÔ˘Ï›ÓË, ·ÚÔ˘ÛÈ¿˙ÂÈ fi¯È ÌfiÓÔÓ Ù·¯‡ÙÂÚË ¤Ó·ÚÍË ‰Ú¿Û˘ ·ÏÏ¿ Î·È Ù·¯‡ÙÂÚË Â›Ù¢ÍË Ì¤ÁÈÛÙ˘ Û˘ÁΤÓÙÚˆÛ˘ ÈÓÛÔ˘Ï›Ó˘ ÔÚÔ‡. ™˘ÁÎÚÈÓfiÌÂÓË Ì ˘Ô‰fiÚÈ· ¯ÔÚËÁÔ‡ÌÂÓÔ Ù·¯‡ ·Ó¿ÏÔÁÔ ÈÓÛÔ˘Ï›Ó˘ (Lispro) Ë ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË ·ÚÔ˘ÛÈ¿˙ÂÈ Ù·¯‡ÙÂÚË ¤Ó·ÚÍË ‰Ú¿Û˘ (28 min vs. 40 min), ·ÏÏ¿

21


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·22

π√À¡π√™ 2007

ÛËÌ·ÓÙÈο ‚Ú·‰‡ÙÂÚË Â›Ù¢ÍË Ù˘ ̤ÁÈÛÙ˘ ÌÂÙ·‚ÔÏÈ΋˜ ‰Ú¿Û˘ (∂ÈÎfiÓ· 1). ∏ ‰È¿ÚÎÂÈ· ‰Ú¿Û˘ Ù˘ Â›Ó·È Û˘ÁÎÚ›ÛÈÌË Ì ÂΛÓË Ù˘ ˘Ô‰ÔÚ›ˆ˜ ¯ÔÚËÁÔ‡ÌÂÓ˘ Ù·¯Â›·˜ ‰Ú¿Û˘ ÈÓÛÔ˘Ï›Ó˘ ηٿ Û˘Ó¤ÂÈ· ÌÔÚ› Ó· ¯ÔÚËÁËı› ˆ˜ ÚÔÁÂ˘Ì·ÙÈ΋ ÈÓÛÔ˘Ï›ÓË, Î·È Ó· ·ÓÙÈηٷÛÙ‹ÛÂÈ ÙËÓ ˘Ô‰fiÚÈ· ¯ÔÚËÁÔ‡ÌÂÓË ÎÚ˘ÛÙ·ÏÏÈ΋ Ù·¯Â›· ÈÓÛÔ˘Ï›ÓË ‹ ÙÔ Ù·¯‡ ·Ó¿ÏÔÁÔ ÈÓÛÔ˘Ï›Ó˘, ÂÂȉ‹ ¤¯ÂÈ ÁÚ‹ÁÔÚË ¤Ó·ÚÍË ‰Ú¿Û˘ Î·È ‰È¿ÚÎÂÈ· ‰Ú¿Û˘ ¿Óˆ ÙˆÓ 3 ˆÚÒÓ. ∏ Èı·ÓfiÙËÙ· ˘ÔÁÏ˘Î·ÈÌÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ ·fi ÙËÓ ¯ÔÚ‹ÁËÛË ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ Â›Ó·È ·ÚfiÌÔÈ· Ì ·˘Ù‹Ó Ô˘ ÚÔ·ÙÂÈ ·fi ÙËÓ ¯ÔÚ‹ÁËÛË ˘Ô‰fiÚÈ· Ù·¯Â›·˜ ‰Ú¿Û˘ ÈÓÛÔ˘Ï›Ó˘. ¢Ú·ÛÙÈÎfiÙËÙ·: ¶ÏÂÈ¿‰· ÌÂÏÂÙÒÓ ¤¯Ô˘Ó ·ԉ›ÍÂÈ ÙËÓ ‚Ú·¯˘ÚfiıÂÛÌË Î·È Ì·ÎÚÔÚfiıÂÛÌË ‰Ú·ÛÙÈÎfiÙËÙ· Ù˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ Î·È ÛÙÔ˘˜ 2 Ù‡Ô˘˜ ۷ί·ÚÒ‰Ë ‰È·‚‹ÙË. ™Â ·ÛıÂÓ›˜ Ì ‰È·‚‹ÙË Ù‡Ô˘ 2, ÌË ·ÓÙ·ÔÎÚÈÓfiÌÂÓÔ˘˜ Û ÎÏ·ÛÛÈ΋ ·fi ÙÔ˘ ÛÙfiÌ·ÙÔ˜ ·ÓÙȉȷ‚ËÙÈ΋ ·ÁˆÁ‹, Ë ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË ¯ÔÚËÁÔ‡ÌÂÓË ÛÂ Û˘Ó‰˘·ÛÌfi Ì ·ÓÙȉȷ‚ËÙÈο ‰ÈÛΛ·, ‚ÂÏÙ›ˆÛ ÛËÌ·ÓÙÈο ÙËÓ HbA 1C, Û ۯ¤ÛË Ì ÙËÓ ÔÌ¿‰· ·ÛıÂÓÒÓ Ô˘ ÂÏ¿Ì‚·Ó ÌfiÓÔÓ ·fi ÙÔ˘ ÛÙfiÌ·ÙÔ˜ ·ÁˆÁ‹. ∂›Û˘ Û˘ÁÎÚ›ÓÔÓÙ·˜ ·ÛıÂÓ›˜ Ì ‰È·‚‹ÙË Ù‡Ô˘ 2 Ô˘ ÂÏ¿Ì‚·Ó·Ó ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË Î·È Ultralente, Ì ·ÛıÂÓ›˜ Ô˘ ÂÏ¿Ì‚·Ó·Ó Û¯‹Ì·Ù· ÔÏÏ·ÏÒÓ ‰fiÛÂˆÓ Ì regular Î·È NPH, ‰ÂÓ ·Ú·ÙËÚ‹ıËΠÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈ΋ ‰È·ÊÔÚ¿ ÛÙȘ ÌÂÈÒÛÂȘ ÙˆÓ HBA1C ÛÙËÓ 12Ë Î·È ÙËÓ 24Ë Â‚‰ÔÌ¿‰· ıÂÚ·›·˜. ŸÌˆ˜ Ë ÔÌ¿‰· Ô˘ ÂÏ¿Ì‚·Ó ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË ÂÌÊ¿ÓÈÛ Û ÌÂÁ·Ï‡ÙÂÚÔ ÔÛÔÛÙfi HBA 1C <7%. (47% vs 32%). ™Â ‰È·‚ËÙÈÎÔ‡˜ Ì ‰È·‚‹ÙË Ù‡Ô˘ 1, Ô˘ ÂÏ¿Ì‚·Ó·Ó Û˘Ó‰˘·ÛÌfi ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ Î·È Ultralente, ‹ Ì›ÁÌ· regular Î·È NPH ˘Ô‰ÔÚ›ˆ˜, ·Ú·ÙËÚ‹ıËÎ·Ó ·ÚfiÌÔȘ ÌÂÈÒÛÂȘ ÛÙËÓ HbA 1C. Δ¤ÏÔ˜ ·ÛıÂÓ›˜ Ì ‰È·‚‹ÙË Ù‡Ô˘ π, ËÏÈΛ·˜ 12-65 ÂÙÒÓ Ô˘

22

ÂÏ¿Ì‚·Ó·Ó NPH Ì ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË ‹ regular ˘Ô‰ÔÚ›ˆ˜ Û ÂÓÙ·ÙÈÎÔÔÈË̤ÓÔ Û¯‹Ì· ·ÚÔ˘Û›·Û·Ó ·ÚfiÌÔȘ ÌÂÈÒÛÂȘ Ù˘ HbA 1C , ·ÏÏ¿ Î·È ·ÚfiÌÔÈÔ ÔÛÔÛÙfi Â›Ù¢Í˘ HbA1C<7% Î·È Û˘ÁÎÚ›ÛÈ̘ ÌÂÈÒÛÂȘ ÛÙȘ ÌÂÙ·ÁÂ˘Ì·ÙÈΤ˜ ÙÈ̤˜ ÁÏ˘Îfi˙˘. ∞ÓÂÈı‡ÌËÙ˜ ÂÓ¤ÚÁÂȘ: ΔÔ ·˙Ï ÙˆÓ ·ÓÂÈı‡ÌËÙˆÓ ÂÓÂÚÁÂÈÒÓ Ù˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ ÂÚÈÏ·Ì‚¿ÓÂÈ ÙËÓ ·‡ÍËÛË ÛˆÌ·ÙÈÎÔ‡ ‚¿ÚÔ˘˜, Ù· ˘ÔÁÏ˘Î·ÈÌÈο ÂÂÈÛfi‰È·, ÙÔÓ ‚‹¯· Î·È ÙËÓ ·‡ÍËÛË Ù›ÙÏÔ˘ ·ÓÙÈ˚ÓÛÔ˘ÏÈÓÈÎÒÓ ·ÓÙÈۈ̿وÓ. ∏ ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË Û˘Óԉ‡ÂÙ·È Ì ·ÚfiÌÔÈ· ·‡ÍËÛË ÛˆÌ·ÙÈÎÔ‡ ‚¿ÚÔ˘˜ Û ۯ¤ÛË Ì ÂΛÓË Ô˘ ·Ú·ÙËÚÂ›Ù·È Û ˘Ô‰fiÚÈ· ¯ÔÚ‹ÁËÛË. Δ· ÔÛÔÛÙ¿ ˘ÔÁÏ˘Î·ÈÌÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ Û ·ÛıÂÓ›˜ Ì ‰È·‚‹ÙË Ù‡Ô˘ 1 Î·È 2 Ô˘ ÂÏ¿Ì‚·Ó·Ó ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË, ‹Ù·Ó Û ‰È¿ÊÔÚ˜ ÌÂϤÙ˜, Û˘ÁÎÚ›ÛÈÌ· Ì ÂΛӷ ÙˆÓ ·ÛıÂÓÒÓ Ô˘ ÂÏ¿Ì‚·Ó·Ó ˘Ô‰ÔÚ›ˆ˜ ÙËÓ ÈÓÛÔ˘Ï›ÓË. ŸÌˆ˜ Ô Î›Ó‰˘ÓÔ˜ ˘ÔÁÏ˘Î·ÈÌ›·˜ ·fi ¯ÔÚ‹ÁËÛË ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ Â›Ó·È ÌÂÁ·Ï‡ÙÂÚÔ˜ ·fi ÙÔÓ ·ÓÙ›ÛÙÔÈ¯Ô ·ÛıÂÓÒÓ Ô˘ Ï·Ì‚¿ÓÔ˘Ó ·fi ÙÔ˘ ÛÙfiÌ·ÙÔ˜ ·ÓÙȉȷ‚ËÙÈο ‰ÈÛΛ·. ∫·Ù¿ Û˘Ó¤ÂÈ· Ô Î›Ó‰˘ÓÔ˜ ˘ÔÁÏ˘Î·ÈÌ›·˜ Â›Ó·È ÛËÌ·ÓÙÈο ÌÂÁ·Ï‡ÙÂÚÔ˜ fiÙ·Ó ¯ÔÚËÁÂ›Ù·È Û˘Ó‰˘·ÛÌfi˜ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ Î·È ·fi ÙÔ˘ ÛÙfiÌ·ÙÔ˜ ‰ÈÛΛˆÓ. ∞˘ÍË̤ÓË Â›ÙˆÛË ‚‹¯· ·Ú·ÙËÚ‹ıËΠ۠·ÛıÂÓ›˜ Ì ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË, Û˘ÁÎÚÈÙÈο Ì ÙËÓ ˘Ô‰fiÚÈ· ¯ÔÚ‹ÁËÛË Ù˘ (15%-20% vs 5% ·ÓÙ›ÛÙÔȯ·) Û ηϿ ÙÂÎÌËÚȈ̤Ó˜ ÌÂϤÙ˜. √ ‚‹¯·˜ ·ÚÔ˘ÛÈ¿˙ÂÙ·È Ï›Á· ÏÂÙ¿ ÌÂÙ¿ ÙËÓ ÂÈÛÓÔ‹ Ù˘ ÈÓÛÔ˘Ï›Ó˘, Â›Ó·È ·Ïfi˜ Î·È fi¯È ·Ú·ÁˆÁÈÎfi˜ Î·È ÌÂÈÒÓÂÙ·È Ë Â›ÙˆÛË ÙÔ˘ Ì ÙËÓ Û˘Ó¤¯ÈÛË Ù˘ ·ÁˆÁ‹˜ Ì ÙËÓ ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË. ¢ÂÓ Û˘Óԉ‡ÂÙ·È Ì ÔÔÈ·‰‹ÔÙ ÏÂÈÙÔ˘ÚÁÈ΋ Ó¢ÌÔÓÈ΋ ‰È·Ù·Ú·¯‹.

∞˘ÍË̤ÓË ·Ú·ÁˆÁ‹ ·ÓÙÈ˚ÓÛÔ˘ÏÈÓÈÎÒÓ ·ÓÙÈÛˆÌ¿ÙˆÓ ·Ú·ÙËÚ‹ıËΠ۠·ÛıÂÓ›˜ Ì ‰È·‚‹ÙË Ù‡Ô˘ 1 Î·È 2 Ô˘ ¤Ï·‚·Ó ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË. ∏ ·‡ÍËÛË ·˘Ù‹ ÛÙÂÚÂ›Ù·È ÎÏÈÓÈ΋˜ ÛËÌ·Û›·˜, fiÛÔÓ ·ÊÔÚ¿ ÙȘ ÂȉڿÛÂȘ ÛÙËÓ HbA 1C, ÛÙȘ ‰fiÛÂȘ ÈÓÛÔ˘Ï›Ó˘, ÛÙËÓ Â›ÙˆÛË ˘ÔÁÏ˘Î·ÈÌÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ Î·È ÛÙËÓ ÂÌÊ¿ÓÈÛË ·ÏÏÂÚÁÈÎÒÓ ·ÓÙȉڿÛˆÓ. ª·ÎÚÔ¯ÚfiÓÈ· ‰Â‰Ô̤ӷ Û¯ÂÙÈο Ì ÙËÓ ‰Ú·ÛÙÈÎfiÙËÙ· Î·È ÙȘ ·ÓÂÈı‡ÌËÙ˜ ÂÓ¤ÚÁÂȘ √È Ì¤¯ÚÈ Û‹ÌÂÚ· ‰ËÌÔÛȇÛÂȘ ‚‚·›ˆ˜ ·ÊÔÚÔ‡Û·Ó ¯ÚÔÓÈÎfi ‰È¿ÛÙËÌ· ·Ú·ÎÔÏÔ‡ıËÛ˘ ̤¯ÚÈ 6 Ì‹Ó˜ Î·È ¤ÙÛÈ Ù· Ì·ÎÚÔ¯ÚfiÓÈ· ‰Â‰Ô̤ӷ ·Ó·Ì¤ÓÔÓÙ·Ó Ì ÂÍ·ÈÚÂÙÈÎfi ÂӉȷʤÚÔÓ. ™ÙÔ ∞ÌÂÚÈοÓÈÎÔ ¢È·‚ËÙÔÏÔÁÈÎfi ™˘Ó¤‰ÚÈÔ ÙÔ 2006 Ë ÔÌ¿‰· ÙÔ˘ JovanÔvic ·ÚÔ˘Û›·Û ‰Â‰Ô̤ӷ 2 ¯ÚfiÓˆÓ ·Ú·ÎÔÏÔ‡ıËÛ˘. ŒÙÛÈ ÌÂÙ¿ 24 Ì‹Ó˜ ·Ú·ÎÔÏÔ‡ıËÛ˘ 291 ·ÙfiÌˆÓ Ì ™¢ Ù‡Ô˘ π, Ô˘ Ù˘¯·ÈÔÔÈ‹ıËÎ·Ó Û ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË (∂.π.) -Exubera- ¤Ó·ÓÙÈ 291 ·ÙfiÌˆÓ Ô˘ Ù˘¯·ÈÔÔÈ‹ıËÎ·Ó Û ˘Ô‰fiÚÈ· (À¢) Ù·¯Â›· ÈÓÛÔ˘Ï›ÓË ‰È·ÈÛÙÒıËΠfiÙÈ: ·) Ë ÔÌ¿‰· ∂.π. ·ÚÔ˘Û›·Û ·ÚfiÌÔÈ· ÁÏ˘Î·ÈÌÈ΋ Ú‡ıÌÈÛË Ì ÙËÓ À¢ (HbA1C 7.5% vs. 7.3%), ‚) Û˘ÓÔÏÈο ÔÈ ˘ÔÁÏ˘Î·È̛˜ ‹Ù·Ó Û˘ÁÎÚ›ÛÈ̘ ÌÂٷ͇ ÙˆÓ 2 ·ÙfiÌˆÓ (∂π vs. À¢: 4 vs. 3.8 Û˘Ì‚¿Ì·Ù·/ ¿ÙÔÌÔ/ Ì‹Ó·), ÂÓÒ ÛÔ‚·Ú¤˜ ˘ÔÁÏ˘Î·È̛˜ ‹Ù·Ó ÛËÌ·ÓÙÈο ÏÈÁfiÙÂÚ˜ ÛÙËÓ ÔÌ¿‰· ∂π (∂π vs. À¢: 2.8 vs. 4.1 Û˘Ì‚¿Ì·Ù·/ 100 ¿ÙÔÌ·/ Ì‹Ó˜), Á) Ù· ۿί·Ú· ÓËÛÙ›·˜ ÌÂÈÒıËÎ·Ó ÂÚÈÛÛfiÙÂÚÔ Ì ÙËÓ ∂π (·fi 170 Û 156 mg% vs. 167 Û 173 mg% ÛÙËÓ À¢ ÔÌ¿‰·), ‰) Ë ÚfiÛÎÙËÛË ‚¿ÚÔ˘˜ ‹Ù·Ó Û·ÊÒ˜ ÏÈÁfiÙÂÚË Ì ÙËÓ ∂π (0.8 kg ÛÙËÓ ∂π vs. 2 kg ÛÙËÓ À¢ ÔÌ¿‰·). ∏ ÔÌ¿‰· ÙÔ˘ Rosenstock ·fi ÙÔ ¡Ù¿Ï·˜ ÛÙÔ ›‰ÈÔ Û˘Ó¤‰ÚÈÔ ·ÚÔ˘Û›·Û Â›Û˘ Ù· ‰Â‰Ô̤ӷ ·fi ·Ú·ÎÔÏÔ‡ıËÛË 2 ÂÙÒÓ, 635 ·ÙfiÌˆÓ Ì ™¢ Ù‡Ô˘ ππ Ô˘ Ù˘¯·ÈÔÔÈ‹ıËÎ·Ó Û ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË (∂.π.) ‹ ˘Ô‰fiÚÈ· (À¢) ÈÓÛÔ˘Ï›ÓË. ΔÔ ÚˆÙÔÁÂÓ¤˜ ÙÂÏÈÎfi ÛËÌÂ›Ô ÛÙËÓ ÌÂϤÙË ‹Ù·Ó Ë Ó¢ÌÔÓÈ΋


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·23

£∂ƒ∞¶∂π∞ - º∞ƒª∞∫∞

EXUBERA PD Profile ŒÓ·ÚÍË ‰Ú¿Û˘:

Mean GR (Percentage Maximum)

100

Exubera: 32 min Lispro: 41 min Soluble: 48 min

80

¢È¿ÚÎÂÈ· ‰Ú¿Û˘:

60

Exubera: 387 min Lispro: 313 min Soluble: 415 min

40 20 0

0

120

240

360

480

600

Time (min) PD= pharmacodynamic GIR= glucose infusion rate. copyright ® 2005 American Diadetes Association from Rate K, et al. Diadetes

Care, Vol. 28, 2005 1077 - 1082 Modified

with permission from The American Diadetes Association Pfizer Inc 2006 All rightsre served Version 1

∂ÈÎfiÓ· 1. ŒÓ·ÚÍË Î·È ‰È¿ÚÎÂÈ· ‰Ú¿Û˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ (Exubera), ˘Ô‰fiÚÈ· ¯ÔÚËÁÔ‡ÌÂÓÔ˘ Ù·¯¤Ô˜ ·Ó¿ÏÔÁÔ˘ ÈÓÛÔ˘Ï›Ó˘ (Lispro) Î·È ÂÓ‰ÔÊϤ‚È· ¯ÔÚËÁÔ‡ÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘

ÏÂÈÙÔ˘ÚÁ›· Î·È Ù· ‰Â˘ÙÂÚÔÁÂÓ‹ ‹Ù·Ó Ë HbA 1C, Ë ˘ÔÁÏ˘Î·ÈÌ›·, ÙÔ Û¿Î¯·ÚÔ ÓËÛÙ›·˜ Î·È ÙÔ ÛˆÌ·ÙÈÎfi ‚¿ÚÔ˜. ∏ ÔÌ¿‰· Ù˘ ∂.π ·ÚÔ˘Û›·Û Ôχ ÌÈÎÚ¤˜ ·ÏÏ·Á¤˜ ÛÙ· ÙÂÛÙ Ù˘ Ó¢ÌÔÓÈ΋˜ ÏÂÈÙÔ˘ÚÁ›·˜ (FEV 1 -ÂÎÓÂfiÌÂÓÔ˜ fiÁÎÔ˜ ·¤Ú· ÛÙÔ 1’’- Î·È DLCO -ÈηÓfiÙËÙ· ‰È¿¯˘Û˘ C√-). OÈ ·ÏÏ·Á¤˜ ·˘Ù¤˜ ‹Ù·Ó ÌÈÎÚfiÙÂÚ˜ ÙÔ˘ 1.5% Ù˘ ̤Û˘ ÙÈÌ‹˜ ÙˆÓ ‰ÂÈÎÙÒÓ ·˘ÙÒÓ, Û˘Ó¤‚ËÛ·Ó ÓˆÚ›˜ Î·È ·Ú¤ÌÂÈÓ·Ó ÛÙ·ıÂÚ¤˜, ¯ˆÚ›˜ ÂͤÏÈÍË Î·Ù¿ ÙËÓ ‰È¿ÚÎÂÈ· Ù˘ 2¯ÚÔÓ˘ ·Ú·ÎÔÏÔ‡ıËÛ˘. √È ‰‡Ô ÔÌ¿‰Â˜ ·ÚÔ˘Û›·Û·Ó ÙËÓ ›‰È· ‚ÂÏÙ›ˆÛË ÛÙË ÁÏ˘Î·ÈÌÈ΋ Ú‡ıÌÈÛË, ÂÓÒ Ë ÔÌ¿‰· Ù˘ ∂.π ·ÚÔ˘Û›·Û ÛËÌ·ÓÙÈο ÏÈÁfiÙÂÚ˜ ˘ÔÁÏ˘Î·È̛˜ (0.4 vs. 0.6 Û˘Ì‚¿Ì·Ù·/ 100 ·ÛıÂÓ›˜/ Ì‹Ó˜), ÌÂÁ·Ï‡ÙÂÚ˜ ‚ÂÏÙÈÒÛÂȘ ÛÙ· ۿί·Ú· ÓËÛÙ›·˜ (·fi 151 Û 135 vs. 148 Û 147 mg%) Î·È ÌÈÎÚfiÙÂÚË ÚfiÛÎÙËÛË ‚¿ÚÔ˘˜ ÛÙËÓ ‰ÈÂÙ›· (·fi 87 Û 88.8. Kg vs. 88 Û 91.5 ÛÙËÓ ÔÌ¿‰· Ù˘ À.π).

∞ÛÊ¿ÏÂÈ·: ¢ÂÓ ¤¯ÂÈ ‰È·ÈÛÙˆı› Û ·ÛıÂÓ›˜ Ì ‰È·‚‹ÙË Ù‡Ô˘ 1 ‹ 2, ·fi ÙȘ ÚÔ‚ÏÂfiÌÂÓ˜ ÏÂÈÙÔ˘ÚÁÈΤ˜ ‰ÔÎÈ̷ۛ˜ ÙˆÓ Ó¢ÌfiÓˆÓ (ÛÈÚÔ̤ÙÚËÛË Î·È Ì¤ÙÚËÛË ‰È·¯˘ÙÈ΋˜ ÈηÓfiÙËÙ·˜ Ó¢ÌfiÓˆÓ) ‰˘ÛÌÂÓ‹˜ Â›‰Ú·ÛË Ù˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘. ŸÌˆ˜ ÛÙËÓ ÏÂÈÔ„ËÊ›· ÙˆÓ ÌÂÏÂÙÒÓ, ‰ÂÓ ÂÌÂÚȤ¯ÂÙ·È Û˘ÓÂÎÙ›ÌËÛË fiÏˆÓ ÙˆÓ ··Ú·›ÙËÙˆÓ ‰ÔÎÈÌ·ÛÈÒÓ ÚÔÎÂÈ̤ÓÔ˘ ÂÍ·¯ıÔ‡Ó ·ÛÊ·Ï‹ Û˘ÌÂÚ¿ÛÌ·Ù·. ∂Ú¢ÓËÙÈο ‰Â‰Ô̤ӷ ¤¯Ô˘Ó ÙÂÎÌËÚÈÒÛÂÈ ÙËÓ ·ÛÊ¿ÏÂÈ· ¯ÔÚ‹ÁËÛ˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ ÌÂÙ¿ Û˘Ó¯‹ ¯ÔÚ‹ÁËÛË 4 ÂÙÒÓ. ¶·Ú’ fiÏ· ·˘Ù¿ Û˘ÓÈÛÙ¿Ù·È Ó· Á›ÓÂÙ·È Û fiÏÔ˘˜ ÙÔ˘˜ ·ÛıÂÓ›˜ ÛÈÚÔ̤ÙÚËÛË Î·È ÂÎÙ›ÌËÛË Î˘Ú›ˆ˜ ÙÔ˘ FEV 1 ÚÈÓ ÙËÓ ¤Ó·ÚÍË ·ÁˆÁ‹˜ Ì ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË. FEVI >70% ·ÔÙÂÏ› ·ÛʷϤ˜ ¯¤ÁÁ˘Ô ÁÈ· ÙËÓ ¤Ó·ÚÍË ÙÔ˘ Exubera. ∂·Ó·ÏËÙÈ΋ ÛÈÚÔ̤ÙÚËÛË Ú¤ÂÈ Ó· Á›ÓÂÙ·È ÛÙÔ˘˜ 6 Ì‹Ó˜. ∂¿Ó ˘¿Ú¯ÂÈ

Ì›ˆÛË Ì¤¯ÚÈ 15% ÙÔ˘ FEVπ, Û˘ÓÈÛÙ¿Ù·È Â·Ó¿ÏË„Ë ÂÙ‹ÛÈ· Ù˘ ÛÈÚÔ̤ÙÚËÛ˘. ∂¿Ó Ë Ì›ˆÛË Â›Ó·È 15-20%, ÙfiÙ Ӥ· ÛÈÚÔ̤ÙÚËÛË Ú¤ÂÈ Ó· Á›ÓÂÈ Û 3 Ì‹Ó˜. ∂¿Ó fï˜ Ë Ì›ˆÛË ÙÔ˘ FEVπ Â›Ó·È ÌÂÁ·Ï‡ÙÂÚË ÙÔ˘ 20%, ÙfiÙ ı· Ú¤ÂÈ Ó· Á›ÓÂÈ ¿ÌÂÛË ‰È·ÎÔ‹ ÙÔ˘ Exubera. ™Â η̛· ÌÂϤÙË ¤ˆ˜ Û‹ÌÂÚ· ‰ÂÓ ¤¯ÂÈ ¯ÔÚËÁËı› ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË Û ‰È·‚ËÙÈÎÔ‡˜ ÌÂ Û˘Ó˘¿Ú¯Ô˘Û· Ó¢ÌÔÓÈ΋ ÓfiÛÔ. ™˘ÓÂÒ˜ ‰ÂÓ ÚÔÙ›ÓÂÙ·È Ë ¯ÔÚ‹ÁËÛË Ù˘ Û ¿ÙÔÌ· ÌÂ Û˘ÓÔ‰¿ Ó¢ÌÔÓÈο ÓÔÛ‹Ì·Ù·. ∏ Û¯¤ÛË ÙÔ˘ ηÓ›ÛÌ·ÙÔ˜ Ì ÙËÓ ·ÔÚÚfiÊËÛË Ù˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ ·ÔÙÂÏ› ‰›Ô ÂÎÙÂٷ̤Ó˘ ¤Ú¢ӷ˜ ·ÏÏ¿ Î·È ÂÈÛÙËÌÔÓÈ΋˜ Û˘˙‹ÙËÛ˘. ªÂϤÙ˜ Û ÂÈÚ·Ì·Ùfi˙ˆ· ·ÏÏ¿ Î·È Û ·ÓıÚÒÔ˘˜ ¤¯Ô˘Ó ‰Â›ÍÂÈ fiÙÈ Ô Î·Ófi˜ ÙÔ˘ ÙÛÈÁ¿ÚÔ˘ ·˘Í¿ÓÂÈ ÙËÓ ‰È·ÂÚ·ÙfiÙËÙ· ÙÔ˘ ΢„ÂÏȉÔÙÚȯÔÂȉÈÎÔ‡ ÊÚ·ÁÌÔ‡, Ì ·ÔÙ¤ÏÂÛÌ· ÔÈ

23


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·24

π√À¡π√™ 2007

∂π™¶¡∂√ª∂¡∏ π¡™√À§π¡∏: ª√ƒº∂™ ∫∞π π¢π√Δ∏Δ∂™ Δø¡ ¢π∞º√ƒø¡ º∞ƒª∞∫∂ÀΔπ∫ø¡ ∂∫¢√Ãø¡ ŸÓÔÌ·

MÔÚÊ‹ ÈÓÛÔ˘Ï›Ó˘

ª¤ÁÂıÔ˜ ™ˆÌ·Ùȉ›ˆÓ (ÌÈÎÚ¿)

ŒÓ·ÚÍË ‰Ú¿Û˘ (ÏÂÙ¿)

ÃÚfiÓÔ˜ ·È¯Ì‹˜ (ÏÂÙ¿)

¢È¿ÚÎÂÈ· ‰Ú¿Û˘ (ÒÚ˜)

º·Ú̷΢ÙÈ΋ ÂÙ·ÈÚ›·

Exubera*

•ËÚ¿ ÎfiÓȘ

3

7

60

4-6

Pfizer, Necktar

AIR

•ËÚ¿ ÎfiÓȘ

10-20

15

30-45

3-5

Eli Lilly, Alkermes

Technosphere

•ËÚ¿ ÎfiÓȘ

2-5

5

39

3-4

MannKind

ÀÁÚ¿ ÌÔÚÊ‹

2-3

5

49-65

4-6

Novo-Nordisk

AERx iDMS

∂ÓÂÎÚ›ıË ·fi ÙÔ FDA, fiÏ· Ù· ¿ÏÏ· Û ʿÛË 3

¶›Ó·Î·˜ 1. ™˘ÛÙ‹Ì·Ù· Î·È Û˘Û΢¤˜ ¯ÔÚ‹ÁËÛ˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ ··ÈÙÔ‡ÌÂÓ˜ ‰fiÛÂȘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ Èı·ÓfiÓ Ó· Â›Ó·È ÛËÌ·ÓÙÈο ÌÈÎÚfiÙÂÚ˜. ¶Ú·ÁÌ·ÙÈο ÌÂϤÙ˜ Û ηÓÈÛÙ¤˜ ÌË ‰È·‚ËÙÈÎÔ‡˜ ¤‰ÂÈÍ·Ó fiÙÈ, Ë Ì¤ÁÈÛÙË Û˘ÁΤÓÙÚˆÛË ÈÓÛÔ˘Ï›Ó˘ fi¯È ÌfiÓÔÓ ‹Ù·Ó ÌÂÁ·Ï‡ÙÂÚË (¤ˆ˜ Î·È 5 ÊÔÚ¤˜) ÂΛӢ ÙˆÓ ÌË Î·ÓÈÛÙÒÓ, ·ÏÏ¿ ÂÈÛ˘Ì‚·›ÓÂÈ Î·È Ù·¯‡ÙÂÚ· (31 vs 53 min). ∞Ó·fiÊ¢ÎÙ· ¤ÙÛÈ ‰ÂÓ ÚÔÙ›ÓÂÙ·È Ë ¯ÔÚ‹ÁËÛË ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ Û ηÓÈÛÙ¤˜ ‰È·‚ËÙÈÎÔ‡˜ ·ÊÔ‡ ‰ÂÓ Â›Ó·È ÚԂϤ„È̘ ÔÈ ÌÂÙ·‚ÔϤ˜ ÛÙËÓ ·ÔÚÚfiÊËÛË Ù˘ ÛÙËÓ Û˘ÛÙËÌ·ÙÈ΋ ΢ÎÏÔÊÔÚ›·. ∫·Ù¿ Û˘Ó¤ÂÈ· ÔÈ ‰È·‚ËÙÈÎÔ› ÚÔ Ù˘ ¯ÔÚ‹ÁËÛ˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ ÂÓı·ÚÚ‡ÓÔÓÙ·È ÁÈ· ‰È·ÎÔ‹ ηÓ›ÛÌ·ÙÔ˜. ŒÍÈ Ì‹Ó˜ ÌÂÙ¿ ÙËÓ ‰È·ÎÔ‹ ηÓ›ÛÌ·ÙÔ˜ Â›Ó·È ‰˘Ó·Ù‹ Ë ¤Ó·ÚÍË ¯ÔÚ‹ÁËÛ˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘. ¢ÂÓ ÚÔÙ›ÓÂÙ·È Â›Û˘ Ë ¯ÔÚ‹ÁËÛË Ù˘ ∂π Â› ÙÔ˘ ·ÚfiÓÙÔ˜ ÛÙ· ·È‰È¿ Î·È ÛÙȘ ΢ÔÊÔÚÔ‡Û˜ ‰È·‚ËÙÈΤ˜ Á˘Ó·›Î˜, ÏfiÁˆ ¤ÏÏÂȄ˘ Û¯ÂÙÈÎÒÓ ÌÂÏÂÙÒÓ.

∞Ô‰Ô¯‹ Î·È Û˘ÌÌfiÚʈÛË ÙˆÓ ·ÛıÂÓÒÓ √È ‰È·‚ËÙÈÎÔ› ·ÛıÂÓ›˜ ÚÔÙÈÌÔ‡Ó ·Ó·ÌÊÈÛ‚‹ÙËÙ· ÙËÓ ÂÈÛÓÂfiÌÂÓË Û˘ÁÎÚÈÙÈο Ì ÙËÓ ˘Ô‰fiÚÈ· ÈÓÛÔ˘Ï›ÓË. ™ËÌ·ÓÙÈο ÂÚÈÛÛfiÙÂÚÔÈ ‰È·‚ËÙÈÎÔ› Ù‡Ô˘ π Ô˘ ¯ÚËÛÈÌÔÔÈÔ‡Û·Ó ÂÈÛÓÂ-

24

fiÌÂÓË ÈÓÛÔ˘Ï›ÓË ‹Ù·Ó Û˘ÓÔÏÈο ÈηÓÔÔÈË̤ÓÔÈ ¤Ó·ÓÙÈ ·˘ÙÒÓ Ô˘ ¯ÚËÛÈÌÔÔÈÔ‡Û·Ó ˘Ô‰fiÚÈ· (35.1% vs. 10.6%, p<0.001). T· Â˘Ú‹Ì·Ù· ÛÙÔ˘˜ ‰È·‚ËÙÈÎÔ‡˜ Ù‡Ô˘ ππ ‹Ù·Ó ·ÚfiÌÔÈ·. ∏ Û˘ÌÌfiÚʈÛË ÙˆÓ ·ÛıÂÓÒÓ Â›Û˘ ‹Ù·Ó ÔˆÛ‰‹ÔÙ Ôχ ÌÂÁ·Ï‡ÙÂÚË Ì ÙËÓ ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË Û˘ÁÎÚÈÙÈο Ì ÙËÓ ˘Ô‰fiÚÈ· (3ÌËÓË ÌÂϤÙË Û ‰È·‚ËÙÈÎÔ‡˜ Ù‡Ô˘ ππ Û˘ÌÌfiÚʈÛË 94% vs. 64%, p<0.001). ™Â ¿ÏÏË Â›Û˘ ÌÂϤÙË ‰Â›¯ıËΠfiÙÈ Ë ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË ·˘Í¿ÓÂÈ Î·Ù¿ ÛËÌ·ÓÙÈο ÌÂÁ·Ï‡ÙÂÚÔ ‚·ıÌfi ÙËÓ Èı·ÓfiÙËÙ· ·Ô‰Ô¯‹˜ Ù˘ ÈÓÛÔ˘ÏÈÓÔıÂÚ·›·˜ Û˘ÁÎÚÈÙÈο Ì ÙËÓ ÚfiÙ·ÛË ÙËÓ ˘Ô‰fiÚÈ·˜ ÈÓÛÔ˘Ï›Ó˘ (43.2% vs. 10.5%).

¶ÚÔ‚ÏËÌ·ÙÈÛÌÔ›, ÂÚˆÙËÌ·ÙÈο √ˆÛ‰‹ÔÙ ÙÔ ÙÔ›Ô Ù˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ ‰ÂÓ Â›Ó·È ·Ôχو˜ ۷ʤ˜ Î·È ÍÂηı·ÚÈṲ̂ÓÔ. ∂ÚˆÙËÌ·ÙÈο ÂÍ·ÎÔÏÔ˘ıÔ‡Ó Ó· ˘¿Ú¯Ô˘Ó, ÚÔ‚ÏËÌ·ÙÈÛÌÔ› Ô˘ ·Ó·˙ËÙÔ‡Ó ÙÂÎÌËÚȈ��¤Ó˜ ··ÓÙ‹ÛÂȘ: ·) Y¿Ú¯Ô˘Ó ÂӉ¯fiÌÂÓ˜ ·ÚÂÓ¤ÚÁÂȘ ÛÙÔ ·Ó·Ó¢ÛÙÈÎfi ÂÈı‹ÏÈÔ Î·È Û ‚¿ıÔ˜ ¯ÚfiÓÔ˘ Ù˘ ¯ÔÚ‹ÁËÛ˘ ۯ‰fiÓ 3 ÊÔÚ¤˜ ÂÚÈÛÛfiÙÂÚ˘ ÈÓÛÔ˘Ï›Ó˘ Ì ÙËÓ ÂÈÛÓ¢ÛÙÈ΋ Û˘ÁÎÚÈÙÈο Ì ÙËÓ ÂÓ¤ÛÈÌË Ì¤ıÔ‰Ô; Δ· ̤¯ÚȘ ÛÙÈÁÌ‹˜ ‰Â‰Ô̤ӷ ‰ÂÓ

ÂÌÓ¤Ô˘Ó ·ÓËÛ˘¯›·, fï˜, Ë È‰È·›ÙÂÚ· Ì·ÎÚfi¯ÚÔÓË ·Ú·ÎÔÏÔ‡ıËÛË ı· ‰ÒÛÂÈ ÔÚÈÛÙÈΤ˜ ··ÓÙ‹ÛÂȘ. ‚) ∏ ¯ÔÚ‹ÁËÛË ÈÓÛÔ˘Ï›Ó˘ ÛÙ· ·È‰È¿ Î·È ÙÔ˘˜ ÂÊ‹‚Ô˘˜ ·ÏÏ¿˙ÂÈ, ÙÚÔÔÔÈ›, ‰È·ÊÔÚÔÔÈ› ÙËÓ Ó¢ÌÔÓÈ΋ ·Ó¿Ù˘ÍË; Á) ∞˘Í¿ÓÂÈ Ë ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË ÙËÓ ÂͤÏÈÍË ÂӉ¯fiÌÂÓ˘ ·Ó·Ù˘ÛÛfiÌÂÓ˘ ηÎÔ‹ıÂÈ·˜ ÛÙÔÓ Ó‡ÌÔÓ· ‹ ÂÈ‚·Ú‡ÓÂÈ ÙËÓ ·ıÔÊ˘ÛÈÔÏÔÁ›· Î·È ÙËÓ ÎÏÈÓÈ΋ ÂÈÎfiÓ· ˘ÔΛÌÂÓ˘ Ó¢ÌÔÓÈ΋˜ ›ÓˆÛ˘; ‰) £· ˘¿ÚÍÂÈ ÌÂÏÏÔÓÙÈο ·ÔÙÂÏÂÛÌ·ÙÈ΋ ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË Ì·ÎÚ¿˜ ‰Ú¿Ûˆ˜; Â) ¶ÔÈÔ ÙÔ Â‡ÚÔ˜ Ù˘ ÌÂÙ·‚ÏËÙfiÙËÙ·˜ ·ÔÚÚfiÊËÛ˘ Ù˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ οو ·fi ÙËÓ Â›‰Ú·ÛË ‰È·ÊfiÚˆÓ ÌÔÚÊÒÓ ¿ÛÎËÛ˘, ·Ó¿ÏÔÁ· Ì ÙËÓ Û˘Û΢‹ ¯ÔÚ‹ÁËÛ˘ Î·È ·Ó¿ÏÔÁ· Ì ÙËÓ Ù¯ÓÈ΋ Ù˘ ÂÈÛÓÔ‹˜;


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·25

£∂ƒ∞¶∂π∞ - º∞ƒª∞∫∞ ™˘ÌÂÚ·ÛÌ·ÙÈο ∏ ÂÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË ÌÔÚ› Ó· ·ÔÙÂϤÛÂÈ ÂÓ·ÏÏ·ÎÙÈ΋ χÛË ÛÙËÓ Ù·¯Â›·˜ ‰Ú¿Û˘ ÈÓÛÔ˘Ï›ÓË Ì ÈÛ¿ÍÈ· ‰Ú·ÛÙÈÎfiÙËÙ· Î·È ·ÛÊ¿ÏÂÈ·, Û˘Á¯ÔÚËÁÔ‡ÌÂÓË Ì ÂӉȿÌÂÛ˘ ‰Ú¿Û˘ ÈÓÛÔ˘Ï›ÓË ‹ ÛÂ Û˘Ó‰˘·ÛÌfi Ì ·ÓÙȉȷ‚ËÙÈο ‰ÈÛΛ·. ¢ÂÓ Ê·›ÓÂÙ·È Ó· ÂËÚ¿˙ÂÈ

ÙËÓ Ó¢ÌÔÓÈ΋ ÏÂÈÙÔ˘ÚÁ›·, ·ÏÏ¿ ‰ÂÓ Û˘ÛÙ‹ÓÂÙ·È Û ‰È·‚ËÙÈÎÔ‡˜ Ì ¯ÚfiÓÈ· ·ÔÊÚ·ÎÙÈ΋ Ó¢ÌÔÓÔ¿ıÂÈ·, ¿ÛıÌ· Û ·È‰È¿ Î·È Û ηÓÈÛÙ¤˜. ∏ ·Ô‰Ô¯‹ Ù˘ Î·È Ë ÈηÓÔÔ›ËÛË ÙˆÓ ‰È·‚ËÙÈÎÒÓ ·fi ÙËÓ ¯ÔÚ‹ÁËÛË Ù˘, (ÁÂÁÔÓfi˜ Ô˘ ‰È·ÈÛÙÒıËΠ۠fiϘ ÙȘ ÌÂϤÙ˜), ÌÔÚ› Ó· ·ÔÙÂϤÛÂÈ ¤Ó·˘ÛÌ·

ÁÈ· ÙËÓ ¯ÔÚ‹ÁËÛË Ù˘ ÛÙ· ¿ÙÔÌ· Ì ۷ί·ÚÒ‰Ë ‰È·‚‹ÙË. ¶¿ÓÙ· fï˜ ı· Ú¤ÂÈ Ó· Û˘ÓÂÎÙÈÌÒÓÙ·È ÔÈ Û¯ÂÙÈΤ˜ ·ÓÙÂӉ›ÍÂȘ fiˆ˜ Î·È ÔÈ ·Ó·Áη›Â˜ ÚÔ¸Ôı¤ÛÂȘ ÒÛÙÂ Ë ¯ÔÚ‹ÁËÛË Ù˘ ÂÈÛÓÂfiÌÂÓ˘ ÈÓÛÔ˘Ï›Ó˘ Ó· Â›Ó·È ·ÔÙÂÏÂÛÌ·ÙÈ΋ Î·È ·ÛÊ·Ï‹˜.

™˘ÓÈÛÙÒÌÂÓË μÈ‚ÏÈÔÁÚ·Ê›· Davidson M. B., Mehta A.E., Siraj E.S., et al: Inhaled Human Insulin: An Inspiration For Patients With Diabetes Mellitus? Cleveland Clinic Journal Of Medicine. 2006; 73, Num. 6. 569-78

4.

2.

Barnett AH. Exubera inhaled insulin: a review. J Clin P 2004; 58: 394-401).

5.

3.

Reinhard H.A. Becker, Sue Sha, Annke D. Frick, et al. The Effect of Smoking Cessation and Subsequent Resumption on Absorption of Inhaled Insulin. Diabetes Care 2006; 29: 277-282

1.

Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005; 28:427–428. ∞. ªÂÏȉÒÓ˘: ∂ÈÛÓÂfiÌÂÓË ÈÓÛÔ˘Ï›ÓË ÛÂÏ. 741-756 ·fi «∫·Ú‰ÈÔÌÂÙ·‚ÔÏÈÎfi˜ ΛӉ˘ÓÔ˜». ∞. ªÂÏȉÒÓ˘ 2007, ÂΉfiÛÂȘ π. ¶·ÚÈÛÈ¿ÓÔ˜.

6.

Barnett AH. Exubera inhaled insulin: a review. J Clin P 2004; 58: 394-401).

7.

Skyler J.S., Jovanovic L., Klioze S. et al. Two-Year Safety and Efficacy of Inhaled

Human Insulin (Exubera) in Adult Patients With Type 1 Diabetes. Diabetes Care 2007; 30: 579-585 8.

Nathan David M.. Counterpoint: No Time to Inhale: Arguments Against Inhaled Insulin in 2007 Diabetes Care 2007; 30: 442- 444

9.

Cefalu W.T.: Point: Pulmonary Inhalation of Insulin: Another "Brick in the Wall". Diabetes Care 2007; 30/

10. McMahon G.R. A. Inhaled Insulin for Diabetes Mellitus .: NEJM 2007; 356: 497- 502

√È ‚-∞ÔÎÏÂÈÛÙ¤˜ ÛÙËÓ ∫ÏÈÓÈ΋ ¶Ú¿ÍË ª. ºÏˆÚÂÓÙ›Ó, ∂ÈÛÙËÌÔÓÈÎfi˜ ™˘ÓÂÚÁ¿Ù˘ ÙÔ˘ π·ÙÚ›Ԣ §Èȉ›ˆÓ ª. ∂ÏÈÛ¿Ê, ∫·ıËÁËÙ‹˜ ¶·ıÔÏÔÁ›·˜ π·ÙÚÈ΋˜ ™¯ÔÏ‹˜ ¶·ÓÂÈÛÙËÌ›Ô˘ πˆ·ÓÓ›ÓˆÓ ΔÔ̤·˜ ¶·ıÔÏÔÁ›·˜ π·ÙÚÈ΋˜ ™¯ÔÏ‹˜ ¶·ÓÂÈÛÙËÌ›Ô˘ πˆ·ÓÓ›ÓˆÓ ∂ÈÛ·ÁˆÁ‹ √È ‚-·ÔÎÏÂÈÛÙ¤˜ ¯ÚËÛÈÌÔÔÈÔ‡ÓÙ·È Â˘Ú‡Ù·Ù· Â‰Ò Î·È 4 ‰ÂηÂٛ˜ Î·È ıˆÚÔ‡ÓÙ·È Ì¤¯ÚÈ Û‹ÌÂÚ·, Û‡Ìʈӷ Ì ÙȘ ηÙ¢ı˘ÓÙ‹ÚȘ Ô‰ËÁ›Â˜, Ê¿Ú̷η ÚÒÙ˘ ÁÚ·ÌÌ‹˜ ÁÈ· ÙËÓ ·ÓÙÈÌÂÙÒÈÛË Ù˘ ·ÚÙËÚȷ΋˜ ˘¤ÚÙ·Û˘ (∞À). øÛÙfiÛÔ, Ù· ÙÂÏÂ˘Ù·›· ¯ÚfiÓÈ· ·ÌÊÈÛ‚ËÙÂ›Ù·È ·fi ÔÏÏÔ‡˜ ÂÚ¢ÓËÙ¤˜ Ë ·ÔÙÂÏÂÛÌ·ÙÈÎfiÙËÙ¿ ÙÔ˘˜ fiÛÔÓ ·ÊÔÚ¿ ÙËÓ ÚfiÏË„Ë ÙˆÓ ÌÂÈ˙fiÓˆÓ Î·Ú‰È·ÁÁÂÈ·ÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ. ªÂÙ·-·Ó·Ï‡ÛÂȘ Ô˘ ÂÚÈÏ·Ì‚¿ÓÔ˘Ó ÙËÓ ÏÂÈÔ„ËÊ›· ÙˆÓ Ù˘¯·ÈÔÔÈËÌ¤ÓˆÓ ÎÏÈÓÈÎÒÓ ÌÂÏÂÙÒÓ, ÔÈ Ôԛ˜ Û˘Ó¤ÎÚÈÓ·Ó ÙÔ˘˜ ‚·ÔÎÏÂÈÛÙ¤˜ Ì ÂÈÎÔÓÈÎfi ‹ ¿ÏÏÔ Ê¿ÚÌ·ÎÔ, ·Ú¤¯Ô˘Ó ÂӉ›ÍÂȘ ηٿ Ù˘ ‰È·Ù‹ÚËÛ‹˜ ÙÔ˘˜ ˆ˜ ·ÓÙÈ˘ÂÚÙ·ÛÈο Ê¿Ú̷η ÚÒÙ˘ ÂÈÏÔÁ‹˜. ¶Ú¤ÂÈ Ó· ÂÈÛËÌ·Óı›, ˆÛÙfiÛÔ, fiÙÈ Ë ·ÔÙÂÏÂÛÌ·ÙÈÎfiÙËÙ¿ ÙÔ˘˜ ‰È·Ê¤ÚÂÈ, ÙfiÛÔ ÌÂٷ͇ ÙˆÓ ‰È·ÊÔÚÂÙÈÎÒÓ Ê·ÚÌ¿ÎˆÓ ·˘Ù‹˜ Ù˘ ÔÌ¿‰·˜, ηıÒ˜ Î·È fiÛÔÓ ·ÊÔÚ¿ ÙȘ ‰È¿ÊÔÚ˜ ËÏÈÎȷΤ˜

ÔÌ¿‰Â˜. ™ÙÔ ¿ÚıÚÔ ·˘Ùfi ı· ·ÚÔ˘ÛÈ·ÛıÔ‡Ó Û˘ÓÔÙÈο ÔÈ ÛËÌ·ÓÙÈÎfiÙÂÚ˜ ÌÂÙ·-·Ó·Ï‡ÛÂȘ ÌÂÏÂÙÒÓ ¯ÔÚ‹ÁËÛ˘ ÙˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ Î·È ı· Û˘˙ËÙËı› ‰ÈÂÍÔ‰Èο Ô ÚfiÏÔ˜ ÙÔ˘˜ ÛÙË ıÂÚ·›· Ù˘ ÚˆÙÔ·ıÔ‡˜ ∞À.

√È ÛËÌ·ÓÙÈÎfiÙÂÚ˜ ÌÂÙ·-·Ó·Ï‡ÛÂȘ ¯ÔÚ‹ÁËÛ˘ ‚-·ÔÎÏÂÈÛÙÒÓ √È ‚-·ÔÎÏÂÈÛÙ¤˜ ¤¯Ô˘Ó ¯ÚËÛÈÌÔÔÈËı› Û ÔÏϤ˜ Ù˘¯·ÈÔÔÈË̤Ó˜ ÎÏÈÓÈΤ˜ ÌÂϤÙ˜ Û ۇÁÎÚÈÛË, ÙfiÛÔ Ì ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ, fiÛÔ Î·È Ì ¿ÏÏ· ·ÓÙÈ˘ÂÚÙ·ÛÈο Ê¿Ú̷η.1-24 √È ÌÂϤÙ˜ ·˘Ù¤˜ ¤¯Ô˘Ó Û˘ÌÂÚÈÏ¿‚ÂÈ ˘ÂÚÙ·ÛÈÎÔ‡˜ ·ÛıÂÓ›˜ Ì ÌÂÁ¿ÏÔ ËÏÈÎÈ·Îfi ‡ÚÔ˜, ÂÓÒ Û˘¯Ó¿ ¯ÚËÛÈÌÔÔÈ‹ıËÎ·Ó Û˘Ó‰˘·ÛÌÔ› Ê·ÚÌ¿ÎˆÓ ÁÈ· Ó· ÂÈÙ¢¯ıÔ‡Ó Ù· ÂÈı˘ÌËÙ¿ Â›‰· ·ÚÙËÚȷ΋˜ ›ÂÛ˘ (∞¶).1, 4, 7, 16, 17 ¶·Ú¿ ÙËÓ ÂÙÂÚÔÁ¤ÓÂÈ· ÌÂٷ͇ ÙˆÓ ‰È·ÊfiÚˆÓ ÌÂÏÂÙÒÓ, ÔÚÈṲ̂Ó˜ ÛËÌ·ÓÙÈΤ˜ ÌÂÙ·-·Ó·Ï‡ÛÂȘ ÚÔÛ¿ıËÛ·Ó Ó· ·ÔÛ·ÊËÓ›ÛÔ˘Ó ÙÔÓ ·ÎÚÈ‚‹ ÚfiÏÔ ÙˆÓ ‚-·ÔÎÏÂÈ-

ÛÙÒÓ ÛÙË ıÂÚ·¢ÙÈ΋ ·ÓÙÈÌÂÙÒÈÛË Ù˘ ÚˆÙÔ·ıÔ‡˜ ∞À.25-28 √ Lindholm Î·È ÔÈ Û˘ÓÂÚÁ¿Ù˜ ÙÔ˘ Û ̛· ÌÂÙ·-·Ó¿Ï˘ÛË 18 Ù˘¯·ÈÔÔÈËÌ¤ÓˆÓ ÎÏÈÓÈÎÒÓ ÌÂÏÂÙÒÓ25 ·Ú·Ù‹ÚËÛ·Ó fiÙÈ Ë ¯ÔÚ‹ÁËÛË ‚-·ÔÎÏÂÈÛÙÒÓ Û˘Óԉ‡ÔÓÙ·Ó ·fi ·˘ÍË̤ÓÔ Î›Ó‰˘ÓÔ ÁÈ· ·ÁÁÂÈ·Îfi ÂÁÎÂÊ·ÏÈÎfi ÂÂÈÛfi‰ÈÔ (∞∂∂) Û ۇÁÎÚÈÛË Ì ÙË ¯ÔÚ‹ÁËÛË ·ÓÙÈ˘ÂÚÙ·ÛÈÎÒÓ Ê·ÚÌ¿ÎˆÓ ¿ÏÏˆÓ Î·ÙËÁÔÚÈÒÓ (relative risk [RR] 1.16, 95% CI 1.04-1.30; p=0.009), ÂÓÒ ‰ÂÓ ˘‹Ú¯·Ó ‰È·ÊÔÚ¤˜ fiÛÔÓ ·ÊÔÚ¿ ÙËÓ Â›ÙˆÛË ÙÔ˘ ÔͤԘ ÂÌÊÚ¿ÁÌ·ÙÔ˜ ÙÔ˘ Ì˘Ôηډ›Ô˘ (√∂ª) ‹ Ù˘ Û˘ÓÔÏÈ΋˜ ıÓËÛÈÌfiÙËÙ·˜ (¶›Ó·Î·˜ 1). Δ· ·ÔÙÂϤÛÌ·Ù· ‹Ù·Ó ·ÚfiÌÔÈ·, ÙfiÛÔ ÛÙȘ ÌÂϤÙ˜ ÛÙȘ Ôԛ˜ ¯ÔÚËÁ‹ıËΠ·ÙÂÓÔÏfiÏË (RR 1.26, 1.15-1.38; p<0.0001), fiÛÔ Î·È Û ÂΛӘ ÛÙȘ Ôԛ˜ ÛÙËÓ ·ÁˆÁ‹ Û˘ÌÂÚÈÏ·Ì‚¿ÓÔÓÙ·Ó Û˘Ó‰˘·ÛÌfi˜ ‚-·ÔÎÏÂÈÛÙ‹ Ì ‰ÈÔ˘ÚËÙÈÎfi (RR 1.09, 0.98-1.21), ÂÓÒ ‰ÂÓ ÌÔÚÔ‡Û·Ó Ó· ÂÍ·¯ıÔ‡Ó ·ÛÊ·Ï‹ Û˘ÌÂ-

25


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·26

π√À¡π√™ 2007

¶›Ó·Î·˜ 1: ‚-·ÔÎÏÂÈÛÙ¤˜ ¤Ó·ÓÙÈ ¿ÏÏˆÓ Ê·ÚÌ¿ÎˆÓ ªÂϤÙË

ΔÂÏÈÎfi ηٷÏËÎÙÈÎfi ÛËÌÂ›Ô (∞∂∂, √∂ª, ı¿Ó·ÙÔ˜)

Lindholm et al25 Khan et al26 RR (95% CI) RR (95% CI) ¡¤ÔÈ ·ÛıÂÓ›˜

RR (95% CI) ∏ÏÈÎȈ̤ÓÔÈ ·ÛıÂÓ›˜

0.97 (0.88-1.07) 1.06 (1.01-1.10)

∞∂∂

1.16 (1.04-1.30) 0.99 (0.67-1.44) 1.18 (1.07-1.30)

√∂ª

1.02 (0.93-1.12) 0.97 (0.86-1.10) 1.06 (0.94-1.20)

∫∞ √ÏÈ΋ ıÓËÛÈÌfiÙËÙ·

0.93 (0.64-1.34) 0.98 (0.87-1.11) 1.03 (0.99-1.08) 0.97 (0.83-1.14) 1.05 (0.99-1.11)

√∂ª: O͇ ¤ÌÊÚ·ÁÌ· ÙÔ˘ Ì˘Ôηډ›Ô˘, ∞∂∂: ·ÁÁÂÈ·Îfi ÂÁÎÂÊ·ÏÈÎfi ÂÂÈÛfi‰ÈÔ, ∫∞: ηډȷ΋ ·ÓÂ¿ÚÎÂÈ·, RR: relative risk (Û¯ÂÙÈÎfi˜ ΛӉ˘ÓÔ˜), CI: confidence interval (‰È¿ÛÙËÌ· ÂÌÈÛÙÔÛ‡Ó˘)

Ú¿ÛÌ·Ù· ÁÈ· ÙȘ ÌÂϤÙ˜ Ô˘ Û˘Ó¤ÎÚÈÓ·Ó ‚-·ÔÎÏÂÈÛÙ¤˜, ÂÎÙfi˜ Ù˘ ·ÙÂÓÔÏfiÏ˘, Ì ¿ÏÏ· Ê¿Ú̷η, ÂÍ·ÈÙ›·˜ ÙÔ˘ ÂÚÈÔÚÈṲ̂ÓÔ˘ ·ÚÈıÌÔ‡ Û˘Ì‚·Ì¿ÙˆÓ. ™Â Û‡ÁÎÚÈÛË Ì ÙÔ ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ ÔÈ ‚·ÔÎÏÂÈÛÙ¤˜ Ê·›ÓÂÙ·È fiÙÈ ÌÂÈÒÓÔ˘Ó ÙÔÓ Î›Ó‰˘ÓÔ ÂÌÊ¿ÓÈÛ˘ ∞∂∂ (RR 0.81, 0.71-0.93), ÂÓÒ ‰ÂÓ ˘‹Ú¯Â ‰È·ÊÔÚ¿ fiÛÔÓ ·ÊÔÚ¿ Ù· √∂ª ‹ ÙË Û˘ÓÔÏÈ΋ ıÓËÛÈÌfiÙËÙ· (¶›Ó·Î·˜ 2). Δ· Â˘Ú‹Ì·Ù· ·˘Ù¿ ·ÊÔÚÔ‡Û·Ó ÙfiÛÔ ÙËÓ ·ÙÂÓÔÏfiÏË (RR 0.85, 0.72-1.01), fiÛÔ Î·È Ù· ˘fiÏÔÈ· Ê¿Ú̷η ·˘Ù‹˜ Ù˘ ÔÌ¿‰·˜ Ô˘ ¯ÔÚËÁ‹ıËÎ·Ó (RR 0.84, 0.64-1.10). ¶Ú¤ÂÈ fï˜ Ó· ·Ó·ÊÂÚı› fiÙÈ Ë Ì›ˆÛË ·˘Ù‹ ·ÓÙÈÛÙÔȯ› ÂÚ›Ô˘ ÛÙÔ 50% Ù˘ ·Ó·ÌÂÓfiÌÂÓ˘ Ì›ˆÛ˘ ÙˆÓ Û˘Ì‚·Ì¿ÙˆÓ Ì ‚¿ÛË ÚÔËÁÔ‡ÌÂÓ˜ ÂȉËÌÈÔÏÔÁÈΤ˜ ÌÂϤÙ˜.29 ΔËÓ ·Ú·¿Óˆ ÌÂÙ·-·Ó¿Ï˘ÛË ·ÎÔÏÔ‡ıËÛ ·˘Ù‹ ÙˆÓ Khan Î·È MacAlister,26 Ë ÔÔ›· ÂÚÈÏ·Ì‚¿-

ÓÂÈ ‰Â‰Ô̤ӷ ·fi 21 Ù˘¯·ÈÔÔÈË̤Ó˜ ÎÏÈÓÈΤ˜ ÌÂϤÙ˜ ¯ÔÚ‹ÁËÛ˘ ‚-·ÔÎÏÂÈÛÙÒÓ Û ۇÁÎÚÈÛË Ì ÂÈÎÔÓÈÎfi ‹ ¿ÏÏÔ Ê¿ÚÌ·ÎÔ ˆ˜ ÚÒÙ˘ ÂÈÏÔÁ‹˜ ·ÓÙÈ˘ÂÚÙ·ÛÈ΋ ·ÁˆÁ‹ ÁÈ· ÙËÓ ÚfiÏË„Ë ÙˆÓ ÌÂÈ˙fiÓˆÓ Î·Ú‰È·ÁÁÂÈ·ÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ (¶›Ó·Î˜ 1 Î·È 2). ∏ ȉȷÈÙÂÚfiÙËÙ· ·˘Ù‹˜ Ù˘ ÌÂÙ·-·Ó¿Ï˘Û˘ ¤ÁÎÂÈÙ·È ÛÙÔ fiÙÈ ÔÈ ÂÚ¢ÓËÙ¤˜ ¯ÒÚÈÛ·Ó ÙȘ 21 ÌÂϤÙ˜ Û 2 ÔÌ¿‰Â˜, ·Ó¿ÏÔÁ· Ì ÙËÓ ËÏÈΛ· ÙˆÓ ·ÛıÂÓÒÓ, ¯ÚËÛÈÌÔÔÈÒÓÙ·˜ ˆ˜ fiÚÈÔ Ù· 60 ¤ÙË. Δ· Û˘ÌÂÚ¿ÛÌ·Ù· ‹Ù·Ó ‰È·ÊÔÚÂÙÈο ÁÈ· ÙȘ ÔÌ¿‰Â˜ ÙˆÓ ·ÛıÂÓÒÓ. ™˘ÁÎÂÎÚÈ̤ӷ. ∏ ¯ÔÚ‹ÁËÛË ‚-·ÔÎÏÂÈÛÙÒÓ ¤Ó·ÓÙÈ ÙÔ˘ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ ˘ÂÚÙÂÚÔ‡Û ÛÙÔ˘˜ Ó¤Ô˘˜ ·ÛıÂÓ›˜ (ËÏÈΛ·˜ <60 ÂÙÒÓ) fiÛÔÓ ·ÊÔÚ¿ ÙÔ ÙÂÏÈÎfi ηٷÏËÎÙÈÎfi ÛËÌÂ›Ô (∞∂∂, √∂ª, ı¿Ó·ÙÔ˜) (RR 0.86, 0.74-0.99), Ù· √∂ª (RR 0.85, 0.71-1.03), Ù· ∞∂∂ (RR 0.84, 0.65-1.10) Î·È ÙÔ˘˜ ı·Ó¿ÙÔ˘˜

¶›Ó·Î·˜ 2: ‚-·ÔÎÏÂÈÛÙ¤˜ ¤Ó·ÓÙÈ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ ªÂϤÙË

ΔÂÏÈÎfi ηٷÏËÎÙÈÎfi ÛËÌÂ›Ô (∞∂∂, √∂ª, ı¿Ó·ÙÔ˜)

Lindholm et al25 Khan et al26 RR (95% CI) RR (95% CI) ¡¤ÔÈ ·ÛıÂÓ›˜

RR (95% CI) ∏ÏÈÎȈ̤ÓÔÈ ·ÛıÂÓ›˜

0.86 (0.74-0.99) 0.89 (0.75-1.05)

∞∂∂

0.81 (0.71-0.93) 0.84 (0.65-1.10) 0.78 (0.63-0.98)

√∂ª

0.93 (0.83-1.05) 0.85 (0.71-1.03) 0.98 (0.83-1.16)

∫∞ √ÏÈ΋ ıÓËÛÈÌfiÙËÙ·

1.05 (0.72-1.54) 0.54 (0.37-0.81) 0.95 (0.86-1.04) 0.94 (0.79-1.10) 0.91 (0.74-1.12)

√∂ª: O͇ ¤ÌÊÚ·ÁÌ· ÙÔ˘ Ì˘Ôηډ›Ô˘, ∞∂∂: ·ÁÁÂÈ·Îfi ÂÁÎÂÊ·ÏÈÎfi ÂÂÈÛfi‰ÈÔ, ∫∞: ηډȷ΋ ·ÓÂ¿ÚÎÂÈ·, RR: relative risk (Û¯ÂÙÈÎfi˜ ΛӉ˘ÓÔ˜), CI: confidence interval (‰È¿ÛÙËÌ· ÂÌÈÛÙÔÛ‡Ó˘)

26

(RR 0.94, 0.79-1.10), fi¯È fï˜ Î·È ÙËÓ Â›ÙˆÛË Ù˘ ηډȷ΋˜ ·ÓÂ¿ÚÎÂÈ·˜ (∫∞). ∞ÓÙ›ıÂÙ·, Û ·ÛıÂÓ›˜ ËÏÈΛ·˜ >60 ÂÙÒÓ ·Ú·ÙËÚ‹ıËΠÌÈ· ÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈ΋ Ì›ˆÛË Û ۇÁÎÚÈÛË Ì ÙÔ ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ ÌfiÓÔ ÙˆÓ ∞∂∂ (RR 0.78, 0.63-0.98) Î·È Ù˘ ∫∞ (RR 0.54, 0.37-0.81). ™Â Û‡ÁÎÚÈÛË Ì ʿÚ̷η ¿ÏÏˆÓ Î·ÙËÁÔÚÈÒÓ, ÔÈ ‚-·ÔÎÏÂÈÛÙ¤˜ ‰ÂÓ ˘ÂÚÙÂÚÔ‡Û·Ó Û ηӤӷ ·fi Ù· ·Ú·¿Óˆ ηٷÏËÎÙÈο ÛËÌ›· ÛÙÔ˘˜ Ó¤Ô˘˜ ·ÛıÂÓ›˜ (ËÏÈΛ·˜ <60 ÂÙÒÓ). øÛÙfiÛÔ, ÛÙ· ËÏÈÎȈ̤ӷ ¿ÙÔÌ· Ë ¯ÔÚ‹ÁËÛË ÙˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ Û˘Û¯ÂÙ›ÛıËΠ̠·˘ÍË̤ÓÔ Î›Ó‰˘ÓÔ ÂÌÊ¿ÓÈÛ˘ ηډȷÁÁÂÈ·ÎÒÓ Û˘Ì‚·Ì¿ÙˆÓ (RR 1.06, 1.01-1.10), ÂÍ·ÈÙ›·˜ Ù˘ ÌÂÁ·Ï‡ÙÂÚ˘ Â›ÙˆÛ˘ ∞∂∂ (RR 1.18, 1.07-1.30). ∞Ó Î·È ÙÔ fiÊÂÏÔ˜ Ô˘ ÚԤ΢„ ·fi ÙȘ ÌÂϤÙ˜ ¯ÔÚ‹ÁËÛ˘ ÛÙÔ˘˜ Ó¤Ô˘˜ ·ÛıÂÓ›˜ ‚-·ÔÎÏÂÈÛÙÒÓ Û ۇÁÎÚÈÛË Ì ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ ‹Ù·Ó Î·È Û ·˘Ù‹ ÙË ÌÂÙ·-·Ó¿Ï˘ÛË ÌÈÎÚfiÙÂÚÔ ·fi ÙÔ ·Ó·ÌÂÓfiÌÂÓÔ Ì ‚¿ÛË ÂȉËÌÈÔÏÔÁÈΤ˜ ÌÂϤÙ˜,29 Ê·›ÓÂÙ·È fiÙÈ Ë ¯ÔÚ‹ÁËÛË ÂÓfi˜ ‚-·ÔÎÏÂÈÛÙ‹ ÌÔÚ› Ó· ¢ÓÔ‹ÛÂÈ Ó¤Ô˘˜ ·ÛıÂÓ›˜ Ì ·ÓÂ›ÏÂÎÙË ∞À. ∂Ô̤ӈ˜, ÔÊ›ÏÔ˘Ì ӷ ·ÍÈÔÏÔÁ‹ÛÔ˘Ì Ì ÎÚÈÙÈ΋ ÛΤ„Ë ÙËÓ ÚfiÙ·ÛË ÔÚÈÛÌ¤ÓˆÓ ÂÚ¢ÓËÙÒÓ ÁÈ· ÔÚÈÛÙÈ΋ ηٿÚÁËÛË ÙˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ ˆ˜ ·ÓÙÈ˘ÂÚÙ·ÛÈÎÒÓ Ê·Ú̿ΈÓ. ∞Í›˙ÂÈ ÛÙÔ ÛËÌÂ›Ô ·˘Ùfi Ó· ‰È¢ÎÚÈÓÈÛı› fiÙÈ Ë ·ıÔÊ˘ÛÈÔÏÔÁ›· Ù˘ ∞À ‰ÂÓ Â›Ó·È Ë ›‰È· Û οı ËÏÈΛ·. ™Ù· Ó¤· ¿ÙÔÌ· Ë ∞À ÔÊ›ÏÂÙ·È Û ·˘ÍË̤ÓË Î·Ú‰È·Î‹ ·ÚÔ¯‹ ·ÚÔ˘Û›· Ê˘ÛÈÔÏÔÁÈÎÒÓ ‹ ÌÂÈˆÌ¤ÓˆÓ ·ÁÁÂÈ·ÎÒÓ ·ÓÙÈÛÙ¿ÛˆÓ,30-32 ÂÓÒ Ë ∞À ÙˆÓ ËÏÈÎÈˆÌ¤ÓˆÓ ·ÙfiÌˆÓ ¯·Ú·ÎÙËÚ›˙ÂÙ·È ·fi ·‡ÍËÛË ÙˆÓ ÂÚÈÊÂÚÈÎÒÓ ·ÓÙÈÛÙ¿ÛÂˆÓ Î·È ¯·ÌËÏ‹ ·ÚÙËÚȷ΋ ÂÓ‰ÔÙÈÎfiÙËÙ· (compliance).30, 31 ∂Ô̤ӈ˜, Ë ¯ÔÚ‹ÁËÛË ÙˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ ÛÙÔ˘˜ Ó¤Ô˘˜ ·ÛıÂÓ›˜ ÌÔÚ› Ó· ‰ÈηÈÔÏÔÁËı› ·fi ÙÂÎÌËÚȈ̤ӷ ·ıÔÊ˘ÛÈÔÏÔÁÈο ‰Â‰Ô̤ӷ.

∏ ·ÙÂÓÔÏfiÏË Î·È ÔÈ ¿ÏÏÔÈ ‚-·ÔÎÏÂÈÛÙ¤˜: ˘¿Ú¯ÂÈ ‰È·ÊÔÚ¿ ÌÂٷ͇ ÙÔ˘˜; √ ÈÔ ‰È·‰Â‰Ô̤ÓÔ˜ ‚-·ÔÎÏÂÈÛÙ‹˜ Â›Ó·È Ë ·ÙÂÓÔÏfiÏË Î·È Û ·˘Ùfi ÙÔ Ê¿ÚÌ·ÎÔ ·Ô‰›‰ÔÓÙ·È Ù· ·ÔÙÂϤÛÌ·Ù· Ù˘ ÏÂÈÔÓfiÙËÙ·˜ ÙˆÓ ÌÂÏÂÙÒÓ Ô˘ ¤¯Ô˘Ó ‰ÈÂÍ·¯ı› Ì ‚-·ÔÎÏÂÈÛÙ¤˜. ¢Â‰Ô̤Ó˘ Ù˘


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·27

£∂ƒ∞¶∂π∞ - º∞ƒª∞∫∞ ‰È·ÊÔÚÂÙÈ΋˜ Ê·ÚÌ·ÎÔÎÈÓËÙÈ΋˜ Ù˘ ·ÙÂÓÔÏfiÏ˘ Û ۇÁÎÚÈÛË Ì ٷ ˘fiÏÔÈ· Ê¿Ú̷η Ù˘ ›‰È·˜ ηÙËÁÔÚ›·˜, Ù¤ıËΠÙÔ ÂÚÒÙËÌ· ηٿ fiÛÔ ÔÈ Ô˘‰¤ÙÂÚ˜ ‹ ·ÚÓËÙÈΤ˜ ÂÈÙÒÛÂȘ Ô˘ ·Ú·ÙËÚ‹ıËÎ·Ó Û ÔÚÈṲ̂Ó˜ ÌÂϤÙ˜ Ì ‚·ÔÎÏÂÈÛÙ¤˜ ÔÊ›ÏÔÓÙ·Ó ÛÙËÓ ·ÙÂÓÔÏfiÏË Î·È ·Ó Ë ÂӉ¯fiÌÂÓË ¯ÔÚ‹ÁËÛË ¿ÏÏˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ ı· ›¯Â ÈÔ Â˘ÓÔ˚ο ·ÔÙÂϤÛÌ·Ù·. √ Carlberg Î·È ÔÈ Û˘ÓÂÚÁ¿Ù˜ ÙÔ˘ ·Ó¤Ï˘Û·Ó Ù· ‰Â‰Ô̤ӷ 9 ÌÂÏÂÙÒÓ Ì ·ÙÂÓÔÏfiÏË: 4 ¤Ó·ÓÙÈ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ (¶›Ó·Î·˜ 3) Î·È 5 ¤Ó·ÓÙÈ ¿ÏÏÔ˘ ·ÓÙÈ˘ÂÚÙ·ÛÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ (¶›Ó·Î·˜ 4).27 ¶·Ú¿ ÙË ÌÂÁ·Ï‡ÙÂÚË Ì›ˆÛË Ù˘ ∞¶ Ô˘ ÂÈÙ‡¯ıËΠ̠ÙËÓ ·ÙÂÓÔÏfiÏË, ‰ÂÓ ·Ú·ÙËÚ‹ıËÎ·Ó ÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈΤ˜ ‰È·ÊÔÚ¤˜ Û ۇÁÎÚÈÛË Ì ÙÔ ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ fiÛÔÓ ·ÊÔÚ¿ Ù· √∂ª, ÙËÓ Î·Ú‰È·ÁÁÂȷ΋ Î·È ÔÏÈ΋ ıÓËÛÈÌfiÙËÙ·, ÂÓÒ Ë ·ÙÂÓÔÏfiÏË Ê·›ÓÂÙ·È fiÙÈ ÂÏ·ÙÙÒÓÂÈ ÙÔÓ Î›Ó‰˘ÓÔ ÙˆÓ ∞∂∂ (RR 0.85, 0.72-1.01). ™Â Û‡ÁÎÚÈÛË Ì ʿÚ̷η ¿ÏÏˆÓ Î·ÙËÁÔÚÈÒÓ Î·È ·Ú¿ ÙËÓ Â›Ù¢ÍË ·ÚfiÌÔÈˆÓ ÂÈ¤‰ˆÓ ∞¶, Ë ·ÙÂÓÔÏfiÏË Û˘Û¯ÂÙ›ÛıËΠ̠ÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈ΋ ÌÂÁ·Ï‡ÙÂÚË ıÓËÛÈÌfiÙËÙ· (RR 1.13, 1.021.25), ·ÏÏ¿ Î·È Î·Ú‰È·ÁÁÂȷ΋ ıÓËÛÈÌfiÙËÙ· (RR 1.16, 1.001.34) Î·È ·˘ÍË̤ÓË Â›ÙˆÛË ∞∂∂ (RR 1.30, 1.12-1.50). ¶·ÚfiÌÔÈ· ·ÔÙÂϤÛÌ·Ù· ÚÔ¤-

΢„·Ó Î·È ·fi ÌÈ· ÌÂÙ·-·Ó¿Ï˘ÛË 10 Ù˘¯·ÈÔÔÈËÌ¤ÓˆÓ ÎÏÈÓÈÎÒÓ ÌÂÏÂÙÒÓ (4 ÌÂٷ͇ ·ÙÂÓÔÏfiÏ˘ Î·È ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘, 5 ÌÂٷ͇ ·ÙÂÓÔÏfiÏ˘ Î·È ¿ÏÏÔ˘ ·ÓÙÈ˘ÂÚÙ·ÛÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ Î·È ÌÈ· ÌÂϤÙË Ô˘ Û˘Ó¤ÎÚÈÓ ÙËÓ ·ÙÂÓÔÏfiÏË ÙfiÛÔ Ì ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ, fiÛÔ Î·È Ì ʿÚÌ·ÎÔ ¿ÏÏ˘ ηÙËÁÔÚ›·˜).28 ¢ÂÓ ·Ú·ÙËÚ‹ıËΠÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈ΋ ‰È·ÊÔÚ¿ ÌÂٷ͇ Ù˘ ·ÙÂÓÔÏfiÏ˘ Î·È ÙÔ˘ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ Û ηӤӷ ·fi Ù· ÙÂÏÈο ηٷÏËÎÙÈο ÛËÌ›· (∞∂∂, √∂ª, ηډȷÁÁÂȷ΋ ‹ ÔÏÈ΋ ıÓËÛÈÌfiÙËÙ·), ÂÓÒ ·ÓÙ›ıÂÙ· Ë ¯ÔÚ‹ÁËÛË Ù˘ ·ÙÂÓÔÏfiÏ˘ ¤Ó·ÓÙÈ Ê·ÚÌ¿ÎˆÓ ¿ÏÏˆÓ Î·ÙËÁÔÚÈÒÓ Û˘Û¯ÂÙ›ÛıËΠ̠·˘ÍË̤ÓÔ Î›Ó‰˘ÓÔ ∞∂∂ (RR 1.27, 1.16-1.38; p=0.0004), ηıÒ˜ Î·È Î·Ú‰È·ÁÁÂȷ΋˜ Î·È ÔÏÈ΋˜ ıÓËÛÈÌfiÙËÙ·˜ (RR 1.13, 1.03-1.23; p=0.008 Î·È RR 1.07, 1.01-1.14; p=0.02, ·ÓÙ›ÛÙÔȯ·). Δ¤ÏÔ˜, ·Ú·ÙËÚ‹ıËΠÌÈ· ·˘ÍËÙÈ΋ Ù¿ÛË fiÛÔÓ ·ÊÔÚ¿ Î·È Ù· √∂ª Ì ÙË ¯ÔÚ‹ÁËÛË Ù˘ ·ÙÂÓÔÏfiÏ˘ (RR 1.02, 0.95-1.11; p=0.55). °È· ÙËÓ ÂÚÌËÓ›· ÙˆÓ ‰È·ÊÔÚÂÙÈÎÒÓ ·ÔÙÂÏÂÛÌ¿ÙˆÓ Ô˘ ·Ú·ÙËÚ‹ıËÎ·Ó ÌÂٷ͇ Ù˘ ·ÙÂÓÔÏfiÏ˘ Î·È ÙˆÓ ˘fiÏÔÈˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ Ú¤ÂÈ Ó· ‰È¢ÎÚÈÓÈÛıÔ‡Ó ÔÈ ‰È·ÊÔÚ¤˜ Ô˘ ˘¿Ú¯Ô˘Ó ÌÂٷ͇ ÙˆÓ Ê·Ú̿ΈÓ. ∏ ·ÙÂÓÔÏfiÏË ÌÂÈÒÓÂÈ Ù· Â›‰·

¶›Ó·Î·˜ 3: ∞ÙÂÓÔÏfiÏË ¤Ó·ÓÙÈ ÂÈÎÔÓÈÎÔ‡ Ê·ÚÌ¿ÎÔ˘ ªÂϤÙË

Carlberg et al27 RR (95% CI)

Karagiannis et al28

√ÏÈ΋ ıÓËÛÈÌfiÙËÙ·

1.01 (0.89-1.15)

1.01 (0.84-1.15)

∫·Ú‰È·ÁÁÂȷ΋ ıÓËÛÈÌfiÙËÙ· 0.99 (0.83-1.18)

0.99 (0.83-1.18)

√∂ª

0.99 (0.83-1.19)

0.99 (0.83-1.19)

∞∂∂

0.85 (0.72-1.01)

0.96 (0.80-1.16)

√∂ª: O͇ ¤ÌÊÚ·ÁÌ· ÙÔ˘ Ì˘Ôηډ›Ô˘, ∞∂∂: ·ÁÁÂÈ·Îfi ÂÁÎÂÊ·ÏÈÎfi ÂÂÈÛfi‰ÈÔ, RR: relative risk (Û¯ÂÙÈÎfi˜ ΛӉ˘ÓÔ˜), CI: confidence interval (‰È¿ÛÙËÌ· ÂÌÈÛÙÔÛ‡Ó˘)

¶›Ó·Î·˜ 4: ∞ÙÂÓÔÏfiÏË ¤Ó·ÓÙÈ ¿ÏÏˆÓ Ê·ÚÌ¿ÎˆÓ ªÂϤÙË

Carlberg et al27 RR (95% CI)

Karagiannis et al28

√ÏÈ΋ ıÓËÛÈÌfiÙËÙ·

1.13 (1.02-1.25)

1.07 (1.01-1.14)

∫·Ú‰È·ÁÁÂȷ΋ ıÓËÛÈÌfiÙËÙ· 1.16 (1.00-1.34)

1.13 (1.03-1.23)

√∂ª

1.04 (0.89-1.20)

1.02 (0.95-1.11)

∞∂∂

1.30 (1.12-1.50)

1.27 (1.16-1.38)

√∂ª: O͇ ¤ÌÊÚ·ÁÌ· ÙÔ˘ Ì˘Ôηډ›Ô˘, ∞∂∂: ·ÁÁÂÈ·Îfi ÂÁÎÂÊ·ÏÈÎfi ÂÂÈÛfi‰ÈÔ, RR: relative risk (Û¯ÂÙÈÎfi˜ ΛӉ˘ÓÔ˜), CI: confidence interval (‰È¿ÛÙËÌ· ÂÌÈÛÙÔÛ‡Ó˘)

Ù˘ ∞¶ Î·È Ì¿ÏÈÛÙ· ÛÙÔÓ ›‰ÈÔ ‚·ıÌfi Ì ʿÚ̷η ¿ÏÏˆÓ Î·ÙËÁÔÚÈÒÓ, fiˆ˜ ÚÔ·ÙÂÈ ·fi ÌÂÙÚ‹ÛÂȘ Ù˘ ∞¶ ÛÙÔ ‚Ú·¯›ÔÓ·. øÛÙfiÛÔ Â›Ó·È ÁÓˆÛÙfi fiÙÈ Ë ∞¶ ÛÙË ‚Ú·¯ÈfiÓÈ· ·ÚÙËÚ›· ‰ÂÓ ·ÓÙÈηÙÔÙÚ›˙ÂÈ Ì ·ÎÚ›‚ÂÈ· ÙË Û˘ÛÙÔÏÈ΋ ∞¶, Ô‡Ù ·ÔÙÂÏ› ηÏfi ‰Â›ÎÙË Ù˘ ÎÂÓÙÚÈ΋˜ ·ÔÚÙÈ΋˜ Û˘ÛÙÔÏÈ΋˜ ›ÂÛ˘.33 ∂ÈÚfiÛıÂÙ·, ÛÙ· Ó¤· ¿ÙÔÌ· Ë ÎÂÓÙÚÈ΋ ·ÔÚÙÈ΋ Û˘ÛÙÔÏÈ΋ ›ÂÛË Â›Ó·È Ôχ ¯·ÌËÏfiÙÂÚË ·fi ÙË ‚Ú·¯ÈfiÓÈ· ·ÚÙËÚȷ΋ Û˘ÛÙÔÏÈ΋ ›ÂÛË.34 ¶·Ú¿ ÙË Ì›ˆÛË Ù˘ ‚Ú·¯ÈfiÓÈ·˜ ∞¶, Ë ·ÙÂÓÔÏfiÏË ‰ÂÓ ÂÏ·ÙÙÒÓÂÈ ÙËÓ ÎÂÓÙÚÈ΋ ·ÔÚÙÈ΋ Û˘ÛÙÔÏÈ΋ ›ÂÛË ÛÙÔÓ ›‰ÈÔ ‚·ıÌfi Ì ÙÔ˘˜ ·ÓÙ·ÁˆÓÈÛÙ¤˜ ·Û‚ÂÛÙ›Ô˘, ÙÔ˘˜ ·Ó·ÛÙÔÏ›˜ ÙÔ˘ ÌÂÙ·ÙÚÂÙÈÎÔ‡ ÂÓ˙‡ÌÔ˘ Ù˘ ·ÁÁÂÈÔÙÂÓÛ›Ó˘ ππ Î·È ÙËÓ ˘‰ÚԯψÚÔıÂÈ·˙›‰Ë.35 ªÂϤÙ˜ ¤‰ÂÈÍ·Ó fiÙÈ Ë Ì›ˆÛË Ù˘ ÎÂÓÙÚÈ΋˜ Î·È fi¯È Ù˘ ‚Ú·¯ÈfiÓÈ·˜ ∞¶, ·ÚÔ˘ÛÈ¿˙ÂÈ ÛËÌ·ÓÙÈ΋ Û˘Û¯¤ÙÈÛË Ì ÙËÓ ˘ÔÛÙÚÔÊ‹ Ù˘ ˘ÂÚÙÚÔÊ›·˜ Ù˘ ·ÚÈÛÙÂÚ‹˜ ÎÔÈÏ›·˜.36 ∂Ô̤ӈ˜, Ë ÌÂÁ·Ï‡ÙÂÚË ·ÔÙÂÏÂÛÌ·ÙÈÎfiÙËÙ· ÙˆÓ ·Ú·¿Óˆ Ê·ÚÌ¿ÎˆÓ ¤Ó·ÓÙÈ Ù˘ ·ÙÂÓÔÏfiÏ˘ fiÛÔÓ ·ÊÔÚ¿ ÙËÓ ÂÏ¿ÙÙˆÛË Ù˘ ˘ÂÚÙÚÔÊ›·˜ Ù˘ ·ÚÈÛÙÂÚ‹˜ ÎÔÈÏ›·˜37 ı· ÌÔÚÔ‡Û ӷ ·Ô‰Ôı› Û ·˘Ù‹ ÙËÓ ·Ú·Ù‹ÚËÛË. ªÈ· ¿ÏÏË ‰È·ÊÔÚ¿ Ù˘ ·ÙÂÓÔÏfiÏ˘ ·fi ÙÔ˘˜ ˘fiÏÔÈÔ˘˜ ‚·ÔÎÏÂÈÛÙ¤˜ Â›Ó·È Ë ˘‰ÚfiÊÈÏË Ê‡ÛË Ù˘ Î·È Ë Ôχ ¯·ÌËÏ‹ ‰È·ÂÚ·ÙfiÙËÙ¿ Ù˘ ÛÙÔ ÎÂÓÙÚÈÎfi Ó¢ÚÈÎfi Û‡ÛÙËÌ·. ¶ÂÈÚ·Ì·ÙÈΤ˜ ÌÂϤÙ˜ ¤‰ÂÈÍ·Ó fiÙÈ Ë ÈηÓfiÙËÙ· ÙˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ Ó· ÚÔÏ·Ì‚¿ÓÔ˘Ó ÙËÓ ÎÔÏÈ΋ Ì·ÚÌ·Ú˘Á‹ ÂÍ·ÚÙ¿Ù·È ·fi Ù· Â›‰¿ ÙÔ˘˜ ÛÙÔ ÎÂÓÙÚÈÎfi Ó¢ÚÈÎfi Û‡ÛÙËÌ·.38 ™Â ·ÓÙ›ıÂÛË Ì ¿ÏÏÔ˘˜ ‚-·ÔÎÏÂÈÛÙ¤˜ (.¯. ÌÂÙÔÚÔÏfiÏË, ·Î‚ԢÙÔÏfiÏË), Ë ·ÙÂÓÔÏfiÏË ‰ÂÓ Ê·›ÓÂÙ·È Ó· ¤¯ÂÈ ÈηÓÔÔÈËÙÈ΋ 24ˆÚË ‰Ú¿ÛË fiÙ·Ó ¯ÔÚËÁÂ›Ù·È ÌÈ· ÊÔÚ¿ ÙËÓ Ë̤ڷ.39 Δ¤ÏÔ˜, ÌÂϤÙ˜ ¤‰ÂÈÍ·Ó fiÙÈ ÔÚÈṲ̂ӷ ·ÓÙÈ˘ÂÚÙ·ÛÈο Ê¿Ú̷η ‚ÂÏÙÈÒÓÔ˘Ó ÙËÓ ·Ó·‰È·ÌfiÚʈÛË (remodelling) Î·È ÙËÓ ÂÓ‰ÔıËÏȷ΋ ‰˘ÛÏÂÈÙÔ˘ÚÁ›· ÙˆÓ ÌÈÎÚÒÓ ·ÚÙËÚÈÒÓ Ô˘ ·Ú·ÙËÚÔ‡ÓÙ·È Û ·ÛıÂÓ›˜ Ì ∞À, Â˘Ú‹Ì·Ù· Ô˘ ‰ÂÓ ·Ú·ÙËÚ‹ıËÎ·Ó ÌÂÙ¿ ÙË ¯ÔÚ‹ÁËÛË ·ÙÂÓÔÏfiÏ˘.40-42 ∫·ı›ÛÙ·Ù·È ÂÔ̤ӈ˜ ۷ʤ˜ fiÙÈ ˘¿Ú¯Ô˘Ó ÔÈΛϘ Î·È ·ÍÈÔÛËÌ›ˆÙ˜ ‰È·ÊÔÚ¤˜ ÌÂٷ͇ Ù˘ ·ÙÂÓÔÏfiÏ˘ Î·È ÙfiÛÔ ÙˆÓ ¿ÏÏˆÓ Ê·Ú-

27


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·28

π√À¡π√™ 2007

Ì¿ÎˆÓ Ù˘ ›‰È·˜ ηÙËÁÔÚ›·˜, fiÛÔ Î·È Ê·ÚÌ¿ÎˆÓ Ô˘ ·Ó‹ÎÔ˘Ó Û ¿ÏϘ ηÙËÁÔڛ˜, ÁÂÁÔÓfi˜ Ô˘ ÌÔÚ› Ó· ÂÚÌËÓ‡ÛÂÈ, ÙÔ˘Ï¿¯ÈÛÙÔÓ ˆ˜ ¤Ó· ‚·ıÌfi, ÙË ‰È·ÊÔÚÂÙÈ΋ ·ÔÙÂÏÂÛÌ·ÙÈÎfiÙËÙ¿ ÙÔ˘˜, fiˆ˜ ·˘Ù‹ ηٷÁÚ¿ÊÂÙ·È ÛÙȘ ‰È¿ÊÔÚ˜ ÌÂϤÙ˜.

¶ÏÂÔÓÂÎÙ‹Ì·Ù· Î·È ÌÂÈÔÓÂÎÙ‹Ì·Ù· ÙˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ ¶·Ú¿ ÙȘ ‰ÈÊÔÚÔ‡ÌÂÓ˜ ·fi„ÂȘ fiÛÔÓ ·ÊÔÚ¿ ÙË ¯ÔÚ‹ÁËÛË ÙˆÓ ‚·ÔÎÏÂÈÛÙÒÓ ÛÙËÓ ÚˆÙÔ·ı‹ ∞À, ˘¿Ú¯Ô˘Ó ÔÚÈṲ̂Ó˜ ÎÏÈÓÈΤ˜ ÔÓÙfiÙËÙ˜ ÛÙȘ Ôԛ˜ ÔÈ ‚-·ÔÎÏÂÈÛÙ¤˜ ¤¯Ô˘Ó ·ԉ‰ÂÈÁ̤ÓË ·ÔÙÂÏÂÛÌ·ÙÈÎfiÙËÙ·. √È ÂÚÈÛÛfiÙÂÚÔÈ ‚-·ÔÎÏÂÈÛÙ¤˜ ÌÂÈÒÓÔ˘Ó ÛËÌ·ÓÙÈο ÙË ÌÂÙÂÌÊÚ·ÁÌ·ÙÈ΋ ıÓËÛÈÌfiÙËÙ· Ì·ÎÚÔÚfiıÂÛÌ·, fiˆ˜ Ê¿ÓËΠ·fi ÌÈ· ÌÂÁ¿ÏË ÌÂÙ·-·Ó¿Ï˘ÛË 31 ÌÂÏÂÙÒÓ (RR 0.77, 0.69-0.85).43 ∂›Û˘ ÚÔÛʤÚÔ˘Ó Û˘Ìو̷ÙÈ΋ ·Ó·ÎÔ‡ÊÈÛË ·fi Ù· ÛÙËı·Á¯Èο ÂÓԯϋ̷ٷ Î·È ¤¯Ô˘Ó ·ÓÙÈ·ıËÚÔÛÎÏËÚˆÙÈ΋ ‰Ú¿ÛË,44 ÂÓÒ Â›Ó·È È‰È·›ÙÂÚ· ¯Ú‹ÛÈÌ· Ê¿Ú̷η Û ·ÛıÂÓ›˜ Ì ∫∞, ·ÊÔ‡ ÂÏ·ÙÙÒÓÔ˘Ó ÙËÓ Î·Ú‰È·ÁÁÂȷ΋ Î·È ÙËÓ ÔÏÈ΋ ıÓËÛÈÌfiÙËÙ·, ÙÔ˘˜ ·ÈÊÓ›‰ÈÔ˘˜ ı·Ó¿ÙÔ˘˜ Î·È ÙȘ ÓÔÛËÏ›˜ ÛÙÔ ÓÔÛÔÎÔÌ›Ô.45-48 ∂Ô̤ӈ˜, Ë ‰Â˘ÙÂÚÔÁÂÓ‹˜ ÚfiÏË„Ë Ù˘ ÛÙÂÊ·ÓÈ·›·˜ ÓfiÛÔ˘ (™¡) Î·È Ë ∫∞ ·ÔÙÂÏÔ‡Ó Û·Ê›˜ ÂӉ›ÍÂȘ ¯ÔÚ‹ÁËÛ˘ ÙˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ. ∞ÎfiÌ· Ë ¯ÔÚ‹ÁËÛË ÙˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ ÌÔÚ› Ó· Â›Ó·È È‰È·›ÙÂÚ· ¯Ú‹ÛÈÌË Û ¿ÙÔÌ· Ì ˘ÂÚ‰Ú·ÛÙËÚÈfiÙËÙ· ÙÔ˘ Û˘Ì·ıËÙÈÎÔ‡ Ó¢ÚÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜ ‹ Ôχ ·Á¯Ò‰Ë, ·ÊÔ‡ ·Ú¿ÏÏËÏ· Ì ÙË Ì›ˆÛË Ù˘ ∞¶ ·˘Ù¿ Ù· Ê¿Ú̷η ·Ú¤¯Ô˘Ó Û˘Ìو̷ÙÈ΋ ·Ó·ÎÔ‡ÊÈÛË. Δ¤ÏÔ˜, Ë ¯ÔÚ‹ÁËÛ‹ ÙÔ˘˜ ÚÈÓ ·fi Ì›˙ÔÓ˜ ·ÁÁÂȷΤ˜ ÂÂÌ‚¿ÛÂȘ Û ·ÛıÂÓ›˜ Ì ÎÏÈÓÈÎÔ‡˜ ·Ú¿ÁÔÓÙ˜ ÎÈÓ‰‡ÓÔ˘ Î·È ·ıÔÏÔÁÈÎfi ˘ÂÚ˯ÔÁÚ¿ÊËÌ· ηډȿ˜ ÌÂÙ¿ ·fi ¯ÔÚ‹ÁËÛË ‰Ô‚Ô˘Ù·Ì›Ó˘ ÌÂÈÒÓÂÈ Ù· ηډȷÁÁÂȷο Û˘Ì‚¿Ì·Ù·,49 ÂÓÒ Ë Û˘Ó¤¯ÈÛË Ù˘ ·ÁˆÁ‹˜ Ì ‚ÈÛÔÚÔÏfiÏË ÁÈ· 2 ¤ÙË ÌÂÙ¿ ÙËÓ Â¤Ì‚·ÛË ÂÏ·ÙÙÒÓÂÈ ÂÚ·ÈÙ¤Úˆ ÙÔ ı¿Ó·ÙÔ Î·Ú‰È·Î‹˜ ·ÈÙÈÔÏÔÁ›·˜ Î·È Ù· √∂ª.50 π‰È·›ÙÂÚË ·ÓËÛ˘¯›· ¤¯ÂÈ ÚÔηϤÛÂÈ Ë Èı·Ó‹ Û˘Û¯¤ÙÈÛË Ù˘ ·ÁˆÁ‹˜ Ì ‚-·ÔÎÏÂÈÛÙ¤˜ Ì ÙËÓ ÂÌÊ¿ÓÈÛË Û·Î¯·ÚÒ‰Ë ‰È·‚‹ÙË (™¢) Ù‡Ô˘2. ªÂÁ¿Ï˜ ÌÂϤÙ˜ Ô˘

28

Û˘Ó¤ÎÚÈÓ·Ó ÙÔ˘˜ ‚-·ÔÎÏÂÈÛÙ¤˜ ÙfiÛÔ Ì ʿÚ̷η ¿ÏÏˆÓ Î·ÙËÁÔÚÈÒÓ (·ÓÙ·ÁˆÓÈÛÙ¤˜ ·Û‚ÂÛÙ›Ô˘, ·ÓÙ·ÁˆÓÈÛÙ¤˜ ÙˆÓ ˘Ô‰Ô¯¤ˆÓ Ù˘ ·ÁÁÂÈÔÙÂÓÛ›Ó˘ ππ, ·Ó·ÛÙÔÏ›˜ ÙÔ˘ ÌÂÙ·ÙÚÂÙÈÎÔ‡ ÂÓ˙‡ÌÔ˘ Ù˘ ·ÁÁÂÈÔÙÂÓÛ›Ó˘), fiÛÔ Î·È Ì ÂÈÎÔÓÈÎfi Ê¿ÚÌ·ÎÔ ¤‰ÂÈÍ·Ó ·˘ÍË̤ÓÔ Î›Ó‰˘ÓÔ ÁÈ· ÓÂÔÂÌÊ·ÓÈ˙fiÌÂÓÔ ™¢ Ì ÙÔ˘˜ ‚-·ÔÎÏÂÈÛÙ¤˜.14, 15, 51, 52 øÛÙfiÛÔ ‰ÂÓ ¤¯ÂÈ ‰È¢ÎÚÈÓÈÛı› ·Ó Ù· ˘fiÏÔÈ· Ê¿Ú̷η ÚÔÏ·Ì‚¿ÓÔ˘Ó ÙËÓ ÂÌÊ¿ÓÈÛË ÙÔ˘ ™¢ ‹ ·Ó fiÓÙˆ˜ ÔÈ ‚·ÔÎÏÂÈÛÙ¤˜ ‰È·Ù·Ú¿ÛÛÔ˘Ó ÙËÓ ÔÌÔÈÔÛÙ·Û›· Ù˘ ÁÏ˘Îfi˙˘, ȉȷ›ÙÂÚ· fiÙ·Ó Û˘Ó‰˘¿˙ÔÓÙ·È Ì ıÂÈ·˙ȉÈο ‰ÈÔ˘ÚËÙÈο.53 ∞ÚÓËÙÈ΋ Ê·›ÓÂÙ·È fiÙÈ Â›Ó·È Ë Â›‰Ú·ÛË ÙˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ Î·È ÛÙÔ ÌÂÙ·‚ÔÏÈÛÌfi ÙˆÓ ÏÈȉ›ˆÓ.54 √È ‚·ÔÎÏÂÈÛÙ¤˜ ¯ˆÚ›˜ ÂÓ‰ÔÁÂÓ‹ Û˘Ì·ıËÙÈÎÔÌÈÌËÙÈ΋ ‰Ú·ÛÙËÚÈfiÙËÙ· ·˘Í¿ÓÔ˘Ó Ù· Â›‰· ÙˆÓ ÙÚÈÁÏ˘ÎÂÚȉ›ˆÓ Î·È ÌÂÈÒÓÔ˘Ó ÙË ¯ÔÏËÛÙÂÚfiÏË ÙˆÓ ÏÈÔÚˆÙÂ˚ÓÒÓ ˘„ËÏ‹˜ ˘ÎÓfiÙËÙ·˜ [high-density lipoprotein (HDL)], ¯ˆÚ›˜ Ó· ÂËÚ¿˙Ô˘Ó ÛËÌ·ÓÙÈο Ù· Â›‰· Ù˘ ÔÏÈ΋˜ ¯ÔÏËÛÙÂÚfiÏ˘ Î·È Ù˘ ¯ÔÏËÛÙÂÚfiÏ˘ ÙˆÓ ÏÈÔÚˆÙÂ˚ÓÒÓ ¯·ÌËÏ‹˜ ˘ÎÓfiÙËÙ·˜ [lowdensity lipoprotein (LDL)].55 √È Î·Ú‰ÈÔÂÎÏÂÎÙÈÎÔ› ‚-·ÔÎÏÂÈÛÙ¤˜ ¤¯Ô˘Ó ÏÈÁfiÙÂÚÔ ·ÚÓËÙÈ΋ Â›‰Ú·ÛË ÛÙÔ ÏÈȉ·ÈÌÈÎfi ÚÔÊ›Ï,56 ÂÓÒ ÔÈ ‚-·ÔÎÏÂÈÛÙ¤˜ Ì ÂÓ‰ÔÁÂÓ‹ Û˘Ì·ıËÙÈÎÔÌÈÌËÙÈ΋ ‰Ú·ÛÙËÚÈfiÙ��Ù· (ÈÓ‰ÔÏfiÏË) ‹ ·ÁÁÂÈԉȷÛÙ·ÏÙÈΤ˜ ȉÈfiÙËÙ˜ (ÛÂÏÈÚÔÏfiÏË) ‰ÂÓ ÂËÚ¿˙Ô˘Ó ÙÔ ÌÂÙ·‚ÔÏÈÛÌfi ÙˆÓ ÏÈȉ›ˆÓ.57, 58 ¶Èı·ÓÒ˜ ÔÈ ‚-·ÔÎÏÂÈÛÙ¤˜ ‰È·Ù·Ú¿ÛÛÔ˘Ó ÙËÓ Ë·ÙÈ΋ Û‡ÓıÂÛË ÙˆÓ ÏÈÔÚˆÙÂ˚ÓÒÓ ‹ ÂÏ·ÙÙÒÓÔ˘Ó ÙË ‰Ú·ÛÙËÚÈfiÙËÙ· Ù˘ ÏÈÔÚˆÙÂ˚ÓÈ΋˜ ÏÈ¿Û˘, ÌÂÈÒÓÔÓÙ·˜ ¤ÙÛÈ ÙÔÓ Î·Ù·‚ÔÏÈÛÌfi ÙˆÓ ÏÈÔÚˆÙÂ˚ÓÒÓ.59, 60 ∏ ·ÓÂÈı‡ÌËÙË ·˘Ù‹ ÂÓ¤ÚÁÂÈ· ¤¯ÂÈ È‰È·›ÙÂÚË ÎÏÈÓÈ΋ ÛËÌ·Û›·, ·ÊÔ‡ ÔÏÏÔ› ·ÛıÂÓ›˜ ¤¯Ô˘Ó ÙfiÛÔ ∞À, fiÛÔ Î·È ‰˘ÛÏÈȉ·ÈÌ›·, ÁÂÁÔÓfi˜ Ô˘ ÙÔ˘˜ ηıÈÛÙ¿ ¿ÙÔÌ· ˘„ËÏÔ‡ ηډȷÁÁÂÈ·ÎÔ‡ ÎÈÓ‰‡ÓÔ˘. ∂Ô̤ӈ˜, ÔÊ›ÏÔ˘Ì ӷ ÂÈϤÍÔ˘Ì ÙËÓ Î·Ù¿ÏÏËÏË ·ÁˆÁ‹, Ë ÔÔ›· ı· ÂÍ·ÛÊ·Ï›ÛÂÈ Ù· ÂÈı˘ÌËÙ¿ Â›‰· ∞À Î·È LDL-¯ÔÏËÛÙÂÚfiÏ˘ Î·È ÂÔ̤ӈ˜ ı· ÂÏ·ÙÙÒÛÂÈ ÙÔÓ Î›Ó‰˘ÓÔ Î·Ú‰È·ÁÁÂȷ΋˜ ÓfiÛÔ˘. ™ÙËÓ Î·ÙËÁÔÚ›· ÙˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ ·Ó‹ÎÔ˘Ó Î¿ÔÈ· ÓÂfiÙÂÚ· Ê¿Ú̷η Ì ¿ÌÂÛË ·ÁÁÂÈԉȷ-

ÛÙ·ÏÙÈ΋ ‰Ú¿ÛË (ÓÂÌÈ‚ÔÏfiÏË, ηڂÂÓÙÈÏfiÏË, ÛÂÏÈÚÔÏfiÏË). ∞Ó Î·È ‰ÂÓ ¤¯Ô˘Ó Á›ÓÂÈ Ù˘¯·ÈÔÔÈË̤Ó˜ ÎÏÈÓÈΤ˜ ÌÂϤÙ˜ ÁÈ· ÙËÓ ·ÓÙÈÌÂÙÒÈÛË Ù˘ ∞À Ì ٷ Û˘ÁÎÂÎÚÈ̤ӷ Û΢¿ÛÌ·Ù·, Ê·›ÓÂÙ·È fiÙÈ ·ÔÙÂÏÔ‡Ó ·ÛÊ·Ï‹ Î·È ·ÔÙÂÏÂÛÌ·ÙÈο Ê¿Ú̷η, ΢ڛˆ˜ fï˜ ÁÈ· ÙË ıÂÚ·›· Ù˘ ∫∞ (ȉȷ›ÙÂÚ· Ë Î·Ú‚ÂÓÙÈÏfiÏË). ∂Í·ÈÙ›·˜ Ù˘ ˘ÂÚÔ¯‹˜ ÙˆÓ ˘fiÏÔÈˆÓ ·ÓÙÈ˘ÂÚÙ·ÛÈÎÒÓ Ê·ÚÌ¿ÎˆÓ ¤Ó·ÓÙÈ ÙˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ Â›Ó·È ·›ı·ÓÔ Ó· ۯ‰ȷÛıÔ‡Ó ÌÂϤÙ˜ Û‡ÁÎÚÈÛ˘ ·˘ÙÒÓ ÙˆÓ Ê·ÚÌ¿ÎˆÓ Ì ÂÈÎÔÓÈÎfi ‹ ¿ÏÏÔ Ê¿ÚÌ·ÎÔ. ¶·ÚfiÏ· ·˘Ù¿ Ê·›ÓÂÙ·È fiÙÈ ·˘ÙÔ› ÔÈ ‚-·ÔÎÏÂÈÛÙ¤˜ Û˘ÓÂÈÛʤÚÔ˘Ó ıÂÙÈο Û ‰Â˘ÙÂÚ‡ÔÓÙ· ηٷÏËÎÙÈο ÛËÌ›·, fiˆ˜ Ë ˘ÂÚÙÚÔÊ›· Ù˘ ·ÚÈÛÙÂÚ‹˜ ÎÔÈÏ›·˜.61 Δ¤ÏÔ˜, Â›Ó·È ÛÎfiÈÌÔ Ó· ÙÔÓÈÛıÔ‡Ó ÔÚÈṲ̂Ó˜ ȉȷÈÙÂÚfiÙËÙ˜ Ô˘ ·ÊÔÚÔ‡Ó ÙÔÓ ÙÚfiÔ ¯ÔÚ‹ÁËÛ˘ ÙˆÓ ‚-·ÔÎÏÂÈÛÙÒÓ. ∏ ·fiÙÔÌË ‰È·ÎÔ‹ ÙÔ˘˜ ··ÈÙ› ȉȷ›ÙÂÚË ÚÔÛÔ¯‹, ÂÍ·ÈÙ›·˜ Ù˘ ·ÓÙ·Ó·ÎÏ·ÛÙÈ΋˜ Ù·¯˘Î·Ú‰›·˜ ‹/Î·È Ù˘ ·‡ÍËÛ˘ Ù˘ ∞¶ Ô˘ ·˘Ù‹ ÌÔÚ› Ó· ÚÔηϤÛÂÈ, ȉȷ›ÙÂÚ· fiÙ·Ó Ù· Ê¿Ú̷η ¯ÔÚËÁÔ‡ÓÙ·È Û ˘„ËϤ˜ ‰fiÛÂȘ, Ì ·ÔÙ¤ÏÂÛÌ· ·ÎfiÌ· Î·È ÙËÓ ÂÌÊ¿ÓÈÛË ÂÓfi˜ √∂ª. ∞Ó ÁÈ· ÔÔÈÔ‰‹ÔÙ ÏfiÁÔ Ú¤ÂÈ Ó· ÛÙ·Ì·Ù‹ÛÂÈ Ë ¯ÔÚ‹ÁËÛ‹ ÙÔ˘˜, ··ÈÙÂ›Ù·È Ë ÛÙ·‰È·Î‹ Ì›ˆÛË Ù˘ ‰fiÛ˘ ÙÔ˘˜ Î·È Ë ·Ú¿ÏÏËÏË ˘ÔηٿÛÙ·ÛË Ì ¿ÏÏÔ ·ÓÙÈ˘ÂÚÙ·ÛÈÎfi Ê¿ÚÌ·ÎÔ. Δ¤ÏÔ˜, Ú¤ÂÈ Ó· ›̷ÛÙ ȉȷ›ÙÂÚ· ÚÔÛÂÎÙÈÎÔ›, ηıfiÛÔÓ ÌÈ· ÌË ÎÏÈÓÈο ¤Î‰ËÏË ™¡ ÌÔÚ› Ó· Û˘ÁÎ·Ï˘Êı› ·fi ÙË ¯ÔÚ‹ÁËÛË ÂÓfi˜ ‚-·ÔÎÏÂÈÛÙ‹.

™˘ÌÂÚ¿ÛÌ·Ù· √È ‚-·ÔÎÏÂÈÛÙ¤˜ ¤¯Ô˘Ó ¯ÚËÛÈÌÔÔÈËı› ÁÈ· ÔÏÏ¿ ¯ÚfiÓÈ· ˆ˜ ·ÓÙÈ˘ÂÚÙ·ÛÈο Ê¿Ú̷η ÚÒÙ˘ ÂÈÏÔÁ‹˜. øÛÙfiÛÔ Ù· ÙÂÏÂ˘Ù·›· ¤ÙË ¿Ú¯ÈÛ ӷ ·ÌÊÈÛ‚ËÙÂ›Ù·È Ë ÛËÌ·Û›· ÙÔ˘˜, ΢ڛˆ˜ ÂÍ·ÈÙ›·˜ Ù˘ ˘ÂÚÔ¯‹˜ ÙˆÓ ÓÂfiÙÂÚˆÓ ·ÓÙÈ˘ÂÚÙ·ÛÈÎÒÓ Ê·Ú̿ΈÓ. ¶·ÚfiÏ· ·˘Ù¿, Ë ÔÚÈÛÙÈ΋ Î·È Ï‹Ú˘ ·fiÛ˘ÚÛ‹ ÙÔ˘˜ ·fi ÙË ıÂÚ·¢ÙÈ΋ Ê·Ú¤ÙÚ· ÁÈ· ÙËÓ ·ÓÙÈÌÂÙÒÈÛË Ù˘ ∞À ‰ÂÓ Ê·›ÓÂÙ·È Ó· ·ÔÙÂÏ› ÙË ÛˆÛÙ‹ ÂÈÏÔÁ‹. À¿Ú¯Ô˘Ó Û˘ÁÎÂÎÚÈ̤Ó˜ ÔÌ¿‰Â˜ ·ÛıÂÓÒÓ ÔÈ Ôԛ˜ ÌÔÚÔ‡Ó Ó· ·ÔÎÔÌ›ÛÔ˘Ó ÔʤÏË ·fi ÙË ıÂÚ·›· Ì ‚-·ÔÎÏÂÈÛÙ¤˜, fiˆ˜ ÔÈ ·ÛıÂÓ›˜ Ì ™¡ ‹/Î·È ∫∞, ηıÒ˜ Î·È Ó¤· ‹ ·Á¯Ò‰Ë ¿ÙÔÌ· Ì ·ÓÂ›ÏÂÎÙË


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·29

£∂ƒ∞¶∂π∞ - º∞ƒª∞∫∞ ∞À. ¢ÂÓ Ú¤ÂÈ Ó· ͯӿÌ ¿ÏψÛÙ ÙÔ ¯·ÌËÏfi ÎfiÛÙÔ˜ ÙˆÓ Û˘ÁÎÂÎÚÈÌ¤ÓˆÓ Ê·Ú̿ΈÓ, ÁÂÁÔÓfi˜ Ô˘ ¤¯ÂÈ ÌÂÁ¿ÏË ÛËÌ·Û›·, ·ÊÔ‡ Ë

·ÓÙÈ˘ÂÚÙ·ÛÈ΋ ·ÁˆÁ‹ ¯ÔÚËÁÂ›Ù·È ‰È· ‚›Ô˘. ™˘ÌÂÚ·ÛÌ·ÙÈο, Ë ·ÓÙÈÌÂÙÒÈÛË ÙÔ˘ ˘ÂÚÙ·ÛÈÎÔ‡ ·ÛıÂÓ‹, fiˆ˜ ‚¤‚·È· Î·È Î¿ı ȷ-

ÙÚÈ΋ Ú¿ÍË, ÔÊ›ÏÂÈ Ó· Á›ÓÂÙ·È Ì ‚¿ÛË ÙȘ ȉȷÈÙÂÚfiÙËÙ˜ ÙÔ˘ οı ·ÙfiÌÔ˘, ÒÛÙ ٷ ÔʤÏË Ó· ˘ÂÚ‚·›ÓÔ˘Ó ÙÔ˘˜ ÎÈÓ‰‡ÓÔ˘˜.

μÈ‚ÏÈÔÁÚ·Ê›· 1.

2.

3.

Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO and Bjorck JE. Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. JAMA 1982; 248: 2004-2011. Wright JT, Jr., Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP and Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.

4.

Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, Hornkvist PE, Pennert K, Tuomilehto J and Wedel H. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5: 561-572.

5.

Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH, Jr., Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A and Anders RJ. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073-2082.

6.

7.

8.

9.

Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T and Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B and Karlberg BE. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359365. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T and de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J,

Safar M, Eckes L and Rizzini P. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, doubleblind, long-term trial. Circulation 2002; 106: 2422-2427. 10. Berglund G, Andersson O and Widgren B. Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide. Acta Med Scand 1986; 220: 419-424. 11. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. BMJ 1985; 291: 97-104. 12. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-412. 13. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-720. 14. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S and Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. 15. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E and Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906. 16. Pepine CJ, Handberg EM, CooperDeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD and Parmley WW. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International VerapamilTrandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816. 17. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH) . J Hypertens 1985; 3: 379-392.

18. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group. Stroke 1993; 24: 543-548. 19. Coope J and Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145-1151. 20. Yurenev AP, Dyakonova HG, Novikov ID, Vitols A, Pahl L, Haynemann G, Wallrabe D, Tsifkova R, Romanovska L, Niderle P and et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. Am J Hypertens 1992; 5: 182S-189S. 21. Eriksson S, Olofsson OB, Wester PO. Atenolol in the secondary prevention after stroke. Cerebrovasc Dis 1995; 5: 21-25. 22. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264. 23. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T and Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calciumchannel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372. 24. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997. 25. Lindholm LH, Carlberg B and Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553. 26. Khan N and McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a metaanalysis. CMAJ 2006; 174: 1737-1742. 27. Carlberg B, Samuelsson O and Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684-1689. 28. Karagiannis A, Athyros VG, Papageorgiou A, Tziomalos K and Elisaf M. Should atenolol still be recommended as first-line therapy for primary hypertension? Hellenic J Cardiol 2006; 47: 298307. 29. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO and Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, Shortterm reductions in blood pressure:

29


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·30

π√À¡π√™ 2007

overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838. 30. Benetos A, Waeber B, Izzo J, Mitchell G, Resnick L, Asmar R and Safar M. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens 2002; 15: 1101-1108. 31. Franklin SS, Gustin Wt, Wong ND, Larson MG, Weber MA, Kannel WB and Levy D. Hemodynamic patterns of agerelated changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-315. 32. Resnick LM and Lester MH. Differential effects of antihypertensive drug therapy on arterial compliance. Am J Hypertens 2002; 15: 1096-1100. 33. Franklin SS, Khan SA, Wong ND, Larson MG and Levy D. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation 1999; 100: 354-360. 34. O'Rourke MF. From theory into practice: arterial haemodynamics in clinical hypertension. J Hypertens 2002; 20: 1901-1915. 35. Morgan T, Lauri J, Bertram D and Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17: 118-123. 36. de Luca N, Asmar RG, London GM, O'Rourke MF and Safar ME. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 2004; 22: 1623-1630. 37. Klingbeil AU, Schneider M, Martus P, Messerli FH and Schmieder RE. A metaanalysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-46. 38. Parker GW, Michael LH, Hartley CJ, Skinner JE and Entman ML. Central beta-adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs. Circ Res 1990; 66: 259-270. 39. Neutel JM, Schnaper H, Cheung DG, Graettinger WF and Weber MA. Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J 1990; 120: 166171. 40. Schiffrin EL, Deng LY and Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin Iconverting enzyme inhibitor. Comparison with effects of a beta-blocker. Am J Hypertens 1995; 8: 229-236. 41. Schiffrin EL, Park JB, Intengan HD and Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the

30

angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-1659. 42. Taddei S, Virdis A, Ghiadoni L, Sudano I and Salvetti A. Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr Hypertens Rep 2000; 2: 64-70. 43. Freemantle N, Cleland J, Young P, Mason J and Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-1737. 44. Hedblad B, Wikstrand J, Janzon L, Wedel H and Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the BetaBlocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-1726. 45. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13. 46. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007. 47. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK and DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658. 48. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I and DeMets DL. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-2199. 49. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR and van Urk H. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341: 17891794. 50. Poldermans D, Boersma E, Bax JJ, Thomson IR, Paelinck B, van de Ven LL, Scheffer MG, Trocino G, Vigna C, Baars HF, van Urk H and Roelandt JR. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. Eur Heart J 2001; 22: 1353-1358.

51. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA, Amerena J, Balazovjech I, Cassel G, Herczeg B, Koylan N, Magometschnigg D, Majahalme S, Martinez F, Oigman W, Seabra Gomes R and Zhu JR. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006; 48: 385-391. 52. Gress TW, Nieto FJ, Shahar E, Wofford MR and Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912. 53. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A and Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-1574. 54. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203-209. 55. Kasiske BL, Ma JZ, Kalil RS and Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122: 133-141. 56. Gonzalez Maqueda I. Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol. Coron Artery Dis 1994; 5: 909918. 57. Lehtonen A. Comparison of the metabolic effects of long-term treatment with pindolol or atenolol by hypertensive patients. Cardiovasc Drugs Ther 1988; 1: 549-551. 58. Sirtori CR, Johnson B, Vaccarino V, Montanari G, Cremoncini M, Gianfranceschi G, Sirtori M and Dujovne CA. Lipid effects of celiprolol, a new cardioselective beta-blocker, versus propranolol. Clin Pharmacol Ther 1989; 45: 617-626. 59. Lijnen P. Biochemical mechanisms involved in the beta-blocker-induced changes in serum lipoproteins. Am Heart J 1992; 124: 549-556. 60. Lithell H, Pollare T and Vessby B. Metabolic effects of pindolol and propranolol in a double-blind crossover study in hypertensive patients. Blood Press 1992; 1: 92-101. 61. Beevers DG. The end of beta blockers for uncomplicated hypertension? Lancet 2005; 366: 1510-1512.


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·31

¶ƒ√Δ∂π¡√ª∂¡∏ μπμ§π√°ƒ∞ºπ∞ ¶ƒ√Δ∂π¡√ª∂¡∏ μπμ§π√°ƒ∞ºπ∞ 1:

Ozsoy RC, van der Steeg WA, Kastelein JJ, Arisz L, Koopman MG. Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin. Nephrol Dial Transplant. 2007 Mar 8; [Epub ahead of print] 2: Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, Schultheiss HP, Rauch U. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterollowering enough to inhibit platelets? J Am Coll Cardiol. 2007 Mar 13;49(10): 1035-42. 3: Athyros VG, Mikhailidis DP, Kakafika AI, Karagiannis A, Hatzitolios A, Tziomalos K, Ganotakis ES, Liberopoulos EN, Elisaf M. Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. Curr Drug Targets. 2007 Mar;8(3):483-8. Review. 4: Ye Y, Lin Y, Perez-Polo JR, Huang MH, Hughes MG, McAdoo DJ, Manickavasagam S, Uretsky BF, Birnbaum Y. Enhanced Cardioprotection Against IschemiaReperfusion Injury with a Dipyridamole and Low-Dose Atorvastatin Combination. Am J Physiol Heart Circ Physiol. 2007 Apr 6; [Epub] 5: Georgescu EF, Georgescu M. Therapeutic Options in Non-Alcoholic Steatohepatitis (NASH). Are all Agents Alike? Results of a Preliminary Study. J Gastrointestin Liver Dis. 2007 Mar;16 (1):39-46. 6: Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007 Apr;11(14):1178. 7: Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, Bots ML; The RADIANCE 1 and 2 Study Investigators. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/ atorvastatin with atorvastatin alone on atherosclerosis. Curr Med Res Opin. 2007 Apr;23(4):885-94. 8: Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin. 2007 Apr;23(4):767-75. 9: Frisbee JC, James ME, Goodwill AG, Balch Samora J, Muller-Delp JM, Frisbee SJ. HMG Co-A REDUCTASE INHIBITORS IMPROVE MICROVASCULAR OUTCOMES IN THE METABOLIC SYNDROME INDEPENDENT OF PLASMA TOTAL CHOLESTEROL. Am J Physiol Heart Circ Physiol. 2007 Mar 30; [Epub ahead of print] 10: O'Malley P. Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable coronary heart disease. Evid Based Med. 2007 Apr;12(2):43. 11: Sakabe K, Fukuda N, Fukuda Y, Wakayama K, Nada T, Morishita S, Shinohara H, Tamura Y. Comparisons of short- and intermediateterm effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and

12:

13:

14:

15:

16:

17:

18:

19:

20:

21:

22:

endothelial function. Int J Cardiol. 2007 Mar 30; [Epub ahead of print] Sakabe K, Fukuda N, Fukuda Y, Wakayama K, Nada T, Morishita S, Shinohara H, Tamura Y. Gender differences in shortterm effects of atorvastatin on lipid profile, fibrinolytic parameters, and endothelial function. Nutr Metab Cardiovasc Dis. 2007 Mar 29; [Epub ahead of print] Perez-Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, Duenas A. Effects of atorvastatin on vitamin d levels in patients with acute ischemic heart disease. Am J Cardiol. 2007 Apr 1;99(7):903-5. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDAACS randomized trial. J Am Coll Cardiol. 2007 Mar 27; 49(12):1272-8. O'leary JG, Chan JL, McMahon CM, Chu-ng RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial. Hepatology 2007 Apr;45(4):895-8. Rasmusen C, Moinard C, Martin C, Tricottet V, Cynober L, Couderc R. lArginine plus atorvastatin for prevention of atheroma formation in genetically hyperchole-sterolaemic rabbits. Br J Nutr. 2007 Mar 29;:1-7 [Epub ahead of print] Yamada K, Sakurai E, Itaya M, Yamasaki S, Ogura Y. Inhibition of laserinduced choroidal neovascularization by atorvastatin by downregulation of monocyte chemotactic protein-1 synthesis in mice. Invest Ophthalmol Vis Sci. 2007 Apr; 48(4):1839-43. Pignatelli P, Sanguigni V, Lenti L, Loffredo L, Carnevale R, Sorge R, Violi F. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia. Effect of atorvastatin. J Thromb Haemost. 2007 Mar 21; [Epub ahead of print] Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. N Engl J Med. 2007 Mar 26; [Epub ahead of print] Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med. 2007 Mar 29;356(13):1364-6. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007 Mar 29;356(13):1304-16. Nissen SE, Nicholls SJ, Wolski K, Howey DC, McErlean E, Wang MD, Gomez EV, Russo JM. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007 Mar 28;297(12):1362-73.

23: Song JC, Wang CC, Huang YC, Sanchez J, Nguyen T, Khan S, Kim MK, Li P. Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population. Am J Health Syst Pharm. 2007 Apr 1; 64(7):767-72. 24: Jose J, Saravu K, Shastry BA. Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephritic syndrome. Am J Health Syst Pharm. 2007 Apr 1; 64(7):726-9. 25: Blank R, Hobbs FD, Zamorano J, Girerd X. A single-pill combination of amlodipine besylate and atorvastatin calcium (update). Drugs Today (Barc). 2007 Mar; 43(3):157-77. 26: Mauser W, Perwitz N, Meier B, Fasshauer M, Klein J. Direct adipotropic actions of atorvastatin: Differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur J Pharmacol. 2007 Feb 22; [Epub ahead of print] 27: Cheng G, Xu G, Cai HW, Wang HH, Bao XF. Effect of atorvastatin on nonischemic heart failure and matrix metalloproteinase-2 and 9 in rats. Acta Pharmacol Sin. 2007 Apr;28(4):511-7. 28: Heering NJ. Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure. Ned Tijdschr Geneeskd. 2007 Mar 3;151(9):565-6 29: Xu YG, Zhou SH, Li YG, Zheng CH, Li XP, Liu QM, Xu DM, Chen S. The Mechanism Underlying Vascular Smooth Muscle Cell Apoptosis Induced by Atorvastatin may be Mainly Associated with Down-regulation of Survivin Expression. Cardiovasc Drugs Ther. 2007 Mar 20; [Epub ahead of print] 30: Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jonsson B. Costeffectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J. 2007 Mar 19; [Epub ahead of print] 31: Peissig P, Sirohi E, Berg RL, BrownSwitzer C, Ghebranious N, McCarty CA, Wilke RA. Construction of atorvastatin doserespon-se relationships using data from a large population-based DNA biobank. Basic Clin Pharmacol Toxicol. 2007 Apr; 100(4):286-8. 32: Betteridge DJ, Gibson JM. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet Med. 2007 Mar 15; [Epub ahead of print] 33: Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of Rosuvastatin: Update on 16,876 Rosuvastatin-Treated Patients in a Multinational Clinical Trial Program. Cardiology. 2007 Mar 16;107(4):433-443 34: Sadoni S, Kaczmarek I, Delgado O, Schmockel M, Reichart B, Meiser B. Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase. Transplant Proc. 2007 Mar; 39(2):558-9. 35: Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on highsensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007 Mar 15;99(6):805-7.

31


ATHIROSK 14

03-07-07

12:06

™ÂÏ›‰·32

π√À¡π√™ 2007

36: Gardner JL, Turner SM, Bautista A, Lindwall G, Awada M, Hellerstein MK. Measurement of Liver Collagen Synthesis by Heavy Water Labeling: Effects of Profibrotic Toxicants and AntiFibrotic Interventions. Am J Physiol Gastrointest Liver Physiol. 2007 Mar 8; [Epub ahead of print] 37: Mulder DJ, van Haelst PL, Wobbes MH, Gans RO, Zijlstra F, May JF, Smit AJ, Tervaert JW, van Doormaal JJ. The Effect of Aggressive Versus Conven-

tional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress. Cardiovasc Drugs Ther. 2007 Mar 7; [Epub ahead of print] 38: Choudhry NK, Levin R, Winkelmayer WC. Statins in elderly acute coronary syndro-me patients: an analysis of dose and class effects in typical practice. Heart. 2007 Mar 7; [Epub ahead of print] 39: Choudhry NK, Levin R, Winkelmayer WC. Statins in elderly acute coronary

syndrome patients: an analysis of dose and class effects in typical practice. Heart. 2007 Mar 7; [Epub ahead of print] 40: Yu CM, Zhang Q, Lam L, et al. Comparison of Intensive and Low-dose Atorvastatin Therapy in the Reduction of Carotid Intimal-Medial Thickness in Patients With Coronary Heart Disease. Heart. 2007 Mar 7; [Epub] ∂È̤ÏÂÈ·: μ·Û›Ï˘ Õı˘ÚÔ˜

¶ƒ√Δ∂π¡√ª∂¡∏ μπμ§π√°ƒ∞ºπ∞ °π∞ Δ∞ ∞¡Δπ∞πª√¶∂Δ∞§π∞∫∞ ¶ÚfiÏË„Ë K·Ú‰È·ÁÁÂÈ·ÎÒÓ ™˘Ì‚·Ì¿ÙˆÓ

AÁÁÂÈÔÏ·ÛÙÈ΋ Î·È stents

1.

1.

°ÂÚÔÙ˙È¿Ê·˜ °, μ·ÛÈÏfiÔ˘ÏÔ˜ ¢, μ¤ÌÌÔ˜ ∫, Î·È Û˘Ó: ∫·Ù¢ı˘ÓÙ‹ÚȘ Ô‰ËÁ›Â˜ ÁÈ· ÙËÓ ·ÓÙÈ·ÈÌÔÂÙ·Ïȷ΋ ·ÁˆÁ‹ Û ·ÛıÂÓ›˜ Ì ·ıËÚÔıÚfiÌ‚ˆÛË ‹ ·ÛıÂÓ›˜ Ì ΛӉ˘ÓÔ ·ıËÚÔıÚfiÌ‚ˆÛ˘. ∂ÏÏ ∫·Ú‰ÈÔÏ ∂Èı 2006; 47 (Û˘ÌÏ ∞):7-48.

2.

Clappers ¡, Brouwer ª∞, Verheugt FWA. Antiplatelet treatment for coronary heart disease. Heart 2007;93;258-265

3.

Hackam DG, Eikelboom JW. Antithrombotic treatment for peripheral arterial disease. Heart 2007;93;303-308;

4.

Liao LJ. Secondary Prevention of Stroke and Transient Ischemic Attack: Is More Platelet Inhibition the Answer?. Circulation. 2007;115:1615-1621

5.

6.

7.

8.

Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL: ∞spirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295:306-313. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease. A Systemic Review JAMA 2007;297:2018-24 Bartolucci AA, Howard G. Metaanalysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006;98:746-750 Eshaghian S, Kaul S, Amin S, Shah P, Diamond GA. Role of clopidogrel in managing atherothrombotic cardiovascular disease. Ann Intern Med. 2007; 146:434-41

2.

Eisenstein EL, Anstrom KI, Dong KF, et al. Clopidogrel use and longterm clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297: 159-168. Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation 2007;115:813-8, J Am Coll Cardiol 2007;49:734-9

AÓÙ›ÛÙ·ÛË Î·È ¢È·Î‡Ì·ÓÛË

8.

Lordkipanidze M, Pharand C, Palisaitis DA, Diodati JG: Aspirin resistance: truth or dare. Pharmacol Ther 2006; 112:733743.

9.

Dalen JE. Aspirin Resistance: Is it Real? Is it Clinically Significant? Am J Med 2007; 120: 1-4

10. ¶··ı·Ó·Û›Ô˘ ∞, °Ô˘‰¤‚ÂÓÔ˜ π, ΔÛÂϤ˘ ∞¢ .∞ÓÙ›ÛÙ·ÛË ÛÙËÓ ·ÛÈÚ›ÓË Î·È ÙËÓ ÎÏÔȉÔÁÚ¤ÏË. ¶Èı·ÓÔ› Ì˯·ÓÈÛÌÔ›, ÂÚÁ·ÛÙËÚȷ΋ ‰ÈÂÚ‡ÓËÛË Î·È ÎÏÈÓÈ΋ ÛËÌ·Û›·. ∂ÏÏ ∫·Ú‰ÈÔÏ ∂Èı. Àfi ‰ËÌÔÛ›Â˘ÛË

1.

Hankey GJ, Eikelboom JW: Aspirin resistance. Lancet 2006; 367:606-617.

™˘Ó‰˘·ÛÌfi˜ ∞ÓÙÈ·ÈÌÔÂÙ·ÏÈ·ÎÒÓ Î·È ∞ÓÙÈıÚÔÌ‚ˆÙÈÎÒÓ

2.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E,etal. Variability in individual responsiveness to clopidogrel. J Am Coll Cardiol 2007;49:1505-16

1.

3.

Wiviott SD. Clopidogrel response variability, resistance or both? Am J Cardiol 2006;98[suppl}:18N-24N

Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006

2.

4.

ªason PJ, Jacobs AK, Freedman JE: Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005; 46:986-993.

Dentaly F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease. A meta-analysis of randomized trials. Arch Intern Med 2007;167:117-124

5.

Gurbel PA, Tantry US: Aspirin and clopidogrel resistance: Consideration and management. J Interv Cardiol 2006; 19:439-448.

3.

Karjalainen PP, Porela P, Ytalo A et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007;28: 726-32

6.

Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006;27:647-54

4.

Sinaeve PR. The good, the bad, and the ugly: triple therapy after PCI in patients requiring chronic anticoagualtion. (Editorial). Eur Heart J 2007;28:657-8

7.

Andrew O. Maree, MSc, MD; Desmond J. Fitzgerald, MD. Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease. Circulation. 2007;115:2196-2207.

5.

¢È¿ÎÔ˘ ª·Ú›·, ∂ÏÈÛ¿Ê ªˆ˘Û‹˜. ¶Ú¤ÂÈ Ó· Û˘Ó¯›˙ÂÙ·È Ë ¯ÔÚ‹ÁËÛË ·ÛÈÚ›Ó˘ Û ·ÛıÂÓ›˜ Ô˘ ·›ÚÓÔ˘Ó ÎÔ˘Ì·ÚÈÓÈο ·ÓÙÈËÎÙÈο;. ∞ıËÚÔÛÎÏ‹ÚˆÛË 2006; Ù‡¯Ô˜ 9,30-31 ∂È̤ÏÂÈ· °È¿ÓÓ˘ °Ô˘‰¤‚ÂÓÔ˜ ∫·ıËÁËÙ‹˜ ∫·Ú‰ÈÔÏÔÁ›·˜ ¶·ÓÂÈÛÙËÌ›Ô˘ πˆ·ÓÓ›ÓˆÓ

32


out14t

03-07-07

12:41

™ÂÏ›‰·5

IATPOI KA§§ITEXNE™

IATPOI KA§§ITEXNE™

IATPOI KA§§ITEXNE™

™øTHPH™ ¶PA¶A™ I·ÙÚfi˜ K·Ú‰ÈÔ¯ÂÈÚÔ˘ÚÁfi˜

O ™ˆÙ‹Ú˘ ¶Ú¿·˜ Â›Ó·È K·Ú‰ÈÔ¯ÂÈÚÔ˘ÚÁfi˜, ¢È¢ı˘ÓÙ‹˜ ÙÔ˘ K·Ú‰ÈÔ¯ÂÈÚÔ˘ÚÁÈÎÔ‡ TÌ‹Ì·ÙÔ˜ ÙÔ˘ NÔÛÔÎÔÌ›Ԣ EÚÚ›ÎÔ˜ NÙ˘Ó¿Ó ·fi ÙÔ 2001. °ÂÓÓ‹ıËΠÙÔ 1954 ÛÙÔ ™˘ÎÔ‡ÚÈÔ §¿ÚÈÛ·˜. ™Ô‡‰·Û ÛÙË £ÂÛÛ·ÏÔÓ›ÎË fiÔ˘ Î·È ÔÏÔÎÏ‹ÚˆÛ ÙËÓ ÂȉÈÎfiÙËÙ· Ù˘ K·Ú‰ÈÔ¯ÂÈÚÔ˘ÚÁÈ΋˜ ÛÙÔ ÓÔÛÔÎÔÌÂ›Ô «°. ¶··ÓÈÎÔÏ¿Ô˘». MÂÙÂÎ·È‰Â‡ıËΠÛÙÔ Brompton ÙÔ˘ §ÔÓ‰›ÓÔ˘ ηٿ ÙË ‰ÈÂÙ›· 1990-1992 Î·È ÂÚÁ¿ÛÙËΠÛÙÔ øÓ¿ÛÂÈÔ K·Ú‰ÈÔ¯ÂÈÚÔ˘ÚÁÈÎfi K¤ÓÙÚÔ (øKK) ˆ˜ ÂÈÌÂÏËÙ‹˜ A’ ÙËÓ ÔÎÙ·ÂÙ›· 1993-2001. H ʈÙÔÁÚ·Ê›· ·ÔÙÂÏ› ÁÈ’·˘ÙfiÓ ÌÓ‹ÌË, ·ÊÔ‡ ‹Ïı Û Â·Ê‹ Ì·˙› Ù˘ ·fi Ù· ·È‰Èο ÙÔ˘ ¯ÚfiÓÈ·, ‚ÔËıÒÓÙ·˜ ÙÔÓ ÔÈÎÔ‰fiÌÔ ·Ù¤Ú· Ô˘ ÁÈ· ‚ÈÔÔÚÈÛÙÈÎÔ‡˜ ÏfiÁÔ˘˜ ·ÛÎÔ‡ÛÂ Î·È ÙÔ Â¿ÁÁÂÏÌ· ÙÔ˘ Ï·Ófi‰ÈÔ˘ ʈÙÔÁÚ¿ÊÔ˘. K·Ù¿ ‰Â‡ÙÂÚÔ ÏfiÁÔ ·ÔÙÂÏ› ¯·Ú¿ ‰ËÌÈÔ˘ÚÁ›·˜, ·ÊÔ‡ ‰›ÓÂÈ ÙË ‰˘Ó·ÙfiÙËÙ· ¤ÎÊÚ·Û˘ Ì ٷ ¯ÚÒÌ·Ù·, ÙÔ Êˆ˜, ÙËÓ ·ÈÛıËÙÈ΋ ÙÔ˘ ı¤Ì·ÙÔ˜ Î·È ÙÔ fiÔÈÔ Ì‹Ó˘Ì· ÌÔÚ› Ó· ‰ÒÛÂÈ. Œ¯ÂÈ Û˘ÌÌÂÙ¿Û¯ÂÈ ÛÙËÓ ¤ÎıÂÛË ÊˆÙÔÁÚ·Ê›·˜ ÙˆÓ ÂÚÁ·˙ÔÌ¤ÓˆÓ ÙÔ˘ øKK ÙÔÓ AÚ›ÏÈÔ ÙÔ˘ 1998. ºˆÙÔÁڷʛ˜ ÙÔ˘ ˘¿Ú¯Ô˘Ó ÛÙ· ¤ÓıÂÙ· ÌÔ˘ÛÈÎÒÓ ¤ÚÁˆÓ ÙÔ˘ §. M·¯·ÈÚ›ÙÛ· (TÔ ‰È¿ÏÂÈÌÌ· ÎÚ·Ù¿ÂÈ ‰˘Ô ˙ˆ¤˜) Î·È ÙÔ˘ A. MÈÙ˙¤ÏÔ˘ (BڢͤÏϘ - Live).


out14t

03-07-07

12:28

™ÂÏ›‰·2

EΉ›‰ÂÙ·È ·fi ÙȘ È·ÙÚÈΤ˜ ÂΉfiÛÂȘ “B·ÁÈÔÓ¿ÎË” Ì ¯ÔÚËÁ›· Ù˘ PFIZER HELLAS. OÈ ·fi„ÂȘ ÛÙÔ Î›ÌÂÓÔ ÂÎÊÚ¿˙Ô˘Ó ÌfiÓÔ ÙÔ˘˜ Û˘ÁÁÚ·Ê›˜ Î·È ‰ÂÓ ·ÓÙÈÚÔÛˆÂ‡Ô˘Ó ÙË ¯ÔÚËÁfi ÂÙ·ÈÚ›·.


ΤΕΥΧΟΣ 14 ΙΟΥΝΙΟΣ 2007 - ΑΘΗΡΟΣΚΛΗΡΩΣΗ